{"questions": [{"body": "Which kinases does baricitinib inhibit?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24965573", "http://www.ncbi.nlm.nih.gov/pubmed/25431052", "http://www.ncbi.nlm.nih.gov/pubmed/26137574", "http://www.ncbi.nlm.nih.gov/pubmed/24818516", "http://www.ncbi.nlm.nih.gov/pubmed/23492738"], "ideal_answer": ["Baricitinib is an inhibitor of Janus kinase family of enzymes (JAKs) with selectivity for JAK1 and JAK2."], "exact_answer": [["JAK1"], ["JAK2"]], "concepts": ["http://www.uniprot.org/uniprot/JAK2_PONAB", "http://www.uniprot.org/uniprot/JAK2_PIG", "http://www.uniprot.org/uniprot/JAK2_MOUSE", "http://www.uniprot.org/uniprot/JAK2_CHICK", "http://www.uniprot.org/uniprot/JAK2_RAT", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053613", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053612", "http://www.uniprot.org/uniprot/JAK2_HUMAN", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053614"], "type": "list", "id": "56c8605b5795f9a73e000014", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137574", "endSection": "title"}, {"offsetInBeginSection": 314, "offsetInEndSection": 462, "text": "A patient with AA was enrolled in a clinical trial to examine the efficacy of baricitinib, a JAK1/2 inhibitor, to treat concomitant CANDLE syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137574", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 291, "text": "Baricitinib (also known as LY3009104 or INCB028050), a novel and potent small molecule inhibitor of Janus kinase family of enzymes (JAKs) with selectivity for JAK1 and JAK2, is currently in clinical development for the treatment of rheumatoid arthritis (RA) and other inflammatory disorders.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24965573", "endSection": "abstract"}, {"offsetInBeginSection": 295, "offsetInEndSection": 585, "text": "A patient with AA was enrolled in a clinical trial to examine the efficacy of baricitinib, a JAK1/2 inhibitor, to treat concomitant CANDLE syndrome. In vivo, preclinical studies were conducted using the C3H/HeJ AA mouse model to assess the mechanism of clinical improvement by baricitinib.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137574", "endSection": "abstract"}, {"offsetInBeginSection": 529, "offsetInEndSection": 580, "text": "Phase II data for four JAK inhibitors (baricitinib,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818516", "endSection": "abstract"}, {"offsetInBeginSection": 819, "offsetInEndSection": 1088, "text": "Positive clinical trial results have also been reported for several other JAK inhibitors including baricitinib. Several other JAK inhibitors and other small molecular entities are also being developed in studies ranging from preclinical models to large clinical trials.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23492738", "endSection": "abstract"}]}, {"body": "Which proteins remove H2A.Z in the yeast Saccharomyces cerevisiae?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26982580", "http://www.ncbi.nlm.nih.gov/pubmed/26142279"], "ideal_answer": ["Removal of H2A.Z by INO80 promotes homologous recombination Budding yeast INO80 can remove H2A.Z/H2B dimers from chromatin and replace them with H2A/H2B dimers. Here, we show that H2A.Z in human cells is indeed rapidly removed from chromatin flanking DNA damage by INO80.", "Here, we show that H2A.Z in human cells is indeed rapidly removed from chromatin flanking DNA damage by INO80. We also report that the histone chaperone ANP32E, which is implicated in removing H2AZ from chromatin, similarly promotes HR and appears to work on the same pathway as INO80 in these assays. Importantly, we demonstrate that the HR defect in cells depleted of INO80 or ANP32E can be rescued by H2A.Z co-depletion, suggesting that H2A.Z removal from chromatin is the primary function of INO80 and ANP32E in promoting homologous recombination.", "Budding yeast INO80 can remove H2A.Z/H2B dimers from chromatin and replace them with H2A/H2B dimers. Here, we show that H2A.Z in human cells is indeed rapidly removed from chromatin flanking DNA damage by INO80. We also report that the histone chaperone ANP32E, which is implicated in removing H2AZ from chromatin, similarly promotes HR and appears to work on the same pathway as INO80 in these assays.", "we also report that the histone chaperone anp32e, which is implicated in removing h2az from chromatin, similarly promotes hr and appears to work on the same pathway as ino80 in these assays.", "Budding yeast INO80 can remove H2A.Z/H2B dimers from chromatin and replace them with H2A/H2B dimers. Removal of H2A.Z by INO80 promotes homologous recombination H2A.Z removal from chromatin is the primary function of INO80 and ANP32E in promoting homologous recombination.", "Budding yeast INO80 can remove H2A.Z/H2B dimers from chromatin and replace them with H2A/H2B dimers. Removal of H2A.Z by INO80 promotes homologous recombination", "Budding yeast INO80 can remove H2A.Z/H2B dimers from chromatin and replace them with H2A/H2B dimers. H2A.Z removal from chromatin is the primary function of INO80 and ANP32E in promoting homologous recombination."], "exact_answer": [["INO80"], ["ANP32E"]], "type": "list", "id": "58de71fa8acda3452900002c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Removal of H2A.Z by INO80 promotes homologous recombination", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26142279", "endSection": "title"}, {"offsetInBeginSection": 135, "offsetInEndSection": 235, "text": "Budding yeast INO80 can remove H2A.Z/H2B dimers from chromatin and replace them with H2A/H2B dimers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26142279", "endSection": "abstract"}, {"offsetInBeginSection": 403, "offsetInEndSection": 513, "text": "Here, we show that H2A.Z in human cells is indeed rapidly removed from chromatin flanking DNA damage by INO80.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26142279", "endSection": "abstract"}, {"offsetInBeginSection": 514, "offsetInEndSection": 704, "text": "We also report that the histone chaperone ANP32E, which is implicated in removing H2AZ from chromatin, similarly promotes HR and appears to work on the same pathway as INO80 in these assays.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26142279", "endSection": "abstract"}, {"offsetInBeginSection": 843, "offsetInEndSection": 954, "text": "H2A.Z removal from chromatin is the primary function of INO80 and ANP32E in promoting homologous recombination.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26142279", "endSection": "abstract"}, {"offsetInBeginSection": 891, "offsetInEndSection": 1011, "text": "Instead, the INO80 complex, which removes H2A.Z(Htz1) from nucleosomes, promotes the ectopic deposition of CENP-A(Cse4).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26982580", "endSection": "abstract"}]}, {"body": "Which diseases that can be treated using the focused ultrasound thalamotomy.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26382842", "http://www.ncbi.nlm.nih.gov/pubmed/25438838", "http://www.ncbi.nlm.nih.gov/pubmed/27822200", "http://www.ncbi.nlm.nih.gov/pubmed/24291848", "http://www.ncbi.nlm.nih.gov/pubmed/25343176", "http://www.ncbi.nlm.nih.gov/pubmed/25512869", "http://www.ncbi.nlm.nih.gov/pubmed/24876191", "http://www.ncbi.nlm.nih.gov/pubmed/27399411", "http://www.ncbi.nlm.nih.gov/pubmed/26499271", "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "http://www.ncbi.nlm.nih.gov/pubmed/24620914", "http://www.ncbi.nlm.nih.gov/pubmed/20033983", "http://www.ncbi.nlm.nih.gov/pubmed/22208894", "http://www.ncbi.nlm.nih.gov/pubmed/23523144", "http://www.ncbi.nlm.nih.gov/pubmed/26769606", "http://www.ncbi.nlm.nih.gov/pubmed/27557301", "http://www.ncbi.nlm.nih.gov/pubmed/24761224", "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "http://www.ncbi.nlm.nih.gov/pubmed/26877873"], "ideal_answer": ["Focused ultrasound thalamotomy is used for treatment of Parkinson disease, essential tremor, obsessive-compulsive disorder and chronic neuropathic pain."], "exact_answer": [["Parkinson disease"], ["essential tremor"], ["obsessive-compulsive disorder"], ["chronic neuropathic pain"]], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D057086"], "type": "list", "id": "58846be0e56acf5176000005", "snippets": [{"offsetInBeginSection": 718, "offsetInEndSection": 927, "text": "Besides DBS and standard thalamotomy, novel surgical approaches for ET are on the horizon. The development of MRI-guided focused ultrasound technique has been the new frontier of deep brain lesional therapies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26382842", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "132\u2003A Randomized, Sham-Controlled Trial of Transcranial Magnetic Resonance-Guided Focused Ultrasound Thalamotomy Trial for the Treatment of Tremor-Dominant, Idiopathic Parkinson Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399411", "endSection": "title"}, {"offsetInBeginSection": 158, "offsetInEndSection": 442, "text": "Recently, transcranial magnetic resonance-guided focused ultrasound (MRgFUS) has been used to successfully perform thalamotomy for essential tremor. We designed a double-blinded, randomized controlled trial to investigate the effectiveness of MRgFUS thalamotomy in tremor-dominant PD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399411", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 398, "text": "Thalamotomy at the ventralis intermedius nucleus has been an effective treatment method for essential tremor, but how the brain network changes immediately responding to this deliberate lesion and then reorganizes afterwards are not clear. Taking advantage of a non-cranium-opening MRI-guided focused ultrasound ablation technique, we investigated functional network changes due to a focal lesion. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27822200", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Unilateral magnetic resonance guided focused ultrasound thalamotomy for essential tremor: practices and clinicoradiological outcomes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24876191", "endSection": "title"}, {"offsetInBeginSection": 1482, "offsetInEndSection": 1637, "text": "CONCLUSIONS: Our results demonstrate that MRgFUS thalamotomy is a safe, effective and less-invasive surgical method for treating medication-refractory ET. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24876191", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 472, "text": "OBJECT: The authors report different MRI patterns in patients with essential tremor (ET) or obsessive-compulsive disorder (OCD) after transcranial MR-guided focused ultrasound (MRgFUS) and discuss possible causes of occasional MRgFUS failure.METHODS: Between March 2012 and August 2013, MRgFUS was used to perform unilateral thalamotomy in 11 ET patients and bilateral anterior limb capsulotomy in 6 OCD patients; in all patients symptoms were refractory to drug therapy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25343176", "endSection": "abstract"}, {"offsetInBeginSection": 203, "offsetInEndSection": 421, "text": "To discern the neurophysiologic correlates of its therapeutic effects, we applied MRgHIFU to an intractable neurologic disorder, essential tremor, while measuring magnetoencephalogram mu rhythms from the motor cortex. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25438838", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "MRI Guided Focused Ultrasound Thalamotomy for Moderate-to-Severe Tremor in Parkinson's Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "title"}, {"offsetInBeginSection": 88, "offsetInEndSection": 416, "text": "Methods. Seven PD patients, mean age 59.4 \u00b1 9.8 years (range, 46-74) with a mean disease duration of 5.4 \u00b1 2.8 years (range, 2-10) suffering from severe refractory tremor, underwent ventral intermediate nucleus thalamotomy using MRI guided focused ultrasound (MRgFUS), an innovative technology that enables noninvasive surgery. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "abstract"}, {"offsetInBeginSection": 1016, "offsetInEndSection": 1078, "text": "Thalamotomy using MRgFUS is safe and effective in PD patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Evolution of Movement Disorders Surgery Leading to Contemporary Focused Ultrasound Therapy for Tremor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26499271", "endSection": "title"}, {"offsetInBeginSection": 338, "offsetInEndSection": 463, "text": "A noninvasive approach using transcranial high-energy focused ultrasound has emerged for the treatment of intractable tremor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26499271", "endSection": "abstract"}, {"offsetInBeginSection": 649, "offsetInEndSection": 775, "text": "This article describes the evolution of magnetic resonance-guided focused ultrasound for ventrolateral thalamotomy for tremor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26499271", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Thalamic connectivity in patients with essential tremor treated with MR imaging-guided focused ultrasound: in vivo fiber tracking by using diffusion-tensor MR imaging.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24620914", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 763, "text": "PURPOSE: To use diffusion-tensor (DT) magnetic resonance (MR) imaging in patients with essential tremor who were treated with transcranial MR imaging-guided focused ultrasound lesion inducement to identify the structural connectivity of the ventralis intermedius nucleus of the thalamus and determine how DT imaging changes correlated with tremor changes after lesion inducement.MATERIALS AND METHODS: With institutional review board approval, and with prospective informed consent, 15 patients with medication-refractory essential tremor were enrolled in a HIPAA-compliant pilot study and were treated with transcranial MR imaging-guided focused ultrasound surgery targeting the ventralis intermedius nucleus of the thalamus contralateral to their dominant hand.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24620914", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "A pilot study of focused ultrasound thalamotomy for essential tremor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "title"}, {"offsetInBeginSection": 168, "offsetInEndSection": 585, "text": "This preliminary study investigates the use of transcranial MRI-guided focused ultrasound thalamotomy for the treatment of essential tremor.METHODS: From February 2011 through December 2011, in an open-label, uncontrolled study, we used transcranial MRI-guided focused ultrasound to target the unilateral ventral intermediate nucleus of the thalamus in 15 patients with severe, medication-refractory essential tremor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "abstract"}, {"offsetInBeginSection": 1599, "offsetInEndSection": 1729, "text": "CONCLUSIONS: In this pilot study, essential tremor improved in 15 patients treated with MRI-guided focused ultrasound thalamotomy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523144", "endSection": "title"}, {"offsetInBeginSection": 383, "offsetInEndSection": 566, "text": "MR-guided focused ultrasound has been developed as a non-invasive means of generating precisely placed focal lesions. We examined its application to the management of essential tremor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523144", "endSection": "abstract"}, {"offsetInBeginSection": 653, "offsetInEndSection": 818, "text": "Four patients with chronic and medication-resistant essential tremor were treated with MR-guided focused ultrasound to ablate tremor-mediating areas of the thalamus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523144", "endSection": "abstract"}, {"offsetInBeginSection": 1540, "offsetInEndSection": 1739, "text": "INTERPRETATION: MR-guided focused ultrasound might be a safe and effective approach to generation of focal intracranial lesions for the management of disabling, medication-resistant essential tremor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523144", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Transcranial magnetic resonance imaging-guided focused ultrasound: noninvasive central lateral thalamotomy for chronic neuropathic pain.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22208894", "endSection": "title"}, {"offsetInBeginSection": 147, "offsetInEndSection": 493, "text": "The goal of this study was to apply the new transcranial magnetic resonance imaging-guided focused ultrasound (tcMRgFUS) technology to perform noninvasive central lateral thalamotomies (CLTs) as a treatment for chronic neuropathic pain.METHODS: In 12 patients suffering from chronic therapy-resistant neuropathic pain, tcMRgFUS CLT was proposed. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22208894", "endSection": "abstract"}, {"offsetInBeginSection": 2063, "offsetInEndSection": 2225, "text": "CONCLUSIONS: The authors assert that tcMRgFUS represents a noninvasive, precise, and radiation-free neurosurgical technique for the treatment of neuropathic pain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22208894", "endSection": "abstract"}, {"offsetInBeginSection": 481, "offsetInEndSection": 585, "text": "A new less invasive treatment of tremor using MR guided focused ultrasound has started and is promising.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24291848", "endSection": "abstract"}, {"offsetInBeginSection": 1541, "offsetInEndSection": 1729, "text": "Quality-of-life scores improved from 37% to 11% (P=0.001).CONCLUSIONS: In this pilot study, essential tremor improved in 15 patients treated with MRI-guided focused ultrasound thalamotomy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "abstract"}, {"offsetInBeginSection": 96, "offsetInEndSection": 413, "text": "Seven PD patients, mean age 59.4 \u00b1 9.8 years (range, 46-74) with a mean disease duration of 5.4 \u00b1 2.8 years (range, 2-10) suffering from severe refractory tremor, underwent ventral intermediate nucleus thalamotomy using MRI guided focused ultrasound (MRgFUS), an innovative technology that enables noninvasive surgery", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "abstract"}, {"offsetInBeginSection": 490, "offsetInEndSection": 975, "text": "We hypothesized that all three would effectively treat the dominant hand and positively impact functional outcomes and quality of life as measured with the Clinical Rating Scale for Tremor and the Quality of Life in Essential Tremor Questionnaire.This is a retrospective study of medication-refractory essential tremor patients treated at the University of Virginia with bilateral Vim DBS (n\u2009=\u200957), unilateral Vim DBS (n\u2009=\u200913), or unilateral focused ultrasound Vim thalamotomy (n\u2009=\u200915)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26769606", "endSection": "abstract"}, {"offsetInBeginSection": 1510, "offsetInEndSection": 1684, "text": "Quality-of-life scores improved from 37% to 11% (P=0.001).In this pilot study, essential tremor improved in 15 patients treated with MRI-guided focused ultrasound thalamotomy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "MRI Guided Focused Ultrasound Thalamotomy for Moderate-to-Severe Tremor in Parkinsons Disease", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "title"}, {"offsetInBeginSection": 97, "offsetInEndSection": 415, "text": "Seven PD patients, mean age 59.4 \u00b1 9.8 years (range, 46-74) with a mean disease duration of 5.4 \u00b1 2.8 years (range, 2-10) suffering from severe refractory tremor, underwent ventral intermediate nucleus thalamotomy using MRI guided focused ultrasound (MRgFUS), an innovative technology that enables noninvasive surgery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 553, "text": "Transcranial magnetic resonance imaging-guided high-intensity focused ultrasound (MRgHIFU) is gaining attention as a potent substitute for surgical intervention in the treatment of neurologic disorders. To discern the neurophysiologic correlates of its therapeutic effects, we applied MRgHIFU to an intractable neurologic disorder, essential tremor, while measuring magnetoencephalogram mu rhythms from the motor cortex. Focused ultrasound sonication destroyed tissues by focusing a high-energy beam on the ventralis intermedius nucleus of the thalamus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25438838", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 585, "text": "BACKGROUND: Recent advances have enabled delivery of high-intensity focused ultrasound through the intact human cranium with magnetic resonance imaging (MRI) guidance. This preliminary study investigates the use of transcranial MRI-guided focused ultrasound thalamotomy for the treatment of essential tremor.METHODS: From February 2011 through December 2011, in an open-label, uncontrolled study, we used transcranial MRI-guided focused ultrasound to target the unilateral ventral intermediate nucleus of the thalamus in 15 patients with severe, medication-refractory essential tremor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "MRI Guided Focused Ultrasound Thalamotomy for Moderate-to-Severe Tremor in Parkinson's Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "132\u2003A Randomized, Sham-Controlled Trial of Transcranial Magnetic Resonance-Guided Focused Ultrasound Thalamotomy Trial for the Treatment of Tremor-Dominant, Idiopathic Parkinson Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399411", "endSection": "title"}, {"offsetInBeginSection": 1572, "offsetInEndSection": 1689, "text": "In this pilot study, essential tremor improved in 15 patients treated with MRI-guided focused ultrasound thalamotomy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27557301", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523144", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Unilateral magnetic resonance guided focused ultrasound thalamotomy for essential tremor: practices and clinicoradiological outcomes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24876191", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Functional assessment and quality of life in essential tremor with bilateral or unilateral DBS and focused ultrasound thalamotomy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26769606", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Transcranial magnetic resonance imaging-guided focused ultrasound: noninvasive central lateral thalamotomy for chronic neuropathic pain.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22208894", "endSection": "title"}, {"offsetInBeginSection": 738, "offsetInEndSection": 977, "text": "This is a retrospective study of medication-refractory essential tremor patients treated at the University of Virginia with bilateral Vim DBS (n\u2009=\u200957), unilateral Vim DBS (n\u2009=\u200913), or unilateral focused ultrasound Vim thalamotomy (n\u2009=\u200915).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26769606", "endSection": "abstract"}, {"offsetInBeginSection": 635, "offsetInEndSection": 776, "text": "Twenty-one consecutive patients suffering from chronic (mean disease duration 29.9\u00a0years), therapy-resistant ET were treated with MRgFUS CTT.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26877873", "endSection": "abstract"}]}, {"body": "What are the effects of depleting protein  km23-1 (DYNLRB1)  in a cell?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15925487", "http://www.ncbi.nlm.nih.gov/pubmed/19711352", "http://www.ncbi.nlm.nih.gov/pubmed/17420258", "http://www.ncbi.nlm.nih.gov/pubmed/22637579", "http://www.ncbi.nlm.nih.gov/pubmed/23079622", "http://www.ncbi.nlm.nih.gov/pubmed/16778097", "http://www.ncbi.nlm.nih.gov/pubmed/19571232"], "triples": [{"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject", "s": "http://linkedlifedata.com/resource/#_41324156523900B", "o": "http://linkedlifedata.com/resource/#_41324156523900A"}], "ideal_answer": ["The knockdown of km23-1 results in numerous effects at the cellular level, such as decreased cell migration. Additionaly, km23-1 is involved in signalling pathways and its knockdown results in decreased RhoA activation, inhibition of TGF\u03b2-mediated activation of ERK and JNK, phosphorylation of c-Jun, transactivation of the c-Jun promoter and decreased TGFbeta responses."], "exact_answer": [["inhibition of cell migration of human colon carcinoma cells (HCCCs) in wound-healing assays"], ["decreased RhoA activation"], ["inhibition of TGF\u03b2-mediated activation of ERK and JNK"], ["phosphorylation of c-Jun"], ["transactivation of the c-Jun promoter"], ["decreased key TGFbeta responses"]], "concepts": ["http://www.uniprot.org/uniprot/DLRB1_HUMAN"], "type": "list", "id": "515a7ffdd24251bc050000a5", "snippets": [{"offsetInBeginSection": 797, "offsetInEndSection": 1156, "text": "Finally, our results demonstrated for the first time that depletion of km23-1 inhibited cell migration of human colon carcinoma cells (HCCCs) in wound-healing assays. Overall, our findings demonstrate that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting that km23-1 may represent a novel target for anti-metastatic therapy.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23079622", "endSection": "sections.0"}, {"offsetInBeginSection": 650, "offsetInEndSection": 798, "text": "Further, knockdown of km23-1 inhibited TGF\u03b2-mediated activation of ERK and JNK, phosphorylation of c-Jun, and transactivation of the c-Jun promoter.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22637579", "endSection": "sections.0"}, {"offsetInBeginSection": 719, "offsetInEndSection": 795, "text": "knockdown (KD) of km23-1 decreased RhoA activation in Mv1Lu epithelial cells", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23079622", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "We have previously reported that the dynein light chain (DLC) km23-1 is required for Smad2-dependent TGFbeta signaling.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19711352", "endSection": "sections.0"}, {"offsetInBeginSection": 701, "offsetInEndSection": 894, "text": "Blockade of km23-1 using a small interfering RNA approach resulted in a reduction in both total intracellular Smad2 levels and in nuclear levels of phosphorylated Smad2 after TGFbeta treatment.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17420258", "endSection": "sections.0"}, {"offsetInBeginSection": 572, "offsetInEndSection": 741, "text": "Blockade of km23 using small interfering RNAs significantly decreased key TGFbeta responses, including induction of fibronectin expression and inhibition of cell growth.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15925487", "endSection": "sections.0"}, {"offsetInBeginSection": 1236, "offsetInEndSection": 1446, "text": "On the other hand, inhibiting the endogenous DYNLRB1 with gene-specific small interfering RNA or pharmacologically with a specific inhibitor (vanadate) led to a significant (P < 0.05) decrease in folate uptake.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19571232", "endSection": "sections.0"}, {"offsetInBeginSection": 189, "offsetInEndSection": 361, "text": "Functional studies showed that some mutations disrupt km23 function, resulting in aberrant transforming growth factor-beta signaling and presumably enhanced tumorigenicity.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16778097", "endSection": "sections.0"}]}, {"body": "Which receptors are targeted by a drug Macitentan?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22311911", "http://www.ncbi.nlm.nih.gov/pubmed/22862294", "http://www.ncbi.nlm.nih.gov/pubmed/23192269", "http://www.ncbi.nlm.nih.gov/pubmed/23830395", "http://www.ncbi.nlm.nih.gov/pubmed/24122306", "http://www.ncbi.nlm.nih.gov/pubmed/23984728", "http://www.ncbi.nlm.nih.gov/pubmed/23900878", "http://www.ncbi.nlm.nih.gov/pubmed/23077657", "http://www.ncbi.nlm.nih.gov/pubmed/22458347", "http://www.ncbi.nlm.nih.gov/pubmed/21611927", "http://www.ncbi.nlm.nih.gov/pubmed/21541781", "http://www.ncbi.nlm.nih.gov/pubmed/18780830", "http://www.ncbi.nlm.nih.gov/pubmed/24297706", "http://www.ncbi.nlm.nih.gov/pubmed/22189899", "http://www.ncbi.nlm.nih.gov/pubmed/20730702", "http://www.ncbi.nlm.nih.gov/pubmed/19765655", "http://www.ncbi.nlm.nih.gov/pubmed/21403842", "http://www.ncbi.nlm.nih.gov/pubmed/24122797", "http://www.ncbi.nlm.nih.gov/pubmed/23204120", "http://www.ncbi.nlm.nih.gov/pubmed/23817130", "http://www.ncbi.nlm.nih.gov/pubmed/23353592", "http://www.ncbi.nlm.nih.gov/pubmed/21175577", "http://www.ncbi.nlm.nih.gov/pubmed/24261583", "http://www.ncbi.nlm.nih.gov/pubmed/23568224", "http://www.ncbi.nlm.nih.gov/pubmed/23682110", "http://www.ncbi.nlm.nih.gov/pubmed/22348175", "http://www.ncbi.nlm.nih.gov/pubmed/23068290", "http://www.ncbi.nlm.nih.gov/pubmed/21670421", "http://www.ncbi.nlm.nih.gov/pubmed/22525377", "http://www.ncbi.nlm.nih.gov/pubmed/23829793", "http://www.ncbi.nlm.nih.gov/pubmed/23997048"], "ideal_answer": ["Endothelin receptor A and endothelin receptor B are targeted by a drug Macitentan. Macitentan is a potent, orally active, non-peptide dual antagonist of endothelin receptors A and B that is approved for the treatment of pulmonary arterial hypertension."], "exact_answer": [["endothelin receptor A"], ["endothelin receptor B"]], "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0004872", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011955", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004364"], "type": "list", "id": "5335d4e8d6d3ac6a34000053", "snippets": [{"offsetInBeginSection": 17, "offsetInEndSection": 168, "text": "Macitentan is a novel dual endothelin receptor antagonist with sustained receptor binding in clinical development for pulmonary arterial hypertension. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23817130", "endSection": "abstract"}, {"offsetInBeginSection": 63, "offsetInEndSection": 304, "text": "This prospective, randomised, double-blind, multicentre, parallel-group, placebo-controlled phase II trial (NCT00903331) investigated the efficacy and safety of the endothelin receptor antagonist macitentan in idiopathic pulmonary fibrosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23682110", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23568224", "endSection": "title"}, {"offsetInBeginSection": 27, "offsetInEndSection": 243, "text": "Macitentan is a potent, orally active, non-peptide antagonist of endothelin receptors with tissue-targeting properties, currently undergoing clinical development for the treatment of pulmonary arterial hypertension. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23568224", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23353592", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Macitentan is a new non-selective endothelin-1 receptor antagonist under development for the treatment of pulmonary arterial hypertension. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23353592", "endSection": "abstract"}, {"offsetInBeginSection": 532, "offsetInEndSection": 796, "text": "This article highlights how the introduction of new compounds such as macitentan, riociguat and selexipag, which act on the endothelin, nitric oxide and prostacyclin pathways, respectively, have the potential to further improve the prognosis for patients with PAH.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204120", "endSection": "abstract"}, {"offsetInBeginSection": 342, "offsetInEndSection": 503, "text": "Dual ETRA/ETRB blockade with macitentan (or the combination of the ETRA and ETRB antagonists BQ123 and BQ788) did not enhance antitumor immune cell recruitment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23192269", "endSection": "abstract"}, {"offsetInBeginSection": 310, "offsetInEndSection": 433, "text": "The novel ERA macitentan has recently concluded testing in a Phase III morbidity/mortality clinical trial in PAH patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23077657", "endSection": "abstract"}, {"offsetInBeginSection": 448, "offsetInEndSection": 781, "text": "Given that the newest PAH drugs include a receptor tyrosine kinase antagonist (imatinib), a soluble guanylate cyclase stimulator (riociguat), an oral analog of prostacyclin (selexipag), and a tissue targeting ERA (macitentan) determination of appropriate combinations for various etiologies and clinical stages is urgently required. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23068290", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 188, "text": "The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22862294", "endSection": "title"}, {"offsetInBeginSection": 285, "offsetInEndSection": 572, "text": "Among these, compound 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ET(A) with significant affinity for the ET(B) receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22862294", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22525377", "endSection": "title"}, {"offsetInBeginSection": 230, "offsetInEndSection": 386, "text": "Here we investigated the effects of macitentan, an orally-active, tissue-targeting dual ET receptor antagonist on chronic complications in type 2 diabetes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22525377", "endSection": "abstract"}, {"offsetInBeginSection": 2936, "offsetInEndSection": 3233, "text": "Several specific therapeutic agents were developed for the medical management of PAH including prostanoids (epoprostenol, trepoprostenil, iloprost), endothelin receptor antagonists (bosentan, ambrisentan, macitentan soon available) and phosphodiesterase type 5 inhibitors (sildenafil, tadalafil). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23829793", "endSection": "abstract"}, {"offsetInBeginSection": 845, "offsetInEndSection": 1229, "text": "The aim of the present study is to evaluate the in vitro effect of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist, and its major metabolite (ACT-132577) on alpha smooth muscle actin (alphaSMA) expression, evaluated on dermal fibroblasts from healthy subjects and on dermal fibroblasts from lesional and non-lesional skin from sclerodermic patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23830395", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23900878", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 266, "text": "This multiple-ascending-dose study investigated safety, tolerability, pharmacokinetics, and pharmacodynamics, of macitentan, a new endothelin receptor antagonist (ERA) with sustained receptor binding and enhanced tissue penetration properties compared to other ERAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23900878", "endSection": "abstract"}, {"offsetInBeginSection": 167, "offsetInEndSection": 324, "text": "We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end point of morbidity and mortality in a long-term trial.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984728", "endSection": "abstract"}, {"offsetInBeginSection": 659, "offsetInEndSection": 866, "text": "Many clinical studies targeting the vasoconstrictor ET-1 pathway with receptor antagonists like bosentan and ambrisentan have shown strong results, even more optimism coming from macitentan, the newest drug.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23997048", "endSection": "abstract"}, {"offsetInBeginSection": 731, "offsetInEndSection": 967, "text": "Promising candidates include tyrosine kinase antagonists (e.g. imatinib); soluble guanylate cyclase stimulators (riociguat); an oral analog of prostacyclin (selexipag); and a tissue targeting endothelin receptor antagonist (macitentan).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24122306", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24122797", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24261583", "endSection": "title"}, {"offsetInBeginSection": 14, "offsetInEndSection": 116, "text": "Macitentan is a novel dual endothelin receptor antagonist (ERA) showing sustained receptor occupancy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24261583", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Macitentan (Opsumit\u00ae) is a novel dual endothelin receptor antagonist (ERA) with sustained receptor binding properties developed by Actelion Pharmaceuticals Ltd. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24297706", "endSection": "abstract"}, {"offsetInBeginSection": 566, "offsetInEndSection": 698, "text": "Endothelin (ET)-1 influences pathological changes via two ET receptor subtypes (ETA and ETB), to which it binds with high affinity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24297706", "endSection": "abstract"}, {"offsetInBeginSection": 1191, "offsetInEndSection": 1359, "text": "Macitentan was developed by modifying the structure of bosentan in the search for an optimal dual ERA with improved efficacy and tolerability compared with other ERAs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24297706", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22458347", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Macitentan is a tissue-targeting, dual endothelin receptor antagonist, currently under phase 3 investigation in pulmonary arterial hypertension. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22458347", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22348175", "endSection": "title"}, {"offsetInBeginSection": 619, "offsetInEndSection": 806, "text": "The nonselective endothelin type A and B receptor antagonists bosentan (100 nmol/L) and macitentan (30 nmol/L) alone relaxed endothelin-contracted rings by 30\u00b15% and 24\u00b13%, respectively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22311911", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Macitentan is a dual endothelin receptor antagonist under phase 3 investigation in pulmonary arterial hypertension.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22189899", "endSection": "abstract"}, {"offsetInBeginSection": 1194, "offsetInEndSection": 1387, "text": "This rise could largely be prevented with the endothelin receptor antagonist macitentan (\u0394BP: 12.3\u00b11.5 mm Hg) and only mildly with Tempol, a superoxide dismutase mimetic (\u0394BP: 25.9\u00b12.3 mm Hg). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21670421", "endSection": "abstract"}, {"offsetInBeginSection": 409, "offsetInEndSection": 643, "text": "Promising study results for the treatment of IPF were published for the triple tyrosine kinase inhibitor intedanib, other drugs such as the endothelin receptor antagonist (ERA) macitentan are currently investigated in clinical trials.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21611927", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 174, "text": "To study the pharmacokinetics, pharmacodynamics, and tolerability of rising single doses of macitentan, an endothelin receptor antagonist, in healthy male subjects. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21541781", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 208, "text": "Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21403842", "endSection": "title"}, {"offsetInBeginSection": 184, "offsetInEndSection": 354, "text": "We investigated the therapeutic efficacy of the dual ETR antagonist, macitentan, on human ovarian cancer cells, SKOV3ip1 and IGROV1, growing orthotopically in nude mice. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21403842", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20730702", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 320, "text": "Macitentan (ACT-064992), under development by Actelion Ltd in collaboration with Japanese licensee Nippon Shinyaku Co Ltd, is an orally active, non-peptide dual endothelin (ET)(A) and ET(B) receptor antagonist for the potential treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20730702", "endSection": "abstract"}, {"offsetInBeginSection": 620, "offsetInEndSection": 836, "text": "Macitentan, because of its ability to target the tissues and to block both ET(A) and ET(B) receptors, is emerging as a new agent to treat cardiovascular disorders associated with chronic tissue ET system activation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20730702", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19765655", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Macitentan (ACT-064992) is an orally active endothelin receptor antagonist. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19765655", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18780830", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 246, "text": "Macitentan, also called Actelion-1 or ACT-064992 [N-[5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)-pyrimidin-4-yl]-N'-propylaminosulfonamide], is a new dual ET(A)/ET(B) endothelin (ET) receptor antagonist designed for tissue targeting.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18780830", "endSection": "abstract"}, {"offsetInBeginSection": 520, "offsetInEndSection": 1013, "text": "Macitentan and its metabolite antagonized the specific binding of ET-1 on membranes of cells overexpressing ET(A) and ET(B) receptors and blunted ET-1-induced calcium mobilization in various natural cell lines, with inhibitory constants within the nanomolar range. In functional assays, macitentan and ACT-132577 inhibited ET-1-induced contractions in isolated endothelium-denuded rat aorta (ET(A) receptors) and sarafotoxin S6c-induced contractions in isolated rat trachea (ET(B) receptors). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18780830", "endSection": "abstract"}, {"offsetInBeginSection": 1362, "offsetInEndSection": 1560, "text": "In conclusion, macitentan, by its tissue-targeting properties and dual antagonism of ET receptors, protects against end-organ damage in diabetes and improves survival in pulmonary hypertensive rats.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18780830", "endSection": "abstract"}]}, {"body": "Which T-UCRs have been implicated in lung cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29180617", "http://www.ncbi.nlm.nih.gov/pubmed/30195756"], "ideal_answer": ["Transcribed ultraconserved regions (T-UCRs) classified as long non-coding RNAs (Lnc-RNAs) are transcripts longer than 200-nt RNA with no protein-coding capacity. The clinicopathologic significance and regulatory mechanism of T-UCRs in lung cancer (LC) remain largely unknown. Uc.454 is downregulated in both non-small-cell LC (NSCLC) tissues and LC cell lines, and the downregulated uc.454 is associated with tumor size and tumors with more advanced stages. Transfection with uc.454 markedly induces apoptosis and inhibites cell proliferation in SPC-A-1 and NCI-H2170 LC cell lines. Thus uc.454 potentially plays a suppressive role in LC. Transcribed uc.339 is upregulated in archival NSCLC samples, functioning as a decoy RNA for miR-339-3p, -663b-3p, and -95-5p. As a result, Cyclin E2, a direct target of all these microRNAs is upregulated, promoting cancer growth and migration. Modulation of uc.339 affects microRNA expression. However, overexpression or downregulation of these microRNAs causes no significant variations in uc.339 levels."], "exact_answer": [["uc.454"], ["uc.339"]], "type": "list", "id": "5e36a901b5b409ea53000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "uc.454 Inhibited Growth by Targeting Heat Shock Protein Family A Member 12B in Non-Small-Cell Lung Cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30195756", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1246, "text": "Transcribed ultraconserved regions (T-UCRs) classified as long non-coding RNAs (Lnc-RNAs) are transcripts longer than 200-nt RNA with no protein-coding capacity. Previous studies showed that T-UCRs serve as novel oncogenes, or tumor suppressors are involved in tumorigenesis and cancer progressive. Nevertheless, the clinicopathologic significance and regulatory mechanism of T-UCRs in lung cancer (LC) remain largely unknown. We found that uc.454 was downregulated in both non-small-cell LC (NSCLC) tissues and LC\u00a0cell lines, and the downregulated uc.454 is associated with tumor size and tumors with more advanced stages. Transfection with uc.454 markedly induced apoptosis and\u00a0inhibited cell proliferation in SPC-A-1 and NCI-H2170 LC cell lines. Above results suggested that uc.454 played a suppressive role in LC. Heat shock protein family\u00a0A member 12B (HSPA12B) protein was negatively regulated by uc.454 at the posttranscriptional level by dual-luciferase reporter assay and affected the expressions of Bcl-2 family members, which finally induced LC apoptosis. The uc.454/HSPA12B axis furthers our understanding of the molecular mechanisms involved in tumor apoptosis, which may potentially serve as a therapeutic target for lung carcinoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30195756", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29180617", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1006, "text": "The transcribed ultraconserved regions (T-UCRs) encode long non-coding RNAs implicated in human carcinogenesis. Their mechanisms of action and the factors regulating their expression in cancers are poorly understood. Here we show that high expression of uc.339 correlates with lower survival in 210 non-small cell lung cancer (NSCLC) patients. We provide evidence from cell lines and primary samples that TP53 directly regulates uc.339. We find that transcribed uc.339 is upregulated in archival NSCLC samples, functioning as a decoy RNA for miR-339-3p, -663b-3p, and -95-5p. As a result, Cyclin E2, a direct target of all these microRNAs is upregulated, promoting cancer growth and migration. Finally, we find that modulation of uc.339 affects microRNA expression. However, overexpression or downregulation of these microRNAs causes no\u00a0significant variations in uc.339 levels, suggesting a type of interaction for uc.339 that we call \"entrapping\". Our results support a key role for uc.339 in lung cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29180617", "endSection": "abstract"}, {"offsetInBeginSection": 949, "offsetInEndSection": 1006, "text": "Our results support a key role for uc.339 in lung cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29180617", "endSection": "abstract"}, {"offsetInBeginSection": 217, "offsetInEndSection": 343, "text": "Here we show that high expression of uc.339 correlates with lower survival in 210 non-small cell lung cancer (NSCLC) patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29180617", "endSection": "abstract"}, {"offsetInBeginSection": 1067, "offsetInEndSection": 1246, "text": "The uc.454/HSPA12B axis furthers our understanding of the molecular mechanisms involved in tumor apoptosis, which may potentially serve as a therapeutic target for lung carcinoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30195756", "endSection": "abstract"}, {"offsetInBeginSection": 749, "offsetInEndSection": 817, "text": "Above results suggested that uc.454 played a suppressive role in LC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30195756", "endSection": "abstract"}, {"offsetInBeginSection": 1067, "offsetInEndSection": 1247, "text": "The uc.454/HSPA12B axis furthers our understanding of the molecular mechanisms involved in tumor apoptosis, which may potentially serve as a therapeutic target for lung carcinoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30195756", "endSection": "abstract"}, {"offsetInBeginSection": 427, "offsetInEndSection": 624, "text": "We found that uc.454 was downregulated in both non-small-cell LC (NSCLC) tissues and LC\u00a0cell lines, and the downregulated uc.454 is associated with tumor size and tumors with more advanced stages.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30195756", "endSection": "abstract"}, {"offsetInBeginSection": 624, "offsetInEndSection": 749, "text": "Transfection with uc.454 markedly induced apoptosis and\u00a0inhibited cell proliferation in SPC-A-1 and NCI-H2170 LC cell lines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30195756", "endSection": "abstract"}, {"offsetInBeginSection": 949, "offsetInEndSection": 1007, "text": "Our results support a key role for uc.339 in lung cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29180617", "endSection": "abstract"}, {"offsetInBeginSection": 217, "offsetInEndSection": 344, "text": "Here we show that high expression of uc.339 correlates with lower survival in 210 non-small cell lung cancer (NSCLC) patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29180617", "endSection": "abstract"}]}, {"body": "List R packages for lipidomics", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30977807", "http://www.ncbi.nlm.nih.gov/pubmed/30500173", "http://www.ncbi.nlm.nih.gov/pubmed/28989334", "http://www.ncbi.nlm.nih.gov/pubmed/32168452"], "ideal_answer": ["R packages for lipidomics: lipidomics, masspix, lipidms, lipidr and lipid mini-on.", "R packages for lipidomics include: lipidr, masspix, lipidms, lipidr and lipid mini-on.", "Lipidomics, masspix, lipidms, lipidr and lipid mini-on are R packages for lipidomics.", "Lipid Mini-On, lipidr, LipidMS and massPix"], "exact_answer": [["massPix"], ["LipidMS"], ["lipidr"], ["Lipid Mini-On"]], "type": "list", "id": "6060838e94d57fd879000042", "snippets": [{"offsetInBeginSection": 161, "offsetInEndSection": 265, "text": "We have developed massPix-an R package for analysing and interpreting data from MSI of lipids in tissue.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28989334", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Lipid Mini-On: mining and ontology tool for enrichment analysis of lipidomic data.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30977807", "endSection": "title"}, {"offsetInBeginSection": 9, "offsetInEndSection": 513, "text": "Here we introduce Lipid Mini-On, an open-source tool that performs lipid enrichment analyses and visualizations of lipidomics data. Lipid Mini-On uses a text-mining process to bin individual lipid names into multiple lipid ontology groups based on the classification (e.g. LipidMaps) and other characteristics, such as chain length. Lipid Mini-On provides users with the capability to conduct enrichment analysis of the lipid ontology terms using a Shiny app with options of five statistical approaches. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30977807", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "lipidr: A Software Tool for Data Mining and Analysis of Lipidomics Datasets.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32168452", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1524, "text": "The rapid evolution of mass spectrometry (MS)-based lipidomics has enabled the simultaneous measurement of numerous lipid classes. With lipidomics datasets becoming increasingly available, lipidomic-focused software tools are required to facilitate data analysis as well as mining of public datasets, integrating lipidomics-unique molecular information such as lipid class, chain length, and unsaturation. To address this need, we developed lipidr, an open-source R/Bioconductor package for data mining and analysis of lipidomics datasets. lipidr implements a comprehensive lipidomic-focused analysis workflow for targeted and untargeted lipidomics. lipidr imports numerical matrices, Skyline exports, and Metabolomics Workbench files directly into R, automatically inferring lipid class and chain information from lipid names. Through integration with the Metabolomics Workbench API, users can search, download, and reanalyze public lipidomics datasets seamlessly. lipidr allows thorough data inspection, normalization, and uni- and multivariate analyses, displaying results as interactive visualizations. To enable interpretation of lipid class, chain length, and total unsaturation data, we also developed and implemented a novel lipid set enrichment analysis. A companion online guide with two live example datasets is presented at https://www.lipidr.org/. We expect that the ease of use and innovative features of lipidr will allow the lipidomics research community to gain novel detailed insights from lipidomics data.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32168452", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "LipidMS: An R Package for Lipid Annotation in Untargeted Liquid Chromatography-Data Independent Acquisition-Mass Spectrometry Lipidomics.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30500173", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 480, "text": "High resolution LC-MS untargeted lipidomics using data independent acquisition (DIA) has the potential to increase lipidome coverage, as it enables the continuous and unbiased acquisition of all eluting ions. However, the loss of the link between the precursor and the product ions combined with the high dimensionality of DIA data sets hinder accurate feature annotation. Here, we present LipidMS, an R package aimed to confidently identify lipid species in untargeted LC-DIA-MS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30500173", "endSection": "abstract"}]}, {"body": "List the main salt-inducible kinases.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33688765", "http://www.ncbi.nlm.nih.gov/pubmed/33989615", "http://www.ncbi.nlm.nih.gov/pubmed/34350957", "http://www.ncbi.nlm.nih.gov/pubmed/34196217", "http://www.ncbi.nlm.nih.gov/pubmed/33148508", "http://www.ncbi.nlm.nih.gov/pubmed/34056256", "http://www.ncbi.nlm.nih.gov/pubmed/33861845"], "ideal_answer": ["SIK1\nSIK2\nSIK3\nHDAC4\nHDAC5"], "exact_answer": [["SIK1"], ["SIK2"], ["SIK3"], ["HDAC4"], ["HDAC5"]], "type": "list", "id": "621b806c3a8413c653000040", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "PTHrP targets salt-inducible kinases, HDAC4 and HDAC5,", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33148508", "endSection": "title"}, {"offsetInBeginSection": 372, "offsetInEndSection": 563, "text": ". SIKs (salt-inducible kinases) are a subfamily of the AMP-activated protein kinase family that play a critical role in metabolic diseases including hepatic lipogenesis and glucose metabolism", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34196217", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 346, "text": "Salt-inducible kinases (SIKs) represent a subfamily of AMPK family kinases. SIK1 has been shown to act as a mediator during the cellular adaptation to variations in intracellular sodium in a variety of cell types. SIK2, as an isoform of the SIK family, modulates various biological functions and acts as a signal transmitter in various pathways. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33688765", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 281, "text": "Type 1 salt-inducible kinases (SIK1) has been shown to act as a mediator during the cellular adaptation to variations in intracellular sodium in a variety of cell types. Type 2 SIK (SIK2) modulates various biological functions and acts as a signal transmitter in various pathways. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33989615", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 222, "text": "Salt-inducible kinases (SIKs) are calcium/calmodulin-dependent protein kinase (CAMK)-like (CAMKL) family members implicated in insulin signal transduction, metabolic regulation, inflammatory response, and other processes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34056256", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 237, "text": "The salt-inducible kinases, SIK1, SIK2 and SIK3, most closely resemble the AMP-activated protein kinase (AMPK) and other AMPK-related kinases, and like these family members they require phosphorylation by LKB1 to be catalytically active.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33861845", "endSection": "abstract"}, {"offsetInBeginSection": 313, "offsetInEndSection": 406, "text": "The first is the activation of the salt-inducible kinases (SIKs; SIK2 and SIK3) by Na+ stress", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34350957", "endSection": "abstract"}]}, {"body": "What 3 organs are the sphincter of Oddi associated with?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7991969", "http://www.ncbi.nlm.nih.gov/pubmed/3058076", "http://www.ncbi.nlm.nih.gov/pubmed/15836453", "http://www.ncbi.nlm.nih.gov/pubmed/11900681", "http://www.ncbi.nlm.nih.gov/pubmed/15143221", "http://www.ncbi.nlm.nih.gov/pubmed/6065875", "http://www.ncbi.nlm.nih.gov/pubmed/3653618", "http://www.ncbi.nlm.nih.gov/pubmed/8419235", "http://www.ncbi.nlm.nih.gov/pubmed/10409171", "http://www.ncbi.nlm.nih.gov/pubmed/31951513", "http://www.ncbi.nlm.nih.gov/pubmed/7549047", "http://www.ncbi.nlm.nih.gov/pubmed/3049055", "http://www.ncbi.nlm.nih.gov/pubmed/2666281", "http://www.ncbi.nlm.nih.gov/pubmed/2052626", "http://www.ncbi.nlm.nih.gov/pubmed/8026537", "http://www.ncbi.nlm.nih.gov/pubmed/19799700"], "ideal_answer": ["Sphincter of Oddi is associated with the pancreatic duct, duodenum and gallbladder.", "The sphincter of Oddi is associated with the pancreatic duct, the duodenal crypts and gallbladder.", "Sphincter of Oddi (SO) is a dynamic structure located strategically at the confluence of the bile duct, the pancreatic duct and the duodenum.", "The sphincter of oddsi is associated with the pancreatic duct, the duodenal crypts and the gallbladder.", "The sphincter ofoddi is associated with the pancreatic duct, the duodenal crypts and gallbladder.", "The sphincter of Oddi is a dynamic structure located strategically at the confluence of the bile duct, the pancreatic duct and the duodenum."], "exact_answer": [["pancreas"], ["bile duct"], ["duodenum"]], "type": "list", "id": "60292e661cb411341a000112", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Sphincter of Oddi (SO) is a dynamic structure located strategically at the confluence of the bile duct, the pancreatic duct and the duodenum. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7991969", "endSection": "abstract"}, {"offsetInBeginSection": 242, "offsetInEndSection": 453, "text": "Because the sphincter of Oddi does not regulate the pancreaticobiliary junction in PBM, pancreatic juice frequently refluxes into the biliary tract and can cause various complications, including biliary cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31951513", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "The most common functional disorders of the biliary tract and pancreas are associated with disordered motility of the sphincter of Oddi (SO). Th", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15836453", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "We have investigated the existence of neural connections between the duodenum and the sphincter of Oddi (SO). St", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10409171", "endSection": "abstract"}, {"offsetInBeginSection": 555, "offsetInEndSection": 799, "text": "nd set of experiments, sphincter of Oddi was divided into two parts and the effects of field stimulation were studied separately on areas close to the duodenal papilla (area I) and areas close to the common bile duct (area II). In the whole sph", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8026537", "endSection": "abstract"}, {"offsetInBeginSection": 918, "offsetInEndSection": 1143, "text": "morphine administered prior to MR cholangiopancreatography can improve image quality by causing the sphincter of Oddi to contract, which increases pressure in and distention of the biliary and pancreatic ducts. Morphine admin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15143221", "endSection": "abstract"}, {"offsetInBeginSection": 412, "offsetInEndSection": 612, "text": "LTS: Two to 3 weeks after gallbladder injection, labeled nerve cell bodies were found in the myenteric plexus of the proximal duodenum but were rare in the duodenum distal to the sphincter of Oddi. No", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8419235", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "The sphincter of Oddi is the smooth muscle connection between the bile duct and the duodenum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3049055", "endSection": "abstract"}, {"offsetInBeginSection": 120, "offsetInEndSection": 262, "text": "The Sphincter of Oddi is a small smooth muscle sphincter strategically placed at the junction of the bile duct, pancreatic duct, and duodenum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19799700", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "The relationship of the sphincter of Oddi to the stomach, duodenum and gall-bladder.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6065875", "endSection": "title"}, {"offsetInBeginSection": 727, "offsetInEndSection": 831, "text": "There is a definite relationship between gastric antral activity and flow through the sphincter of Oddi.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6065875", "endSection": "abstract"}, {"offsetInBeginSection": 383, "offsetInEndSection": 494, "text": "The sphincter of Oddi appears to be partially autonomous but is readily affected by changes in duodenal tone.2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6065875", "endSection": "abstract"}, {"offsetInBeginSection": 892, "offsetInEndSection": 1021, "text": "Mechanical or electrical stimulation of the stomach, duodenum, or upper small bowel influences the tone of the sphincter of Oddi.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6065875", "endSection": "abstract"}, {"offsetInBeginSection": 466, "offsetInEndSection": 582, "text": "Two thirds of patients with biliary sphincter of Oddi dysfunction have elevated pancreatic basal sphincter pressure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11900681", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Major papilla pancreatic sphincter dysfunction, a variant of sphincter of Oddi dysfunction, causes pancreatitis and pancreatic-type pain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11900681", "endSection": "abstract"}, {"offsetInBeginSection": 1027, "offsetInEndSection": 1226, "text": "Biliary and pancreatic endoscopic sphincterotomies are associated with two- to fourfold increased incidence of pancreatitis following the procedure in patients with pancreatic sphincter hypertension.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11900681", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "It has been reported that interdigestive motor activities occur in the gallbladder and sphincter of Oddi as well as in the gastroduodenal tract and truncal vagus nerves modulate the gastroduodenal motility pattern.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7549047", "endSection": "abstract"}, {"offsetInBeginSection": 1043, "offsetInEndSection": 1215, "text": "The results imply that celiac branches of the vagus nerve modulate the interdigestive motor activity in the stomach, descending duodenum, gallbladder and sphincter of Oddi.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7549047", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "The sphincter of Oddi is a small sphincter which is strategically placed at the junction of the bile duct and pancreatic duct with the duodenum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2052626", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "[Lesions of the area of Oddi's sphincter: incidence and association with biliary and pancreatic lesions in a series of 109 autopsies].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3653618", "endSection": "title"}, {"offsetInBeginSection": 527, "offsetInEndSection": 801, "text": "These studies support Oddi's original description that the sphincter has a major role in the control of flow of bile and pancreatic juice into the duodenum, and equally importantly helps prevent the reflux of duodenal contents into the biliary and pancreatic ductal systems.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2666281", "endSection": "abstract"}, {"offsetInBeginSection": 1264, "offsetInEndSection": 1453, "text": "We have used the term sphincter of Oddi dysfunction to define manometric abnormalities in patients who present with signs and symptoms consistent with a biliary or pancreatic ductal origin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2666281", "endSection": "abstract"}, {"offsetInBeginSection": 641, "offsetInEndSection": 833, "text": "Chronic pancreatitis was more frequently associated with an abnormal sphincter of Oddi, but in these cases, another associated disease could explain pancreatitis (alcoholism, hemochromatosis).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3653618", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "The sphincter of Oddi (SO) is critically located at the junction of the common bile duct (CBD), main pancreatic duct, and the duodenum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3058076", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Sphincter of Oddi (SO) is a dynamic structure located strategically at the confluence of the bile duct, the pancreatic duct and the duodenum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7991969", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "The most common functional disorder of the biliary tract and pancreas relates to the activity of the Sphincter of Oddi.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19799700", "endSection": "abstract"}]}, {"body": "Which ones are the ESKAPE organisms?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22366995", "http://www.ncbi.nlm.nih.gov/pubmed/25124187", "http://www.ncbi.nlm.nih.gov/pubmed/24342634", "http://www.ncbi.nlm.nih.gov/pubmed/26139286", "http://www.ncbi.nlm.nih.gov/pubmed/21659436", "http://www.ncbi.nlm.nih.gov/pubmed/23548324", "http://www.ncbi.nlm.nih.gov/pubmed/24794971", "http://www.ncbi.nlm.nih.gov/pubmed/25232168", "http://www.ncbi.nlm.nih.gov/pubmed/24392752", "http://www.ncbi.nlm.nih.gov/pubmed/25498089", "http://www.ncbi.nlm.nih.gov/pubmed/23267668"], "ideal_answer": ["The 6 ESKAPE pathogens are Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species."], "exact_answer": [["Enterococcus faecium"], ["Staphylococcus aureus"], ["Klebsiella pneumoniae"], ["Acinetobacter baumannii"], ["Pseudomonas aeruginosa"], ["Enterobacter species"]], "type": "list", "id": "56d2ac03f22319765a000004", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 313, "text": "The aim of this study was to test in the clinic whether antimicrobial diversity affects resistance of Enterococcus faecium, Staphylococcus aureus, Klebsiella species, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species (ESKAPE) pathogens in ventilator-associated pneumonia (VAP).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21659436", "endSection": "abstract"}, {"offsetInBeginSection": 19, "offsetInEndSection": 298, "text": "Despite important geographical variations, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species (ESKAPE) pathogens constitute more than 80% of ventilator-associated pneumonia (VAP) episodes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22366995", "endSection": "abstract"}, {"offsetInBeginSection": 75, "offsetInEndSection": 375, "text": "Multidrug resistance among the 'ESKAPE' organisms - encompassing Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp. - is of particular concern because they are responsible for many serious infections in hospitals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26139286", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 388, "text": "Patients recovering from traumatic injuries or surgery often require weeks to months of hospitalization, increasing the risk for wound and surgical site infections caused by ESKAPE pathogens, which include A. baumannii (the ESKAPE pathogens are Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24342634", "endSection": "abstract"}, {"offsetInBeginSection": 117, "offsetInEndSection": 374, "text": "'ESKAPE' (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acintobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) pathogens play a major role in the rapidly changing scenario of antimicrobial resistance in the 21st century.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24392752", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 337, "text": "Although bacteremias caused by the 6 ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) have recently been highlighted as a serious complication in solid organ transplant (SOT), more information is urgently needed. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25124187", "endSection": "abstract"}, {"offsetInBeginSection": 276, "offsetInEndSection": 478, "text": "Multidrug resistance among the 'ESKAPE' organisms - encompassing Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26139286", "endSection": "abstract"}, {"offsetInBeginSection": 75, "offsetInEndSection": 376, "text": "Multidrug resistance among the 'ESKAPE' organisms - encompassing Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp. - is of particular concern because they are responsible for many serious infections in hospitals. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26139286", "endSection": "abstract"}]}, {"body": "List factors that promote lymphangiogenesis.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28087639", "http://www.ncbi.nlm.nih.gov/pubmed/28228406", "http://www.ncbi.nlm.nih.gov/pubmed/27527525", "http://www.ncbi.nlm.nih.gov/pubmed/27787629", "http://www.ncbi.nlm.nih.gov/pubmed/28723974"], "ideal_answer": ["VEGF-C\nVEGF-D\nVEGF-R3"], "exact_answer": [["VEGF-C"], ["VEGF-D"], ["VEGF-R3"]], "type": "list", "id": "5a89a20ffcd1d6a10c00000e", "snippets": [{"offsetInBeginSection": 101, "offsetInEndSection": 271, "text": "Lymphangiogenesis plays an important role in cancer progression and is regulated by a complex mechanism that includes vascular endothelial growth factor (VEGF) signaling.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27527525", "endSection": "abstract"}, {"offsetInBeginSection": 1639, "offsetInEndSection": 1733, "text": "ur results demonstrate that NHT stimulates lymphangiogenesis via upregulation of VEGF-C and -D", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27527525", "endSection": "abstract"}, {"offsetInBeginSection": 246, "offsetInEndSection": 328, "text": "Vegfc is essential for secondary angiogenesis, giving rise to veins and lymphatics", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28087639", "endSection": "abstract"}, {"offsetInBeginSection": 609, "offsetInEndSection": 755, "text": "vegfc and vegfd cooperatively control lymphangiogenesis throughout the embryo, including during the formation of the trunk lymphatic vasculature. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28087639", "endSection": "abstract"}, {"offsetInBeginSection": 823, "offsetInEndSection": 889, "text": "The signals for lymphangiogenesis, VEGF-C and its receptor VEGF-R3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28228406", "endSection": "abstract"}, {"offsetInBeginSection": 301, "offsetInEndSection": 430, "text": "Vascular endothelial growth factor (VEGF) members VEGF-C and VEGF-D are both potent candidates for stimulating lymphangiogenesis,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28723974", "endSection": "abstract"}]}, {"body": "What is the treatment of triiodothyronine toxicosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8154510", "http://www.ncbi.nlm.nih.gov/pubmed/7296908", "http://www.ncbi.nlm.nih.gov/pubmed/578375", "http://www.ncbi.nlm.nih.gov/pubmed/16042328", "http://www.ncbi.nlm.nih.gov/pubmed/16889493"], "ideal_answer": ["Treatment of T3 toxicosis is a complex medical problem because not well responsive to the various options. Usual treatment includes antithyroid drugs such as propyltiouracil, radioactive iodine or beta blockers like propanol; surgery may be also necessary in some cases."], "exact_answer": [["Propyltiouracil"], ["Radioiodine"], ["beta blockers"], ["thyroidectomy"]], "type": "list", "id": "518cb6ab310faafe08000009", "snippets": [{"offsetInBeginSection": 1346, "offsetInEndSection": 1650, "text": "Three patients met the criteria for free T3 toxicosis and three had subclinical hyperthyroidism. All six patients had either multinodular glands or a single nodule on thyroid exam. Four patients were treated with radioactive iodine or surgery, resulting in reversal of the TSH suppression in three cases.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8154510", "endSection": "sections.0"}, {"offsetInBeginSection": 69, "offsetInEndSection": 308, "text": "6 months treatment with propranolol (160 mg/day) in eight patients with T3 (triiodothyronine) toxicosis. Serum total T3 concentrations showed a significant (p less than 0.01) and sustained fall to approximately 80% of pre-treatment values.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7296908", "endSection": "sections.0"}, {"offsetInBeginSection": 490, "offsetInEndSection": 547, "text": "Both patients responded to therapy with propylthiouracil.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/578375", "endSection": "sections.0"}]}, {"body": "Which syndromes are associated with heterochromia iridum?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25971175", "http://www.ncbi.nlm.nih.gov/pubmed/22174915", "http://www.ncbi.nlm.nih.gov/pubmed/8981698", "http://www.ncbi.nlm.nih.gov/pubmed/6823113", "http://www.ncbi.nlm.nih.gov/pubmed/23840513", "http://www.ncbi.nlm.nih.gov/pubmed/21339912", "http://www.ncbi.nlm.nih.gov/pubmed/7702105", "http://www.ncbi.nlm.nih.gov/pubmed/20199465", "http://www.ncbi.nlm.nih.gov/pubmed/17878817", "http://www.ncbi.nlm.nih.gov/pubmed/1480396", "http://www.ncbi.nlm.nih.gov/pubmed/8092450", "http://www.ncbi.nlm.nih.gov/pubmed/24194866", "http://www.ncbi.nlm.nih.gov/pubmed/12825064", "http://www.ncbi.nlm.nih.gov/pubmed/3792843", "http://www.ncbi.nlm.nih.gov/pubmed/16814183", "http://www.ncbi.nlm.nih.gov/pubmed/16826074", "http://www.ncbi.nlm.nih.gov/pubmed/14166458"], "ideal_answer": ["The syndromes that are associated with heterochromia iridum are:\n1) Ascher's syndrome\n2) Waardenburg Syndrome type II (WS2)\n3) Horner's syndrome."], "exact_answer": [["Ascher's syndrome"], ["Waardenburg Syndrome type II", "WS2", "WS Type II"], ["Horner's syndrome"]], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577"], "type": "list", "id": "58b52c8822d3005309000001", "snippets": [{"offsetInBeginSection": 532, "offsetInEndSection": 797, "text": "To our knowledge, this is the first reported case of Ascher's syndrome associated with iris coloboma, heterochromia iridum, and narrowing of horizontal palpebral fissure and decreased outer intercanthal distance secondary to lengthening of lateral canthal ligament.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25971175", "endSection": "abstract"}, {"offsetInBeginSection": 604, "offsetInEndSection": 763, "text": " Sensorineural hearing loss (17/20, 85.0%) and heterochromia iridum (20/20, 100.0%) were the most commonly observed clinical features in Chinese WS2 patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194866", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 280, "text": "Waardenburg Syndrome (WS) is an autosomal-dominant disorder characterized by sensorineural hearing loss and pigmentary abnormalities of the eyes, hair, and skin. Microphthalmia-associated transcription factor (MITF) gene mutations account for about 15% of WS type II (WS2) cases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194866", "endSection": "abstract"}, {"offsetInBeginSection": 659, "offsetInEndSection": 815, "text": "The association of congenital Horner's syndrome and hypochromia iridum without anhidrosis is highly suggestive of sympathetic pathway injury early in life. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21339912", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 246, "text": "The Waardenburg syndrome (WS) consists of at least two distinct autosomal dominant hereditary disorders. WS Type I has been mapped to the distal part of chromosome 2q and the gene identified as PAX3. Other gene(s) are responsible for WS Type II. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7702105", "endSection": "abstract"}, {"offsetInBeginSection": 574, "offsetInEndSection": 704, "text": "Sensorineural hearing loss (77%) and heterochromia iridum (47%) were the two most important diagnostic indicators for WS Type II. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7702105", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "WAARDENBURG'S SYNDROME AND HETEROCHROMIA IRIDUM IN A DEAF SCHOOL POPULATION.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14166458", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 216, "text": "Waardenburg's syndrome consists of lateral displacement of the inner canthi of the eyes (dystopia canthorum), a broad nasal root and confluent eyebrows, heterochromia iridum, a white forelock and congenital deafness.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14166458", "endSection": "abstract"}, {"offsetInBeginSection": 528, "offsetInEndSection": 793, "text": "To our knowledge, this is the first reported case of Ascher's syndrome associated with iris coloboma, heterochromia iridum, and narrowing of horizontal palpebral fissure and decreased outer intercanthal distance secondary to lengthening of lateral canthal ligament.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25971175", "endSection": "abstract"}, {"offsetInBeginSection": 569, "offsetInEndSection": 698, "text": "Sensorineural hearing loss (77%) and heterochromia iridum (47%) were the two most important diagnostic indicators for WS Type II.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7702105", "endSection": "abstract"}, {"offsetInBeginSection": 600, "offsetInEndSection": 757, "text": "Sensorineural hearing loss (17/20, 85.0%) and heterochromia iridum (20/20, 100.0%) were the most commonly observed clinical features in Chinese WS2 patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194866", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 278, "text": "We present the genetic analyses conducted on a three-generation family (14 individuals) with three members affected with isolated-Hirschsprung disease (HSCR) and one with HSCR and heterochromia iridum (syndromic-HSCR), a phenotype reminiscent of Waardenburg-Shah syndrome (WS4).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23840513", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Heterochromia iridis and Horner's syndrome due to paravertebral neurilemmoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6823113", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 51, "text": "[Iris heterochromia in acquired Horner's syndrome].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17878817", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "BACKGROUND: Heterochromia iridis, asymmetry of iris pigmentation, has been well described with congenital Horner syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1480396", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "A case of heterochromia iridis and Horner's syndrome is reported in a 7-year old girl with paravertebral neurilemmoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6823113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 277, "text": "We present the genetic analyses conducted on a three-generation family (14 individuals) with three members affected with isolated-Hirschsprung disease (HSCR) and one with HSCR and heterochromia iridum (syndromic-HSCR), a phenotype reminiscent of Waardenburg-Shah syndrome (WS4)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23840513", "endSection": "abstract"}, {"offsetInBeginSection": 531, "offsetInEndSection": 794, "text": "To our knowledge, this is the first reported case of Aschers syndrome associated with iris coloboma, heterochromia iridum, and narrowing of horizontal palpebral fissure and decreased outer intercanthal distance secondary to lengthening of lateral canthal ligament", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25971175", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "WAARDENBURGS SYNDROME AND HETEROCHROMIA IRIDUM IN A DEAF SCHOOL POPULATION", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14166458", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Waardenburgs syndrome consists of lateral displacement of the inner canthi of the eyes (dystopia canthorum), a broad nasal root and confluent eyebrows, heterochromia iridum, a white forelock and congenital deafness", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14166458", "endSection": "abstract"}, {"offsetInBeginSection": 605, "offsetInEndSection": 761, "text": "Sensorineural hearing loss (17/20, 85.0%) and heterochromia iridum (20/20, 100.0%) were the most commonly observed clinical features in Chinese WS2 patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194866", "endSection": "abstract"}, {"offsetInBeginSection": 605, "offsetInEndSection": 763, "text": "Sensorineural hearing loss (17/20, 85.0%) and heterochromia iridum (20/20, 100.0%) were the most commonly observed clinical features in Chinese WS2 patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194866", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "A dominantly inherited syndrome associated with hypopigmentation, heterochromia irides, colobomatous eyes and bilateral hearing loss has been ascertained in Fleckvieh cattle (German White Fleckvieh syndrome). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22174915", "endSection": "abstract"}, {"offsetInBeginSection": 574, "offsetInEndSection": 703, "text": "Sensorineural hearing loss (77%) and heterochromia iridum (47%) were the two most important diagnostic indicators for WS Type II.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7702105", "endSection": "abstract"}, {"offsetInBeginSection": 605, "offsetInEndSection": 762, "text": "Sensorineural hearing loss (17/20, 85.0%) and heterochromia iridum (20/20, 100.0%) were the most commonly observed clinical features in Chinese WS2 patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194866", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "WAARDENBURG'S SYNDROME AND HETEROCHROMIA IRIDUM IN A DEAF SCHOOL POPULATION.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14166458", "endSection": "title"}]}, {"body": "List 3 NK3R antagonists.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28977601", "http://www.ncbi.nlm.nih.gov/pubmed/26653113", "http://www.ncbi.nlm.nih.gov/pubmed/28380486", "http://www.ncbi.nlm.nih.gov/pubmed/27636018"], "ideal_answer": ["NK3 receptor antagonists include MLE4901 (also known as AZD4901), SB222200 and ESN364."], "exact_answer": [["MLE4901", "AZD4901"], ["SB222200"], ["ESN364"]], "type": "list", "id": "5e55046fb761aafe09000004", "snippets": [{"offsetInBeginSection": 344, "offsetInEndSection": 457, "text": "Eleven postmenopausal women were administered the NK3R antagonist MLE4901 at 40 mg twice daily orally for 7 days.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28380486", "endSection": "abstract"}, {"offsetInBeginSection": 678, "offsetInEndSection": 1225, "text": "Results indicate that (1) similar to those previously reported for GnRH stimulation by the KISS1R agonist (i.e., human kisspeptin-10), the NK3R agonist senktide stimulated GnRH release in a dose-responsive manner in both prepubertal and pubertal monkeys; (2) the senktide-induced GnRH release was blocked in the presence of the KISS1R antagonist peptide 234 in pubertal but not prepubertal monkeys; and (3) the kisspeptin-induced GnRH release was blocked in the presence of the NK3R antagonist SB222200 in the pubertal but not prepubertal monkeys.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28977601", "endSection": "abstract"}, {"offsetInBeginSection": 608, "offsetInEndSection": 738, "text": "NK3R antagonist AZD4901 40 mg twice daily orally was taken from cycle day 4-6 for 6 days (n = 10, with 10 no treatment controls). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27636018", "endSection": "abstract"}, {"offsetInBeginSection": 1797, "offsetInEndSection": 2043, "text": " Oral administration of the NK3R antagonist, ESN364, suppressed the hypothalamic-pituitary-gonadal axis in healthy volunteers by selective modulation of gonadotropin secretion, leading to a restrained decrease in ovarian hormone levels in women. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26653113", "endSection": "abstract"}]}, {"body": "Which histone modifications are associated with constitutive heterochromatin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17710556", "http://www.ncbi.nlm.nih.gov/pubmed/11850619", "http://www.ncbi.nlm.nih.gov/pubmed/11356363", "http://www.ncbi.nlm.nih.gov/pubmed/16705169", "http://www.ncbi.nlm.nih.gov/pubmed/18004385", "http://www.ncbi.nlm.nih.gov/pubmed/20599948", "http://www.ncbi.nlm.nih.gov/pubmed/22572731", "http://www.ncbi.nlm.nih.gov/pubmed/14506132", "http://www.ncbi.nlm.nih.gov/pubmed/18987983", "http://www.ncbi.nlm.nih.gov/pubmed/19786836", "http://www.ncbi.nlm.nih.gov/pubmed/15368356", "http://www.ncbi.nlm.nih.gov/pubmed/20562223", "http://www.ncbi.nlm.nih.gov/pubmed/21267468", "http://www.ncbi.nlm.nih.gov/pubmed/12581305", "http://www.ncbi.nlm.nih.gov/pubmed/21803857"], "triples": [{"p": "http://linkedlifedata.com/resource/relationontology/hasLocalization", "s": "http://purl.uniprot.org/uniprot/Q58E49", "o": "http://linkedlifedata.com/resource/geneontology/id/GO:0000792"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_5135384534390011", "o": "Histone deacetylase"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/geneontology/id/GO:0000792", "o": "heterochromatin"}, {"p": "http://purl.uniprot.org/core/classifiedWith", "s": "http://purl.uniprot.org/uniprot/Q58E49", "o": "http://purl.uniprot.org/go/0000792"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://purl.uniprot.org/go/0000792", "o": "heterochromatin"}, {"p": "http://www.w3.org/2004/02/skos/core#exactMatch", "s": "http://purl.uniprot.org/go/0000792", "o": "http://www.geneontology.org/go#GO:0000792"}, {"p": "http://linkedlifedata.com/resource/relationontology/hasLocalization", "s": "http://purl.uniprot.org/uniprot/O09106", "o": "http://linkedlifedata.com/resource/geneontology/id/GO:0000792"}, {"p": "http://purl.uniprot.org/core/shortName", "s": "http://linkedlifedata.com/resource/#_4F30393130360026", "o": "HD1"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_4F30393130360026", "o": "Histone deacetylase 1"}, {"p": "http://purl.uniprot.org/core/classifiedWith", "s": "http://purl.uniprot.org/uniprot/O09106", "o": "http://purl.uniprot.org/go/0000792"}, {"p": "http://purl.uniprot.org/core/classifiedWith", "s": "http://purl.uniprot.org/uniprot/P29227", "o": "http://purl.uniprot.org/go/0016568"}, {"p": "http://purl.uniprot.org/core/shortName", "s": "http://linkedlifedata.com/resource/#_50323932323700B", "o": "HP1"}, {"p": "http://purl.uniprot.org/core/recommendedName", "s": "http://purl.uniprot.org/uniprot/P29227", "o": "http://linkedlifedata.com/resource/#_50323932323700B"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://purl.uniprot.org/go/0016568", "o": "chromatin modification"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_50323932323700B", "o": "Heterochromatin protein 1"}, {"p": "http://www.w3.org/2004/02/skos/core#exactMatch", "s": "http://purl.uniprot.org/go/0016568", "o": "http://www.geneontology.org/go#GO:0016568"}], "ideal_answer": ["Strong methylation at H3 lysine 9 occurred preferentially in heterochromatic chromocenters of Arabidopsis nuclei. In general, heterochromatin has been linked to trimethylation of H3 at lysine 9 and parsimony analysis reveal that histone H3K9 methylation is, next to histone deacetylation, the evolutionary most stable heterochromatic mark. Classical histone modifications associated with heterochromatin also include H3K27me1 and H3K27me2. H3K36me3 function is not restricted to actively transcribed regions only and may contribute to the composition of heterochromatin. Other histone methylation marks usually found in constitutive heterochromatin are H4K20me3, H3K9me3, and H3K79me3. H3S10P is a good marker of pericentromeric heterochromatin.", "H3K9 methylation\nH3S10 phosphorylation\nH3K79 and H4K20 methylation"], "exact_answer": [["H3K9Me1", "H3K9Me2", "H3K9me3", "H3K9 trimethylation"], ["H3K27me1"], ["H3K27me2"], ["H4K20me3", "H4K20 trimethylation"], ["H3K79me3", "H3K79 methylation"], ["H3S10", "H3S10 phosphorylation"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056284", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0001207", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0034729", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0032452", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031445", "http://www.uniprot.org/uniprot/CBX5_MOUSE", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0033182", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:1900049", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D042421", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056545", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0035097", "http://www.biosemantics.org/jochem#4262550", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031452", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031453", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056464", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031454", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056466", "http://www.uniprot.org/uniprot/H4_ORENI", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011495", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0070870", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0035067", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0035066", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0035065", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056264", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0003886", "http://www.uniprot.org/uniprot/SIR1_YEAS1", "http://www.biosemantics.org/jochem#4278518", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031056", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031057", "http://www.uniprot.org/uniprot/HP1B3_RAT", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031933", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011484", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0033696", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0033697", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:1900410", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056484", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0070868", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0070869", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006570", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0070829", "http://www.uniprot.org/uniprot/H4_ASEAQ", "http://www.uniprot.org/uniprot/LHP1_ARATH", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0000123", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0004402", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0004407", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0010390", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005724", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005723", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005722", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005721", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005720", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031063", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031062", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031061", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031060", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031065", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0071110", "http://www.uniprot.org/uniprot/CBX1_MOUSE", "http://www.uniprot.org/uniprot/H4_PLADU", "http://www.uniprot.org/uniprot/H42_BLEJA", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056245", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031400", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0000792", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0042054", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0006324", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0033553", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050836", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016203", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015257", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0009007", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051548", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:1900051", "http://www.uniprot.org/uniprot/HP1_DROVI", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006657", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006656", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0015667", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016568", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0043486", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031058", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031507", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031508", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031509", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031052", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0070828", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0033129", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0033127", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0008469", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0097355", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0035034", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0035035", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016576", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016577", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016574", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016575", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016572", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016573", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016570", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016571", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016578"], "type": "list", "id": "52e0c9a298d0239505000010", "snippets": [{"offsetInBeginSection": 163, "offsetInEndSection": 432, "text": "Remarkably, in mammalian somatic cells, H3S10P initiates in the pericentromeric heterochromatin during the late G2 phase, and phosphorylation spreads throughout the chromosomes arms in prophase, being maintained until the onset of anaphase when it gets dephosphorylated", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22572731", "endSection": "abstract"}, {"offsetInBeginSection": 1432, "offsetInEndSection": 1744, "text": "Based on these findings, we believe that H3S10P is a good marker of pericentromeric heterochromatin, especially in the late 1- and 2-cell stages as it labels both parental genomes and that it can be used to further investigate epigenetic regulation and heterochromatin mechanisms in early preimplantation embryos", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22572731", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 120, "text": "3S10 phosphorylation marks constitutive heterochromatin during interphase in early mouse embryos until the 4-cell stage", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22572731", "endSection": "title"}, {"offsetInBeginSection": 8, "offsetInEndSection": 102, "text": "H3 trimethylation at lysine 36 is associated with constitutive and facultative heterochromatin", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21803857", "endSection": "title"}, {"offsetInBeginSection": 393, "offsetInEndSection": 664, "text": "We show here that the maternally inherited Snurf-Snrpn 3-Mb region, which is silenced by a potent transcription repressive mechanism, is uniformly enriched in histone methylation marks usually found in constitutive heterochromatin, such as H4K20me3, H3K9me3, and H3K79me3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21803857", "endSection": "abstract"}, {"offsetInBeginSection": 899, "offsetInEndSection": 1117, "text": "We show that H3K36me3 deposition within this large heterochromatin domain does not correlate with transcription events, suggesting the existence of an alternative pathway for the deposition of this histone modification", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21803857", "endSection": "abstract"}, {"offsetInBeginSection": 1119, "offsetInEndSection": 1275, "text": "In addition, we demonstrate that H3K36me3 is markedly enriched at the level of pericentromeric heterochromatin in mouse embryonic stem cells and fibroblasts", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21803857", "endSection": "abstract"}, {"offsetInBeginSection": 1277, "offsetInEndSection": 1381, "text": "This result indicates that H3K36me3 is associated with both facultative and constitutive heterochromatin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21803857", "endSection": "abstract"}, {"offsetInBeginSection": 1383, "offsetInEndSection": 1584, "text": "Our data suggest that H3K36me3 function is not restricted to actively transcribed regions only and may contribute to the composition of heterochromatin, in combination with other histone modifications.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21803857", "endSection": "abstract"}, {"offsetInBeginSection": 21, "offsetInEndSection": 174, "text": "accumulation of histone H3.3 and euchromatic histone modifications in pericentromeric heterochromatin in response to a decrease in DNA methylation levels", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20599948", "endSection": "title"}, {"offsetInBeginSection": 247, "offsetInEndSection": 440, "text": "In this study, we show that inhibition of DNA methylation in mouse fibroblast cells affects histone modification and the subnuclear localization of histone H3.3 in a cell cycle-dependent manner", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20599948", "endSection": "abstract"}, {"offsetInBeginSection": 1169, "offsetInEndSection": 1325, "text": "Moreover, we found that histone H3.3 was deposited on the pericentromeric heterochromatin prior to the accumulation of the euchromatic histone modifications", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20599948", "endSection": "abstract"}, {"offsetInBeginSection": 464, "offsetInEndSection": 623, "text": "Classical histone modifications associated with heterochromatin, including H3K9me2, H3K27me1 and H3K27me2, were distributed throughout both A and B chromosomes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18987983", "endSection": "abstract"}, {"offsetInBeginSection": 625, "offsetInEndSection": 790, "text": "However, H3K27me2 showed a reduced level on the B chromosome compared with the A chromosomes and was not associated with some classes of constitutive heterochromatin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18987983", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 388, "text": "Recently analyzed H3K9 methyltransferases (HMTases) as SUV39H1, Clr4p, DIM-5, Su(var)3-9 or SUVH2 are responsible for the establishment of histone H3 lysine 9 methylation (H3K9me), which is intimately connected with heterochromatinization", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17710556", "endSection": "abstract"}, {"offsetInBeginSection": 23, "offsetInEndSection": 92, "text": "heterochromatic histone H3K9 methyltransferases left its marks behind", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17710556", "endSection": "title"}, {"offsetInBeginSection": 815, "offsetInEndSection": 1092, "text": "Compilation and parsimony analysis reveal that histone H3K9 methylation is, next to histone deacetylation, the evolutionary most stable heterochromatic mark, which is established by at least two subfamilies of specialized heterochromatic HMTases in almost all studied eukaryote", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17710556", "endSection": "abstract"}, {"offsetInBeginSection": 280, "offsetInEndSection": 445, "text": "Trimethylated H3(K9) marks pericentromeric constitutive heterochromatin and the male Y chromosome, while H2A.Z is dramatically reduced at these chromosomal locations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16705169", "endSection": "abstract"}, {"offsetInBeginSection": 448, "offsetInEndSection": 754, "text": "Of eight tested antibodies, the one for histone H4 acetylated at lysine 4, 8, 12, or 16 was best for distinguishing constitutive heterochromatin from unexpressed euchromatin, but differences in the extent of immunoprecipitation of these two types of chromatin were only modest, although highly reproducible", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15368356", "endSection": "abstract"}, {"offsetInBeginSection": 1255, "offsetInEndSection": 1465, "text": "In addition, immunocytochemical analysis was done with an antibody to heterochromatin protein 1alpha (HP1alpha), whose preferential binding to heterochromatin has been linked to trimethylation of H3 at lysine 9", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15368356", "endSection": "abstract"}, {"offsetInBeginSection": 1467, "offsetInEndSection": 1756, "text": "Our combined ChIP and immunocytochemical results suggest that factors other than hypoacetylation of the N-terminal tails of H4 and hypermethylation of H3 at lysine 9 can play an important role in determining whether a chromatin sequence in mammalian cells is constitutively heterochromatic", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15368356", "endSection": "abstract"}, {"offsetInBeginSection": 599, "offsetInEndSection": 819, "text": "To test for the putative heterochromatinization, we quantitated chromatin immunoprecipitation with an antibody for acetylated histone H4 that discriminates between constitutive heterochromatin and unexpressed euchromatin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14506132", "endSection": "abstract"}, {"offsetInBeginSection": 38, "offsetInEndSection": 117, "text": "high methylation of H3 lysine 9 is dispensable for constitutive heterochromatin", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12581305", "endSection": "title"}, {"offsetInBeginSection": 546, "offsetInEndSection": 729, "text": "Strong methylation at H3 lysine 4 was restricted to euchromatin, while strong methylation at H3 lysine 9 occurred preferentially in heterochromatic chromocenters of Arabidopsis nuclei", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12581305", "endSection": "abstract"}]}, {"body": "List psychiatric diseases that are associated with Synaptosome Associated Protein 25 (snap25).", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24885975", "http://www.ncbi.nlm.nih.gov/pubmed/24391914", "http://www.ncbi.nlm.nih.gov/pubmed/23732542", "http://www.ncbi.nlm.nih.gov/pubmed/27582038", "http://www.ncbi.nlm.nih.gov/pubmed/27888397"], "ideal_answer": ["attention-deficit/hyperactivity disorder\nbipolar\nschizophrenia"], "exact_answer": [["schizophrenia"], ["attention-deficit/hyperactivity disorder"], ["bipolar"]], "type": "list", "id": "5e6e5d1d51b80c9423000003", "snippets": [{"offsetInBeginSection": 1076, "offsetInEndSection": 1201, "text": "In addition, SNAP25, RAB18, FABP5, ARF5 and LDHA, which are related genes to schizophrenia and methamphetamine sensitization,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27582038", "endSection": "abstract"}, {"offsetInBeginSection": 616, "offsetInEndSection": 756, "text": "We aimed to study a SNAP-25 gene polymorphism, which is related to many psychiatric diseases, and FMS association in this prospective study.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24885975", "endSection": "abstract"}, {"offsetInBeginSection": 596, "offsetInEndSection": 884, "text": "Studies have shown a correlation between aberrant expression of the SNAP25 and a variety of brain diseases. Single nucleotide polymorphisms (SNPs) in this gene are associated with several psychiatric diseases, such as bipolar, schizophrenia, and attention-deficit/hyperactivity disorder. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27888397", "endSection": "abstract"}, {"offsetInBeginSection": 263, "offsetInEndSection": 496, "text": "Polymorphic variants of the SNAP-25 gene emerged as putative genetic components of impulsivity, as SNAP-25 protein plays an important role in the central nervous system, and its SNPs are associated with several psychiatric disorders.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24391914", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "SNAP-25 is a key component of the synaptic-vesicle fusion machinery, involved in several psychiatric diseases including schizophrenia and ADHD", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23732542", "endSection": "abstract"}]}, {"body": "Which growth factors are known to be involved in the induction of EMT?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23027863", "http://www.ncbi.nlm.nih.gov/pubmed/23437179", "http://www.ncbi.nlm.nih.gov/pubmed/17720949", "http://www.ncbi.nlm.nih.gov/pubmed/22547830", "http://www.ncbi.nlm.nih.gov/pubmed/16365168", "http://www.ncbi.nlm.nih.gov/pubmed/21680037", "http://www.ncbi.nlm.nih.gov/pubmed/15121845", "http://www.ncbi.nlm.nih.gov/pubmed/11790801", "http://www.ncbi.nlm.nih.gov/pubmed/7593195", "http://www.ncbi.nlm.nih.gov/pubmed/24045665", "http://www.ncbi.nlm.nih.gov/pubmed/11526479", "http://www.ncbi.nlm.nih.gov/pubmed/16868306", "http://www.ncbi.nlm.nih.gov/pubmed/18792103", "http://www.ncbi.nlm.nih.gov/pubmed/20531305", "http://www.ncbi.nlm.nih.gov/pubmed/22627188", "http://www.ncbi.nlm.nih.gov/pubmed/23810808", "http://www.ncbi.nlm.nih.gov/pubmed/20075196"], "ideal_answer": ["EMT is characterized by acquisition of cell motility, modifications of cell morphology, and cell dissociation correlating with the loss of desmosomes from the cellular cortex. A number of growth factors have been shown to be involved in this process. These include fibroblast growth factors (FGFs), TGF-\u03b21, TGF-\u03b22, TNF-\u03b1, CCN family, Sonic Hedgehog (SHh), Notch1, GF-\u03b2, Wnt, EGF, bFGF, IGF-I and IGF-II."], "exact_answer": [["fibroblast growth factors (FGFs)"], ["TGF-\u03b21"], ["TGF-\u03b22"], ["TNF-\u03b1"], ["CCN family"], ["Sonic Hedgehog (SHh)"], ["Notch1"], ["GF-\u03b2"], ["Wnt"], ["EGF"], ["bFGF"], ["IGF-I"], ["IGF-II"]], "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0070848", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005346", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0019838", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0001837", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017978", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0008083", "http://www.biosemantics.org/jochem#4249315", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058750", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D036341"], "type": "list", "id": "5319abffb166e2b80600002f", "snippets": [{"offsetInBeginSection": 475, "offsetInEndSection": 755, "text": "Moreover, recent studies have shown that most EMT cases are regulated by soluble growth factors or cytokines. Among these factors, fibroblast growth factors (FGFs) execute diverse functions by binding to and activating members of the FGF receptor (FGFR) family, including FGFR1-4.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24045665", "endSection": "abstract"}, {"offsetInBeginSection": 756, "offsetInEndSection": 904, "text": "Fibroblast growth factor receptor 1 is an oncoprotein that is involved in tumorigenesis, and PD173074 is known to be a selective inhibitor of FGFR1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24045665", "endSection": "abstract"}, {"offsetInBeginSection": 1485, "offsetInEndSection": 1595, "text": "Fibroblast growth factor receptor 1 was also overexpressed in EMT cell lines compared with non-EMT cell lines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24045665", "endSection": "abstract"}, {"offsetInBeginSection": 1596, "offsetInEndSection": 1734, "text": "Furthermore, treatment of HOC313 cells with PD173074 suppressed cellular proliferation and invasion and reduced ERK1/2 and p38 activation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24045665", "endSection": "abstract"}, {"offsetInBeginSection": 1846, "offsetInEndSection": 2060, "text": "In addition, the expression levels of certain matrix metalloproteinases (MMPs), whose genes contain activator protein-1 (AP-1) promoter sites, as well as Snail1 and Snail2 were reduced following PD173074 treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24045665", "endSection": "abstract"}, {"offsetInBeginSection": 2073, "offsetInEndSection": 2202, "text": "Taken together, these data suggest that PD173074 inhibits the MAPK pathway, which regulates the activity of AP-1 and induces MET.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24045665", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 136, "text": "egulation of Na,K-ATPase \u03b21-subunit in TGF-\u03b22-mediated epithelial-to-mesenchymal transition in human retinal pigmented epithelial cells", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23810808", "endSection": "title"}, {"offsetInBeginSection": 421, "offsetInEndSection": 518, "text": "The EMT process is mediated via exposure to vitreous cytokines and growth factors such as TGF-\u03b22.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23810808", "endSection": "abstract"}, {"offsetInBeginSection": 519, "offsetInEndSection": 747, "text": "Previous studies have shown that Na,K-ATPase is required for maintaining a normal polarized epithelial phenotype and that decreased Na,K-ATPase function and subunit levels are associated with TGF-\u03b21-mediated EMT in kidney cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23810808", "endSection": "abstract"}, {"offsetInBeginSection": 1868, "offsetInEndSection": 1954, "text": "loss of Na,K-ATPase \u03b21 is a potential contributor to TGF-\u03b22-mediated EMT in RPE cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23810808", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 319, "text": "MT (epithelial-mesenchymal transition) is crucial for cancer cells to acquire invasive phenotypes. In A549 lung adenocarcinoma cells, TGF-\u03b2 elicited EMT in Smad-dependent manner and TNF-\u03b1 accelerated this process, as confirmed by cell morphology, expression of EMT markers, capacity of gelatin lysis and cell invasion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23437179", "endSection": "abstract"}, {"offsetInBeginSection": 446, "offsetInEndSection": 719, "text": "Comprehensive expression analysis unraveled genes differentially regulated by TGF-\u03b2 and TNF-\u03b1, such as cytokines, chemokines, growth factors and ECM (extracellular matrices), suggesting the drastic change in autocrine/paracrine signals as well as cell-to-ECM interactions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23437179", "endSection": "abstract"}, {"offsetInBeginSection": 192, "offsetInEndSection": 320, "text": "Our recent studies found that CCN1 plays a critical role in pancreatic carcinogenesis through the induction of EMT and stemness.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23027863", "endSection": "abstract"}, {"offsetInBeginSection": 552, "offsetInEndSection": 694, "text": "Here we show that CCN1 regulates the Sonic Hedgehog (SHh) signaling pathway, which is associated with the PDAC progression and poor prognosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23027863", "endSection": "abstract"}, {"offsetInBeginSection": 695, "offsetInEndSection": 784, "text": "SHh regulation by CCN1 in pancreatic cancer cells is mediated through the active Notch-1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23027863", "endSection": "abstract"}, {"offsetInBeginSection": 1297, "offsetInEndSection": 1580, "text": "These extensive studies propose that targeting CCN1 can provide a new treatment option for patients with pancreatic cancer since blocking CCN1 simultaneously blocks two critical pathways (i.e. SHh and Notch1) associated with the development of the disease as well as drug resistance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23027863", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 47, "text": "GF-\u03b2-induced epithelial-mesenchymal transition", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627188", "endSection": "title"}, {"offsetInBeginSection": 691, "offsetInEndSection": 1133, "text": "The cytokine TGF-\u03b2, which is expressed by tumor-infiltrating immune cells, stands out as a master regulator of the pro-invasive tumor microenvironment. TGF-\u03b2 cooperates with stem cell pathways, such as Wnt and Ras signaling, to induce EMT. In addition, TGF-\u03b2 contributes to an EMT-permissive microenvironment by switching the phenotypes of tumor-infiltrating immune cells, which thereby mount pro-invasive and pro-metastatic immune responses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627188", "endSection": "abstract"}, {"offsetInBeginSection": 1134, "offsetInEndSection": 1367, "text": "In this review, we discuss the role of TGF-\u03b2-induced EMT as a link between cancer and inflammation in the context of questions, which from our point of view are key to answer in order to understand the functionality of EMT in tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627188", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 157, "text": "ranscription factors c-Myc and CDX2 mediate E-selectin ligand expression in colon cancer cells undergoing EGF/bFGF-induced epithelial-mesenchymal transition", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22547830", "endSection": "title"}, {"offsetInBeginSection": 516, "offsetInEndSection": 693, "text": "Treatment of HT29 and DLD-1 cells with EGF and/or basic FGF (bFGF) induced EMT and significantly increased sLe(x/a) expression resulting in enhanced E-selectin binding activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22547830", "endSection": "abstract"}, {"offsetInBeginSection": 853, "offsetInEndSection": 1130, "text": "Upon hypoxia, TGF\u03b2 addition or EGFRvIII expression, MCF7, A549 and NMuMG epithelial cells acquired a spindle shape and lost cell-cell contacts. Expression of epithelial markers such as E-cadherin decreased, whereas mesenchymal markers such as vimentin and N-cadherin increased.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21680037", "endSection": "abstract"}, {"offsetInBeginSection": 293, "offsetInEndSection": 494, "text": "The EMT process can be regulated by a diverse array of cytokines and growth factors, such as transforming growth factor (TGF)-beta, whose activities are dysregulated during malignant tumor progression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20531305", "endSection": "abstract"}, {"offsetInBeginSection": 1247, "offsetInEndSection": 1524, "text": "Transforming growth factor-beta-induced tubular cell EMT in C1.1 cells was inhibited by MMP-2/9 inhibitor. Our in vitro study provides evidence that MMPs, specifically MMP-9, secreted by effector macrophages can induce tubular cell EMT and thereby contribute to renal fibrosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20075196", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 123, "text": "nflammatory cytokines augments TGF-beta1-induced epithelial-mesenchymal transition in A549 cells by up-regulating TbetaR-I", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18792103", "endSection": "title"}, {"offsetInBeginSection": 226, "offsetInEndSection": 481, "text": "In this study, we report that cytomix (a mixture of IL-1beta, TNF-alpha and IFN-gamma) significantly enhances TGF-beta1-induced EMT in A549 cells as evidenced by acquisition of fibroblast-like cell shape, loss of E-cadherin, and reorganization of F-actin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18792103", "endSection": "abstract"}, {"offsetInBeginSection": 482, "offsetInEndSection": 643, "text": "IL-1beta or TNF-alpha alone can also augment TGF-beta1-induced EMT. However, a combination of IL-1beta and TNF-alpha or the cytomix is more potent to induce EMT.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18792103", "endSection": "abstract"}, {"offsetInBeginSection": 1000, "offsetInEndSection": 1207, "text": "These results indicate that inflammatory cytokines together with TGF-beta1 may play an important role in the development of fibrosis and tumor progress via the mechanism of epithelial-mesenchymal transition.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18792103", "endSection": "abstract"}, {"offsetInBeginSection": 1130, "offsetInEndSection": 1329, "text": "TGF-beta stimulated epithelial to mesenchyme transdifferentiation (EMT) in the presence of TGF-alpha, as characterized by increased expression of fibronectin and changes in TGF-beta receptor binding.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17720949", "endSection": "abstract"}, {"offsetInBeginSection": 127, "offsetInEndSection": 248, "text": "EMT is typically induced by transforming growth factor-beta1 (TGF-beta1) and inhibited by hepatocyte growth factor (HGF).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16868306", "endSection": "abstract"}, {"offsetInBeginSection": 923, "offsetInEndSection": 1112, "text": "Exposure of MDCK cells to 10 ng/ml TGF-beta1 for 72 h induced EMT as evidenced by conversion to the spindle-like morphology, loss of E-cadherin, and activation of alpha-smooth muscle actin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16868306", "endSection": "abstract"}, {"offsetInBeginSection": 446, "offsetInEndSection": 856, "text": "In contrast, Akt1 down-regulation in IGF-IR-stimulated cells promoted dramatic neomorphic effects characteristic of an epithelial-mesenchymal transition (EMT) and enhanced cell migration induced by IGF-I or EGF stimulation. The phenotypic effects of Akt1 down-regulation were accompanied by enhanced extracellular signal-related kinase (ERK) activation, which contributed to the induction of migration and EMT.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16365168", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 164, "text": "ransforming growth factors beta (TGF-betas) inhibit growth of epithelial cells and induce differentiation changes, such as epithelial-mesenchymal transition (EMT).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15121845", "endSection": "abstract"}, {"offsetInBeginSection": 485, "offsetInEndSection": 711, "text": "Ha-Ras cooperates with transforming growth factor beta (TGFbeta) to cause epithelial mesenchymal transition (EMT) characterized by spindle-like cell morphology, loss of epithelial markers, and induction of mesenchymal markers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11790801", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11526479", "endSection": "title"}, {"offsetInBeginSection": 664, "offsetInEndSection": 745, "text": "We can show that (1) IGF-II induces a rapid epithelium to mesenchymal transition;", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11526479", "endSection": "abstract"}, {"offsetInBeginSection": 1082, "offsetInEndSection": 1268, "text": "Based on the given case of IGF-II and E-cadherin/beta-catenin complex, this study reveals the backbone of a cascade connecting growth factor signaling with cell-cell adhesion during EMT.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11526479", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 224, "text": "The NBT-II rat carcinoma cell line exhibits two mutually exclusive responses to FGF-1 and EGF, entering mitosis at cell confluency while undergoing an epithelium-to-mesenchyme transition (EMT) when cultured at subconfluency.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7593195", "endSection": "abstract"}, {"offsetInBeginSection": 712, "offsetInEndSection": 842, "text": "EMT requires continuous TGFbeta receptor (TGFbeta-R) and oncogenic Ras signaling and is stabilized by autocrine TGFbeta production", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11790801", "endSection": "abstract"}, {"offsetInBeginSection": 1533, "offsetInEndSection": 1656, "text": "EMT seems to be a close in vitro correlate of metastasis, both requiring synergism between TGFbeta-R and Raf/MAPK signaling", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11790801", "endSection": "abstract"}]}, {"body": "Which databases exist for experimentally determined topologies of \u03b1-helical transmembrane proteins ?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12520035", "http://www.ncbi.nlm.nih.gov/pubmed/20601677"], "ideal_answer": ["ExTopoDB and TMPDB."], "exact_answer": [["ExTopoDB"], ["TMPDB"]], "type": "list", "id": "55414a763f2354b713000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "ExTopoDB: a database of experimentally derived topological models of transmembrane proteins", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20601677", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 726, "text": "ExTopoDB is a publicly accessible database of experimentally derived topological models of transmembrane proteins. It contains information collected from studies in the literature that report the use of biochemical methods for the determination of the topology of \u03b1-helical transmembrane proteins. Transmembrane protein topology is highly important in order to understand their function and ExTopoDB provides an up to date, complete and comprehensive dataset of experimentally determined topologies of \u03b1-helical transmembrane proteins. Topological information is combined with transmembrane topology prediction resulting in more reliable topological models. AVAILABILITY: http://bioinformatics.biol.uoa.gr/ExTopoDB", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20601677", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "TMPDB: a database of experimentally-characterized transmembrane topologies", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12520035", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 895, "text": "TMPDB is a database of experimentally-characterized transmembrane (TM) topologies. TMPDB release 6.2 contains a total of 302 TM protein sequences, in which 276 are alpha-helical sequences, 17 beta-stranded, and 9 alpha-helical sequences with short pore-forming helices buried in the membrane. The TM topologies in TMPDB were determined experimentally by means of X-ray crystallography, NMR, gene fusion technique, substituted cysteine accessibility method, N-linked glycosylation experiment and other biochemical methods. TMPDB would be useful as a test and/or training dataset in improving the proposed TM topology prediction methods or developing novel methods with higher performance, and as a guide for both the bioinformaticians and biologists to better understand TM proteins. TMPDB and its subsets are freely available at the following web site: http://bioinfo.si.hirosaki-u.ac.jp/~TMPDB/", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12520035", "endSection": "abstract"}, {"offsetInBeginSection": 295, "offsetInEndSection": 533, "text": "Transmembrane protein topology is highly important in order to understand their function and ExTopoDB provides an up to date, complete and comprehensive dataset of experimentally determined topologies of \u0436\u2534-helical transmembrane proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20601677", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "TMPDB: a database of experimentally-characterized transmembrane topologies.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12520035", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "TMPDB is a database of experimentally-characterized transmembrane (TM) topologies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12520035", "endSection": "abstract"}, {"offsetInBeginSection": 289, "offsetInEndSection": 518, "text": "The TM topologies in TMPDB were determined experimentally by means of X-ray crystallography, NMR, gene fusion technique, substituted cysteine accessibility method, N-linked glycosylation experiment and other biochemical methods.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12520035", "endSection": "abstract"}, {"offsetInBeginSection": 295, "offsetInEndSection": 533, "text": "Transmembrane protein topology is highly important in order to understand their function and ExTopoDB provides an up to date, complete and comprehensive dataset of experimentally determined topologies of \u03b1-helical transmembrane proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20601677", "endSection": "abstract"}, {"offsetInBeginSection": 310, "offsetInEndSection": 547, "text": "Transmembrane protein topology is highly important in order to understand their function and ExTopoDB provides an up to date, complete and comprehensive dataset of experimentally determined topologies of \ufffd-helical transmembrane proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20601677", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "UNLABELLED: ExTopoDB is a publicly accessible database of experimentally derived topological models of transmembrane proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20601677", "endSection": "abstract"}, {"offsetInBeginSection": 293, "offsetInEndSection": 521, "text": "The TM topologies in TMPDB were determined experimentally by means of X-ray crystallography, NMR, gene fusion technique, substituted cysteine accessibility method, N-linked glycosylation experiment and other biochemical methods.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12520035", "endSection": "abstract"}, {"offsetInBeginSection": 298, "offsetInEndSection": 534, "text": "Transmembrane protein topology is highly important in order to understand their function and ExTopoDB provides an up to date, complete and comprehensive dataset of experimentally determined topologies of \u03b1-helical transmembrane proteins", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20601677", "endSection": "abstract"}, {"offsetInBeginSection": 293, "offsetInEndSection": 520, "text": "The TM topologies in TMPDB were determined experimentally by means of X-ray crystallography, NMR, gene fusion technique, substituted cysteine accessibility method, N-linked glycosylation experiment and other biochemical methods", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12520035", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "TMPDB is a database of experimentally-characterized transmembrane (TM) topologies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12520035", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "ExTopoDB: a database of experimentally derived topological models of transmembrane proteins.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20601677", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "ExTopoDB is a publicly accessible database of experimentally derived topological models of transmembrane proteins", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20601677", "endSection": "abstract"}]}, {"body": "Where is the klotho protein primarily expressed in the body", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19184092", "http://www.ncbi.nlm.nih.gov/pubmed/9791011", "http://www.ncbi.nlm.nih.gov/pubmed/23838326", "http://www.ncbi.nlm.nih.gov/pubmed/32466632", "http://www.ncbi.nlm.nih.gov/pubmed/23928372", "http://www.ncbi.nlm.nih.gov/pubmed/32347987", "http://www.ncbi.nlm.nih.gov/pubmed/23375286", "http://www.ncbi.nlm.nih.gov/pubmed/15665504", "http://www.ncbi.nlm.nih.gov/pubmed/32052504", "http://www.ncbi.nlm.nih.gov/pubmed/22396165", "http://www.ncbi.nlm.nih.gov/pubmed/23748218", "http://www.ncbi.nlm.nih.gov/pubmed/30233703", "http://www.ncbi.nlm.nih.gov/pubmed/12204354", "http://www.ncbi.nlm.nih.gov/pubmed/32005658", "http://www.ncbi.nlm.nih.gov/pubmed/31920703", "http://www.ncbi.nlm.nih.gov/pubmed/17287345", "http://www.ncbi.nlm.nih.gov/pubmed/28709936", "http://www.ncbi.nlm.nih.gov/pubmed/29053774", "http://www.ncbi.nlm.nih.gov/pubmed/19464978", "http://www.ncbi.nlm.nih.gov/pubmed/31928223", "http://www.ncbi.nlm.nih.gov/pubmed/31951006", "http://www.ncbi.nlm.nih.gov/pubmed/32479899", "http://www.ncbi.nlm.nih.gov/pubmed/33179086", "http://www.ncbi.nlm.nih.gov/pubmed/32438076", "http://www.ncbi.nlm.nih.gov/pubmed/30358003", "http://www.ncbi.nlm.nih.gov/pubmed/25466545", "http://www.ncbi.nlm.nih.gov/pubmed/24457979", "http://www.ncbi.nlm.nih.gov/pubmed/22338062", "http://www.ncbi.nlm.nih.gov/pubmed/26307633", "http://www.ncbi.nlm.nih.gov/pubmed/21496980", "http://www.ncbi.nlm.nih.gov/pubmed/16358222", "http://www.ncbi.nlm.nih.gov/pubmed/12362891"], "ideal_answer": ["The klotho protein is primarily expressed in the lungs, kidney, lens, cerebellum, trpc6, renal cells and the brain.", "Klotho is primarily expressed in the kidney but also in the brain, lens of the eye, and heart.", "Klotho is primarily expressed in the lungs, kidney, lens, cerebellum, trpc6, renal cells and the brain."], "exact_answer": [["kidney"], ["brain", "cerebellum", "choroid plexus"], ["heart"], ["eye", "lens"], ["parathyroid"], ["inner ear"], ["reproductive organs", "ovaries"], ["intestine"], ["lens", "eye"]], "type": "list", "id": "6060996394d57fd879000045", "snippets": [{"offsetInBeginSection": 395, "offsetInEndSection": 559, "text": "The present study explored the relevance of the aging suppressor, Klotho, which has anti\u2011aging activity and is highly expressed in murine renal cells/kidney tissues", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33179086", "endSection": "abstract"}, {"offsetInBeginSection": 77, "offsetInEndSection": 220, "text": "rming growth factor-\u03b2 (TGF-\u03b2) and insulin-like growth factor (IGF). Renal expression of klotho is diminished in polycystic kidney disease (PKD)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31928223", "endSection": "abstract"}, {"offsetInBeginSection": 160, "offsetInEndSection": 426, "text": "One of the crucial symptoms is pulmonary emphysema, although \u03b1-Klotho is not expressed in the lungs. \u03b1-Klotho secreted from the kidneys is probably involved in the pathology of emphysema because kidney-specific knockout mice exhibit emphysematous structural changes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31951006", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 225, "text": "The fortuitously discovered antiaging membrane protein \u03b1Klotho (Klotho) is highly expressed in the kidney, and deletion of the Klotho gene in mice causes a phenotype strikingly similar to that of chronic kidney disease (CKD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32005658", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "High-intensity interval training increases myocardial levels of Klotho and protects the heart against ischaemia-reperfusion injury.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32052504", "endSection": "title"}, {"offsetInBeginSection": 434, "offsetInEndSection": 723, "text": "he increase of plasma and myocardial levels of Klotho as a result of preconditioning with HIIT and prevention of a significant reduction of Klotho during IR injury can promote cardioprotection and reduce damage by attenuating myocardial TRPC6 expression and increasing antioxidant defence.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32052504", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 210, "text": "Klotho is an anti-aging protein expressed in Purkinje cells of the cerebellum. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32479899", "endSection": "abstract"}, {"offsetInBeginSection": 202, "offsetInEndSection": 260, "text": "Klotho is expressed in limited tissues including the lens.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32438076", "endSection": "abstract"}, {"offsetInBeginSection": 383, "offsetInEndSection": 637, "text": "Thus, upregulating Klotho in the brain may lead to novel therapeutics to people suffering or at risk for neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis, and demyelinating diseases such as multiple sclerosis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32347987", "endSection": "abstract"}, {"offsetInBeginSection": 502, "offsetInEndSection": 622, "text": "Klotho, a transmembrane protein expressed primarily in renal tubules, functions as an obligatory co-receptor for FGF-23.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23748218", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Klotho is a protein primarily expressed in renal tubular epithelial cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30358003", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": "BACKGROUND: Klotho, a single-pass transmembrane protein primarily expressed in the kidneys, parathyroid glands, and choroid plexus of the brain, has a short cytoplasmic tail and a long extracellular domain, which can be cleaved and released as a soluble form.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23375286", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Klotho is a transmembrane protein expressed primarily in kidney, parathyroid gland, and choroid plexus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24457979", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "The Klotho gene has been identified as an aging suppressor gene that encodes a transmembrane protein, which is expressed primarily in renal tubules.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22338062", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Klotho is a putative aging suppressor gene that is primarily expressed in renal tubular epithelial cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32466632", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 253, "text": "Klotho, an antiaging gene with restricted organ distribution, is mainly expressed in the kidney tubules; the mutant mice have shortened life span, arteriosclerosis, anemia, and osteoporesis, features common to patients with chronic renal failure. Concei", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17287345", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Klotho, a membrane protein mainly expressed in parathyroid glands, kidney, and choroid plexus, counteracts aging and increases the life span. Accor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19184092", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "UNLABELLED: Klotho, a protein expressed mainly in the kidney, is required for the inhibitory effect of FGF23 on renal 1,25(OH)2D3 form", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26307633", "endSection": "abstract"}, {"offsetInBeginSection": 532, "offsetInEndSection": 681, "text": "ing of FGF23 to a FGF receptor requires a protein named Klotho that is expressed in the kidney in the distal but not in the proximal tubule. The mech", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19464978", "endSection": "abstract"}, {"offsetInBeginSection": 106, "offsetInEndSection": 182, "text": "lotho, an anti-aging gene, is mainly expressed in the brain and kidney. The ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30233703", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Klotho is a membrane-bound protein predominantly expressed in the kidney, where it acts as a permissive co-receptor for Fibroblast Growth Factor 23.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28709936", "endSection": "abstract"}, {"offsetInBeginSection": 432, "offsetInEndSection": 663, "text": "Klotho protein was mainly expressed in the stria vascularis and spiral ligament of the inner ear and in the distal convoluted tubule of the kidney, likely serving a common function in the two organs, i.e., modulating ion transport.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12204354", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "The antiaging protein of Klotho is a transmembrane protein mainly expressed in the kidney, parathyroid glands and choroid plexus of the brain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25466545", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "BACKGROUND: The hormone klotho, encoded by the gene klotho, is primarily expressed in the kidney and choroid plexus of the brain", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29053774", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Klotho is a recently discovered anti-aging gene and is primarily expressed in kidneys.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23928372", "endSection": "abstract"}, {"offsetInBeginSection": 185, "offsetInEndSection": 341, "text": "Klotho is most abundant in kidney and expressed in a limited number of other organs, including the brain, where klotho levels are highest in choroid plexus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23838326", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 258, "text": "BACKGROUND: Klotho, a single-pass transmembrane protein primarily expressed in the kidneys, parathyroid glands, and choroid plexus of the brain, has a short cytoplasmic tail and a long extracellular domain, which can be cleaved and released as a soluble form", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23375286", "endSection": "abstract"}, {"offsetInBeginSection": 499, "offsetInEndSection": 669, "text": "Klotho also is expressed in the parathyroid gland, where FGF-23 decreases parathyroid hormone expression and secretion, further suppressing vitamin D synthesis in kidney.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21496980", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Expression of klotho mRNA and protein in rat brain parenchyma from early postnatal development into adulthood.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23838326", "endSection": "title"}, {"offsetInBeginSection": 342, "offsetInEndSection": 502, "text": "Reports vary on where klotho is expressed within the brain parenchyma, and no data is available as to whether klotho levels change across postnatal development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23838326", "endSection": "abstract"}, {"offsetInBeginSection": 851, "offsetInEndSection": 997, "text": "Immunohistochemistry revealed a protein expression pattern similar to the mRNA results, with klotho protein expressed widely throughout the brain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23838326", "endSection": "abstract"}, {"offsetInBeginSection": 105, "offsetInEndSection": 177, "text": "Klotho, an anti-aging gene, is mainly expressed in the brain and kidney.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30233703", "endSection": "abstract"}, {"offsetInBeginSection": 267, "offsetInEndSection": 385, "text": "Klotho mRNA, however, is expressed only in brain, kidney, reproductive organs, pituitary gland, and parathyroid gland.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15665504", "endSection": "abstract"}, {"offsetInBeginSection": 759, "offsetInEndSection": 887, "text": "Our results confirmed that the full-length (130 kDa) and shorter-form (65 kDa) \u03b1-klotho were primarily expressed in the kidneys.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31920703", "endSection": "abstract"}, {"offsetInBeginSection": 500, "offsetInEndSection": 738, "text": "Northern blot analysis using the rat klotho cDNA probe identified a single transcript of 5.2 kb in size expressed predominantly in the kidney, while RT-PCR detected low levels of expression also in the brain, lung, intestine, and ovaries.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9791011", "endSection": "abstract"}, {"offsetInBeginSection": 775, "offsetInEndSection": 929, "text": "In brain, Klotho proteins were localized at choroid plexus, where the proteins were dominantly localized at the apical plasma membrane of ependymal cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15665504", "endSection": "abstract"}, {"offsetInBeginSection": 888, "offsetInEndSection": 1067, "text": "Moreover, we found that, except for the kidneys and brain, other tissues primarily expressed the shorter-form \u03b1-klotho, including liver, which was in contrast to previous reports.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31920703", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Klotho is an anti-aging protein predominantly expressed in the kidney, parathyroid glands and choroid plexus of the brain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22396165", "endSection": "abstract"}, {"offsetInBeginSection": 472, "offsetInEndSection": 691, "text": "Furthermore, the klotho gene is expressed principally in the important tissues for calcium homeostasis such as distal tubule cells of the kidney, choroid plexus in the brain, and the main cells of the parathyroid gland.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12362891", "endSection": "abstract"}, {"offsetInBeginSection": 806, "offsetInEndSection": 989, "text": "The klotho gene is predominantly expressed in the kidney and the expression level of klotho RNA was shown to be greatly reduced in the kidneys of chronic renal failure (CRF) patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16358222", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "The klotho gene: a gene predominantly expressed in the kidney is a fundamental regulator of aging and calcium/phosphorus metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16358222", "endSection": "title"}, {"offsetInBeginSection": 493, "offsetInEndSection": 683, "text": "Klotho mRNA and protein expression levels in rat brain and kidney tissues were examined using reverse transcription-quantitative polymerase chain reaction and western blotting, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30233703", "endSection": "abstract"}]}, {"body": "List major features of TEMPI Syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25216227", "http://www.ncbi.nlm.nih.gov/pubmed/27501129", "http://www.ncbi.nlm.nih.gov/pubmed/25143825", "http://www.ncbi.nlm.nih.gov/pubmed/25911963", "http://www.ncbi.nlm.nih.gov/pubmed/30100329"], "ideal_answer": ["TEMPI syndrome includes telangiectasias, erythrocytosis with elevated erythropoietin, monoclonal gammopathy, perinephric fluid collections, intrapulmonary shunting. It is a newly described clinical entity that is generally considered a plasma cell dyscrasia with multiple system involvement."], "exact_answer": [["telangiectasias"], ["erythrocytosis with elevated erythropoietin"], ["monoclonal gammopathy"], ["perinephric fluid collections"], ["intrapulmonary shunting"]], "type": "list", "id": "5c6b7daa7c78d6947100002b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "TEMPI Syndrome: Erythrocytosis in Plasma Cell Dyscrasia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30100329", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 281, "text": "TEMPI (telangiectasias, erythrocytosis with elevated erythropoietin, monoclonal gammopathy, perinephric fluid collections, intrapulmonary shunting) syndrome is a newly described clinical entity that is generally considered a plasma cell dyscrasia with multiple system involvement. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30100329", "endSection": "abstract"}, {"offsetInBeginSection": 1695, "offsetInEndSection": 1920, "text": "In other MGCS, such as scleromyxedema, Clarkson syndrome, TEMPI syndrome, cutis laxa and the neutrophilic dermatoses, the link between the monoclocal component and the entity is clearly established, but not understood so far.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27501129", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 269, "text": "TEMPI syndrome (telangiectasias, elevated erythropoietin level and erythrocytosis, monoclonal gammopathy, perinephric fluid collections, and intrapulmonary shunting) is a recently described syndrome that, owing to erythrocytosis, may be confused with polycythemia vera.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25216227", "endSection": "abstract"}, {"offsetInBeginSection": 1592, "offsetInEndSection": 1697, "text": "In conclusion, TEMPI syndrome should be considered when erythrocytosis and plasma cell dyscrasia coexist.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25216227", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 267, "text": "BACKGROUND\nThe TEMPI syndrome was recently described in 2011, and is characterized by the constellation of five hallmarks: Telangiectasias, Erythrocytosis and elevated Erythropoietin, Monoclonal gammopathy, Perinephric fluids collections, and Intrapulmonary shunting.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25143825", "endSection": "abstract"}, {"offsetInBeginSection": 234, "offsetInEndSection": 438, "text": "TEMPI syndrome is a recently described condition defined by teleangiectasias, elevated erythropoietin and erythrocytosis, monoclonal gammopathy, perinephric fluid collections, and intrapulmonary shunting.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25911963", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 267, "text": "BACKGROUND The TEMPI syndrome was recently described in 2011, and is characterized by the constellation of five hallmarks: Telangiectasias, Erythrocytosis and elevated Erythropoietin, Monoclonal gammopathy, Perinephric fluids collections, and Intrapulmonary shunting.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25143825", "endSection": "abstract"}]}, {"body": "Which factors are considered in the ABCD2 score?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21646462", "http://www.ncbi.nlm.nih.gov/pubmed/21554497", "http://www.ncbi.nlm.nih.gov/pubmed/23983858", "http://www.ncbi.nlm.nih.gov/pubmed/23683740", "http://www.ncbi.nlm.nih.gov/pubmed/22237056", "http://www.ncbi.nlm.nih.gov/pubmed/21388829", "http://www.ncbi.nlm.nih.gov/pubmed/20582954", "http://www.ncbi.nlm.nih.gov/pubmed/19803400", "http://www.ncbi.nlm.nih.gov/pubmed/19556026", "http://www.ncbi.nlm.nih.gov/pubmed/20421579", "http://www.ncbi.nlm.nih.gov/pubmed/23871489"], "ideal_answer": ["Age, Blood pressure, Clinical features, Duration of symptoms and Diabetes are included in the ABCD2 score, which is used to identify patients having a transient ischemic attack who are at high risk for imminent stroke."], "exact_answer": [["Age"], ["Blood pressure"], ["Clinical features"], ["Duration of symptoms"], ["Diabetes"]], "type": "list", "id": "551adceb622b194345000018", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 272, "text": "The 'accuracy' of age, blood pressure, clinical features, duration and diabetes (ABCD(2)) scoring by non-stroke specialists referring patients to a daily Rapid Access Stroke Prevention (RASP) service is unclear, as is the accuracy of ABCD(2) scoring by trainee residents. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23871489", "endSection": "abstract"}, {"offsetInBeginSection": 448, "offsetInEndSection": 694, "text": " Classification of low risk was based on an age, blood pressure, clinical features, duration of symptoms and diabetes (ABCD2) score <4 and the absence of high risk features, including known carotid disease, crescendo TIA, or atrial fibrillation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683740", "endSection": "abstract"}, {"offsetInBeginSection": 165, "offsetInEndSection": 669, "text": "Our goal was to compare the very early predictive accuracy of the most relevant clinical scores [age, blood pressure, clinical features and duration of symptoms (ABCD) score, ABCD and diabetes (ABCD2) score, ABCD and brain infarction on imaging score, ABCD2 and brain infarction on imaging score, ABCD and prior TIA within 1 week of the index event (ABCD3) score, California Risk Score, Essen Stroke Risk Score and Stroke Prognosis Instrument II] in consecutive transient ischemic attack (TIA) patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22237056", "endSection": "abstract"}, {"offsetInBeginSection": 162, "offsetInEndSection": 374, "text": "We examined the association of the age, blood pressure, clinical features, duration of symptoms and diabetes (ABCD2) score, a validated risk prediction model for stroke after TIA, and the presence of ICS or ECS. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983858", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "BACKGROUND: The ABCD2 score (Age, Blood pressure, Clinical features, Duration of symptoms and Diabetes) is used to identify patients having a transient ischemic attack who are at high risk for imminent stroke. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21646462", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 216, "text": "BACKGROUND AND PURPOSE: The risk of stroke after a transient ischaemic attack (TIA) can be predicted by scores incorporating age, blood pressure, clinical features, duration (ABCD-score), and diabetes (ABCD2-score). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21554497", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 331, "text": "BACKGROUND: Modifications to the age, blood pressure, clinical symptoms, duration of symptoms, and diabetes (ABCD2) score, which incorporate history of hypertension and acute hyperglycemia in addition to acute blood pressure (BP) elevation and history of diabetes, have been proposed to increase the predictive value of the score. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21388829", "endSection": "abstract"}, {"offsetInBeginSection": 155, "offsetInEndSection": 322, "text": "ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score and magnetic resonance imaging abnormalities help to identify patients at high risk of stroke.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20582954", "endSection": "abstract"}, {"offsetInBeginSection": 334, "offsetInEndSection": 835, "text": "METHODS: We prospectively calculated the ABCD(2) score (age [> or = 60 years: 1 point]; blood pressure [systolic >140 mm Hg or diastolic >90 mm Hg: 1[; clinical features [unilateral weakness: 2, speech disturbance without weakness: 1, other symptom: 0]; duration of symptoms [ <10 minutes: 0, 10-59 minutes: 1, > or = 60 minutes: 2]; diabetes mellitus [yes: 1]) in consecutive TIA patients hospitalized in 3 tertiary care neurology departments across 2 different racial populations (white and Asian). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20421579", "endSection": "abstract"}, {"offsetInBeginSection": 669, "offsetInEndSection": 1250, "text": "Early stroke risk is especially high in TIA patients with a high ABCD2 score of 4 or more (A age over 60 years [1 point]: B blood pressure > 140/90 mmHg [1 point]: C Clinical features, including unilateral weakness [2 points] and speech disturbance without weakness [1 point] D2: Diabetes [1 point] and Duration of symptoms [1 point for < 60 min and 2 points for > 60 min]), acute ischemic lesions on diffusion weighted image, > 50% carotid stenosis, severe intracranial artery stenosis, microembolic signals on transcranial Doppler, atrial fibrillation, or hypercoagulable states.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19803400", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 311, "text": "STUDY OBJECTIVE: We evaluate, in admitted patients with transient ischemic attack, the accuracy of the ABCD(2) (age [A], blood pressure [B], clinical features [weakness/speech disturbance] [C], transient ischemic attack duration [D], and diabetes history [D]) score in predicting ischemic stroke within 7 days. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19556026", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 654, "text": "Our goal was to compare the very early predictive accuracy of the most relevant clinical scores [age, blood pressure, clinical features and duration of symptoms (ABCD) score, ABCD and diabetes (ABCD2) score, ABCD and brain infarction on imaging score, ABCD2 and brain infarction on imaging score, ABCD and prior TIA within 1 week of the index event (ABCD3) score, California Risk Score, Essen Stroke Risk Score and Stroke Prognosis Instrument II] in consecutive transient ischemic attack (TIA) patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22237056", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "The risk of stroke after a transient ischaemic attack (TIA) can be predicted by scores incorporating age, blood pressure, clinical features, duration (ABCD-score), and diabetes (ABCD2-score).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21554497", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "BACKGROUND AND PURPOSE: The risk of stroke after a transient ischaemic attack (TIA) can be predicted by scores incorporating age, blood pressure, clinical features, duration (ABCD-score), and diabetes (ABCD2-score).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21554497", "endSection": "abstract"}]}, {"body": "Which are the main advantages of kallisto against similar methodologies?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27043002", "http://www.ncbi.nlm.nih.gov/pubmed/28484260", "http://www.ncbi.nlm.nih.gov/pubmed/28868134", "http://www.ncbi.nlm.nih.gov/pubmed/28361706", "http://www.ncbi.nlm.nih.gov/pubmed/28096075", "http://www.ncbi.nlm.nih.gov/pubmed/31357172", "http://www.ncbi.nlm.nih.gov/pubmed/30168903"], "ideal_answer": ["Kallisto is a pseudo-alignment algorithm, which is a way of quantifying RNA-sequencing. It's used in RNA-seq because it's much faster and more efficient than other methodologies.", "Kallisto is two orders of magnitude faster than similar methodologies. It uses a novel efficient approach to perform this analysis and to calculate informative metrics at each depth required to inform a broad range of functional and evolutionary studies. It improves performance and speed of RNA sequencing analysis of large data sets.", "kallisto, an RNA-seq quantification program that is two orders of magnitude faster than previous approaches and achieves similar accuracy.", "kallisto is an RNA-seq quantification program that is two orders of magnitude faster than previous approaches and achieves similar accuracy. Kallisto pseudoaligns reads to a reference, producing a list of transcripts that are compatible with each read while avoiding alignment of individual bases."], "exact_answer": [["pseudoalignment"], ["speed"], ["avoids alignment of individual bases"]], "type": "list", "id": "5fdb420fa43ad3127800001f", "snippets": [{"offsetInBeginSection": 946, "offsetInEndSection": 1138, "text": "Results show that count data gives poor parameter estimations, large intercepts and high inter-sample variability; while TPM value from Kallisto and Salmon shows high linearity in all analyses", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28361706", "endSection": "abstract"}, {"offsetInBeginSection": 1152, "offsetInEndSection": 1355, "text": "Salmon and Kallisto TPM data gives the best fit to the linear model studied. This suggests that TPM values estimated from Salmon and Kallisto are the ideal RNA-seq measurements for deconvolution studies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28361706", "endSection": "abstract"}, {"offsetInBeginSection": 720, "offsetInEndSection": 833, "text": " Similarly, new pseudo-alignment-based protocols like Kallisto and Sleuth reduce runtime and improve performance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30168903", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "The recently introduced Kallisto pseudoaligner has radically simplified the quantification of transcripts in RNA-sequencing experiments.\u00a0", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28868134", "endSection": "abstract"}, {"offsetInBeginSection": 621, "offsetInEndSection": 1081, "text": "Arkas-Quantification deploys Kallisto for parallel cloud computations and is conveniently integrated downstream from the BaseSpace Sequence Read Archive (SRA) import/conversion application titled SRA Import.\u00a0 Arkas-Analysis annotates the Kallisto results by extracting structured information directly from source FASTA files with per-contig metadata, calculates the differential expression and gene-set enrichment analysis on both coding genes and transcripts.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28868134", "endSection": "abstract"}, {"offsetInBeginSection": 507, "offsetInEndSection": 778, "text": "RNA-sequencing reads were processed using five workflows (Tophat-HTSeq, Tophat-Cufflinks, STAR-HTSeq, Kallisto and Salmon) and resulting gene expression measurements were compared to expression data generated by wet-lab validated qPCR assays for all protein coding genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28484260", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 306, "text": "kallisto, an RNA-seq quantification program that is two orders of magnitude faster than previous approaches and achieves similar accuracy. Kallisto pseudoaligns reads to a reference, producing a list of transcripts that are compatible with each read while avoiding alignment of individual bases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27043002", "endSection": "abstract"}, {"offsetInBeginSection": 722, "offsetInEndSection": 1074, "text": "It features six independent core-workflows comprising the state-of-the-art technology with dozens of popular cutting-edge tools such as Tophat-Cufflink-Cuffdiff, Subread-featureCounts-DESeq2, STAR-RSEM-EBSeq, Bowtie-eXpress-edgeR, kallisto-sleuth, HISAT-StringTie-Ballgown, and embeds itself in Snakemake, which is a modern pipeline management system. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28096075", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "We present kallisto, an RNA-seq quantification program that is two orders of magnitude faster than previous approaches and achieves similar accuracy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27043002", "endSection": "abstract"}, {"offsetInBeginSection": 311, "offsetInEndSection": 424, "text": "se kallisto to analyze 30 million unaligned paired-end RNA-seq reads in <10 min on a standard laptop computer. Th", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27043002", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 306, "text": "Kallisto pseudoaligns reads to a reference, producing a list of transcripts that are compatible with each read while avoiding alignment of individual bases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27043002", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "The recently introduced Kallisto pseudoaligner has radically simplified the quantification of transcripts in RNA-sequencing experiments.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28868134", "endSection": "abstract"}, {"offsetInBeginSection": 721, "offsetInEndSection": 833, "text": "Similarly, new pseudo-alignment-based protocols like Kallisto and Sleuth reduce runtime and improve performance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30168903", "endSection": "abstract"}]}, {"body": "Name two inhalable insulin products.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25485886"], "ideal_answer": ["Despite discontinuation of the first inhalable insulin, Exubera(r), due to suboptimal market acceptance, development of orally inhaled insulin delivery systems has been galvanized by the recent approval of Afrezza(r)."], "exact_answer": [["Exubera"], ["Afrezza"]], "type": "list", "id": "5e7768f9835f4e477700000b", "snippets": [{"offsetInBeginSection": 196, "offsetInEndSection": 446, "text": "Despite discontinuation of the first inhalable insulin, Exubera\u00ae, due to suboptimal market acceptance, development of orally inhaled insulin delivery systems has been galvanized by the recent approval of Afrezza\u00ae and several others awaiting approval.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25485886", "endSection": "abstract"}]}, {"body": "For which indications has midostaurin received FDA and EMA approval?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30069632"], "ideal_answer": ["Midostaurin was approved by the Food and Drug Administration (FDA) and the European Medical Agency (EMA) for acute myeloid leukemia with activating FLT3 mutations in combination with intensive induction and consolidation therapy as well as aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN) or mast cell leukemia (MCL)."], "exact_answer": [["Acute myeloid leukemia with activating FLT3 mutations"], ["Aggressive systemic mastocytosis"], ["Systemic mastocytosis with associated hematological neoplasm"], ["Mast cell leukemia"]], "type": "list", "id": "5c6585287c78d69471000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30069632", "endSection": "title"}, {"offsetInBeginSection": 283, "offsetInEndSection": 661, "text": "Midostaurin was approved by the Food and Drug Administration (FDA) and the European Medical Agency (EMA) for acute myeloid leukemia with activating FLT3 mutations in combination with intensive induction and consolidation therapy as well as aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN) or mast cell leukemia (MCL).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30069632", "endSection": "abstract"}]}, {"body": "What are the functions of DNA and RNA G-quadruplexes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32545267", "http://www.ncbi.nlm.nih.gov/pubmed/26350216", "http://www.ncbi.nlm.nih.gov/pubmed/34148284", "http://www.ncbi.nlm.nih.gov/pubmed/32056246", "http://www.ncbi.nlm.nih.gov/pubmed/33021960", "http://www.ncbi.nlm.nih.gov/pubmed/22388183", "http://www.ncbi.nlm.nih.gov/pubmed/34285374", "http://www.ncbi.nlm.nih.gov/pubmed/22488917", "http://www.ncbi.nlm.nih.gov/pubmed/22376111", "http://www.ncbi.nlm.nih.gov/pubmed/34166611", "http://www.ncbi.nlm.nih.gov/pubmed/19330720", "http://www.ncbi.nlm.nih.gov/pubmed/25207541", "http://www.ncbi.nlm.nih.gov/pubmed/34162892", "http://www.ncbi.nlm.nih.gov/pubmed/21416921", "http://www.ncbi.nlm.nih.gov/pubmed/33733306", "http://www.ncbi.nlm.nih.gov/pubmed/23012368", "http://www.ncbi.nlm.nih.gov/pubmed/29517770", "http://www.ncbi.nlm.nih.gov/pubmed/23458775"], "ideal_answer": ["G-Quadruplex, a unique secondary structure in nucleic acids found throughout human genome, elicited widespread interest in the field of therapeutic research. Being present in key regulatory regions of oncogenes, RNAs and telomere, G-Quadruplex structure regulates transcription, translation, splicing, etc"], "exact_answer": [["transcription"], ["translation"], ["splicing"], ["RNA regulation"]], "type": "list", "id": "6220ce4c3a8413c653000068", "snippets": [{"offsetInBeginSection": 189, "offsetInEndSection": 364, "text": "G-quadruplexes (G4s) was demonstrated. G4s are alternative nucleic acid structures, which influence many cellular pathways on a transcriptional and post-transcriptional level.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33021960", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Guanine quadruplexes (G4s) are non-canonical nucleic acid structures commonly found in regulatory genomic regions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34166611", "endSection": "abstract"}, {"offsetInBeginSection": 155, "offsetInEndSection": 293, "text": "DNA G-quadruplex (G4)-folded regions in cells were reported to be associated with either increased or decreased transcriptional activity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34162892", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 306, "text": "G-Quadruplex, a unique secondary structure in nucleic acids found throughout human genome, elicited widespread interest in the field of therapeutic research. Being present in key regulatory regions of oncogenes, RNAs and telomere, G-Quadruplex structure regulates transcription, translation, splicing, etc.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34148284", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 387, "text": "G-quadruplexes (G4s) are higher-order structures formed by guanine-rich sequences of nucleic acids, such as the telomeric 5'-TTAGGG-3'/5'-UUAGGG-3' repeats and those in gene regulatory regions. G4s regulate various biological events, including replication, transcription, and translation. Imbalanced G4 dynamics is associated with diseases, such as cancer and neurodegenerative diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34285374", "endSection": "abstract"}, {"offsetInBeginSection": 791, "offsetInEndSection": 894, "text": "Further, the plausible functions of RNA G-quadruplexes such as translational suppression, splicing etc.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22376111", "endSection": "abstract"}, {"offsetInBeginSection": 155, "offsetInEndSection": 397, "text": "G-quadruplexes have various biological functions, including inhibition of telomerase and the regulation of gene transcription and translation, and have become an active target for drug development, particularly for novel anticancer therapies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19330720", "endSection": "abstract"}, {"offsetInBeginSection": 822, "offsetInEndSection": 1029, "text": "Here we briefly discuss various aspects of reporter assays followed by a review of available studies using reporter assays to understand the role and functions of DNA and RNA quadruplexes in gene expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22388183", "endSection": "abstract"}, {"offsetInBeginSection": 647, "offsetInEndSection": 864, "text": " review, we summarize recent evidence for the in vivo presence and function of DNA and RNA G-quadruplexes in various cellular pathways including DNA replication, gene expression and telomere maintenance. We also highl", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26350216", "endSection": "abstract"}, {"offsetInBeginSection": 134, "offsetInEndSection": 334, "text": "im was to investigate their interaction with DNA and RNA G-quadruplexes, their uptake in malignant and nonmalignant cells, and their capacity to modulate gene expression and inhibit cell growth. Flow ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23458775", "endSection": "abstract"}, {"offsetInBeginSection": 287, "offsetInEndSection": 472, "text": "particular, G-quadruplexes occupy strategic locations in genomic DNA and both coding and noncoding RNA molecules, being involved in many essential cellular and organismal functions. In ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32545267", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 203, "text": "Growing evidence indicates that RNA G-quadruplexes have important roles in various processes such as transcription, translation, regulation of telomere length, and formation of telomeric heterochromatin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29517770", "endSection": "abstract"}, {"offsetInBeginSection": 338, "offsetInEndSection": 484, "text": "RNA G-quadruplexes at these specific locations play important roles in key cellular functions, including telomere homeostasis and gene expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22488917", "endSection": "abstract"}, {"offsetInBeginSection": 799, "offsetInEndSection": 949, "text": " the plausible functions of RNA G-quadruplexes such as translational suppression, splicing etc. are discussed in brief, suggesting scope for an extens", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22376111", "endSection": "abstract"}, {"offsetInBeginSection": 82, "offsetInEndSection": 341, "text": "Accumulating evidence indicates that G-quadruplexes serve important regulatory roles in fundamental biological processes such as DNA replication, transcription, and translation, while aberrant G-quadruplex formation is linked to genome instability and cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33733306", "endSection": "abstract"}, {"offsetInBeginSection": 485, "offsetInEndSection": 643, "text": "Indeed, RNA G-quadruplexes appear as important regulators of pre-mRNA processing (splicing and polyadenylation), RNA turnover, mRNA targeting and translation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22488917", "endSection": "abstract"}, {"offsetInBeginSection": 913, "offsetInEndSection": 1084, "text": "We show that G-quadruplexes formed by both (G(4)C(2))(4) RNA and DNA not only complex tightly with heme but also enhance its intrinsic peroxidase and oxidase propensities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25207541", "endSection": "abstract"}, {"offsetInBeginSection": 802, "offsetInEndSection": 965, "text": "The formation of the DNA-RNA G-quadruplex causes a significant increase in the clonogenic capacity of cells and has an effect on inhibition of cellular senescence.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23012368", "endSection": "abstract"}, {"offsetInBeginSection": 287, "offsetInEndSection": 473, "text": "Meanwhile, the different conformations of G-quadruplexes have certain influences on their biological functions, such as the inhibition of transcription, translation, and DNA replication.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32056246", "endSection": "abstract"}, {"offsetInBeginSection": 236, "offsetInEndSection": 471, "text": "G-quadruplex has been implicated by a lot of studies as an important structure in many biological processes including gene stability, telomere synthesis, transcriptional or translational regulation of gene expression and recombination.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21416921", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "RNA and DNA G-quadruplexes bind to human dicer and inhibit its activity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33733306", "endSection": "title"}]}, {"body": "In what states are GDF15 expression increased?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28081177", "http://www.ncbi.nlm.nih.gov/pubmed/28062617", "http://www.ncbi.nlm.nih.gov/pubmed/28025863", "http://www.ncbi.nlm.nih.gov/pubmed/27750354", "http://www.ncbi.nlm.nih.gov/pubmed/28159780"], "ideal_answer": ["Growth differentiation factor 15 (GDF-15) is expressed and secreted in response to inflammation, oxidative stress, hypoxia, telomere erosion, and oncogene activation."], "exact_answer": [["inflammation"], ["oxidative stress"], ["hypoxia"], ["telomere erosion"], ["oncogene activation"], ["tissue injury"]], "type": "list", "id": "5ad303970340b9f05800001a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Macrophage inhibitory cytokine-1 (MIC-1), also known as growth differentiation factor 15 (GDF15), is a stress response cytokine.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28081177", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 178, "text": "Growth differentiation factor 15 (GDF-15) is expressed and secreted in response to inflammation, oxidative stress, hypoxia, telomere erosion, and oncogene activation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28062617", "endSection": "abstract"}, {"offsetInBeginSection": 501, "offsetInEndSection": 711, "text": "the tumour-derived macrophage inhibitory cytokine-1 (MIC-1) emerged as a possible mediator of cancer anorexia because lesions of these brainstem areas attenuated the anorectic effect of exogenous MIC-1 in mice.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28025863", "endSection": "abstract"}, {"offsetInBeginSection": 195, "offsetInEndSection": 393, "text": "Growth differentiation factor-15, also known as macrophage inhibitory cytokine-1 (MIC-1/GDF15) is a member of the transforming growth factor- \u03b2 super family and increases during inflammatory states.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27750354", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Growth differentiation factor-15 (GDF-15) is a member of the TGF-\u03b2cytokine superfamily that is widely expressed and may be induced in response to tissue injury. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28159780", "endSection": "abstract"}]}, {"body": "What are the major classes of retrotransposons active in the human genome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22528351", "http://www.ncbi.nlm.nih.gov/pubmed/23282240", "http://www.ncbi.nlm.nih.gov/pubmed/15867427", "http://www.ncbi.nlm.nih.gov/pubmed/22923465", "http://www.ncbi.nlm.nih.gov/pubmed/2165587", "http://www.ncbi.nlm.nih.gov/pubmed/16511833", "http://www.ncbi.nlm.nih.gov/pubmed/10677855", "http://www.ncbi.nlm.nih.gov/pubmed/16399224", "http://www.ncbi.nlm.nih.gov/pubmed/12213770", "http://www.ncbi.nlm.nih.gov/pubmed/11343131", "http://www.ncbi.nlm.nih.gov/pubmed/12167372", "http://www.ncbi.nlm.nih.gov/pubmed/22093876", "http://www.ncbi.nlm.nih.gov/pubmed/17431169"], "ideal_answer": ["LINE-1 (L1), Alu, SVA"], "exact_answer": [["LINE-1", "L1"], ["Alu"], ["SVA"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018626"], "type": "list", "id": "517843638ed59a060a000036", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 286, "text": "Half of the human genome is composed of repeated DNA, and some types are mobile within our genome (transposons and retrotransposons). Despite their abundance, only a small fraction of them are currently active in our genome (Long Interspersed Element-1 (LINE-1), Alu, and SVA elements).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22528351", "endSection": "sections.0"}, {"offsetInBeginSection": 114, "offsetInEndSection": 343, "text": "Since certain types of retrotransposons, particularly members of the Alu, L1, and SVA families, are still active, their recent and ongoing propagation generates a unique and important class of human genomic diversity/polymorphism", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16511833", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Alu elements are the most successful SINEs (Short INterspersed Elements) in primate genomes and have reached more than 1,000,000 copies in the human genome", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15867427", "endSection": "sections.0"}, {"offsetInBeginSection": 120, "offsetInEndSection": 201, "text": "1 and Alu represent the most prolific human LINE and SINE families, respectively.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12213770", "endSection": "sections.0"}, {"offsetInBeginSection": 202, "offsetInEndSection": 328, "text": "Only a few Alu elements are able to retropose, and the factors determining their retroposition capacity are poorly understood.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12213770", "endSection": "sections.0"}]}, {"body": "What are the 3 types of ultraviolet (UV) solar radiation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24891049", "http://www.ncbi.nlm.nih.gov/pubmed/16117741", "http://www.ncbi.nlm.nih.gov/pubmed/23834148", "http://www.ncbi.nlm.nih.gov/pubmed/11100018"], "ideal_answer": ["Solar ultraviolet (UV) radiation, an ubiquitous environmental carcinogen, is classified depending on the wavelength, into three regions; short-wave UVC (200-280 nm), mid-wave UVB (280-320 nm), and long-wave UVA (320- 400 nm)", "short-wave UVC (200-280 nm), medium-wave UVB (280-320 nm), and long-wave UVA (320-400 nm).", "short-wave UVC (200-280 nm), medium-wave UVB (280-320 nm), and long-wave UVA (320-400 nm). "], "exact_answer": [["short wave UVC (200-280 nm)"], ["mid-wave UVB (280-320 nm)"], ["long-wave UVA (320- 400 nm)"]], "concepts": ["https://meshb.nlm.nih.gov/record/ui?ui=D012993", "https://meshb.nlm.nih.gov/record/ui?ui=D014466"], "type": "list", "id": "5aae6a86fcf456587200000e", "snippets": [{"offsetInBeginSection": 269, "offsetInEndSection": 359, "text": "short-wave UVC (200-280 nm), medium-wave UVB (280-320 nm), and long-wave UVA (320-400 nm).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16117741", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 224, "text": " short-wave UVC (200-280 nm), mid-wave UVB (280-320 nm), and long-wave UVA (320- 400 nm)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23834148", "endSection": "abstract"}, {"offsetInBeginSection": 272, "offsetInEndSection": 488, "text": "solar UV, largely confined to the UVB (290-320 nm) and short-wavelength UVA (320-340 nm) region, there is currently no agreed-upon method to measure broad-spectrum protection against long-wavelength UVA (340-400 nm).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11100018", "endSection": "abstract"}, {"offsetInBeginSection": 178, "offsetInEndSection": 235, "text": "Ultraviolet radiation is made up of UV-C, UV-B, and UV-A.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24891049", "endSection": "abstract"}]}, {"body": "List the human genes encoding for the dishevelled proteins?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12883684", "http://www.ncbi.nlm.nih.gov/pubmed/24040443", "http://www.ncbi.nlm.nih.gov/pubmed/19618470", "http://www.ncbi.nlm.nih.gov/pubmed/8817329", "http://www.ncbi.nlm.nih.gov/pubmed/8856345", "http://www.ncbi.nlm.nih.gov/pubmed/23836490", "http://www.ncbi.nlm.nih.gov/pubmed/8149913", "http://www.ncbi.nlm.nih.gov/pubmed/7958461", "http://www.ncbi.nlm.nih.gov/pubmed/16457155"], "ideal_answer": ["DVL-1\nDVL-2\nDVL-3"], "exact_answer": [["DVL-1"], ["DVL-2"], ["DVL-3"]], "type": "list", "id": "5709e4b2cf1c32585100001c", "snippets": [{"offsetInBeginSection": 294, "offsetInEndSection": 516, "text": "Dishevelled (Dvl/Dsh) is a multi-module protein and a key regulator of both the canonical Wnt and the PCP pathway. In mouse, all Dvl1(-/-) ; Dvl2(-/-) double mutants display craniorachischisis, a severe form of open NTDs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836490", "endSection": "abstract"}, {"offsetInBeginSection": 315, "offsetInEndSection": 511, "text": " In this study, we explore the cause of HSCR by studying the expression of DVL-1 and DVL-3 genes and their proteins in the aganglionic segment and the ganglionic segment of colon in HSCR patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24040443", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 299, "text": "Dishevelled (Dvl) proteins are key transducers of Wnt signaling encoded by members of a multi-gene family in vertebrates. We report here the divergent, tissue-specific expression patterns for all three Dvl genes in Xenopus embryos, which contrast dramatically with their expression patterns in mice.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19618470", "endSection": "abstract"}, {"offsetInBeginSection": 145, "offsetInEndSection": 346, "text": "velopmental processes, including segmentation and neuroblast specification. We have isolated and characterized cDNA clones from two different human dsh-homologous genes, designated as DVL-1 and DVL-3. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8817329", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 394, "text": "In the Drosophila embryo dishevelled (dsh) function is required by target cells in order to respond to wingless (wg, the homolog of Wnt-1), demonstrating a role for dsh in Wnt signal transduction. We have isolated a mouse homolog of the Drosophila dsh segment polarity gene. The 695-amino-acid protein encoded by the mouse dishevelled gene (Dvl-1) shares 50% identity (65% similarity) with dsh.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7958461", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 282, "text": "The Dvl-1 gene on chromosome 1p36 belongs to a family of highly conserved secreted proteins which regulates embryonic induction, generation of cell polarity and specification of cell fate through activation of Wnt signaling pathways. Wnt signaling activates the gene encoding DVL-1;", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12883684", "endSection": "abstract"}, {"offsetInBeginSection": 453, "offsetInEndSection": 629, "text": "We report here that the mouse Dishevelled-1 (Dvl-1) and Dishevelled-2 genes encode proteins that are differentially localized in Wnt-overexpressing PC12 cell lines (PC12/Wnt). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8856345", "endSection": "abstract"}, {"offsetInBeginSection": 152, "offsetInEndSection": 255, "text": "Recently, the DVL1 gene was identified as a middle molecule of the Wnt/beta-catenin signaling pathway. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16457155", "endSection": "abstract"}]}, {"body": "Which are the families of mammalian DNA-(cytosine-5)-methyltransferases?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21846773", "http://www.ncbi.nlm.nih.gov/pubmed/18367714", "http://www.ncbi.nlm.nih.gov/pubmed/22815530", "http://www.ncbi.nlm.nih.gov/pubmed/20838592", "http://www.ncbi.nlm.nih.gov/pubmed/23302691", "http://www.ncbi.nlm.nih.gov/pubmed/22133874", "http://www.ncbi.nlm.nih.gov/pubmed/23357425", "http://www.ncbi.nlm.nih.gov/pubmed/23393137", "http://www.ncbi.nlm.nih.gov/pubmed/21378119", "http://www.ncbi.nlm.nih.gov/pubmed/20679393", "http://www.ncbi.nlm.nih.gov/pubmed/18413740", "http://www.ncbi.nlm.nih.gov/pubmed/21559294", "http://www.ncbi.nlm.nih.gov/pubmed/17616512", "http://www.ncbi.nlm.nih.gov/pubmed/22737219", "http://www.ncbi.nlm.nih.gov/pubmed/22134929", "http://www.ncbi.nlm.nih.gov/pubmed/20071334", "http://www.ncbi.nlm.nih.gov/pubmed/22328086", "http://www.ncbi.nlm.nih.gov/pubmed/23033272", "http://www.ncbi.nlm.nih.gov/pubmed/22210859", "http://www.ncbi.nlm.nih.gov/pubmed/19173286", "http://www.ncbi.nlm.nih.gov/pubmed/19322801", "http://www.ncbi.nlm.nih.gov/pubmed/18437543", "http://www.ncbi.nlm.nih.gov/pubmed/17371843", "http://www.ncbi.nlm.nih.gov/pubmed/22140515", "http://www.ncbi.nlm.nih.gov/pubmed/17890317", "http://www.ncbi.nlm.nih.gov/pubmed/20547750", "http://www.ncbi.nlm.nih.gov/pubmed/16999741", "http://www.ncbi.nlm.nih.gov/pubmed/19626461", "http://www.ncbi.nlm.nih.gov/pubmed/22088914", "http://www.ncbi.nlm.nih.gov/pubmed/16236173", "http://www.ncbi.nlm.nih.gov/pubmed/15962389", "http://www.ncbi.nlm.nih.gov/pubmed/19576953", "http://www.ncbi.nlm.nih.gov/pubmed/19386473", "http://www.ncbi.nlm.nih.gov/pubmed/18974146", "http://www.ncbi.nlm.nih.gov/pubmed/17182866", "http://www.ncbi.nlm.nih.gov/pubmed/16575165", "http://www.ncbi.nlm.nih.gov/pubmed/17929180", "http://www.ncbi.nlm.nih.gov/pubmed/21549127", "http://www.ncbi.nlm.nih.gov/pubmed/18544619"], "ideal_answer": ["DNA (cytosine-5)-methyltransferases catalyze the specific transfer of a methyl group  to the C5 position of cytosine residues in DNA. Three families of DNA (cytosine-5)-methyltransferases have been identified in mammals: DNMT1, DNMT2 and DNMT3 (including DNMT3a, DNMT3b and DNMT3L isoforms). All of them share homologous catalytic domains. DNMT1 is the \ufffd\ufffd\ufffdmaintenance\u201d methyltransferase family. DNMT1 is specific for hemi-methylated DNA and ensures the faithful transmission of DNA methylation patterns in every replication cycle. DNMT3 is required for de novo methylation of DNA. DNMT3 targets unmethylated DNA and is responsible for the establishment of new methylation patterns. Dnmt2, in contrast to all other mammalian DNA (cytosine-5)-methyltransferases, does not possess a large N-terminal regulatory domain. The DNA methylation activity of DNMT2 is still controversial."], "exact_answer": [["DNMT1"], ["DNMT2"], ["DNMT3"]], "concepts": ["http://www.uniprot.org/uniprot/DNMT1_CHICK", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004248", "http://www.uniprot.org/uniprot/CMT3_MAIZE", "http://www.uniprot.org/uniprot/DNM3A_RAT", "http://www.uniprot.org/uniprot/DNMT1_ARATH", "http://www.uniprot.org/uniprot/DNM3A_CHICK", "http://www.uniprot.org/uniprot/DNM3B_MOUSE", "http://www.uniprot.org/uniprot/CMT2_MAIZE", "http://www.biosemantics.org/jochem#4250454", "http://www.uniprot.org/uniprot/CMT1_DICDI", "http://www.uniprot.org/uniprot/DCM_ECOLI", "http://www.uniprot.org/uniprot/DNM3A_HUMAN", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015257", "http://www.uniprot.org/uniprot/DNMT1_RAT", "http://www.uniprot.org/uniprot/DNMT1_MOUSE", "http://www.uniprot.org/uniprot/DNMT1_HUMAN", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003596", "http://www.uniprot.org/uniprot/CMT1_MAIZE", "http://www.uniprot.org/uniprot/DNM3A_MOUSE", "http://www.uniprot.org/uniprot/DCM_ECO57", "http://www.uniprot.org/uniprot/DNMT_FRG3G", "http://www.biosemantics.org/jochem#4273977", "http://www.uniprot.org/uniprot/DNMT1_BOVIN", "http://www.uniprot.org/uniprot/DNM3B_HUMAN", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0003886"], "type": "list", "id": "516c3960298dcd4e51000073", "snippets": [{"offsetInBeginSection": 449, "offsetInEndSection": 529, "text": "Of the DNMTs, DNMT1 and DNMT3a are most highly expressed in postmitotic neurons.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134929", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "DNA methyltransferase 3B (Dnmt3b) belongs to a family of enzymes responsible for methylation of cytosine residues in mammals.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22133874", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Bovine DNA methylation imprints are established in an oocyte size-specific manner, which are coordinated with the expression of the DNMT3 family proteins.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22088914", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 197, "text": "The DNMT3B de novo DNA methyltransferase (DNMT) plays a major role in establishing DNA methylation patterns in early mammalian development, but its catalytic mechanism remains poorly characterized.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549127", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "Dnmt2 proteins are the most conserved members of the DNA methyltransferase enzyme family, but their substrate specificity and biological functions have been a subject of controversy.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20679393", "endSection": "sections.0"}, {"offsetInBeginSection": 265, "offsetInEndSection": 456, "text": "This promoter hypermethylation may be mediated not only by DNMT-1 but also by an entire family of de novo DNA-methyltransferases, such as DNA-methyltransferase-3a (DNMT-3a) and -3b (DNMT-3b).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19386473", "endSection": "sections.0"}, {"offsetInBeginSection": 114, "offsetInEndSection": 494, "text": "Within the family of DNA methyltransferases (Dnmts), Dnmt3a and 3b establish methylation marks during early development, while Dnmt1 maintains methylation patterns after DNA replication. The maintenance function of Dnmt1 is regulated by its large regulatory N-terminal domain that interacts with other chromatin factors and is essential for the recognition of hemi-methylated DNA.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19173286", "endSection": "sections.0"}, {"offsetInBeginSection": 166, "offsetInEndSection": 324, "text": "In this study, we examined a role for the DNA methyltransferase DNMT3B, in particular, the truncated isoform DNMT3B7, which is generated frequently in cancer.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22815530", "endSection": "sections.0"}, {"offsetInBeginSection": 741, "offsetInEndSection": 908, "text": "DNMT1 is a widely expressed DNA methyltransferase maintaining methylation patterns in development, and mediating transcriptional repression by direct binding to HDAC2.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22328086", "endSection": "sections.0"}, {"offsetInBeginSection": 106, "offsetInEndSection": 337, "text": "DNA methyltransferases (DNMTs) are a family of related proteins that both catalyze the de novo formation of 5-methylcytosine and maintain these methylation marks in cell-specific patterns in virtually all mitotic cells of the body.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134929", "endSection": "sections.0"}, {"offsetInBeginSection": 209, "offsetInEndSection": 340, "text": "This methylation is critical for imprinting; a reduction in the DNA methyltransferase DNMT1 causes a widespread loss of imprinting.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20547750", "endSection": "sections.0"}, {"offsetInBeginSection": 124, "offsetInEndSection": 218, "text": "DNA methyltransferase 3B (DNMT3B) is the key methyltransferase in DNA methylation regulations.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19576953", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "DNA methyltransferases (DNMTs) are a family of enzymes that methylate DNA at the C5 position of cytosine residues, and their inhibition is a promising strategy for the treatment of various developmental and proliferative diseases, particularly cancers.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19322801", "endSection": "sections.0"}, {"offsetInBeginSection": 137, "offsetInEndSection": 203, "text": "DNA methylation is mediated by a family of DNA methyltransferases.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18437543", "endSection": "sections.0"}, {"offsetInBeginSection": 1194, "offsetInEndSection": 1357, "text": "These results suggest that DNMT1 and DNMT3B regulate BAG-1 expression via insulator protein DNA-binding and chromatin dynamics by regulating histone dimethylation.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18413740", "endSection": "sections.0"}, {"offsetInBeginSection": 336, "offsetInEndSection": 468, "text": "Here we show that human miR-148 represses DNA methyltransferase 3b (Dnmt3b) gene expression through a region in its coding sequence.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18367714", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "DNA methylation is catalyzed by a family of DNA methyltransferases (DNMTs) including the maintenance enzyme DNMT 1 and de novo methyltransferases DNMT 3a and DNMT 3b.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17929180", "endSection": "sections.0"}, {"offsetInBeginSection": 325, "offsetInEndSection": 676, "text": "Among the reported down-regulated miRNAs in lung cancer, the miRNA (miR)-29 family (29a, 29b, and 29c) has intriguing complementarities to the 3'-UTRs of DNA methyltransferase (DNMT)3A and -3B (de novo methyltransferases), two key enzymes involved in DNA methylation, that are frequently up-regulated in lung cancer and associated with poor prognosis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17890317", "endSection": "sections.0"}, {"offsetInBeginSection": 658, "offsetInEndSection": 797, "text": "Furthermore, we have examined the roles of the de novo methyltransferases (Dnmt3a and Dnmt3b) and related protein (Dnmt3L) in this process.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17616512", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "DNA methyltransferase 1 (DNMT1) has been reported to interact with a wide variety of factors and to contain intrinsic transcriptional repressor activity.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17371843", "endSection": "sections.0"}, {"offsetInBeginSection": 462, "offsetInEndSection": 690, "text": "Inactivation of both Dnmt3a and Dnmt3b, DNA methyltransferases essential for the initiation of de novo DNA methylation, abolished the establishment of DNA methylation and the silencing of Rhox cluster genes in the embryo proper.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17182866", "endSection": "sections.0"}, {"offsetInBeginSection": 411, "offsetInEndSection": 553, "text": "Rather, in vitro analysis indicates that Dnmt3L stimulates DNA methylation by both Dnmt3a and Dnmt3b through direct binding to these proteins.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16999741", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 235, "text": "OBJECTIVE: To investigate the association between single nucleotide polymorphism (SNP) in promoter of the DNA methyltransferase 3B (DNMT3B) gene and risk for development and lymphatic metastasis of gastric cardiac adenocarcinoma (GCA).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15962389", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "Methylation at the 5-position of DNA cytosine on the vertebrate genomes is accomplished by the combined catalytic actions of three DNA methyltransferases (DNMTs), the de novo enzymes DNMT3A and DNMT3B and the maintenance enzyme DNMT1.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23393137", "endSection": "sections.0"}, {"offsetInBeginSection": 221, "offsetInEndSection": 303, "text": "There are two major categories of DNA methyltransferases: de novo and maintenance.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23357425", "endSection": "sections.0"}, {"offsetInBeginSection": 274, "offsetInEndSection": 366, "text": "Some, but not all, murine H1 subtypes interact with DNA methyltransferases DNMT1 and DNMT3B.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23302691", "endSection": "sections.0"}]}, {"body": "Which neuroendocrine tumors are associated with specific tumor syndromes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23010473", "http://www.ncbi.nlm.nih.gov/pubmed/21181474", "http://www.ncbi.nlm.nih.gov/pubmed/19708762", "http://www.ncbi.nlm.nih.gov/pubmed/22041710", "http://www.ncbi.nlm.nih.gov/pubmed/14685672"], "ideal_answer": ["Neuroendocrine tumors are a heterogeneous group of benign and malignant neoplasias, detectable in the context of hereditary tumor syndromes in up to 30% of cases. Neuroendocrine tumors include medullary thyroid carcinoma, gastroenteropancreatic tumors, pheochromocytoma, and paraganglioma."], "exact_answer": [["medullary thyroid carcinoma"], ["gastroenteropancreatic tumors"], ["pheochromocytoma"], ["paraganglioma"]], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:169"], "type": "list", "id": "55031628e9bde69634000024", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Pheochromocytomas are neuroendocrine tumors of the adrenal medulla which can occur either sporadically or in the context of hereditary tumor syndromes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23010473", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 237, "text": "Pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare neuroendocrine tumors of the adrenal glands and the sympathetic and parasympathetic paraganglia. They can occur sporadically or as a part of different hereditary tumor syndromes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22041710", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 184, "text": "Pancreatic neuroendocrine tumors (PNETs) are a characteristic feature of the tumor syndromes multiple endocrine neoplasia type 1 (MEN-1) and von Hippel-Lindau disease (VHL)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21181474", "endSection": "abstract"}, {"offsetInBeginSection": 1297, "offsetInEndSection": 1804, "text": "This review focuses on hereditary syndromes with neuroendocrine tumors, including multiple endocrine neoplasia types 1 and 2, Von Hippel-Lindau disease, neurofibromatosis type 1, Carney complex, pheochromocytoma-paraganglioma syndrome, and familial nonmedullary thyroid carcinoma. In addition, several individual neuroendocrine tumors are described, such as medullary thyroid carcinoma, gastroenteropancreatic tumors, pheochromocytoma, and paraganglioma, emphasizing specific histopathologic characteristics", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19708762", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Neuroendocrine tumors (NETs) are a heterogeneous group of benign and malignant neoplasias, detectable in the context of hereditary tumor syndromes in up to 30% of cases", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14685672", "endSection": "abstract"}, {"offsetInBeginSection": 1110, "offsetInEndSection": 1218, "text": "RET gene analysis can identify individuals with a very high risk to develop familial medullary cancer (MEN2)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14685672", "endSection": "abstract"}, {"offsetInBeginSection": 1577, "offsetInEndSection": 1803, "text": "In addition, several individual neuroendocrine tumors are described, such as medullary thyroid carcinoma, gastroenteropancreatic tumors, pheochromocytoma, and paraganglioma, emphasizing specific histopathologic characteristics", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19708762", "endSection": "abstract"}]}, {"body": "List adenosine A2A receptor antagonists that are used for Parkinson's disease treatment.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23748382", "http://www.ncbi.nlm.nih.gov/pubmed/20182024", "http://www.ncbi.nlm.nih.gov/pubmed/24687255", "http://www.ncbi.nlm.nih.gov/pubmed/15298067", "http://www.ncbi.nlm.nih.gov/pubmed/22585137", "http://www.ncbi.nlm.nih.gov/pubmed/25175961", "http://www.ncbi.nlm.nih.gov/pubmed/15974638", "http://www.ncbi.nlm.nih.gov/pubmed/23483627", "http://www.ncbi.nlm.nih.gov/pubmed/16004599", "http://www.ncbi.nlm.nih.gov/pubmed/23642267"], "ideal_answer": ["Istradefylline and preladenant are adenosine A2A receptor antagonists that are used for Parkinson's disease treatment."], "exact_answer": [["istradefylline"], ["preladenant"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058917", "http://www.disease-ontology.org/api/metadata/DOID:14330", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010300"], "type": "list", "id": "54fc9b236ad7dcbc12000005", "snippets": [{"offsetInBeginSection": 177, "offsetInEndSection": 323, "text": "Adenosine A2A antagonists, such as istradefylline, improve motor function in PD, but their effect on cognitive impairment has not been determined.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23748382", "endSection": "abstract"}, {"offsetInBeginSection": 862, "offsetInEndSection": 995, "text": "Both istradefylline and preladenant have demonstrated moderate efficacy in reducing off time in PD patients with motor fluctuations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22585137", "endSection": "abstract"}, {"offsetInBeginSection": 1067, "offsetInEndSection": 1310, "text": " The available data also suggest that caffeine can improve the motor deficits of PD and that adenosine A2A receptor antagonists such as istradefylline reduces OFF time and dyskinesia associated with standard 'dopamine replacement' treatments. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20182024", "endSection": "abstract"}, {"offsetInBeginSection": 955, "offsetInEndSection": 1228, "text": "Istradefylline (KW-6002) is the first of several adenosine A2A receptor antagonists in development for PD to advance to phase III clinical trials. Initial studies indicate that in patients with motor fluctuations on levodopa, addition of istradefylline reduces 'off' time. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15974638", "endSection": "abstract"}, {"offsetInBeginSection": 858, "offsetInEndSection": 1240, "text": "These include alpha2 adrenergic receptor antagonists (eg, fipamezole), adenosine A2A receptor antagonists (eg, istradefylline), AMPA receptor antagonists (eg, talampanel), neuronal synchronization modulators (eg, levetiracetam) and agents that interact with serotonergic systems such as 5-hydroxytryptamine (5-HT)1A agonists (eg, sarizotan) and 5-HT2A antagonists (eg, quetiapine). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15298067", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 266, "text": "BACKGROUND: We evaluated the efficacy and safety of istradefylline, a selective adenosine A2A receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double-blind manner in Parkinsons disease patients with motor complications in Japan.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23483627", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinsons disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16004599", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16004599", "endSection": "title"}, {"offsetInBeginSection": 431, "offsetInEndSection": 606, "text": "In this article, the author discusses the potential role of A2A adenosine receptor antagonists in the treatment of Parkinson's disease through the evaluation of istradefylline", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23642267", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23642267", "endSection": "title"}]}, {"body": "Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23279763", "http://www.ncbi.nlm.nih.gov/pubmed/10664520", "http://www.ncbi.nlm.nih.gov/pubmed/9820618", "http://www.ncbi.nlm.nih.gov/pubmed/17455252", "http://www.ncbi.nlm.nih.gov/pubmed/23024266", "http://www.ncbi.nlm.nih.gov/pubmed/20175448", "http://www.ncbi.nlm.nih.gov/pubmed/11914929", "http://www.ncbi.nlm.nih.gov/pubmed/18172277", "http://www.ncbi.nlm.nih.gov/pubmed/9236523", "http://www.ncbi.nlm.nih.gov/pubmed/21302639", "http://www.ncbi.nlm.nih.gov/pubmed/23435440", "http://www.ncbi.nlm.nih.gov/pubmed/10614532", "http://www.ncbi.nlm.nih.gov/pubmed/7962349", "http://www.ncbi.nlm.nih.gov/pubmed/21613051", "http://www.ncbi.nlm.nih.gov/pubmed/9735087", "http://www.ncbi.nlm.nih.gov/pubmed/10496602", "http://www.ncbi.nlm.nih.gov/pubmed/10502325"], "ideal_answer": ["Multiple endocrine neoplasia type 1 syndrome is an inherited cancer syndrome defined by occurrence of multiple neuro-endocrine tumors and is classically associated with the combined occurrence of two or more tumors involving parathyroid gland, pancreas and pituitary gland. Other tumors, including but not limited to adrenal cortical tumor, carcinoid tumors lipoma, leiomyoma, duodenal gastrinoma, hepatic focal nodular hyperplasia, and renal angiomyolipoma, angiofibroma, colagenoma, thyroid tumor and meningioma, may also be present."], "exact_answer": [["parathyroid gland"], ["pancreas"], ["pituitary gland"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009369", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018761"], "type": "list", "id": "51477de5d24251bc05000020", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 275, "text": "Multiple endocrine neoplasia type 1 (MEN1; formerly known as Wermer syndrome) is a rare disorder characterized by the combined occurrence of two or more tumors involving parathyroid, pancreatic islets and anterior pituitary glands; some other tumors have also been described.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435440", "endSection": "sections.0"}, {"offsetInBeginSection": 950, "offsetInEndSection": 1154, "text": " Hyperparathyroidism is the most common feature of MEN1 (95% of patients), pancreatic islet tumors or pancreatic NET (neuroendocrine tumor) occur in 40-70% and pituitary tumors in 30-40% of MEN 1 patients", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435440", "endSection": "sections.0"}, {"offsetInBeginSection": 1155, "offsetInEndSection": 1302, "text": " In addition, other tumors, such as adrenal cortical tumors, carcinoid tumors, lipomas, angiofibromas, colagenomas and meningiomas may be present. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435440", "endSection": "sections.0"}, {"offsetInBeginSection": 1705, "offsetInEndSection": 1803, "text": "the most important causes malignant pancreatic neuroendocrine tumors (NET) and thymic carcinoids. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435440", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 292, "text": "Multiple endocrine neoplasia type 1 (MEN1) is inherited in an autosomal dominant fashion and predisposes to the development of hyperplastic or neoplastic changes in the parathyroid and pituitary glands and the endocrine pancreas, along with numerous other characteristic tumors and features. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23279763", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 224, "text": "Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by the combined occurrence of parathyroid and adrenocortical tumors, and neuroendocrine tumors (NETs) of the pancreas and pituitary. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23024266", "endSection": "sections.0"}, {"offsetInBeginSection": 224, "offsetInEndSection": 362, "text": "The pancreatic NETs are predominantly gastrinomas and insulinomas, and the pituitary NETs are mostly prolactinomas and somatotrophinomas. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23024266", "endSection": "sections.0"}, {"offsetInBeginSection": 461, "offsetInEndSection": 617, "text": "We address the potential role of miRNAs in the endocrine pancreas, the pituitary gland, and the parathyroid glands-areas where MEN 1 shows high penetrance. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21613051", "endSection": "sections.0"}, {"offsetInBeginSection": 749, "offsetInEndSection": 921, "text": "Moreover, studies have provided evidence that dysregulation of miRNAs was responsible for endocrine carcinogenesis, including pancreatic, pituitary, and parathyroid tumors.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21613051", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "MEN1 and MEN2 are rare inherited cancer syndromes which express a variety of endocrine and nonendocrine tumors.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21302639", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Multiple endocrine neoplasia Type 1 (MEN1) is a rare hereditary tumor syndrome predisposing to tumor development in several endocrine organs.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20175448", "endSection": "sections.0"}, {"offsetInBeginSection": 141, "offsetInEndSection": 240, "text": " Its major manifestations include hyperparathyroidism, tumors of endocrine pancreas and pituitary. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20175448", "endSection": "sections.0"}, {"offsetInBeginSection": 241, "offsetInEndSection": 459, "text": "eside these three, several other endocrine (adrenocortical, foregut carcinoid) and nonendocrine (lipoma, angiofibroma, collagenoma, ependymoma, meningioma) tumors have been described to be associated with this syndrome", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20175448", "endSection": "sections.0"}, {"offsetInBeginSection": 461, "offsetInEndSection": 764, "text": "Both familial and sporadic forms of the disease are known. The diagnosis of MEN1 can be established if two of the three major manifestations are found in the same patient, whereas the diagnosis of familial MEN1 requires one MEN1 patient and a first degree relative with at least one MEN1 manifestation. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20175448", "endSection": "sections.0"}, {"offsetInBeginSection": 875, "offsetInEndSection": 997, "text": "Both benign (parathyroid, anterior pituitary) and malignant (gastrinoma, glucagonoma) lesions may develop in MEN1 patients", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20175448", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 203, "text": "Multiple endocrine neoplasia type 1 (MEN1) is a classic hereditary tumor syndrome characterized by a genetic predisposition to develop a variety of neuroendocrine neoplasias and hormone excess syndromes.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11914929", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Multiple endocrine neoplasia type 1 (MEN 1) is a familial syndrome characterized by parathyroid, enteropancreatic and pituitary tumors. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10664520", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant inherited tumor syndrome characterized by the development of multiple endocrine tumors", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9820618", "endSection": "sections.0"}, {"offsetInBeginSection": 698, "offsetInEndSection": 1175, "text": "Multiple facial angiofibromas were observed in 28 (88%) of the patients with MEN1, with 16 patients (50%) having 5 or more. Angiofibromas were clinically and histologically identical to those in individuals with tuberous sclerosis. Collagenomas were observed in 23 patients (72%). Also observed were cafe au lait macules in 12 patients (38%), lipomas in 11 patients (34%), confetti-like hypopigmented macules in 2 patients (6%), and multiple gingival papules in 2 patients (6%)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9236523", "endSection": "sections.0"}, {"offsetInBeginSection": 1190, "offsetInEndSection": 1484, "text": "Multiple angiofibromas, collagenomas, lipomas, confetti-like hypopigmented macules and multiple gingival papules are cutaneous manifestations of MEN1 and should be looked for in both family members of patients with MEN1 and individuals with hyperparathyroidism of other MEN1-associated tumors. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9236523", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 266, "text": "Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant inherited disorder characterized by nodular proliferation of the parathyroid glands and tumors of the anterior pituitary gland, the endocrine pancreas, and the neuroendocrine cell system of the gut.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7962349", "endSection": "sections.0"}, {"offsetInBeginSection": 400, "offsetInEndSection": 613, "text": "We report here a genetic study of a female MEN1 patient with the association of nodular hyperplasia of two parathyroid glands, an insulinoma, multiple duodenal gastrinomas, a prolactinoma, and a gastric carcinoid.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7962349", "endSection": "sections.0"}, {"offsetInBeginSection": 11, "offsetInEndSection": 213, "text": "Multiple endocrine neoplasia type 1 (MEN1) is defined clinically by the combined occurrence of multiple tumors, typically of the parathyroid glands, pancreatic islet cells, and anterior pituitary gland.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18172277", "endSection": "sections.0"}, {"offsetInBeginSection": 1125, "offsetInEndSection": 1485, "text": "In support of previous findings in islet tumors, we found down-regulation of the cell-cycle regulator, p18, in both the pancreatic islet and pituitary adenomas, suggesting that reduced p18 levels may be important for Men1-related tumorigenesis in multiple tissues. Surprisingly, we identified increased p16 transcript in pancreatic islet and pituitary tumors. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17455252", "endSection": "sections.0"}, {"offsetInBeginSection": 163, "offsetInEndSection": 458, "text": " The patient was studied and diagnosed with a multiple endocrine neoplasia type I (MEN I), familiar (mother with MEN I). A scintigraphic study with 99mTc-MIBI was performed in order to localize hyperfunctioning parathyroid glands because of biochemical diagnosis of primary hyperparathyroidism. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10614532", "endSection": "sections.0"}, {"offsetInBeginSection": 761, "offsetInEndSection": 869, "text": "The tumor was removed and histologically confirmed as a carcinoid within a thymus in a MEN type I syndrome. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10614532", "endSection": "sections.0"}, {"offsetInBeginSection": 869, "offsetInEndSection": 1040, "text": "MEN I patients can benefit from the examination with this agent which can potentially localize not only parathyroid endocrine pathology but also unknown associated tumors.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10614532", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Pancreatic endocrine tumors occur sporadically and as part of the multiple endocrine neoplasia type 1 (MEN 1) and von Hippel-Lindau (VHL) syndromes. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10502325", "endSection": "sections.0"}, {"offsetInBeginSection": 436, "offsetInEndSection": 701, "text": "We have analyzed 22 nonfamilial and 16 MEN 1-associated pancreatic endocrine tumors for loss of heterozygosity (LOH) at 3p, 11q13, and 18q. LOH at 3p was revealed in 45% and 36% of tumors from 31 patients with nonfamilial and MEN 1-associated disease, respectively.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10502325", "endSection": "sections.0"}, {"offsetInBeginSection": 1470, "offsetInEndSection": 1670, "text": "The data indicate involvement of tumor suppressor genes on 3p and 18q, in addition to the MEN1 gene at 11q13, in the tumorigenesis of both nonfamilial and MEN 1-associated pancreatic endocrine tumors.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10502325", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 282, "text": "Multiple endocrine neoplasia type 1 (MEN1) is characterized by the development of endocrine tumors of the parathyroid and pituitary glands, pancreas, and duodenum. Less frequently occurring tumors associated with MEN1 include non-endocrine tumors such as lipomas and angiofibromas. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10496602", "endSection": "sections.0"}, {"offsetInBeginSection": 282, "offsetInEndSection": 468, "text": "An increased incidence of thyroid neoplasms, leiomyomas, adrenal cortical hyperplasia, hepatic focal nodular hyperplasia, and renal angiomyolipoma has been noted in the MEN1 population. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10496602", "endSection": "sections.0"}, {"offsetInBeginSection": 768, "offsetInEndSection": 1055, "text": "A germline mutation of the MEN1 gene was detected, and deletions of the MEN1 gene were consistently detected in multiple neuroendocrine tumors involving the parathyroid glands and the pancreas and a hepatic neuroendocrine tumor metastasis, as predicted by Knudson's \"two hit\" hypothesis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10496602", "endSection": "sections.0"}, {"offsetInBeginSection": 1071, "offsetInEndSection": 1232, "text": "Two hits of the MEN1 gene were also detected in esophageal leiomyoma tissue, suggesting that tumorigenesis was directly related to the patient's underlying MEN1.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10496602", "endSection": "sections.0"}, {"offsetInBeginSection": 1237, "offsetInEndSection": 1612, "text": " In contrast, follicular thyroid adenoma, papillary thyroid carcinoma, hepatic focal nodular hyperplasia, and adrenal cortical hyperplasia consistently showed retained heterozygosity of the MEN1 gene with flanking markers and an intragenic marker. Therefore, these tumors appear to develop along pathogenetic pathways that are different from classical MEN1-associated tumors.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10496602", "endSection": "sections.0"}, {"offsetInBeginSection": 312, "offsetInEndSection": 624, "text": "Twelve unrelated (German MEN1 families and their associated tumors (5 parathyroid tumors, 1 vipoma, 1 gastrinoma, 1 insulinoma) were characterized for MEN1 gene mutations by single-strand conformational variant (SSCV) analysis and DNA sequence analysis as well as for loss of heterozygosity on chromosome 11q13. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9820618", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 277, "text": "Multiple endocrine neoplasia type 1 (MEN1) consists of benign, and sometimes malignant, tumors (often multiple in a tissue) of the parathyroids, enteropancreatic neuroendocrine system, anterior pituitary, and other tissues. Skin angiofibromas and skin collagenomas are common. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9735087", "endSection": "sections.0"}]}, {"body": "List features of the Thrombotic Thrombocytopenic Purpura pentad.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16104532", "http://www.ncbi.nlm.nih.gov/pubmed/1605172", "http://www.ncbi.nlm.nih.gov/pubmed/21415981", "http://www.ncbi.nlm.nih.gov/pubmed/23263974", "http://www.ncbi.nlm.nih.gov/pubmed/2647685", "http://www.ncbi.nlm.nih.gov/pubmed/18097325", "http://www.ncbi.nlm.nih.gov/pubmed/23767207", "http://www.ncbi.nlm.nih.gov/pubmed/11399382", "http://www.ncbi.nlm.nih.gov/pubmed/32190437", "http://www.ncbi.nlm.nih.gov/pubmed/23738162", "http://www.ncbi.nlm.nih.gov/pubmed/22233953", "http://www.ncbi.nlm.nih.gov/pubmed/21850657", "http://www.ncbi.nlm.nih.gov/pubmed/30447150", "http://www.ncbi.nlm.nih.gov/pubmed/32699732", "http://www.ncbi.nlm.nih.gov/pubmed/16616715", "http://www.ncbi.nlm.nih.gov/pubmed/29123569", "http://www.ncbi.nlm.nih.gov/pubmed/12423834", "http://www.ncbi.nlm.nih.gov/pubmed/9360410", "http://www.ncbi.nlm.nih.gov/pubmed/29270999", "http://www.ncbi.nlm.nih.gov/pubmed/1821908", "http://www.ncbi.nlm.nih.gov/pubmed/25512716", "http://www.ncbi.nlm.nih.gov/pubmed/22574558", "http://www.ncbi.nlm.nih.gov/pubmed/1171419", "http://www.ncbi.nlm.nih.gov/pubmed/10775033", "http://www.ncbi.nlm.nih.gov/pubmed/8427289", "http://www.ncbi.nlm.nih.gov/pubmed/16913442", "http://www.ncbi.nlm.nih.gov/pubmed/7863389", "http://www.ncbi.nlm.nih.gov/pubmed/12745043", "http://www.ncbi.nlm.nih.gov/pubmed/26634125", "http://www.ncbi.nlm.nih.gov/pubmed/17525362", "http://www.ncbi.nlm.nih.gov/pubmed/29340125", "http://www.ncbi.nlm.nih.gov/pubmed/19665681", "http://www.ncbi.nlm.nih.gov/pubmed/33024522", "http://www.ncbi.nlm.nih.gov/pubmed/30072561", "http://www.ncbi.nlm.nih.gov/pubmed/4038757", "http://www.ncbi.nlm.nih.gov/pubmed/12753286", "http://www.ncbi.nlm.nih.gov/pubmed/10541941", "http://www.ncbi.nlm.nih.gov/pubmed/12938786"], "ideal_answer": ["Thrombotic thrombocytopenic purpura (TTP) is typically characterized by the symptomatic pentad of fever, thrombocytopenia, microangiopathic hemolytic anemia, neurologic abnormalities, and renal failure."], "exact_answer": [["fever"], ["thrombocytopenia"], ["microangiopathic hemolytic anemia"], ["neurologic abnormalities"], ["renal failure"]], "type": "list", "id": "60274aca1cb411341a0000e3", "snippets": [{"offsetInBeginSection": 147, "offsetInEndSection": 291, "text": "Our patient presented with the classic pentad of TTP symptoms: anemia, thrombocytopenia, fever, elevated creatinine, and altered mental status. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32190437", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 203, "text": "Thrombotic thrombocytopenic purpura (TTP) is typically characterized by the symptomatic pentad of fever, thrombocytopenia, microangiopathic hemolytic anemia, neurologic abnormalities, and renal failure.\u00a0", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32699732", "endSection": "abstract"}, {"offsetInBeginSection": 388, "offsetInEndSection": 584, "text": "Nonetheless, the classical pentad of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, neurological dysfunction, kidney dysfunction and fever are seen only in 40 percent of the patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33024522", "endSection": "abstract"}, {"offsetInBeginSection": 216, "offsetInEndSection": 458, "text": "TTP has been characterized by the classical pentad of thrombocytopenia, hemolysis, fever, renal injury and neurological deficits, yet the patient may present with any atypical symptom related to microthrombi formation in the microcirculation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30447150", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 309, "text": "Thrombotic thrombocytopenic purpura (TTP) is an acute, life-threatening illness with disseminated platelet-rich thromboses of small vessels that variably presents with the classic clinical \"pentad\" of microangiopathic hemolytic anemia, thrombocytopenia, fever, altered mental status, and acute kidney injury. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29270999", "endSection": "abstract"}, {"offsetInBeginSection": 509, "offsetInEndSection": 775, "text": "Thrombotic thrombocytopenic purpura (TTP) is a distinct, rare but potentially life-threatening entity that classically but not invariably presents with a pentad of acute onset haemolytic anaemia, thrombocytopenia, neurological symptoms, renal impairment and fevers. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30072561", "endSection": "abstract"}, {"offsetInBeginSection": 425, "offsetInEndSection": 627, "text": "The patient was diagnosed thrombotic thrombocytopenic purpura (TTP) following pentad of clinical features: microangiopathic hemolytic anemia, thrombocytopenia, fever neurologic, and renal abnormalities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22574558", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "Thrombotic thrombocytopenic purpura (TTP) is a disorder of blood coagulation that presents classically with the pentad of fever, thrombocytopenia, microangiopathic hemolytic anemia, renal dysfunction and mental status changes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17525362", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Thrombotic thrombocytopenic purpura (TTP) is characterized by the pentad of fever, thrombocytopenia, microangiopathic hemolytic anemia, fluctuating neurologic symptoms, and renal dysfunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1605172", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "Thrombotic thrombocytopenic purpura (TTP) is typically characterized by the symptomatic pentad of fever, thrombocytopenia, microangiopathic hemolytic anemia, neurologic abnormalities, and renal failure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32699732", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "Thrombotic thrombocytopenic purpura (TTP) is a multisystem disorder characterized by a pentad consisting of thrombocytopenic, microangiopathic hemolytic anemia, renal dysfunction, neurological signs and fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23767207", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 188, "text": "Clinical thrombotic thrombocytopenic purpura (TTP) is characterized by a pentad of microangiopathic hemolytic anemia, thrombocytopenia, neurological symptoms, renal involvement, and fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10775033", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "UNLABELLED: The pentad of thrombocytopenia, haemolytic anaemia, mild renal dysfunction, neurological signs and fever, classically characterizes the syndrome of thrombotic thrombocytopenic purpu", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10541941", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "BACKGROUND: The pentad of thrombocytopenia, hemolytic anemia, mild renal dysfunction, neurologic signs, and fever, classically characterizes the syndrome of thrombotic thrombocytopenic purpur", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12753286", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "Thrombotic thrombocytopenic purpura (TTP) is a disorder of blood coagulation that presents classically with the pentad of fever, thrombocytopenia, microangiopathic hemolytic anemia, renal dysfunction and mental status changes. How", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17525362", "endSection": "abstract"}, {"offsetInBeginSection": 227, "offsetInEndSection": 421, "text": "botic thrombocytopenic purpura has classically been characterized by the pentad of fever, microangiopathic hemolytic anemia, neurologic symptoms, renal dysfunction, and thrombocytopenia. The pat", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11399382", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 219, "text": "Thrombotic thrombocytopenic purpura (TTP) is a syndrome characterised by the clinical pentad of microangiopathic haemolytic anaemia (MAHA), thrombocytopenia, renal failure, fluctuating neurologic signs, and fever. The a", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9360410", "endSection": "abstract"}, {"offsetInBeginSection": 196, "offsetInEndSection": 397, "text": "hrombotic thrombocytopenic purpura was first described in 1924 by Moschowitz as a disease presenting with a pentad of signs and symptoms (anemia, thrombocytopenia, fever, hemiparesis and hematuria). Pr", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29340125", "endSection": "abstract"}, {"offsetInBeginSection": 514, "offsetInEndSection": 784, "text": "botic thrombocytopenic purpura (TTP) is a distinct, rare but potentially life-threatening entity that classically but not invariably presents with a pentad of acute onset haemolytic anaemia, thrombocytopenia, neurological symptoms, renal impairment and fevers. Autoimmun", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30072561", "endSection": "abstract"}, {"offsetInBeginSection": 126, "offsetInEndSection": 286, "text": "s clinically characterized by the pentad of thrombocytopenia, Coombs-negative hemolytic anemia, fever, renal abnormalities and neurological disturbances. Advanc", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21415981", "endSection": "abstract"}, {"offsetInBeginSection": 435, "offsetInEndSection": 641, "text": "t was diagnosed thrombotic thrombocytopenic purpura (TTP) following pentad of clinical features: microangiopathic hemolytic anemia, thrombocytopenia, fever neurologic, and renal abnormalities. Magnetic reso", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22574558", "endSection": "abstract"}, {"offsetInBeginSection": 528, "offsetInEndSection": 879, "text": "He was later diagnosed with thrombotic thrombocytopenic purpura (TTP) based on the fact that he presented with most components of the TTP pentad (except for fever), which included altered mental status, acute kidney injury, thrombocytopenia, and evidence of red cell fragmentation and his ADAMTS13 level was found to be less than 10% prior to therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25512716", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 308, "text": "Thrombotic thrombocytopenic purpura (TTP) is an acute, life-threatening illness with disseminated platelet-rich thromboses of small vessels that variably presents with the classic clinical \"pentad\" of microangiopathic hemolytic anemia, thrombocytopenia, fever, altered mental status, and acute kidney injury.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29270999", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 222, "text": "Thrombotic thrombocytopenic purpura (TTP) is a rapidly progressive hematological syndrome defined by the pentad of thrombocytopenia, microangiopathic hemolytic anemia, neurologic abnormalities, fever and renal dysfunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16913442", "endSection": "abstract"}, {"offsetInBeginSection": 124, "offsetInEndSection": 295, "text": "It is characterized by a pentad of clinical findings, including microangiopathic hemolytic anemia, thrombocytopenic purpura, neurologic and renal abnormalities, and fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2647685", "endSection": "abstract"}, {"offsetInBeginSection": 69, "offsetInEndSection": 270, "text": "It is a multi-systemic disorder characterized by a clinical pentad of thrombocytopenia, microangiopathic hemolytic anemia, diffuse and nonfocal neurologic symptoms, decreased renal function, and fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12745043", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 333, "text": "Initially presenting a fever and systemic upset she progressed to develop dialysis dependent acute renal failure, seizures, thrombocytopenia and a haemolytic anaemia--the pentad of features seen in TTP.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16616715", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Thrombotic thrombocytopenic purpura (TTP) consists of the pentad of thrombocytopenia, hemolytic anemia, fever, neurologic abnormalities, and renal disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23738162", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Thrombotic thrombocytopenic purpura is a clinical syndrome defined by the pentad of thrombocytopenia, microangiopathic hemolytic anemia, fever, and renal and neurologic abnormalities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8427289", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "UNLABELLED: The pentad of thrombocytopenia, haemolytic anaemia, mild renal dysfunction, neurological signs and fever, classically characterizes the syndrome of thrombotic thrombocytopenic purpura (TTP).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10541941", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Thrombotic thrombocytopenic purpura (TTP) is characterized by the pentad of microangiopathic hemolytic anemia, thrombocytopenia, neurologic symptoms, renal insufficiency, and fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12938786", "endSection": "abstract"}, {"offsetInBeginSection": 183, "offsetInEndSection": 327, "text": "It is characterized by the pentad of thrombocytopenia, microangiopathic hemolytic anemia, neurological symptoms, fever, and renal abnormalities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12423834", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 239, "text": "Thrombotic thrombocytopenic purpura (TTP) is a rare disorder of unknown etiology, clinically characterized by a diagnostic pentad (thrombocytopenia, microangiopathic hemolytic anemia, neurologic signs and symptoms, fever and renal damage).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1821908", "endSection": "abstract"}, {"offsetInBeginSection": 112, "offsetInEndSection": 278, "text": "TTP is characterized by a pentad of clinical findings, including microangiopathic hemolytic anemia, thrombocytopenia, renal abnormalities, neurologic signs and fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7863389", "endSection": "abstract"}, {"offsetInBeginSection": 169, "offsetInEndSection": 384, "text": "While the pentad of thrombocytopenia, microangiopathic hemolytic anemia, fever, and renal and neurologic abnormalities characterize the clinical presentation of TTP, few patients present with all signs and symptoms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19665681", "endSection": "abstract"}, {"offsetInBeginSection": 457, "offsetInEndSection": 619, "text": " no cases of congenital TTP. The classic pentad of TTP (microangiopathic hemolytic anemia, thrombocytopenia, neurologic symptoms, renal dysfunction and fever) was", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23263974", "endSection": "abstract"}, {"offsetInBeginSection": 395, "offsetInEndSection": 579, "text": "TTP is a life-threatening disease, characterized by Moschcowitz's pentad: thrombocytopenia, microangiopathic hemolytic anemia, fluctuating neurological signs, renal failure, and fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16104532", "endSection": "abstract"}, {"offsetInBeginSection": 528, "offsetInEndSection": 867, "text": "1 This case presented with the pentad of thrombotic thrombocytopenic purpura: severe thrombocytopenia (platelets 9\u2009\u00d7\u2009109/L), microangiopathic haemolytic anaemia (reticular count 245\u2009\u00d7\u2009109/L (20-110)), LDH >5000 U/L (<425)), neurological abnormalities (Glasgow Coma Scale 10/15), renal failure (creatinine 140\u2009\u00b5mol/L (<97)), fever (37.7\u2103). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29123569", "endSection": "abstract"}, {"offsetInBeginSection": 584, "offsetInEndSection": 775, "text": "All 31 patients had diagnostic criteria for TTP; 16 (52%) had the complete \"pentad\" of microangiopathic hemolytic anemia, thrombocytopenia, neurologic abnormalities, renal failure, and fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21850657", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "Thrombotic thrombocytopenic purpura (TTP) is an uncommon disorder characterized by a pentad of microangiopathic hemolytic anemia, thrombocytopenia, renal dysfunction, fever, and a fluctuating neurologic syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18097325", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 274, "text": "BACKGROUND: Idiopathic thrombotic thrombocytopenic purpura (TTP) is a rare hematological emergency characterized by the pentad of microangiopathic hemolytic anemia, thrombocytopenia, neurological symptoms, renal injury, and fever that is invariably fatal if left untreated. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26634125", "endSection": "abstract"}, {"offsetInBeginSection": 197, "offsetInEndSection": 337, "text": "Diagnosis of TTP is usually made on the basis of the pentad of anemia, thrombocytopenia, renal disease, neurologic abnormalities, and fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1171419", "endSection": "abstract"}, {"offsetInBeginSection": 966, "offsetInEndSection": 1173, "text": "Later on he was referred to our intensive care unit; having classical pentad of thrombocytopenic purpura, i.e., thrombocytopenia, micro-angiopathic hemolytic anemia, renal failure, encephalopathy, and fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22233953", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 268, "text": "Thrombotic thrombocytopenic purpura (TTP) is an uncommon disorder which usually occurs in young adults. It is characterized by a pentad of clinical findings: fever, neurological abnormalities, renal dysfunction, microangiopathic hemolytic anemia and thrombocytopenia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/4038757", "endSection": "abstract"}]}, {"body": "Which are the roles of chromatin compartments in the eukaryotic nucleus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15791412", "http://www.ncbi.nlm.nih.gov/pubmed/18974210", "http://www.ncbi.nlm.nih.gov/pubmed/21637796", "http://www.ncbi.nlm.nih.gov/pubmed/15140983", "http://www.ncbi.nlm.nih.gov/pubmed/22198682", "http://www.ncbi.nlm.nih.gov/pubmed/11909528", "http://www.ncbi.nlm.nih.gov/pubmed/9636146", "http://www.ncbi.nlm.nih.gov/pubmed/9291094", "http://www.ncbi.nlm.nih.gov/pubmed/24002784", "http://www.ncbi.nlm.nih.gov/pubmed/9587055", "http://www.ncbi.nlm.nih.gov/pubmed/18434402", "http://www.ncbi.nlm.nih.gov/pubmed/25409831", "http://www.ncbi.nlm.nih.gov/pubmed/11186332"], "ideal_answer": ["The complexity in composition and function of the eukaryotic nucleus is achieved through its organization in specialized nuclear compartments. Chromosome conformation capture approaches have shown that interphase chromatin is partitioned into spatially segregated Mb-sized compartments and sub-Mb-sized topological domains. This compartmentalization is thought to facilitate the matching of genes and regulatory elements. Cohesin-based chromatin interactions enable regulated gene expression within preexisting architectural compartments. Therefore, concentrating proteins needed to perform different steps of RNA synthesis within specialized nuclear compartments is important in orchestrating events required for efficient gene expression."], "exact_answer": [["providing complex regulation"], ["facilitating matching genes and regulatory elements"], ["efficient trancription"]], "type": "list", "id": "56ebfa13107309bc2f000004", "snippets": [{"offsetInBeginSection": 1047, "offsetInEndSection": 1242, "text": "concentrating proteins needed to perform different steps of RNA synthesis within specialized nuclear compartments will be important in orchestrating events required for efficient gene expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9291094", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Chromatin domains and nuclear compartments: establishing sites of gene expression in eukaryotic nuclei.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9291094", "endSection": "title"}, {"offsetInBeginSection": 332, "offsetInEndSection": 529, "text": "Using the adult bovine lens as a model system, nuclear changes accompanying denucleation are described with particular emphasis on the lamina, nucleolar and coiled body compartments in lens nuclei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9587055", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Changes in the nucleolar and coiled body compartments precede lamina and chromatin reorganization during fibre cell denucleation in the bovine lens", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9587055", "endSection": "title"}, {"offsetInBeginSection": 1271, "offsetInEndSection": 1419, "text": "Prior to chromatin condensation, coilin redistributed to the nucleolar compartment and was absent from nuclei where chromatin had begun to condense.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9587055", "endSection": "abstract"}, {"offsetInBeginSection": 738, "offsetInEndSection": 876, "text": "These constraints reflect the physical attachment of chromatin to nuclear compartments or steric impairment caused by local ultrastructure", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11909528", "endSection": "abstract"}, {"offsetInBeginSection": 793, "offsetInEndSection": 964, "text": "A number of these proteins accumulate in viral replication compartments in the infected cell nucleus, indicating that these proteins may have a role in viral replication. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15140983", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Nuclear marginalization of host cell chromatin associated with expansion of two discrete virus-induced subnuclear compartments during baculovirus infection", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18434402", "endSection": "title"}, {"offsetInBeginSection": 729, "offsetInEndSection": 898, "text": "In the late stage of infection, however, the peristromal region (PR), another virus-induced subnuclear compartment, was also excluded from the chromatin-localizing area.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18434402", "endSection": "abstract"}, {"offsetInBeginSection": 1587, "offsetInEndSection": 1818, "text": "This correlation between compartmentalization and chromatin exclusion suggests the possibility that a chromatin-exclusive property of viral molecules, at least in part, supports nuclear compartmentalization of virus-infected cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18434402", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Chromatin modifications in hematopoietic multipotent and committed progenitors are independent of gene subnuclear positioning relative to repressive compartments", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18974210", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 374, "text": "To further clarify the contribution of nuclear architecture in the regulation of gene expression patterns during differentiation of human multipotent cells, we analyzed expression status, histone modifications, and subnuclear positioning relative to repressive compartments, of hematopoietic loci in multipotent and lineage-committed primary human hematopoietic progenitors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18974210", "endSection": "abstract"}, {"offsetInBeginSection": 375, "offsetInEndSection": 638, "text": "We report here that positioning of lineage-affiliated loci relative to pericentromeric heterochromatin compartments (PCH) is identical in multipotent cells from various origins and is unchanged between multipotent and lineage-committed hematopoietic progenitors. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18974210", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "The complexity in composition and function of the eukaryotic nucleus is achieved through its organization in specialized nuclear compartments.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21637796", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Cohesin-based chromatin interactions enable regulated gene expression within preexisting architectural compartments.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24002784", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 278, "text": "Chromosome conformation capture approaches have shown that interphase chromatin is partitioned into spatially segregated Mb-sized compartments and sub-Mb-sized topological domains. This compartmentalization is thought to facilitate the matching of genes and regulatory elements,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24002784", "endSection": "abstract"}, {"offsetInBeginSection": 741, "offsetInEndSection": 869, "text": "we find that architectural compartments are maintained in noncycling mouse thymocytes after genetic depletion of cohesin in vivo", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24002784", "endSection": "abstract"}, {"offsetInBeginSection": 1256, "offsetInEndSection": 1410, "text": "Our findings indicate that cohesin-mediated long-range interactions facilitate discrete gene expression states within preexisting chromosomal compartments", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24002784", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Histone posttranslational modifications mediate establishment of structurally and functionally distinct chromatin compartments of eukaryotic nuclei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15791412", "endSection": "abstract"}, {"offsetInBeginSection": 683, "offsetInEndSection": 910, "text": "Recent studies employing chromatin conformation capture techniques indicate that Hox clusters adopt a remarkable spatial configuration, in which active and inactive genes are segregated into two distinct chromatin compartments.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22198682", "endSection": "abstract"}, {"offsetInBeginSection": 953, "offsetInEndSection": 1189, "text": "Recent Hi-C mapping has unveiled substructure within chromatin compartments called topologically associating domains (TADs) that are largely conserved in their positions between cell types and are similar in size to replication domains.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25409831", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Interaction of SP100 with HP1 proteins: a link between the promyelocytic leukemia-associated nuclear bodies and the chromatin compartment.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9636146", "endSection": "title"}, {"offsetInBeginSection": 1344, "offsetInEndSection": 1940, "text": "We propose that basically three nuclear compartments exist, an &quot;open&quot; higher-order chromatin compartment with chromatin domains containing active genes, a &quot;closed&quot; chromatin compartment comprising inactive genes, and an interchromatin domain (ICD) compartment (Cremer et al., 1993; Zirbel et al., 1993) that contains macromolecular complexes for transcription, splicing, DNA replication, and repair. Genes in &quot;open,&quot; but not in &quot;closed&quot; higher-order chromatin compartments have access to transcription and splicing complexes located in the ICD compartment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11186332", "endSection": "abstract"}, {"offsetInBeginSection": 1764, "offsetInEndSection": 2180, "text": "Genes in &quot;open,&quot; but not in &quot;closed&quot; higher-order chromatin compartments have access to transcription and splicing complexes located in the ICD compartment. Chromatin domains that build the &quot;open&quot; chromatin compartment are organized in a way that allows the direct contact of genes and nascent RNA to transcription and splicing complexes, respectively, preformed in the ICD compartment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11186332", "endSection": "abstract"}, {"offsetInBeginSection": 1344, "offsetInEndSection": 1638, "text": "We propose that basically three nuclear compartments exist, an &quot;open&quot; higher-order chromatin compartment with chromatin domains containing active genes, a &quot;closed&quot; chromatin compartment comprising inactive genes, and an interchromatin domain (ICD) compartment (Cremer et al.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11186332", "endSection": "abstract"}]}, {"body": "Which two genes are predominantly considered by warfarin initial dosing algorithms?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32710457", "http://www.ncbi.nlm.nih.gov/pubmed/31673144"], "ideal_answer": ["Polymorphisms in CYP2C9 and VKORC1 are taken into consideration by warfarin initial dosing algorithms."], "exact_answer": [["CYP2C9"], ["VKORC1"]], "type": "list", "id": "606a23c694d57fd87900004d", "snippets": [{"offsetInBeginSection": 392, "offsetInEndSection": 570, "text": " 507 adults were randomized to receive initial dosing as determined by an algorithm containing genetic (VKORC1 and CYP2C9) plus clinical information or only clinical information.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32710457", "endSection": "abstract"}]}, {"body": "Which CYP genes' expression is decreased at the in vivo level following pomegranate juice consumption?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18158835"], "ideal_answer": ["It was found that pomegranate juice consumption decreased total hepatic CYP content as well as the expression of CYP1A2 and CYP3A."], "exact_answer": [["CYP1A2"], ["CYP3A"]], "type": "list", "id": "620c01ae3a8413c653000005", "snippets": [{"offsetInBeginSection": 859, "offsetInEndSection": 990, "text": "It was found that pomegranate juice consumption decreased total hepatic CYP content as well as the expression of CYP1A2 and CYP3A. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18158835", "endSection": "abstract"}]}, {"body": "Which two drugs are included in the MAVYRET pill?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28929412", "http://www.ncbi.nlm.nih.gov/pubmed/29089721"], "ideal_answer": ["MAVYRET pill includes glecaprevir and pibrentasvir. It is used for treatment of hepatitis C infection."], "exact_answer": [["glecaprevir"], ["pibrentasvir"]], "type": "list", "id": "5c6e146a7c78d6947100004c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "A fixed-dose combination tablet of the hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) glecaprevir and the HCV NS5A inhibitor pibrentasvir [glecaprevir/pibrentasvir; MAVIRET\u2122 (EU); MAVYRET\u2122 (USA)] has been developed by AbbVie.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28929412", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 235, "text": "Aminolevulinic acid hydrochloride (Gleolan) for the visualization of malignant tissue during surgery; delafloxacin (Baxdela) for certain acute bacterial skin infections; and glecaprevir/pibrentasvir (Mavyret) for chronic HCV infection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29089721", "endSection": "abstract"}]}, {"body": "List the releases of tmVar", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28968638", "http://www.ncbi.nlm.nih.gov/pubmed/23564842"], "ideal_answer": ["TmVar is a text mining approach for extracting sequence variants in biomedical literature. TmVar 2.0 integrates genomic variant information from literature with dbSNP and ClinVar for precision medicine."], "exact_answer": [["TmVar"], ["TmVar 2.0"]], "type": "list", "id": "5c561da707647bbc4b00000f", "snippets": [{"offsetInBeginSection": 702, "offsetInEndSection": 1409, "text": "Here, we report tmVar, a text-mining approach based on conditional random field (CRF) for extracting a wide range of sequence variants described at protein, DNA and RNA levels according to a standard nomenclature developed by the Human Genome Variation Society. By doing so, we cover several important types of mutations that were not considered in past studies. Using a novel CRF label model and feature set, our method achieves higher performance than a state-of-the-art method on both our corpus (91.4 versus 78.1% in F-measure) and their own gold standard (93.9 versus 89.4% in F-measure). These results suggest that tmVar is a high-performance method for mutation extraction from biomedical literature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "tmVar 2.0: integrating genomic variant information from literature with dbSNP and ClinVar for precision medicine.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968638", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "tmVar: a text mining approach for extracting sequence variants in biomedical literature.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842", "endSection": "title"}, {"offsetInBeginSection": 1347, "offsetInEndSection": 1850, "text": "To our knowledge, this is the first large-scale study to analyze and integrate text-mined variant data with curated knowledge in existing databases. Our results suggest that databases can be significantly enriched by text mining and that the combined information can greatly assist human efforts in evaluating/prioritizing variants in genomic research.Availability and implementation: The tmVar 2.0 source code and corpus are freely available at https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/tmvar/", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968638", "endSection": "abstract"}, {"offsetInBeginSection": 695, "offsetInEndSection": 964, "text": "RESULTS\nHere, we report tmVar, a text-mining approach based on conditional random field (CRF) for extracting a wide range of sequence variants described at protein, DNA and RNA levels according to a standard nomenclature developed by the Human Genome Variation Society.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842", "endSection": "abstract"}, {"offsetInBeginSection": 1297, "offsetInEndSection": 1410, "text": "These results suggest that tmVar is a high-performance method for mutation extraction from biomedical literature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842", "endSection": "abstract"}, {"offsetInBeginSection": 1413, "offsetInEndSection": 1572, "text": "AVAILABILITY\ntmVar software and its corpus of 500 manually curated abstracts are available for download at http://www.ncbi.nlm.nih.gov/CBBresearch/Lu/pub/tmVar", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842", "endSection": "abstract"}, {"offsetInBeginSection": 1703, "offsetInEndSection": 1854, "text": "Availability and implementation\nThe tmVar 2.0 source code and corpus are freely available at https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/tmvar/.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968638", "endSection": "abstract"}, {"offsetInBeginSection": 695, "offsetInEndSection": 964, "text": "RESULTS Here, we report tmVar, a text-mining approach based on conditional random field (CRF) for extracting a wide range of sequence variants described at protein, DNA and RNA levels according to a standard nomenclature developed by the Human Genome Variation Society.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842", "endSection": "abstract"}, {"offsetInBeginSection": 1413, "offsetInEndSection": 1572, "text": "AVAILABILITY tmVar software and its corpus of 500 manually curated abstracts are available for download at http://www.ncbi.nlm.nih.gov/CBBresearch/Lu/pub/tmVar", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842", "endSection": "abstract"}, {"offsetInBeginSection": 1703, "offsetInEndSection": 1854, "text": "Availability and implementation The tmVar 2.0 source code and corpus are freely available at https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/tmvar/.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968638", "endSection": "abstract"}, {"offsetInBeginSection": 584, "offsetInEndSection": 981, "text": "As such, new automatic approaches are greatly needed for extracting different kinds of mutations with high accuracy.<br><b>RESULTS</b>: Here, we report tmVar, a text-mining approach based on conditional random field (CRF) for extracting a wide range of sequence variants described at protein, DNA and RNA levels according to a standard nomenclature developed by the Human Genome Variation Society.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842", "endSection": "abstract"}, {"offsetInBeginSection": 1314, "offsetInEndSection": 1602, "text": "These results suggest that tmVar is a high-performance method for mutation extraction from biomedical literature.<br><b>AVAILABILITY</b>: tmVar software and its corpus of 500 manually curated abstracts are available for download at http://www.ncbi.nlm.nih.gov/CBBresearch/Lu/pub/tmVar<br>", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842", "endSection": "abstract"}, {"offsetInBeginSection": 1514, "offsetInEndSection": 1923, "text": "Our results suggest that databases can be significantly enriched by text mining and that the combined information can greatly assist human efforts in evaluating/prioritizing variants in genomic research.<br><b>Availability and implementation</b>: The tmVar 2.0 source code and corpus are freely available at https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/tmvar/.<br><b>Contact</b>: zhiyong.lu@nih.gov.<br>", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968638", "endSection": "abstract"}, {"offsetInBeginSection": 1390, "offsetInEndSection": 1536, "text": "tmVar software and its corpus of 500 manually curated abstracts are available for download at http://www.ncbi.nlm.nih.gov/CBBresearch/Lu/pub/tmVar", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842", "endSection": "abstract"}, {"offsetInBeginSection": 1680, "offsetInEndSection": 1799, "text": "The tmVar 2.0 source code and corpus are freely available at https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/tmvar/.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968638", "endSection": "abstract"}, {"offsetInBeginSection": 1276, "offsetInEndSection": 1389, "text": "These results suggest that tmVar is a high-performance method for mutation extraction from biomedical literature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842", "endSection": "abstract"}]}, {"body": "What is included in the Mentzer index?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18445163", "http://www.ncbi.nlm.nih.gov/pubmed/26187724", "http://www.ncbi.nlm.nih.gov/pubmed/18192142", "http://www.ncbi.nlm.nih.gov/pubmed/8162086"], "ideal_answer": ["Mentzer index (MCV/RBC) is mean corpuscular volume (MCV) and red blood cell count (RBC) ratio. It is used for differentiation of thalassemia and iron deficiency anemia."], "exact_answer": [["mean corpuscular volume"], ["red blood cell count"]], "type": "list", "id": "5a736f0c3b9d13c708000007", "snippets": [{"offsetInBeginSection": 608, "offsetInEndSection": 1010, "text": "In this study, macrocytic anemia due to FAD was defined as having an MCV \u2265100 fL and folic acid \u22646 ng/mL; pernicious anemia as having MCV \u2265100 fL, vitamin B12<200 pg/mL, and serum gastric parietal cell antibody positivity; iron deficiency anemia as having MCV<80 fL and iron<60 \u03bcg/dL; and thalassemia trait as having MCV<74 fL, red blood cell (RBC) count>5.0 \u00d7 10(12)/L, and Mentzer index (MCV/RBC)<13.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26187724", "endSection": "abstract"}, {"offsetInBeginSection": 338, "offsetInEndSection": 876, "text": "Complete blood count (CBC) parameters of 2196 certainly diagnosed (1272 beta-thalassaemia minor and 924 iron deficiency) samples were used to evaluate the following indices and formulas: Bessman index (RDW), Mentzer formula (MCV/RBC), England and Fraser formula (MCV - RBC - 5 x Hb- 3.4), Shine and Lal formula (MCV2 x MCH/100), Ehsani formula (MCV-10 x RBC), Srivastava formula (MCH/RBC), Green and King formula (MCV2 x RDW/Hb x 100), red distribution width index RDWI (RDW x MCV/RBC), RDW/RBC, as well as our formula (MCV-RBC -3 x Hb). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18445163", "endSection": "abstract"}, {"offsetInBeginSection": 79, "offsetInEndSection": 525, "text": "The ratio of the mean corpuscular volume (MCV) and red blood cell count (RBC) can be automatically calculated with any of the newer hematology analyzers.METHODS: The results of 398 patient screens were collected. Data from the set were divided into training and validation subsets. The Mentzer ratio was determined through a receiver operating characteristic (ROC) curve on the first subset, and screened for thalassemia using the second subset. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18192142", "endSection": "abstract"}, {"offsetInBeginSection": 776, "offsetInEndSection": 889, "text": "Mentzer ratio MCV/RBC detected all cases of beta thalassemia but was a poor index for iron deficiency detection. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8162086", "endSection": "abstract"}]}, {"body": "What are the reported adverse effects of gabapentin used in children?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10030434", "http://www.ncbi.nlm.nih.gov/pubmed/11274308", "http://www.ncbi.nlm.nih.gov/pubmed/16490100", "http://www.ncbi.nlm.nih.gov/pubmed/8603631", "http://www.ncbi.nlm.nih.gov/pubmed/15072101", "http://www.ncbi.nlm.nih.gov/pubmed/12199723", "http://www.ncbi.nlm.nih.gov/pubmed/8617181", "http://www.ncbi.nlm.nih.gov/pubmed/9120226", "http://www.ncbi.nlm.nih.gov/pubmed/8648543", "http://www.ncbi.nlm.nih.gov/pubmed/7489697", "http://www.ncbi.nlm.nih.gov/pubmed/11305405", "http://www.ncbi.nlm.nih.gov/pubmed/12022084", "http://www.ncbi.nlm.nih.gov/pubmed/22134010", "http://www.ncbi.nlm.nih.gov/pubmed/11361047", "http://www.ncbi.nlm.nih.gov/pubmed/19193587", "http://www.ncbi.nlm.nih.gov/pubmed/23112238"], "ideal_answer": ["Limited literature data, suggest that gabapentin may cause rash that is severe enough to necessitate discontinuation in a small percentage of children.\nIn a large survey of all age groups: The commonest adverse effects seen were somnolence, fainting, ataxia, nystagmus, tremor and headache, fatigue. However, their incidence was low and intensity mild. In a pediatric group only somnolence and dizziness were reported in 2 out of 33 patients.\nBehavioural adverse effects are more common  in children with intellectual disability and attention deficit, worse in <10yo :  hyperactivity, defiance, irritability, agitation, aggression, explosive outbursts, oppositional behavior, often  warranting discontinuation of the medication."], "exact_answer": [["Skin reactions"], ["Somnolence", "drowsiness", "sedation", "lassitude"], ["Dizziness"], ["hyperactivity"], ["defiance"], ["irritability"], ["agitation"], ["aggression"], ["explosive outbursts"], ["oppositional behavior"], ["malaise"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004362", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002648", "http://www.biosemantics.org/jochem#4258191"], "type": "list", "id": "515db70c298dcd4e51000017", "snippets": [{"offsetInBeginSection": 156, "offsetInEndSection": 288, "text": "he purpose of our study was to review our experience with using gabapentin to treat insomnia in children. We identified 23 children,", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23112238", "endSection": "sections.0"}, {"offsetInBeginSection": 839, "offsetInEndSection": 880, "text": "Adverse effects were noted in 6 children.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23112238", "endSection": "sections.0"}, {"offsetInBeginSection": 11, "offsetInEndSection": 129, "text": "To determine the effectiveness of gabapentin as an add-on therapy in children presenting with overactive bladder (OAB)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134010", "endSection": "sections.0"}, {"offsetInBeginSection": 651, "offsetInEndSection": 741, "text": "Data were analyzed in 30 patients as treatment was terminated in 1 due to adverse effects.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134010", "endSection": "sections.0"}, {"offsetInBeginSection": 1307, "offsetInEndSection": 1473, "text": "Gabapentin gives moderate results in children with OAB refractory to conventional anticholinergics. In general, the drug is well tolerated with fewer adverse effects.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134010", "endSection": "sections.0"}, {"offsetInBeginSection": 11, "offsetInEndSection": 159, "text": "To describe a child who developed a skin reaction during gabapentin therapy and discuss how we evaluated the probability of an adverse drug reaction", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19193587", "endSection": "sections.0"}, {"offsetInBeginSection": 725, "offsetInEndSection": 1093, "text": "In contrast to other antiepileptic drugs, skin reactions to gabapentin are considered uncommon. In adults, reported prevalence of rash possibly related to gabapentin range from 1% to 10%. A postmarketing surveillance study reported gabapentin treatment failure as a consequence of rash in 0.4% of 3000 patients. The product monograph does not mention rash in children.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19193587", "endSection": "sections.0"}, {"offsetInBeginSection": 1227, "offsetInEndSection": 1514, "text": "This case, and limited literature data, suggest that gabapentin may cause rash that is severe enough to necessitate discontinuation in a small percentage of children. Further research is needed to determine the actual incidence and severity of gabapentin-related rash in this population.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19193587", "endSection": "sections.0"}, {"offsetInBeginSection": 285, "offsetInEndSection": 425, "text": "Five patients treated in the Children's Hospital Pain Control Service for intractable neuropathic pain were included in gabapentin treatment", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16490100", "endSection": "sections.0"}, {"offsetInBeginSection": 614, "offsetInEndSection": 738, "text": "We noticed a rapid improvement, in 1 week, of our patients' VAS scores (from 9 or 10 to 4 or 3) with minimal adverse effects", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16490100", "endSection": "sections.0"}, {"offsetInBeginSection": 206, "offsetInEndSection": 277, "text": "The charts of all children given gabapentin for seizures were reviewed.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15072101", "endSection": "sections.0"}, {"offsetInBeginSection": 906, "offsetInEndSection": 990, "text": "Only 8 children (7%) reported adverse effects, and the drug was discontinued in two.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15072101", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12199723", "endSection": "title"}, {"offsetInBeginSection": 880, "offsetInEndSection": 948, "text": "The cohort comprised 3,100 patients, of whom 136 (4%) were children.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12199723", "endSection": "sections.0"}, {"offsetInBeginSection": 998, "offsetInEndSection": 1252, "text": "The most frequently reported adverse events reported during the first month of treatment, drowsiness/sedation, dizziness, and malaise/lassitude, also were the commonest reasons for discontinuing GBP and reported as suspected adverse drug reactions (ADRs)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12199723", "endSection": "sections.0"}, {"offsetInBeginSection": 1495, "offsetInEndSection": 1667, "text": "Neurologic-related events were the most frequently reported adverse events. They also were the commonest reasons for discontinuing treatment and reported as suspected ADRs.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12199723", "endSection": "sections.0"}, {"offsetInBeginSection": 144, "offsetInEndSection": 391, "text": "We reviewed the reports in the literature on the safety, adverse effects and tolerance of GBP as treatment, used as monotherapy or associated with other drugs, in epilepsies in patients of all age groups, including children, adults and the elderly", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12022084", "endSection": "sections.0"}, {"offsetInBeginSection": 437, "offsetInEndSection": 815, "text": "GBP is a well tolerated drug when used for monotherapy or associated with other antiepileptic drugs. The commonest adverse effects seen were somnolence, fainting, ataxia, nystagmus, tremor and headache. However, their incidence was low and intensity mild. There was no clear relationship between the dose given and appearance of side effects, except for fainting and somnolence.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12022084", "endSection": "sections.0"}, {"offsetInBeginSection": 829, "offsetInEndSection": 1049, "text": "GBP is a drug which is free of unwanted side effects. Its safety and tolerability profile is excellent for treatment of simple and complex partial crises, with or without generalization in epileptic patients of all ages.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12022084", "endSection": "sections.0"}, {"offsetInBeginSection": 168, "offsetInEndSection": 378, "text": "Two studies were conducted to determine the single-dose pharmacokinetics of gabapentin in healthy subjects age 1 month to 12 years and to guide dose selection in safety and efficacy trials in pediatric patients", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11361047", "endSection": "sections.0"}, {"offsetInBeginSection": 612, "offsetInEndSection": 689, "text": "Single doses of gabapentin were well tolerated by healthy pediatric subjects.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11361047", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "The efficacy and safety of gabapentin as add-on therapy for refractory partial seizures in 237 children, aged 3 to 12 years were evaluated over a 6-month period.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11305405", "endSection": "sections.0"}, {"offsetInBeginSection": 655, "offsetInEndSection": 739, "text": "Thirteen patients (5%) withdrew during the 6-month period because of adverse events.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11305405", "endSection": "sections.0"}, {"offsetInBeginSection": 457, "offsetInEndSection": 626, "text": "Male or female patients, at least 12 years old, with a recent history of partial seizures with or without secondary generalization, were randomized to receive gabapentin", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11274308", "endSection": "sections.0"}, {"offsetInBeginSection": 1045, "offsetInEndSection": 1256, "text": "Of the four most common adverse events (somnolence, dizziness, ataxia, fatigue), only one, dizziness, occurred more often in the nontitrated (Rapid initiation) group than in the titrated (Slow initiation) group.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11274308", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 276, "text": "Twenty-six children with intellectual disability and six normal children, all suffering from refractory partial seizures, received open-label gabapentin (range = 10-50 mg kg(-1) day(-1); mean = 26.7 mg kg(-1) day(-1) as an add-on medication to their antiepileptic drug regimen", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10030434", "endSection": "sections.0"}, {"offsetInBeginSection": 768, "offsetInEndSection": 1371, "text": "In the present patient population, patients younger than 10 years of age, all of whom had intellectual disability, were more likely to have side-effects than those older than 10 years of age. Observed adverse effects, which were generally mild, occurred in patients with baseline intellectual disability, attention deficit disorder and behavioural problems. Behavioural adverse effects warranted discontinuation of the medication in only three patients. The severity of intellectual disability (mild versus moderate or severe) did not affect the extent of the response or the occurrence of side-effects.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10030434", "endSection": "sections.0"}, {"offsetInBeginSection": 1527, "offsetInEndSection": 1703, "text": "However, children with intellectual disability who also are less than 10 years of age with baseline attention deficit appear to be at a higher risk of behavioural side-effects.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10030434", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Efficacy and safety of gabapentin monotherapy were evaluated in 33 children with newly diagnosed absence epilepsy", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9120226", "endSection": "sections.0"}, {"offsetInBeginSection": 712, "offsetInEndSection": 928, "text": "Somnolence and dizziness were the only adverse events reported by at least two patients during gabapentin treatment. No clinically important changes in laboratory assessments or other safety parameters were observed.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9120226", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Thirty-two children with refractory partial epilepsy received open-label gabapentin as an additional medication to their antiepileptic drug regimen", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8648543", "endSection": "sections.0"}, {"offsetInBeginSection": 757, "offsetInEndSection": 950, "text": "The major reported side effects were behavioral. These consisted of hyperactivity, irritability, and agitation that occurred in patients with baseline mental retardation with attention deficit.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8648543", "endSection": "sections.0"}, {"offsetInBeginSection": 176, "offsetInEndSection": 454, "text": "We report 2 children who received GBP for intractable seizures and who developed intolerable aggressive behavior requiring dose reduction or drug discontinuation. Behavioral changes should be recognized as a possible side effect of GBP, especially in mentally retarded children.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8617181", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 564, "text": "We report 7 children who received gabapentin (GBP) as adjunctive medic ation and subsequently developed behavioral side effects. These behavioral changes consisted of intensification of baseline behaviors as well as new behavioral problems. Behaviors that parents considered most troublesome were tantrums, aggression directed toward others, hyperactivity, and defiance. All behavioral changes were reversible and were managed by dose reduction or discontinuation of GBP. All children had baseline attention deficit hyperactivity disorder and developmental delays.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8603631", "endSection": "sections.0"}, {"offsetInBeginSection": 88, "offsetInEndSection": 511, "text": "We described 3 learning disabled children, 1 aged 7 and 2 aged 10 years, with intractable partial seizures who developed severe behavioral problems while receiving modest doses of GBP. The children became hyperactive and had explosive outburst consisting of aggressive and oppositional behavior. The behavioral problems were sufficiently severe to require discontinuation of GBP despite moderately improved seizure control.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7489697", "endSection": "sections.0"}]}, {"body": "Which syndromes are associated with mutations in the EZH2 gene?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21856302", "http://www.ncbi.nlm.nih.gov/pubmed/24507812", "http://www.ncbi.nlm.nih.gov/pubmed/24953053", "http://www.ncbi.nlm.nih.gov/pubmed/10780782", "http://www.ncbi.nlm.nih.gov/pubmed/24218139", "http://www.ncbi.nlm.nih.gov/pubmed/23592277", "http://www.ncbi.nlm.nih.gov/pubmed/24852293", "http://www.ncbi.nlm.nih.gov/pubmed/22177091", "http://www.ncbi.nlm.nih.gov/pubmed/23099237", "http://www.ncbi.nlm.nih.gov/pubmed/25177364", "http://www.ncbi.nlm.nih.gov/pubmed/22475286", "http://www.ncbi.nlm.nih.gov/pubmed/24214728", "http://www.ncbi.nlm.nih.gov/pubmed/22190405", "http://www.ncbi.nlm.nih.gov/pubmed/24760151"], "ideal_answer": ["EZH2 mutations that cause Weaver syndrome are primarily missense variants and the rare truncating mutations reported to date are in the last exon, suggesting that simple haploinsufficiency is unlikely to be generating the overgrowth phenotype although the exact mechanism has not yet been determined. Recent studies have shown that EZH2 mutations are often associated with RUNX1 mutations in MDS patients, although its pathological function remains to be addressed. These data show that mutations in EZH2 cause Weaver syndrome. The EZH2 gene is a homolog of the Drosophila Polycomb group (PcG) gene enhancer of zest, a crucial regulator of homeotic gene expression.", "Loss-of-function mutations of EZH2, a catalytic component of polycomb repressive complex 2 (PRC2), are observed in ~\\n10% of patients with myelodysplastic syndrome (MDS), but are rare in acute myeloid leukaemia (AML). Constitutional NSD1 and EZH2 mutations cause Sotos and Weaver syndromes respectively, overgrowth syndromes with considerable phenotypic overlap. Mutations at tyrosine 641 (Y641F, Y641N, Y641S and Y641H) in the SET domain of EZH2 have been identified in patients with certain subtypes of non-Hodgkin lymphoma (NHL). The EZH2 gene is involved in the pathogenesis of 7q35-q36 aberrations in myeloid leukaemia."], "exact_answer": [["myelodysplastic syndrome (MDS)"], ["Acquired aplastic anemia (AA)"], ["Weaver syndrome"], ["non-Hodgkin lymphoma (NHL)"], ["myeloid leukaemia"]], "concepts": ["http://www.uniprot.org/uniprot/EZH2_MACFA", "http://www.uniprot.org/uniprot/EZH2_HUMAN", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577"], "type": "list", "id": "57090784cf1c325851000011", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 216, "text": "Loss-of-function mutations of EZH2, a catalytic component of polycomb repressive complex 2 (PRC2), are observed in ~\\n10% of patients with myelodysplastic syndrome (MDS), but are rare in acute myeloid leukaemia (AML)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24953053", "endSection": "abstract"}, {"offsetInBeginSection": 249, "offsetInEndSection": 491, "text": "We describe the use of an oligo-SNP array for genomic profiling of aCNA and cnLOH, together with sequence analysis of recurrently mutated genes, in a patient with myelodysplastic syndrome (MDS) presenting with normal karyotype and FISH result", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25177364", "endSection": "abstract"}, {"offsetInBeginSection": 780, "offsetInEndSection": 970, "text": " Conditionally deleting Ezh2 in mature T cells dramatically reduced the production of BM-destructive Th1 cells in vivo, decreased BM-infiltrating Th1 cells, and rescued mice from BM failure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760151", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Acquired aplastic anemia (AA) is a potentially fatal bone marrow (BM) failure syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760151", "endSection": "abstract"}, {"offsetInBeginSection": 823, "offsetInEndSection": 967, "text": "Constitutional NSD1 and EZH2 mutations cause Sotos and Weaver syndromes respectively, overgrowth syndromes with considerable phenotypic overlap.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23592277", "endSection": "abstract"}, {"offsetInBeginSection": 1123, "offsetInEndSection": 1422, "text": "EZH2 mutations that cause Weaver syndrome are primarily missense variants and the rare truncating mutations reported to date are in the last exon, suggesting that simple haploinsufficiency is unlikely to be generating the overgrowth phenotype although the exact mechanism has not yet been determined", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23592277", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 34, "text": "Weaver syndrome and EZH2 mutations", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24214728", "endSection": "title"}, {"offsetInBeginSection": 143, "offsetInEndSection": 237, "text": "In 2011, mutations in the histone methyltransferase, EZH2, were shown to cause Weaver syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24214728", "endSection": "abstract"}, {"offsetInBeginSection": 1225, "offsetInEndSection": 1410, "text": "The identification of an EZH2 mutation can therefore provide an objective means of confirming a subtle presentation of Weaver syndrome and/or distinguishing Weaver and Sotos syndromes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24214728", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 39, "text": "Mutations in EZH2 cause Weaver syndrome", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22177091", "endSection": "title"}, {"offsetInBeginSection": 436, "offsetInEndSection": 496, "text": "These data show that mutations in EZH2 cause Weaver syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22177091", "endSection": "abstract"}, {"offsetInBeginSection": 649, "offsetInEndSection": 808, "text": "The EZH2 mutation spectrum in Weaver syndrome shows considerable overlap with the inactivating somatic EZH2 mutations recently reported in myeloid malignancies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22190405", "endSection": "abstract"}, {"offsetInBeginSection": 829, "offsetInEndSection": 963, "text": "EZH2 mutations as the cause of Weaver syndrome and provide further links between histone modifications and regulation of human growth.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22190405", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Mutations at tyrosine 641 (Y641F, Y641N, Y641S and Y641H) in the SET domain of EZH2 have been identified in patients with certain subtypes of non-Hodgkin lymphoma (NHL)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21856302", "endSection": "abstract"}, {"offsetInBeginSection": 452, "offsetInEndSection": 616, "text": "The EZH2 gene was previously reported to be located on chromosome 21q22 and was proposed as a candidate gene for some characteristics of the Down syndrome phenotype", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10780782", "endSection": "abstract"}, {"offsetInBeginSection": 405, "offsetInEndSection": 727, "text": "Recent extensive mutation analyses of the myeloid malignancies have revealed that inactivating somatic mutations in PcG genes such as EZH2 and ASXL1 occur frequently in patients with myelodysplastic disorders including myelodysplastic syndromes (MDSs) and MDS/myeloproliferative neoplasm (MPN) overlap disorders (MDS/MPN).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24218139", "endSection": "abstract"}, {"offsetInBeginSection": 626, "offsetInEndSection": 833, "text": "EZH2 is frequently overexpressed and considered to be an oncogene in cancers; nevertheless, EZH2 is considered as a candidate tumor suppressor gene in MDS due to EZH2 mutations associated with poor survival.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22475286", "endSection": "abstract"}, {"offsetInBeginSection": 237, "offsetInEndSection": 332, "text": "In 2011, mutations in the histone methyltransferase, EZH2, were shown to cause Weaver syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24214728", "endSection": "abstract"}, {"offsetInBeginSection": 377, "offsetInEndSection": 509, "text": "Among them, Sotos and Weaver syndromes are clinically well defined and due to heterozygous mutations in NSD1 and EZH2, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24852293", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Weaver syndrome and EZH2 mutations: Clarifying the clinical phenotype.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24214728", "endSection": "title"}, {"offsetInBeginSection": 963, "offsetInEndSection": 1107, "text": "Constitutional NSD1 and EZH2 mutations cause Sotos and Weaver syndromes respectively, overgrowth syndromes with considerable phenotypic overlap.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23592277", "endSection": "abstract"}, {"offsetInBeginSection": 1400, "offsetInEndSection": 1584, "text": "The identification of an EZH2 mutation can therefore provide an objective means of confirming a subtle presentation of Weaver syndrome and/or distinguishing Weaver and Sotos syndromes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24214728", "endSection": "abstract"}, {"offsetInBeginSection": 777, "offsetInEndSection": 966, "text": "We postulated that mutations in writers of these two chromatin marks could cause overgrowth conditions, resembling Sotos or Weaver syndromes, in patients with no NSD1 or EZH2 abnormalities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24852293", "endSection": "abstract"}, {"offsetInBeginSection": 84, "offsetInEndSection": 407, "text": "Recent extensive mutation analyses of the myeloid malignancies have revealed that inactivating somatic mutations in PcG genes such as EZH2 and ASXL1 occur frequently in patients with myelodysplastic disorders including myelodysplastic syndromes (MDSs) and MDS/myeloproliferative neoplasm (MPN) overlap disorders (MDS/MPN). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24218139", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Somatic mutations of epigenetic gene regulators are common in patients with myelodysplastic syndromes (MDS) and correlate with some clinical and laboratory features. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23099237", "endSection": "abstract"}, {"offsetInBeginSection": 354, "offsetInEndSection": 745, "text": "Recently, the advent of next generation sequencing (NGS) techniques has helped identify somatic gene mutations in 75-80% of MDS, that cluster mainly in four functional groups, i.e. cytokine signaling (RAS genes), DNA methylation, (TET2, IDH1/2, DNMT3a genes) histone modifications (ASXL1 and EZH2 genes), and spliceosome (SF3B1 and SRSF2 genes) along with mutations of RUNX1 and TP 53 genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24507812", "endSection": "abstract"}, {"offsetInBeginSection": 824, "offsetInEndSection": 1123, "text": "Constitutional NSD1 and EZH2 mutations cause Sotos and Weaver syndromes respectively, overgrowth syndromes with considerable phenotypic overlap. NSD1 mutations that cause Sotos syndrome are loss-of-function, primarily truncating mutations or missense mutations at key residues in functional domains.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23592277", "endSection": "abstract"}, {"offsetInBeginSection": 515, "offsetInEndSection": 630, "text": "EZH2 is considered as a candidate tumor suppressor gene in MDS due to EZH2 mutations associated with poor survival.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22475286", "endSection": "abstract"}, {"offsetInBeginSection": 1146, "offsetInEndSection": 1414, "text": "Considerable phenotypic overlap between Sotos and Weaver syndromes is also evident. The identification of an EZH2 mutation can therefore provide an objective means of confirming a subtle presentation of Weaver syndrome and/or distinguishing Weaver and Sotos syndromes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24214728", "endSection": "abstract"}, {"offsetInBeginSection": 423, "offsetInEndSection": 630, "text": "EZH2 is frequently overexpressed and considered to be an oncogene in cancers; nevertheless, EZH2 is considered as a candidate tumor suppressor gene in MDS due to EZH2 mutations associated with poor survival.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22475286", "endSection": "abstract"}, {"offsetInBeginSection": 824, "offsetInEndSection": 968, "text": "Constitutional NSD1 and EZH2 mutations cause Sotos and Weaver syndromes respectively, overgrowth syndromes with considerable phenotypic overlap.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23592277", "endSection": "abstract"}, {"offsetInBeginSection": 639, "offsetInEndSection": 776, "text": "The deletion involved multiple genes, including two tumor suppressor candidate genes (CTNNA1 and HSPA9) that are associated with MDS/AML.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25177364", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Somatic mutations of epigenetic gene regulators are common in patients with myelodysplastic syndromes (MDS) and correlate with some clinical and laboratory features.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23099237", "endSection": "abstract"}]}, {"body": "Which enzymes are involved in global genome nucleotide excision repair (GG-NER) in bacteria?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20004108", "http://www.ncbi.nlm.nih.gov/pubmed/19617358", "http://www.ncbi.nlm.nih.gov/pubmed/19933360", "http://www.ncbi.nlm.nih.gov/pubmed/24290807", "http://www.ncbi.nlm.nih.gov/pubmed/23963890", "http://www.ncbi.nlm.nih.gov/pubmed/23245695", "http://www.ncbi.nlm.nih.gov/pubmed/21145481", "http://www.ncbi.nlm.nih.gov/pubmed/19762288", "http://www.ncbi.nlm.nih.gov/pubmed/22559785", "http://www.ncbi.nlm.nih.gov/pubmed/25463394"], "ideal_answer": ["Nucleotide excision repair (NER) is universally used to recognize and remove many types of DNA damage. In eubacteria, the NER system typically consists of UvrA, UvrB, UvrC, the UvrD helicase, DNA polymerase I, and ligase.  Damage recognition during bacterial NER depends upon UvrA, which binds to the damage and loads UvrB onto the DNA. Subsequently, UvrA, UvrB and UvrC form the excinuclease protein UvrABC endonuclease, a multi-enzymatic complex which carries out repair of damaged DNA in sequential manner. In some cases, Cho may be the effective nuclease for NER, rather than UvrC. UvrC nuclease and the short oligonucleotide that contains the DNA lesion are removed from the post-incision complex by UvrD, a superfamily 1A helicase. In gram-positive organisms, PcrA helicase can also displace UvrC and the excised oligonucleotide from a post-incision NER complex."], "exact_answer": [["UvrA"], ["UvrB"], ["UvrC nuclease"], ["UvrD 1A helicase"], ["DNA polymerase I"], ["Ligase"], ["Cho nuclease (instead of UvrC)"], ["PcrA helicase (instead of Uvrd, in gram-positive bacteria)"]], "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0000720", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0000109", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0006289", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0070911", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004260"], "type": "list", "id": "5547a7e9f35db75526000006", "snippets": [{"offsetInBeginSection": 169, "offsetInEndSection": 455, "text": "we evaluated the in vivo role of NER in the repair of DNA adducts generated by psoralens (mono- or bi-functional) and UV-A light (PUVA) in E. coli. Cultures of wild-type E. coli K12 and mutants for uvrA, uvrB, uvrC or uvrAC genes were treated with PUVA and cell survival was determined.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20004108", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 221, "text": "Nucleotide excision repair (NER) is universally used to recognize and remove many types of DNA damage. In eubacteria, the NER system typically consists of UvrA, UvrB, UvrC, the UvrD helicase, DNA polymerase I, and ligase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19933360", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "During nucleotide excision repair (NER) in bacteria the UvrC nuclease and the short oligonucleotide that contains the DNA lesion are removed from the post-incision complex by UvrD, a superfamily 1A helicase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19762288", "endSection": "abstract"}, {"offsetInBeginSection": 349, "offsetInEndSection": 416, "text": "UvrD interacts with UvrB, a component of the post-incision complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19762288", "endSection": "abstract"}, {"offsetInBeginSection": 1162, "offsetInEndSection": 1400, "text": "PcrA helicase from Bacillus stearothermophilus can also displace UvrC and the excised oligonucleotide from a post-incision NER complex, which supports the idea that PcrA performs a UvrD-like function during NER in gram-positive organisms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19762288", "endSection": "abstract"}, {"offsetInBeginSection": 957, "offsetInEndSection": 1032, "text": "Cho rather than UvrC seems to be an effective nuclease for the NER of DPCs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19617358", "endSection": "abstract"}, {"offsetInBeginSection": 312, "offsetInEndSection": 478, "text": "Nucleotide excision repair consists of excinuclease protein UvrABC endonuclease, multi-enzymatic complex which carries out repair of damaged DNA in sequential manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23963890", "endSection": "abstract"}, {"offsetInBeginSection": 223, "offsetInEndSection": 502, "text": "Escherichia coli K12 mutant strains deficient in nucleotide excision repair (NER) were submitted to increasing concentrations of cisplatin, and the results revealed that uvrA and uvrB mutants are sensitive to this agent, while uvrC and cho mutants remain as the wild type strain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23245695", "endSection": "abstract"}, {"offsetInBeginSection": 401, "offsetInEndSection": 1194, "text": "we used a genetic approach to investigate the roles of nucleotide excision repair (NER) pathway components in H. pylori mutation and recombination. RESULTS: Inactivation of any of the four uvr genes strongly increased the susceptibility of H. pylori to DNA damage by ultraviolet light. Inactivation of uvrA and uvrB significantly decreased mutation frequencies whereas only the uvrA deficient mutant exhibited a significant decrease of the recombination frequency after natural transformation. A uvrC mutant did not show significant changes in mutation or recombination rates; however, inactivation of uvrC promoted the incorporation of significantly longer fragments of donor DNA (2.2-fold increase) into the recipient chromosome. A deletion of uvrD induced a hyper-recombinational phenotype.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22559785", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 586, "text": "Transcription-coupled DNA repair (TCR) is a subpathway of nucleotide excision repair (NER) that is triggered when RNA polymerase is stalled by DNA damage. Lesions targeted by TCR are repaired more quickly than lesions repaired by the transcription-independent \"global\" NER pathway, but the mechanism underlying this rate enhancement is not understood. Damage recognition during bacterial NER depends upon UvrA, which binds to the damage and loads UvrB onto the DNA. Bacterial TCR additionally requires the Mfd protein, a DNA translocase that removes the stalled transcription complexes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21145481", "endSection": "abstract"}]}, {"body": "What laboratory abnormalities are commonly seen in patients with COVID-19?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33973190", "http://www.ncbi.nlm.nih.gov/pubmed/33726761", "http://www.ncbi.nlm.nih.gov/pubmed/32542934", "http://www.ncbi.nlm.nih.gov/pubmed/33936225", "http://www.ncbi.nlm.nih.gov/pubmed/32336069", "http://www.ncbi.nlm.nih.gov/pubmed/34374346", "http://www.ncbi.nlm.nih.gov/pubmed/32501877", "http://www.ncbi.nlm.nih.gov/pubmed/32344313", "http://www.ncbi.nlm.nih.gov/pubmed/32656888", "http://www.ncbi.nlm.nih.gov/pubmed/33548996", "http://www.ncbi.nlm.nih.gov/pubmed/33210948", "http://www.ncbi.nlm.nih.gov/pubmed/33986318", "http://www.ncbi.nlm.nih.gov/pubmed/32877961", "http://www.ncbi.nlm.nih.gov/pubmed/34258956", "http://www.ncbi.nlm.nih.gov/pubmed/33522493", "http://www.ncbi.nlm.nih.gov/pubmed/32352401", "http://www.ncbi.nlm.nih.gov/pubmed/34383402", "http://www.ncbi.nlm.nih.gov/pubmed/32449374", "http://www.ncbi.nlm.nih.gov/pubmed/32721958", "http://www.ncbi.nlm.nih.gov/pubmed/33482780", "http://www.ncbi.nlm.nih.gov/pubmed/33407543"], "ideal_answer": ["Common laboratory abnormalities among patients with COVID-19 include:\n\n1. Elevated inflammatory markers (e.g., ferritin, C-reactive protein, and erythrocyte sedimentation rate).\n2. Elevated aminotransaminase levels (i.e., AST, ALT).\n3. Elevated lactate dehydrogenase (LDH) levels.\n4. Lymphopenia, leucocytosis.\n\nAbnormalities in coagulation testing (e.g., increased D-Dimers, decreased platelets), elevated procalcitonin levels, and elevated troponin levels have also been reported. The degree of these abnormalities tends to correlate with disease severity."], "exact_answer": [["Elevated ferritin", "Increased serum ferritin"], ["Elevated CRP", "Elevated C-reactive protein", "High C-reactive protein", "Elevated high sensitivity C-reactive protein (hs-CRP)"], ["Elevated ESR", "Increased ESR", "High erythrocyte sedimentation rate (ESR)"], ["Leucocytosis", "Increased white blood cells (WBC)", "Increased polymorphonuclear leukocytes (PMN)"], ["Lymphopenia", "Decreased lymphocyte count"], ["Elevated aminotransferases", "Increased alanine aminotransferase (ALT)", "Increased aspartate aminotransferase (AST)", "Increased ALT", "Increased AST"], ["Elevated lactate dehydrogenase (LDH)", "Elevated lactic dehydrogenase (LDH)", "Increased LDH"], ["Elevated D-dimers", "Elevated levels of D-dimer", "Increased D-Dimer"], ["Increased troponin", "Elevated troponin", "Elevated hypersensitive cardiac troponin I (hs-CTnI)"], ["Hyponatremia"], ["Decreased platelet count", "Decreased platelets"], ["Decreased albumin"], ["Increased procalcitonin (PCT)", "Elevated procalcitonin"], ["Increased total bilirubin", "Increased bilirubin"], ["Increased creatinine"]], "type": "list", "id": "627a70e656bf9aee6f000021", "snippets": [{"offsetInBeginSection": 819, "offsetInEndSection": 999, "text": "Increased serum ferritin (74.2%), high C-reactive protein (73.3%), and high erythrocyte sedimentation rate (ESR) (72.2%) were the most frequently reported laboratory abnormalities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33548996", "endSection": "abstract"}, {"offsetInBeginSection": 1674, "offsetInEndSection": 1983, "text": "Some specific laboratory indicators implied the deterioration of disease, such as leucocytosis, lymphopenia, platelet, alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, creatinine, creatine kinase (CK), lactic dehydrogenase (LDH), C-reactive protein, procalcitonin (PCT), and D-dimer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33548996", "endSection": "abstract"}, {"offsetInBeginSection": 2130, "offsetInEndSection": 2422, "text": "Most COVID-19 patients have fever and cough with lymphopenia and increased inflammatory indices, and the main CT feature is GGO involved bilateral lung. Patients with comorbidities and worse clinical symptoms, laboratory characteristics, and CT findings tend to have poor disease progression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33548996", "endSection": "abstract"}, {"offsetInBeginSection": 757, "offsetInEndSection": 1022, "text": "Multivariate logistic regression analysis showed that lymphopenia, elevated level of d-dimer, hypersensitive cardiac troponin I (hs-CTnI) and high sensitivity C-reactive protein (hs-CRP) were independent predictors of mortality in young adults with severe COVID-19.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33407543", "endSection": "abstract"}, {"offsetInBeginSection": 1272, "offsetInEndSection": 1396, "text": "Lymphopenia, elevated level of d-dimer, hs-CTnI and hs-CRP predicted clinical outcomes of young adults with severe COVID-19.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33407543", "endSection": "abstract"}, {"offsetInBeginSection": 726, "offsetInEndSection": 1165, "text": "Compared to patients with a non-severe form of COVID-19, patients who had a severe form of disease revealed higher values for white blood cells (WBC), polymorphonuclear leukocytes (PMN), total bilirubin, alanine aminotransferase (ALT), creatinine, troponin, procalcitonin, lactate dehydrogenase (LDH), and D-dimer. By contrast, platelet count, lymphocyte count, and albumin levels were decreased in patients with a severe form of COVID-19.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33973190", "endSection": "abstract"}, {"offsetInBeginSection": 1277, "offsetInEndSection": 1516, "text": "Hyponatremia (50%), elevated C-reactive protein (CRP; 100%), and lactate dehydrogenase (LDH; 80%) were common. Acute renal failure, myocardial injury, and elevation in aminotransferases occurred in 69%, 19%, and 38% patients, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32352401", "endSection": "abstract"}, {"offsetInBeginSection": 279, "offsetInEndSection": 529, "text": "The most common laboratory abnormalities in COVID\u201119 include decreased lymphocyte count (35%-82.1%), thrombocytopenia (17%-36.2%), elevated serum C\u2011reactive protein (60.7%-93%), lactate dehydrogenase (41%-76%), and D\u2011dimer concentrations (36%-46.4%).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32336069", "endSection": "abstract"}, {"offsetInBeginSection": 343, "offsetInEndSection": 524, "text": "Thrombocytopenia, coagulation abnormalities, and disseminated intravascular coagulation were observed in COVID-19 patients, especially those with critical illness and non-survivors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32721958", "endSection": "abstract"}, {"offsetInBeginSection": 588, "offsetInEndSection": 732, "text": "In conclusion, abnormalities in aminotransferase, lactate dehydrogenase, and ferritin levels are commonly seen in COVID-19 related liver injury.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32501877", "endSection": "abstract"}, {"offsetInBeginSection": 932, "offsetInEndSection": 1220, "text": "In severe COVID-19 patients laboratory markers of inflammation such as C-reactive protein, IL-6, D-dimer, serum ferritin and lactate dehydrogenase are elevated in many patients; assessed since the 4th-6th day of illness onset, such increases seem to be predictive of an adverse prognosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32344313", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 219, "text": "Clinical observations demonstrated that COVID-19 related pneumonia is often accompanied by hematological and coagulation abnormalities including lymphopenia, thrombocytopenia, and prolonged prothrombin time.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33210948", "endSection": "abstract"}, {"offsetInBeginSection": 1406, "offsetInEndSection": 1517, "text": "Lymphopenia is the mostly commonly reported laboratory abnormality and occurs in over 50% of COVID-19 patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32542934", "endSection": "abstract"}, {"offsetInBeginSection": 1341, "offsetInEndSection": 1575, "text": "Laboratory findings are unspecific in COVID-19 patients; laboratory abnormalities include lymphopenia, elevated of LDH, CPK and the inflammatory markers, such as C reactive protein, ferritinemia and the erythrocyte sedimentation rate.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33522493", "endSection": "abstract"}, {"offsetInBeginSection": 966, "offsetInEndSection": 1092, "text": "The common laboratory features reported include lymphopenia, elevated levels of C-reactive proteins and lactate dehydrogenase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33482780", "endSection": "abstract"}]}, {"body": "Which are the causes of the Koebner phenomenon?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24011283", "http://www.ncbi.nlm.nih.gov/pubmed/12195563", "http://www.ncbi.nlm.nih.gov/pubmed/26557075", "http://www.ncbi.nlm.nih.gov/pubmed/10884082", "http://www.ncbi.nlm.nih.gov/pubmed/10884083", "http://www.ncbi.nlm.nih.gov/pubmed/18499373", "http://www.ncbi.nlm.nih.gov/pubmed/16476320", "http://www.ncbi.nlm.nih.gov/pubmed/15893715", "http://www.ncbi.nlm.nih.gov/pubmed/19894099", "http://www.ncbi.nlm.nih.gov/pubmed/8507375", "http://www.ncbi.nlm.nih.gov/pubmed/23302147", "http://www.ncbi.nlm.nih.gov/pubmed/26131802", "http://www.ncbi.nlm.nih.gov/pubmed/15683664", "http://www.ncbi.nlm.nih.gov/pubmed/8056902", "http://www.ncbi.nlm.nih.gov/pubmed/12634998", "http://www.ncbi.nlm.nih.gov/pubmed/12444521", "http://www.ncbi.nlm.nih.gov/pubmed/21396563", "http://www.ncbi.nlm.nih.gov/pubmed/1702353", "http://www.ncbi.nlm.nih.gov/pubmed/9169322", "http://www.ncbi.nlm.nih.gov/pubmed/10748764", "http://www.ncbi.nlm.nih.gov/pubmed/11089373", "http://www.ncbi.nlm.nih.gov/pubmed/19489859", "http://www.ncbi.nlm.nih.gov/pubmed/27106503", "http://www.ncbi.nlm.nih.gov/pubmed/15854039", "http://www.ncbi.nlm.nih.gov/pubmed/20042161", "http://www.ncbi.nlm.nih.gov/pubmed/2102235", "http://www.ncbi.nlm.nih.gov/pubmed/21715249", "http://www.ncbi.nlm.nih.gov/pubmed/23588149", "http://www.ncbi.nlm.nih.gov/pubmed/25046469", "http://www.ncbi.nlm.nih.gov/pubmed/10348006", "http://www.ncbi.nlm.nih.gov/pubmed/8175343", "http://www.ncbi.nlm.nih.gov/pubmed/17656943", "http://www.ncbi.nlm.nih.gov/pubmed/11056428", "http://www.ncbi.nlm.nih.gov/pubmed/9173061"], "ideal_answer": ["The causes of the Koebner phenomenon are:\n1) Lichen sclerosus\n2) Vitiligo\n3) Psoriasis and \n4) Physical stress."], "exact_answer": [["Lichen sclerosus"], ["Vitiligo"], ["Psoriasis"], ["Physical stress"], ["Lichen planus"]], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:12306", "http://www.disease-ontology.org/api/metadata/DOID:9201", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014820", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011565", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008010"], "type": "list", "id": "58bfcb8702b8c60953000016", "snippets": [{"offsetInBeginSection": 205, "offsetInEndSection": 284, "text": "Lichen sclerosus has been reported at sites of injury as a Koebner phenomenon. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25046469", "endSection": "abstract"}, {"offsetInBeginSection": 1260, "offsetInEndSection": 1504, "text": "Therefore, lower expression of keratinocyte-derived factors, including SCF, in vitiliginous keratinocytes, which could result from keratinocyte apoptosis, might be responsible for passive melanocyte death and may explain the Koebner phenomenon.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15854039", "endSection": "abstract"}, {"offsetInBeginSection": 88, "offsetInEndSection": 300, "text": "Deprivation of survival factors causes the apoptosis of melanocytes. Vitiligo often develops following physical trauma, even if this is minor. The exact mechanism of the Koebner phenomenon in vitiligo is unclear.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15854039", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "First described in 1877 as the appearance of psoriatic lesions in the uninvolved skin of psoriatic patients as a consequence of trauma, the Koebner phenomenon has since been described in numerous diseases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12195563", "endSection": "abstract"}, {"offsetInBeginSection": 983, "offsetInEndSection": 1210, "text": "The Koebner phenomenon is known to occur (lichen sclerosus occurs in skin already scarred or damaged), so trauma, injury, and sexual abuse have been suggested as possible triggers of symptoms in genetically predisposed people. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10348006", "endSection": "abstract"}, {"offsetInBeginSection": 764, "offsetInEndSection": 948, "text": "The triggering role of physical stress is seen in the \"deep Koebner\" phenomenon, which causes inflammation in the synovial membrane and in enthesis, resulting in peripheral arthritis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715249", "endSection": "abstract"}, {"offsetInBeginSection": 758, "offsetInEndSection": 941, "text": "The triggering role of physical stress is seen in the \"deep Koebner\" phenomenon, which causes inflammation in the synovial membrane and in enthesis, resulting in peripheral arthritis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715249", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Two patients with unusual skin stimuli causing koebner phenomenon in psoriasis are reported.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17656943", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "To document the role of striae distensae and striae gravidarum in causing Koebner phenomenon in cases of vitiligo, psoriasis and lichen planus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19489859", "endSection": "abstract"}, {"offsetInBeginSection": 146, "offsetInEndSection": 239, "text": "In addition, psoriasis can be caused by a\u00a0local cutaneus trauma, known as Koebner phenomenon.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27106503", "endSection": "abstract"}, {"offsetInBeginSection": 143, "offsetInEndSection": 373, "text": "Striae are documented to cause Koebner phenomenon in patients with preexisting vitiligo, psoriasis and lichen planus, the three conditions where 'true kobenerisation' has been suggested according to Boyd and Nelder classification.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19489859", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "[Unusual Koebner phenomenon in psoriasis caused by varicella and UVB].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9173061", "endSection": "title"}, {"offsetInBeginSection": 259, "offsetInEndSection": 412, "text": "A 48 year-old woman developed an exacerbation of a latent psoriasis as a Koebner phenomenon in a migrating erythema caused by Borrelia afzelii infection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12444521", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "[Psoriasis as Koebner phenomenon in erythma migrans].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12444521", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "[Characteristics of the Koebner phenomenon in patients with psoriasis vulgaris].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11089373", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Vitiligo appearing in striae distensae as a Koebner phenomenon.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20042161", "endSection": "title"}, {"offsetInBeginSection": 511, "offsetInEndSection": 615, "text": "The appearance of vitiligo in striae distensae as a form of Koebner phenomenon has been reported rarely.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20042161", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "The Koebner phenomenon originally described the appearance of psoriatic lesions in the uninvolved skin of patients with psoriasis as a consequence of trauma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18499373", "endSection": "abstract"}, {"offsetInBeginSection": 764, "offsetInEndSection": 946, "text": "The triggering role of physical stress is seen in the \"deep Koebner\" phenomenon, which causes inflammation in the synovial membrane and in enthesis, resulting in peripheral arthritis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715249", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 438, "text": "To document the role of striae distensae and striae gravidarum in causing Koebner phenomenon in cases of vitiligo, psoriasis and lichen planus.Striae are documented to cause Koebner phenomenon in patients with preexisting vitiligo, psoriasis and lichen planus, the three conditions where true kobenerisation has been suggested according to Boyd and Nelder classification.Striae distensae and striae gravidarum are examples of blunt trauma", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19489859", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "[Unusual Koebner phenomenon in psoriasis caused by varicella and UVB]", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9173061", "endSection": "title"}, {"offsetInBeginSection": 261, "offsetInEndSection": 413, "text": "A 48 year-old woman developed an exacerbation of a latent psoriasis as a Koebner phenomenon in a migrating erythema caused by Borrelia afzelii infection", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12444521", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Intradermal antigen tests and the Koebner phenomenon in psoriasis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9169322", "endSection": "title"}, {"offsetInBeginSection": 950, "offsetInEndSection": 1283, "text": "In addition, intensity of delayed hypersensitivity reaction and resolution times demonstrate no significant difference between psoriatic and nonpsoriatic subjects statistically (P > 0.05).These findings may indicate that intradermal antigens used in this study were more effective in inducing the Koebner phenomenon than injury alone", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9169322", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 390, "text": "RESULTS: Striae are documented to cause Koebner phenomenon in patients with preexisting vitiligo, psoriasis and lichen planus, the three conditions where 'true kobenerisation' has been suggested according to Boyd and Nelder classification. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19489859", "endSection": "abstract"}, {"offsetInBeginSection": 702, "offsetInEndSection": 1021, "text": "According to the presence of Koebner phenomenon they were divided in two groups, one with positive and the other with negative Koebner phenomenon which presented the control group at the same time.RESULTS AND DISCUSSION: The Koebner reaction is often thought to be more frequent in actively spreading, severe psoriasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11089373", "endSection": "abstract"}, {"offsetInBeginSection": 158, "offsetInEndSection": 312, "text": "We describe a case of concurrent lichen planus and sarcoidosis in the auditory canal, which represents an unusual manifestation of the Koebner phenomenon.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18499373", "endSection": "abstract"}, {"offsetInBeginSection": 639, "offsetInEndSection": 999, "text": "According to the presence of Koebner phenomenon they were divided into two groups, 20 patients with positive and 40 patients with negative Koebner reaction, who were the control group at the same time.RESULTS AND DISCUSSION: 95% of patients treated with PUVA, were cleared of psoriatic changes in the Koebner positive, as well as in the Koebner negative group.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10748764", "endSection": "abstract"}, {"offsetInBeginSection": 144, "offsetInEndSection": 374, "text": "Striae are documented to cause Koebner phenomenon in patients with preexisting vitiligo, psoriasis and lichen planus, the three conditions where 'true kobenerisation' has been suggested according to Boyd and Nelder classification.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19489859", "endSection": "abstract"}]}, {"body": "List features of the DOOR syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12457410", "http://www.ncbi.nlm.nih.gov/pubmed/7808978", "http://www.ncbi.nlm.nih.gov/pubmed/8256819", "http://www.ncbi.nlm.nih.gov/pubmed/15279406", "http://www.ncbi.nlm.nih.gov/pubmed/19830001", "http://www.ncbi.nlm.nih.gov/pubmed/18263975", "http://www.ncbi.nlm.nih.gov/pubmed/21743113", "http://www.ncbi.nlm.nih.gov/pubmed/17994565"], "ideal_answer": ["DOOR syndrome is a rare multisystem genetic disorder, consisting of deafness (sensorineural), onychodystrophy, osteodystrophy, and mental retardation."], "exact_answer": [["deafness"], ["onychodystrophy"], ["osteodystrophy"], ["mental retardation"]], "type": "list", "id": "5c73ace67c78d69471000083", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "DOOR syndrome is a rare multisystem genetic disorder, consisting of deafness (sensorineural), onychodystrophy, osteodystrophy, and mental retardation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21743113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 218, "text": "We report the anaesthetic management of a 48-year-old male patient with Deafness, Onycho-Osteodystrophy and mental Retardation syndrome, epilepsy and cerebral palsy who had two dental procedures under anaesthetic care.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19830001", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 289, "text": "We present the case of a 9-year-old boy with DOOR syndrome recognized in the first year of his life because of a delayed development of speech. The diagnosis was based on characteristic abnormalities, including congenital deafness, nail and bone abnormalities, and mild mental retardation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18263975", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "DOOR syndrome (deafness, onychodystrophy, osteodystrophy, and mental retardation) is a rarely described disorder with less than 35 reports in the literature. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17994565", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "[DOOR (deafness, onychodystrophy, osteodystrophy, mental retardation) syndrome].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15279406", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "DOOR syndrome (deafness, onychodystrophy, osteodystrophy, and mental retardation) is a rarely described disorder with less than 35 reports in the literature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17994565", "endSection": "abstract"}, {"offsetInBeginSection": 158, "offsetInEndSection": 388, "text": "The hallmarks of the syndrome, represented in the DOOR acronym, include sensorineural hearing loss, hypoplastic or absent nails on the hands and feet, small or absent distal phalanges of the hands and feet, and mental retardation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17994565", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 225, "text": "Four patients from three families with the clinical features of DOOR syndrome (onycho-osteodystrophy, dystrophic thumbs, sensorineural deafness, and increased urinary levels of 2-oxoglutarate) are the subjects of this report.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12457410", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "The acronym DOOR was first used by Cantwell in 1975 to describe a syndrome comprising sensorineural deafness, osteodystrophy, onychodystrophy, and mental retardation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7808978", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "DOOR syndrome (deafness, onycho-osteodystrophy, and mental retardation): a new patient and delineation of neurologic variability among recessive cases.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8256819", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 258, "text": "Congenital heart disease and urinary tract abnormalities in two siblings with DOOR syndrome.The acronym DOOR was first used by Cantwell in 1975 to describe a syndrome comprising sensorineural deafness, osteodystrophy, onychodystrophy, and mental retardation. ", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7808978", "endSection": "title"}]}, {"body": "Name triad of Wernicke encephalopathy.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21121997", "http://www.ncbi.nlm.nih.gov/pubmed/10328278", "http://www.ncbi.nlm.nih.gov/pubmed/24099834", "http://www.ncbi.nlm.nih.gov/pubmed/25550705", "http://www.ncbi.nlm.nih.gov/pubmed/3469966", "http://www.ncbi.nlm.nih.gov/pubmed/9417174", "http://www.ncbi.nlm.nih.gov/pubmed/21519777", "http://www.ncbi.nlm.nih.gov/pubmed/17595443", "http://www.ncbi.nlm.nih.gov/pubmed/19571457", "http://www.ncbi.nlm.nih.gov/pubmed/14644703", "http://www.ncbi.nlm.nih.gov/pubmed/22332852", "http://www.ncbi.nlm.nih.gov/pubmed/25515801", "http://www.ncbi.nlm.nih.gov/pubmed/23935638", "http://www.ncbi.nlm.nih.gov/pubmed/24620429", "http://www.ncbi.nlm.nih.gov/pubmed/24379094", "http://www.ncbi.nlm.nih.gov/pubmed/7424767"], "ideal_answer": ["Wernicke's encephalopathy is a triad of ophthalmoplegia, ataxia and confusion seen in alcoholics with dietary vitamin B1 (thiamine) deficiency."], "exact_answer": [["ophthalmoplegia"], ["ataxia"], ["confusion"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014899", "http://www.disease-ontology.org/api/metadata/DOID:2384"], "type": "list", "id": "56be143eef6e394741000009", "snippets": [{"offsetInBeginSection": 150, "offsetInEndSection": 324, "text": "In the classical form it is characterized by a typical triad (confusion, oculomotor disturbance and ataxia), however, in the majority of the cases only confusion is present. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24379094", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Wernicke's encephalopathy is an acute neurological disorder characterized by mental confusion, oculomotor dysfunction, and ataxia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25550705", "endSection": "abstract"}, {"offsetInBeginSection": 896, "offsetInEndSection": 1023, "text": "The classic triad consists of encephalopathy, oculomotor dysfunction and gait ataxia but is not seen in a majority of patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25515801", "endSection": "abstract"}, {"offsetInBeginSection": 315, "offsetInEndSection": 442, "text": "After frequent vomiting, he presented with mental status changes, ocular abnormalities, and truncal ataxia (the classic triad).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24620429", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Wernicke's encephalopathy is a triad of ophthalmoplegia, ataxia and confusion seen in alcoholics with dietary vitamin B1 (thiamine) deficiency.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24099834", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Wernicke encephalopathy is caused by thiamine deficiency in the central nervous system, and is defined by the triad of confusional symptoms, ocular alterations and ataxia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19571457", "endSection": "abstract"}, {"offsetInBeginSection": 275, "offsetInEndSection": 447, "text": "The classical triad of clinical symptoms described by Wernicke (gait ataxia, ophthalmoplegia, and confusion) are found in only a third of patients upon initial examination.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14644703", "endSection": "abstract"}, {"offsetInBeginSection": 330, "offsetInEndSection": 484, "text": "It was found that only 0.4% of the population studied had the classical triad of Wernicke's encephalopathy, namely confusion, ophthalmoplegia, and ataxia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3469966", "endSection": "abstract"}, {"offsetInBeginSection": 409, "offsetInEndSection": 617, "text": "The triad of Wernicke's encephalopathy--global confusional state, ophthalmoplegia and nystagmus, and ataxia--is occasionally seen in chronic alcoholics and is often attenuated by immediate thiamine treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7424767", "endSection": "abstract"}, {"offsetInBeginSection": 1123, "offsetInEndSection": 1303, "text": "Only six presented with the Wernicke's encephalopathy clinical triad (mental status changes, ocular signs, and ataxia) at neurologic onset; nine eventually demonstrated this triad.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10328278", "endSection": "abstract"}, {"offsetInBeginSection": 145, "offsetInEndSection": 277, "text": "Wernicke's encephalopathy is a well-described syndrome characterized by the classic triad of confusion, ataxia, and ophthalmoplegia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23935638", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Wernicke&apos;s encephalopathy is a triad of ophthalmoplegia, ataxia and confusion seen in alcoholics with dietary vitamin B1 (thiamine) deficiency", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24099834", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Wernicke encephalopathy (WE) is an acute neurologic disorder characterized by a triad of ophthalmoplegia, ataxia, and mental confusion", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9417174", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 244, "text": "Wernicke&apos;s encephalopathy is a metabolic disorder caused by deficiency of thiamine (vitamin B1) seen in alcoholics and even in nonalcoholic patients, classically presenting with a triad of ataxia, ophthalmoplegia, and altered mental status", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21121997", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "Wernicke&apos;s encephalopathy is an acute neurological syndrome due to thiamine deficiency, which is characterized by a typical triad of mental status changes, oculomotor dysfunction and ataxia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21519777", "endSection": "abstract"}, {"offsetInBeginSection": 213, "offsetInEndSection": 425, "text": "The triad of Wernicke&apos;s encephalopathy--global confusional state, ophthalmoplegia and nystagmus, and ataxia--is occasionally seen in chronic alcoholics and is often attenuated by immediate thiamine treatment", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7424767", "endSection": "abstract"}, {"offsetInBeginSection": 164, "offsetInEndSection": 300, "text": "In 25/73 (35%) of the patients the classic triad of Wernicke&apos;s encephalopathy with ocular symptoms, ataxia and confusion, was found", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22332852", "endSection": "abstract"}, {"offsetInBeginSection": 187, "offsetInEndSection": 345, "text": "It was found that only 0.4% of the population studied had the classical triad of Wernicke&apos;s encephalopathy, namely confusion, ophthalmoplegia, and ataxia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3469966", "endSection": "abstract"}, {"offsetInBeginSection": 359, "offsetInEndSection": 589, "text": "Wernicke&apos;s encephalopathy (WE) is a serious, potentially fatal, neurologic disorder caused by thiamine deficiency (vitamin B(1)), classically described as presenting with a triad of ocular abnormalities, ataxia, and confusion", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17595443", "endSection": "abstract"}, {"offsetInBeginSection": 973, "offsetInEndSection": 1309, "text": "Only six presented with the Wernicke&apos;s encephalopathy clinical triad (mental status changes, ocular signs, and ataxia) at neurologic onset; nine eventually demonstrated this triad. The high rate of patients diagnosed only at postmortem examination (41.9%) confirms that Wernicke&apos;s encephalopathy is underdiagnosed in children.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10328278", "endSection": "abstract"}]}, {"body": "Which are the components of the pre-replication complex (pre-RC) in eukaryotes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19531585", "http://www.ncbi.nlm.nih.gov/pubmed/16257456", "http://www.ncbi.nlm.nih.gov/pubmed/22421151", "http://www.ncbi.nlm.nih.gov/pubmed/22412905", "http://www.ncbi.nlm.nih.gov/pubmed/15065651", "http://www.ncbi.nlm.nih.gov/pubmed/22645314", "http://www.ncbi.nlm.nih.gov/pubmed/24699916", "http://www.ncbi.nlm.nih.gov/pubmed/20705581", "http://www.ncbi.nlm.nih.gov/pubmed/22134836", "http://www.ncbi.nlm.nih.gov/pubmed/23720738", "http://www.ncbi.nlm.nih.gov/pubmed/20097898", "http://www.ncbi.nlm.nih.gov/pubmed/19910535", "http://www.ncbi.nlm.nih.gov/pubmed/22801552", "http://www.ncbi.nlm.nih.gov/pubmed/25374915", "http://www.ncbi.nlm.nih.gov/pubmed/23093411", "http://www.ncbi.nlm.nih.gov/pubmed/15201046", "http://www.ncbi.nlm.nih.gov/pubmed/16322558", "http://www.ncbi.nlm.nih.gov/pubmed/19285403", "http://www.ncbi.nlm.nih.gov/pubmed/22250202", "http://www.ncbi.nlm.nih.gov/pubmed/9159120"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0684063", "o": "Eukaryota"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0684063", "o": "http://linkedlifedata.com/resource/umls/label/A18622894"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18622894", "o": "eukaryota"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0449432", "o": "http://linkedlifedata.com/resource/umls/label/A18657821"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18657821", "o": "components"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0684063", "o": "http://linkedlifedata.com/resource/umls/label/A18585798"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18585798", "o": "eukaryotes"}], "ideal_answer": ["The components of the pre-replication complex (pre-RC) in eukaryotes are:\n1) Cdc6/Cdc18, \n2) MCM, \n3) ORC1-6,\n4) Cdt1 and\n5) Sap1/Gi."], "exact_answer": [["Cdc6/Cdc18"], ["MCM"], ["ORC1-6"], ["Cdt1"], ["Sap1/Gi"]], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:0036387", "http://amigo.geneontology.org/amigo/term/GO:0036388", "http://amigo.geneontology.org/amigo/term/GO:1902299", "http://amigo.geneontology.org/amigo/term/GO:1902985", "http://amigo.geneontology.org/amigo/term/GO:0006267", "http://amigo.geneontology.org/amigo/term/GO:0005656"], "type": "list", "id": "58dcecf58acda34529000023", "snippets": [{"offsetInBeginSection": 496, "offsetInEndSection": 915, "text": " The first step of replication initiation is the assembly of pre-replication complex (pre-RC). Since 1973, four proteins, Cdc6/Cdc18, MCM, ORC and Cdt1, have been extensively studied and proved to be pre-RC components. Recently, a novel pre-RC component called Sap1/Girdin was identified. Sap1/Girdin is required for loading Cdc18/Cdc6 to origins for pre-RC assembly in the fission yeast and human cells, respectively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24699916", "endSection": "abstract"}, {"offsetInBeginSection": 97, "offsetInEndSection": 390, "text": "In eukaryotes, the pre-replication complex is composed of the Origin Recognition Complex (ORC), Cdc6 and the MCM replicative helicase in conjunction with Cdt1. Eukaryotic ORC is considered to be composed of six subunits, named Orc1-6, and monomeric Cdc6 is closely related in sequence to Orc1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22412905", "endSection": "abstract"}, {"offsetInBeginSection": 201, "offsetInEndSection": 676, "text": "The sequencing of the Plasmodium genome has also revealed the apparent absence of many key components (e.g. Cdt1, DDK and Cdc45) of the eukaryotic cell cycle machinery that are responsible for the formation of the pre-replication complex (pre-RC). We have characterized the Plasmodium falciparum minichromosome maintenance complex (MCM) that plays a key role in the transition of pre-RC to the RC. Similar to other eukaryotes, the Plasmodium genome encodes six MCM subunits. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16257456", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "During pre-replication complex (pre-RC) formation, origin recognition complex (ORC), Cdc6, and Cdt1 cooperatively load the 6-subunit mini chromosome maintenance (MCM2-7) complex onto DNA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19910535", "endSection": "abstract"}, {"offsetInBeginSection": 99, "offsetInEndSection": 218, "text": "ORC1 is an essential component of the pre-replicative complex (pre-RC) that licenses eukaryote DNA replication origins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801552", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "In higher eukaryotes, the pre-replication complex (pre-RC) component Cdt1 is the major regulator in licensing control for DNA replication.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19531585", "endSection": "abstract"}, {"offsetInBeginSection": 201, "offsetInEndSection": 447, "text": "The sequencing of the Plasmodium genome has also revealed the apparent absence of many key components (e.g. Cdt1, DDK and Cdc45) of the eukaryotic cell cycle machinery that are responsible for the formation of the pre-replication complex (pre-RC)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16257456", "endSection": "abstract"}, {"offsetInBeginSection": 702, "offsetInEndSection": 811, "text": "We examined the mRNA expression of the components of pre-replication complex (Pre-RC), CDC6, CDT1, and MCM2-7", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25374915", "endSection": "abstract"}, {"offsetInBeginSection": 107, "offsetInEndSection": 301, "text": "Replication initiation is a multi-step process involving many factors including ORC, Cdt1p, Mcm2-7p and other proteins that bind to replication origins to form a pre-replicative complex (pre-RC)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22250202", "endSection": "abstract"}, {"offsetInBeginSection": 201, "offsetInEndSection": 448, "text": "The sequencing of the Plasmodium genome has also revealed the apparent absence of many key components (e.g. Cdt1, DDK and Cdc45) of the eukaryotic cell cycle machinery that are responsible for the formation of the pre-replication complex (pre-RC).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16257456", "endSection": "abstract"}, {"offsetInBeginSection": 271, "offsetInEndSection": 519, "text": "Different components of the ORC complex and Cdc6 stimulated prereplicative complex (pre-RC) formation and replication initiation when fused to the GAL4 DNA-binding domain and recruited to plasmid DNA containing a tandem array of GAL4-binding sites.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16322558", "endSection": "abstract"}, {"offsetInBeginSection": 309, "offsetInEndSection": 448, "text": "Cdt1, DDK and Cdc45) of the eukaryotic cell cycle machinery that are responsible for the formation of the pre-replication complex (pre-RC).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16257456", "endSection": "abstract"}, {"offsetInBeginSection": 715, "offsetInEndSection": 784, "text": "Recently, a novel pre-RC component called Sap1/Girdin was identified.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24699916", "endSection": "abstract"}, {"offsetInBeginSection": 155, "offsetInEndSection": 322, "text": "MCM2-7 is a key component of the prereplicative complex (pre-RC), which is loaded onto chromatin by the concerted action of origin recognition complex, Cdc6, and Cdt1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23093411", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "The pre-replicative complex (pre-RC) is formed at all potential origins of replication through the action of the origin recognition complex (ORC), Cdc6, Cdt1, and the Mcm2-7 complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20097898", "endSection": "abstract"}]}, {"body": "List the classical symptoms of the Moschcowitz syndrome (Thrombotic thrombocytopenic purpura).", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/3752426", "http://www.ncbi.nlm.nih.gov/pubmed/6757857", "http://www.ncbi.nlm.nih.gov/pubmed/16388418", "http://www.ncbi.nlm.nih.gov/pubmed/6752882", "http://www.ncbi.nlm.nih.gov/pubmed/21853406", "http://www.ncbi.nlm.nih.gov/pubmed/21184040", "http://www.ncbi.nlm.nih.gov/pubmed/14727263", "http://www.ncbi.nlm.nih.gov/pubmed/10668344", "http://www.ncbi.nlm.nih.gov/pubmed/2107174", "http://www.ncbi.nlm.nih.gov/pubmed/9036362", "http://www.ncbi.nlm.nih.gov/pubmed/16240903", "http://www.ncbi.nlm.nih.gov/pubmed/7712934", "http://www.ncbi.nlm.nih.gov/pubmed/10714127", "http://www.ncbi.nlm.nih.gov/pubmed/7863389", "http://www.ncbi.nlm.nih.gov/pubmed/25168331", "http://www.ncbi.nlm.nih.gov/pubmed/11450586", "http://www.ncbi.nlm.nih.gov/pubmed/12923683"], "ideal_answer": ["The typical manifestations of Moschocowitz syndrome (Thrombotic-thrombocytopenic purpura) are:\n1) thrombocytopenia, \n2) haemolysis, \n3) fever, \n4) coma and \n5) renal failure."], "exact_answer": [["thrombocytopenia", "thrombotic microangiopathy"], ["haemolysis", "hemolytic anemia"], ["fever"], ["coma", "neurological symptoms"], ["renal failure"]], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011696", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011697", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", "http://www.disease-ontology.org/api/metadata/DOID:225", "http://www.disease-ontology.org/api/metadata/DOID:10772"], "type": "list", "id": "58dd07488acda34529000025", "snippets": [{"offsetInBeginSection": 1439, "offsetInEndSection": 1602, "text": "The combination of neurological symptoms, thrombocytopenia, fever, renal failure and hemolytic anemia in a patient taking ticlopidine points to a diagnosis of TTP.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10668344", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 224, "text": "In addition to the typical manifestations of thrombotic-thrombocytopenic purpura like thrombocytopenia, haemolysis, fever, coma and renal failure, signs of a beginning DIC could be seen in a patient after abdominal surgery. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3752426", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "Moschcowitz syndrome or thrombotic thrombocytopenic purpura is a rare disorder with a poor prognosis. This syndrome is characterized by a microangiopathic hemolytic anemia with thrombocytopenia, neurologic symptoms and renal disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6752882", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 203, "text": "Moschcowitz's syndrome is a rare condition with poor prognosis. It is characterized by a microangiopathic haemolytic anaemia associated with thrombocytopenia, neurological symptoms and renal involvement.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6757857", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 238, "text": "Thrombotic thrombocytopenic purpura (TTP), in 1924 first described by Moschcowitz, is a clinically heterogeneous syndrome associated with thrombocytopenia, Coombs-negative hemolytic anemia, neurologic changes, renal impairment, and fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11450586", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 237, "text": "Thrombotic thrombocytopenic purpura (TTP), in 1924 first described by Moschcowitz, is a clinically heterogeneous syndrome associated with thrombocytopenia, Coombs-negative hemolytic anemia, neurologic changes, renal impairment, and fever", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11450586", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Thrombotic thrombocytopenic purpura (TTP, Moschcowitz disease) is characterized by thrombotic microangiopathy leading to microvascular occlusion and ischemic dysfunction of various organs including the brain", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25168331", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 337, "text": "Severe deficiency of von Willebrand factor-cleaving protease (ADAMTS-13) activity (<5% of normal) is specific for classical thrombotic thrombocytopenic purpura (TTP), a disorder presenting with thrombocytopenia, microangiopathic haemolytic anaemia and often with organ dysfunction such as neurological symptoms, renal failure, and fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12923683", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 370, "text": "In a 57-year-old female patient, who was admitted with fluctuating central neurological abnormalities and generalized purpura, was made the diagnosis of a thrombotic thrombocytopenic purpura (TTP, Moschcowitz' syndrome).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10714127", "endSection": "abstract"}, {"offsetInBeginSection": 619, "offsetInEndSection": 862, "text": "Thrombotic thrombocytopenic purpura (TTP) is a syndrome that occurs mainly in adults with multiorgan microvascular thrombosis consisting of thrombocytopenia, microangiopathic hemolytic anemia, neurologic symptoms, renal involvement, and fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2107174", "endSection": "abstract"}]}, {"body": "List components of the CRSP/Med complex.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/14759369", "http://www.ncbi.nlm.nih.gov/pubmed/12050112", "http://www.ncbi.nlm.nih.gov/pubmed/15175162", "http://www.ncbi.nlm.nih.gov/pubmed/9989412", "http://www.ncbi.nlm.nih.gov/pubmed/12509459", "http://www.ncbi.nlm.nih.gov/pubmed/24820420", "http://www.ncbi.nlm.nih.gov/pubmed/15195149", "http://www.ncbi.nlm.nih.gov/pubmed/10377381", "http://www.ncbi.nlm.nih.gov/pubmed/19571180", "http://www.ncbi.nlm.nih.gov/pubmed/11834832"], "ideal_answer": ["Mediator of RNA polymerase II transcription subunit 7\nMediator of RNA polymerase II transcription subunit 14\nMediator of RNA polymerase II transcription subunit 17\nMediator of RNA polymerase II transcription subunit 23\nMediator of RNA polymerase II transcription subunit 24\nMediator of RNA polymerase II transcription subunit 26\nMediator of RNA polymerase II transcription subunit 27"], "exact_answer": [["Mediator of RNA polymerase II transcription subunit 7"], ["Mediator of RNA polymerase II transcription subunit 14"], ["Mediator of RNA polymerase II transcription subunit 17"], ["Mediator of RNA polymerase II transcription subunit 23"], ["Mediator of RNA polymerase II transcription subunit 26"], ["Mediator of RNA polymerase II transcription subunit 27"], ["Mediator of RNA polymerase II transcription subunit 24"]], "concepts": ["http://www.uniprot.org/uniprot/MED17_XENTR", "http://www.uniprot.org/uniprot/MED27_BOVIN", "http://www.uniprot.org/uniprot/MED7_PIG", "http://www.uniprot.org/uniprot/MED23_DANRE", "http://www.uniprot.org/uniprot/MED7_BOVIN", "http://www.uniprot.org/uniprot/MED7_HUMAN", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016329", "http://www.uniprot.org/uniprot/MED27_XENTR", "http://www.uniprot.org/uniprot/MED17_DANRE", "http://www.uniprot.org/uniprot/MED26_DANRE", "http://www.uniprot.org/uniprot/MED26_HUMAN", "http://www.uniprot.org/uniprot/MED17_BOVIN", "http://www.uniprot.org/uniprot/MED7_XENTR", "http://www.uniprot.org/uniprot/MED27_DANRE", "http://www.uniprot.org/uniprot/MED23_MOUSE", "http://www.uniprot.org/uniprot/MED27_HUMAN", "http://www.uniprot.org/uniprot/MED23_RAT", "http://www.uniprot.org/uniprot/MED27_PIG", "http://www.uniprot.org/uniprot/MED14_HUMAN", "http://www.uniprot.org/uniprot/MED7_DANRE", "http://www.uniprot.org/uniprot/MED26_MOUSE", "http://www.uniprot.org/uniprot/MED27_PONAB", "http://www.uniprot.org/uniprot/MED14_MOUSE", "http://www.uniprot.org/uniprot/MD27A_XENLA", "http://www.uniprot.org/uniprot/MED7_MOUSE", "http://www.uniprot.org/uniprot/MED17_CHICK", "http://www.uniprot.org/uniprot/MED26_XENLA", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003067", "http://www.uniprot.org/uniprot/MED17_HUMAN", "http://www.uniprot.org/uniprot/MED7A_XENLA", "http://www.uniprot.org/uniprot/MED17_MOUSE", "http://www.uniprot.org/uniprot/MED27_MOUSE", "http://www.uniprot.org/uniprot/MED23_HUMAN", "http://www.uniprot.org/uniprot/MED24_HUMAN", "http://www.uniprot.org/uniprot/MED7B_XENLA", "http://www.uniprot.org/uniprot/MD27B_XENLA", "http://www.uniprot.org/uniprot/MED26_BOVIN"], "type": "list", "id": "54e0dfa91388e8454a000018", "snippets": [{"offsetInBeginSection": 622, "offsetInEndSection": 1322, "text": " Here we describe a new human factor, CRSP, that is required together with the TAF(II)s for transcriptional activation by Sp1. Purification of CRSP identifies a complex of approximate relative molecular mass 700,000 (M(r) approximately 700K) that contains nine subunits with M(r) values ranging from 33K to 200K. Cloning of genes encoding CRSP subunits reveals that CRSP33 is a homologue of the yeast mediator subunit Med7, whereas CRSP150 contains a domain conserved in yeast mediator subunit Rgr1. CRSP p200 is identical to the nuclear hormone-receptor co-activator subunit TRIP2/PBP. CRSPs 34, 77 and 130 are new proteins, but the amino terminus of CRSP70 is homologous to elongation factor TFIIS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9989412", "endSection": "abstract"}, {"offsetInBeginSection": 805, "offsetInEndSection": 905, "text": "CRSP contains unique subunits as well as polypeptides that are shared with other cofactor complexes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10377381", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 432, "text": "The multi-subunit, human CRSP coactivator-also known as Mediator (Med)-regulates transcription by mediating signals between enhancer-bound factors (activators) and the core transcriptional machinery. Interestingly, different activators are known to bind distinct subunits within the CRSP/Med complex. We have isolated a stable, endogenous CRSP/Med complex (CRSP/Med2) that specifically lacks both the Med220 and the Med70 subunits. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15175162", "endSection": "abstract"}]}, {"body": "List drugs withdrawn from the market for cardiovascular adverse events.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21265828", "http://www.ncbi.nlm.nih.gov/pubmed/21412876", "http://www.ncbi.nlm.nih.gov/pubmed/26934640", "http://www.ncbi.nlm.nih.gov/pubmed/19034038", "http://www.ncbi.nlm.nih.gov/pubmed/21249650", "http://www.ncbi.nlm.nih.gov/pubmed/25084209", "http://www.ncbi.nlm.nih.gov/pubmed/16255660", "http://www.ncbi.nlm.nih.gov/pubmed/19933959", "http://www.ncbi.nlm.nih.gov/pubmed/25114779", "http://www.ncbi.nlm.nih.gov/pubmed/23424288", "http://www.ncbi.nlm.nih.gov/pubmed/16119973", "http://www.ncbi.nlm.nih.gov/pubmed/25806762", "http://www.ncbi.nlm.nih.gov/pubmed/25340915", "http://www.ncbi.nlm.nih.gov/pubmed/21751825", "http://www.ncbi.nlm.nih.gov/pubmed/18782007"], "ideal_answer": ["Over the years, a number of different drugs have been withdrawn for Cardiotoxicity. Drugs like Clobutinol, that  induce cardiac arrhythmias by a blockade of the potassium channel coded by the hERG channel, sibutramine for weight loss and Cox2 inhibitors, Rofecoxib and Valdecoxib have been withdrawn from the market."], "exact_answer": [["Rofecoxib"], ["Valdecoxib"], ["Sibutramine"], ["Clobutinol"], ["Sertindole"], ["aprotinin"]], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064420", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000069451"], "type": "list", "id": "58a326da60087bc10a00000e", "snippets": [{"offsetInBeginSection": 351, "offsetInEndSection": 538, "text": " rofecoxib was voluntarily removed from the market for increased cardiovascular risk and in April 2005, valdecoxib was also withdrawn, at least in part, due to excess cardiovascular risk.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16255660", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 255, "text": "A common over-the-counter (OTC) non-opioid antitussive drug, clobutinol, was recently withdrawn from the market due to its potential to induce cardiac arrhythmias by a blockade of the potassium channel coded by the human ether-\u00e0-go-go-related gene (hERG).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19034038", "endSection": "abstract"}, {"offsetInBeginSection": 902, "offsetInEndSection": 1186, "text": "n. However, despite this, at the time of writing orlistat (Europe; USA) remains the only drug currently marketed for the treatment of obesity, with sibutramine having recently been withdrawn from sale globally due to the increased incidence of serious, non-fatal cardiovascular events", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21265828", "endSection": "abstract"}, {"offsetInBeginSection": 1775, "offsetInEndSection": 1900, "text": "Diclofenac has a risk very similar to rofecoxib, which was withdrawn from worldwide markets owing to cardiovascular toxicity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23424288", "endSection": "abstract"}, {"offsetInBeginSection": 648, "offsetInEndSection": 832, "text": "Sibutramine was associated with an increase in major adverse cardiovascular events in the Sibutramine Cardiovascular Outcomes (SCOUT) trial and it was withdrawn from the market in 2010", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25114779", "endSection": "abstract"}, {"offsetInBeginSection": 499, "offsetInEndSection": 1238, "text": "The safety of the most popular agent, aprotinin, has been challenged, and it was withdrawn from world markets in May 2008 because of concerns that it increased the risk of cardiovascular complications and death.To assess the comparative effects of the anti-fibrinolytic drugs aprotinin, tranexamic acid (TXA), and epsilon aminocaproic acid (EACA) on blood loss during surgery, the need for red blood cell (RBC) transfusion, and adverse events, particularly vascular occlusion, renal dysfunction, and death.We searched: the Cochrane Injuries Groups Specialised Register (July 2010), Cochrane Central Register of Controlled Trials (The Cochrane Library 2010, Issue 3), MEDLINE (Ovid SP) 1950 to July 2010, EMBASE (Ovid SP) 1980 to July 2010.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21412876", "endSection": "abstract"}, {"offsetInBeginSection": 499, "offsetInEndSection": 1238, "text": "The safety of the most popular agent, aprotinin, has been challenged, and it was withdrawn from world markets in May 2008 because of concerns that it increased the risk of cardiovascular complications and death.To assess the comparative effects of the anti-fibrinolytic drugs aprotinin, tranexamic acid (TXA), and epsilon aminocaproic acid (EACA) on blood loss during surgery, the need for red blood cell (RBC) transfusion, and adverse events, particularly vascular occlusion, renal dysfunction, and death.We searched: the Cochrane Injuries Groups Specialised Register (July 2010), Cochrane Central Register of Controlled Trials (The Cochrane Library 2010, Issue 3), MEDLINE (Ovid SP) 1950 to July 2010, EMBASE (Ovid SP) 1980 to July 2010.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21249650", "endSection": "abstract"}, {"offsetInBeginSection": 580, "offsetInEndSection": 801, "text": "Rofecoxib and valdecoxib have been withdrawn from the market worldwide due to safety concerns (most importantly for cardiovascular adverse events) and lumiracoxib has been withdrawn in many countries due to liver toxicity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340915", "endSection": "abstract"}, {"offsetInBeginSection": 556, "offsetInEndSection": 777, "text": "In the SCOUT (Sibutramine Cardiovascular OUTcomes) study, sibutramine increased serious cardiovascular events, such as stroke or myocardial infarction, compared with placebo, and was consequently withdrawn from the market", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21751825", "endSection": "abstract"}, {"offsetInBeginSection": 1777, "offsetInEndSection": 1903, "text": "Diclofenac has a risk very similar to rofecoxib, which was withdrawn from worldwide markets owing to cardiovascular toxicity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23424288", "endSection": "abstract"}, {"offsetInBeginSection": 580, "offsetInEndSection": 802, "text": "Rofecoxib and valdecoxib have been withdrawn from the market worldwide due to safety concerns (most importantly for cardiovascular adverse events) and lumiracoxib has been withdrawn in many countries due to liver toxicity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340915", "endSection": "abstract"}, {"offsetInBeginSection": 235, "offsetInEndSection": 357, "text": "Sertindole , first withdrawn from the market for cardiovascular safety concerns, is currently available in many countries.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25084209", "endSection": "abstract"}, {"offsetInBeginSection": 556, "offsetInEndSection": 1193, "text": "In the SCOUT (Sibutramine Cardiovascular OUTcomes) study, sibutramine increased serious cardiovascular events, such as stroke or myocardial infarction, compared with placebo, and was consequently withdrawn from the market. The lesson learnt from this is the importance of patient selection, limiting the duration of treatment and stopping treatment in non-responders. Currently, phentermine and amfepramone (diethylpropion) are approved for short-term treatment of obesity (up to 3 months) and orlistat is approved for longer-term treatment; however, the gastrointestinal adverse effects of orlistat may be intolerable for some patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21751825", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "BACKGROUND: Certain non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., rofecoxib [Vioxx]) increase the risk of heart attack and stroke and should be avoided in patients at high risk of cardiovascular events.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23424288", "endSection": "abstract"}, {"offsetInBeginSection": 556, "offsetInEndSection": 778, "text": "In the SCOUT (Sibutramine Cardiovascular OUTcomes) study, sibutramine increased serious cardiovascular events, such as stroke or myocardial infarction, compared with placebo, and was consequently withdrawn from the market.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21751825", "endSection": "abstract"}, {"offsetInBeginSection": 1730, "offsetInEndSection": 1855, "text": "Diclofenac has a risk very similar to rofecoxib, which was withdrawn from worldwide markets owing to cardiovascular toxicity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23424288", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 303, "text": " Rofecoxib, a selective cyclo-oxygenase (COX)-2 inhibitor, was a widely marketed drug that was used for relief of pain and inflammation in arthritic conditions. It was withdrawn from the market worldwide in September 2004 because of an increased risk of cardiovascular events. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16119973", "endSection": "abstract"}]}, {"body": "List two most common symptoms of Aagenaes syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19498211", "http://www.ncbi.nlm.nih.gov/pubmed/23626552", "http://www.ncbi.nlm.nih.gov/pubmed/10968776", "http://www.ncbi.nlm.nih.gov/pubmed/25039919", "http://www.ncbi.nlm.nih.gov/pubmed/9350821", "http://www.ncbi.nlm.nih.gov/pubmed/24086631", "http://www.ncbi.nlm.nih.gov/pubmed/16635916", "http://www.ncbi.nlm.nih.gov/pubmed/27614462", "http://www.ncbi.nlm.nih.gov/pubmed/25317502", "http://www.ncbi.nlm.nih.gov/pubmed/8278949", "http://www.ncbi.nlm.nih.gov/pubmed/12712065", "http://www.ncbi.nlm.nih.gov/pubmed/20170991", "http://www.ncbi.nlm.nih.gov/pubmed/11446017"], "ideal_answer": ["Aagenaes syndrome, also called lymphoedema cholestasis syndrome 1, is characterized by neonatal intrahepatic cholestasis, often lessening and becoming intermittent with age and severe chronic lymphoedema, mainly affecting the lower extremities."], "exact_answer": [["intrahepatic cholestasis"], ["lymphoedema"]], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:6691", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012816"], "type": "list", "id": "5895f9cf78275d0c4a000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "Aagenaes syndrome, also called lymphoedema cholestasis syndrome 1 (LSC1), is characterized by neonatal intrahepatic cholestasis, often lessening and becoming intermittent with age and severe chronic lymphoedema, mainly affecting the lower extremities. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27614462", "endSection": "abstract"}, {"offsetInBeginSection": 127, "offsetInEndSection": 319, "text": "In this study, 17 out of 20 Norweigian adult patients with lymphedema cholestasis syndrome 1 (LCS1)/Aagenaes syndrome were examined. The patients exhibited lymphedema and sporadic cholestasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25317502", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 268, "text": "BACKGROUND: Lymphedema-cholestasis syndrome (LCS; Aagenaes syndrome) is a rare autosomal recessive disorder, characterized by 1) neonatal intrahepatic cholestasis, often lessening and becoming intermittent with age, and 2) severe chronic lymphedema, mainly lower limb.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24086631", "endSection": "abstract"}, {"offsetInBeginSection": 163, "offsetInEndSection": 325, "text": "The disease was thought to be caused by a congenital cholestatic syndrome associated with intermittent oedema in childhood, resembling the rare Aagenaes syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23626552", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Do patients with lymphoedema cholestasis syndrome 1/Aagenaes syndrome need dietary counselling outside cholestatic episodes?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20170991", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "BACKGROUND & AIMS: Patients with lymphoedema cholestasis syndrome 1/Aagenaes Syndrome need a fat reduced diet when cholestatic.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20170991", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Aagenaes syndrome, also called Lymphedema Cholestasis Syndrome (LSC 1), is a form of idiopathic familial intrahepatic cholestasis associated with lymphedema of the lower extremities. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19498211", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "Aagenaes syndrome, also called Lymphedema Cholestasis Syndrome (LSC 1), is a form of idiopathic familial intrahepatic cholestasis associated with lymphedema of the lower extremities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19498211", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Parent-child transmission of infantile cholestasis with lymphoedema (Aagenaes syndrome).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9350821", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10968776", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Lymphedema-cholestasis syndrome (LCS, Aagenaes syndrome) is the only known form of hereditary lymphedema associated with cholestasis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12712065", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 308, "text": "OBJECTIVE: To investigate the prognosis of liver disease in Aagenaes syndrome (lymphoedema cholestasis syndrome 1 (LCS1)), which is an autosomal recessive inherited syndrome consisting of neonatal cholestasis with intermittent cholestatic episodes in childhood into adulthood and development of lymphoedema. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16635916", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 269, "text": "BACKGROUND: Lymphedema-cholestasis syndrome (LCS; Aagenaes syndrome) is a rare autosomal recessive disorder, characterized by 1) neonatal intrahepatic cholestasis, often lessening and becoming intermittent with age, and 2) severe chronic lymphedema, mainly lower limb. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24086631", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "[Aagenaes syndrome--lymphedema and intrahepatic cholestasis].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11446017", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Parent-child transmission of infantile cholestasis with lymphoedema (Aagenaes syndrome).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9350821", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Hereditary lymphedema, characteristics, and variations in 17 adult patients with lymphedema cholestasis syndrome 1/Aagenaes syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25317502", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Lymphedema-cholestasis syndrome (LCS, Aagenaes syndrome) is the only known form of hereditary lymphedema associated with cholestasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12712065", "endSection": "abstract"}]}, {"body": "Between which probes does the recurrent translocation breakpoint on chromosome 22 of neuroepithelioma lie?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2303258"], "ideal_answer": ["The recurrent translocation breakpoint on chromosome 22 of neuroepithelioma has been localized between two probes, D22S1 and D22S15, by both in situ hybridization and somatic cell hybrids", "The recurrent translocation breakpoint on chromosome 22 of neuroepithelioma has been localized between two probes, D22S1 and D22S15, by both in situ hybridization and somatic cell hybrids. ", "The recurrent translocation breakpoint on chromosome 22 of neuroepithelioma has been localized between two probes, D22S1 and D22S15, by both in situ hybridization and somatic cell hybrids.", "The recurrent translocation breakpoint on chromosome 22 of neuroepithelioma has been localized between two probes, D22S1 and D22S15, by both in situ hybridization and somatic cell hybrids  "], "exact_answer": [["D22S1"], ["D22S15"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056905", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014178", "http://www.disease-ontology.org/api/metadata/DOID:4388", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015342", "http://www.disease-ontology.org/api/metadata/DOID:4389"], "type": "list", "id": "5536554abc4f83e828000008", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "The recurrent translocation breakpoint on chromosome 22 of neuroepithelioma has been localized between two probes, D22S1 and D22S15, by both in situ hybridization and somatic cell hybrids", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2303258", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 188, "text": "The recurrent translocation breakpoint on chromosome 22 of neuroepithelioma has been localized between two probes, D22S1 and D22S15, by both in situ hybridization and somatic cell hybrids.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2303258", "endSection": "abstract"}]}, {"body": "What is SCENAR therapy used for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20396722", "http://www.ncbi.nlm.nih.gov/pubmed/20879466", "http://www.ncbi.nlm.nih.gov/pubmed/16924799", "http://www.ncbi.nlm.nih.gov/pubmed/8779182"], "ideal_answer": ["all patients experienced substantial relief of pain from the first treatment. an electronic biofeedback device (scenar) may be successfully utilized in the management of post-herpetic neuralgia. scenar) as effective in the treatment of neurogenic dysfunction of the bladder in children with nocturnal enuresis. post-herpetic neuralgia using a bioelectronical device (scenar). addition of scenar therapy to the complex conventional pharmacotherapy fastened ulcer healing, increased the effectiveness of helicobacter pylori eradication, and improved the condition of the gastroduodenal mucosa. scenar therapy to patients with localized suppurative peritonitis in the postoperative period. a new technique of low-frequency modulated electric current therapy, scenar therapy, was used in treatment of 103 patients with duodenal ulcer (du). ", "localized suppurative peritonitis in the postoperative period\nmanagement of post-herpetic neuralgia\ntreatment of 103 patients with duodenal ulcer\ntreatment of neurogenic dysfunction of the bladder in children with nocturnal enuresis"], "exact_answer": [["peritonitis postoperative"], ["pain in postherpetic neuralgia"], ["duodenal ulcer"], ["nocturnal enuresis"]], "type": "list", "id": "535d69177d100faa09000003", "snippets": [{"offsetInBeginSection": 48, "offsetInEndSection": 141, "text": "SCENAR therapy to patients with localized suppurative peritonitis in the postoperative period", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20396722", "endSection": "abstract"}, {"offsetInBeginSection": 94, "offsetInEndSection": 157, "text": "post-herpetic neuralgia using a bioelectronical device (SCENAR)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20879466", "endSection": "abstract"}, {"offsetInBeginSection": 397, "offsetInEndSection": 474, "text": "All patients experienced substantial relief of pain from the first treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20879466", "endSection": "abstract"}, {"offsetInBeginSection": 715, "offsetInEndSection": 831, "text": "An electronic biofeedback device (SCENAR) may be successfully utilized in the management of post-herpetic neuralgia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20879466", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "A new technique of low-frequency modulated electric current therapy, SCENAR therapy, was used in treatment of 103 patients with duodenal ulcer (DU).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16924799", "endSection": "abstract"}, {"offsetInBeginSection": 433, "offsetInEndSection": 648, "text": "Addition of SCENAR therapy to the complex conventional pharmacotherapy fastened ulcer healing, increased the effectiveness of Helicobacter pylori eradication, and improved the condition of the gastroduodenal mucosa.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16924799", "endSection": "abstract"}, {"offsetInBeginSection": 68, "offsetInEndSection": 184, "text": "SCENAR) as effective in the treatment of neurogenic dysfunction of the bladder in children with nocturnal enuresis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8779182", "endSection": "abstract"}]}, {"body": "What is being measured with an accelerometer in back pain patients", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23865908", "http://www.ncbi.nlm.nih.gov/pubmed/18752975", "http://www.ncbi.nlm.nih.gov/pubmed/19945891", "http://www.ncbi.nlm.nih.gov/pubmed/16426878", "http://www.ncbi.nlm.nih.gov/pubmed/15271728", "http://www.ncbi.nlm.nih.gov/pubmed/21872993", "http://www.ncbi.nlm.nih.gov/pubmed/21195646", "http://www.ncbi.nlm.nih.gov/pubmed/23560880", "http://www.ncbi.nlm.nih.gov/pubmed/19895697", "http://www.ncbi.nlm.nih.gov/pubmed/16437292", "http://www.ncbi.nlm.nih.gov/pubmed/20921030", "http://www.ncbi.nlm.nih.gov/pubmed/11387574", "http://www.ncbi.nlm.nih.gov/pubmed/19402888", "http://www.ncbi.nlm.nih.gov/pubmed/20457489", "http://www.ncbi.nlm.nih.gov/pubmed/19945334"], "triples": [{"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A10992203", "o": "15-810"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/label/A10992203"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A10992203", "o": "Accelerometers"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/label/A10992203"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A10992203", "o": "UMDNS"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention_type", "s": "http://data.linkedct.org/resource/intervention/36966", "o": "Device"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://data.linkedct.org/resource/intervention/36966", "o": "Intervention #36966 (Device:accelerometer and pedometer)"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention_name", "s": "http://data.linkedct.org/resource/intervention/36966", "o": "accelerometer and pedometer"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention_id", "s": "http://data.linkedct.org/resource/intervention/36966", "o": "36966"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention", "s": "http://data.linkedct.org/resource/trials/NCT00315029", "o": "http://data.linkedct.org/resource/intervention/36966"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://data.linkedct.org/resource/trials/NCT00315029", "o": "Trial NCT00315029"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention_type", "s": "http://data.linkedct.org/resource/intervention/12088", "o": "Device"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://data.linkedct.org/resource/intervention/12088", "o": "Intervention #12088 (Device:Rate-adaptive pacemaker: accelerometer)"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention_name", "s": "http://data.linkedct.org/resource/intervention/12088", "o": "Rate-adaptive pacemaker: accelerometer"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention_id", "s": "http://data.linkedct.org/resource/intervention/12088", "o": "12088"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention", "s": "http://data.linkedct.org/resource/trials/NCT00391430", "o": "http://data.linkedct.org/resource/intervention/12088"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://data.linkedct.org/resource/trials/NCT00391430", "o": "Trial NCT00391430"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention_id", "s": "http://data.linkedct.org/resource/intervention/802", "o": "802"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention_name", "s": "http://data.linkedct.org/resource/intervention/802", "o": "Accelerometer (PAM; Personal Activity Monitor)"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://data.linkedct.org/resource/intervention/802", "o": "Intervention #802 (Device:Accelerometer (PAM; Personal Activity Monitor))"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention_type", "s": "http://data.linkedct.org/resource/intervention/802", "o": "Device"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention", "s": "http://data.linkedct.org/resource/trials/NCT00621517", "o": "http://data.linkedct.org/resource/intervention/802"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://data.linkedct.org/resource/trials/NCT00621517", "o": "Trial NCT00621517"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention_id", "s": "http://data.linkedct.org/resource/intervention/54815", "o": "54815"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention_name", "s": "http://data.linkedct.org/resource/intervention/54815", "o": "McROB Hybrid node 3-axes accelerometers and 3-axes gyroscopes"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://data.linkedct.org/resource/intervention/54815", "o": "Intervention #54815 (Device:McROB Hybrid node 3-axes accelerometers and 3-axes gyroscopes)"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention_type", "s": "http://data.linkedct.org/resource/intervention/54815", "o": "Device"}, {"p": "http://data.linkedct.org/resource/linkedct/description", "s": "http://data.linkedct.org/resource/intervention/36966", "o": "Energy balance estimation using bodybugg\u00ae and Step Diet Book systems"}, {"p": "http://data.linkedct.org/resource/linkedct/description", "s": "http://data.linkedct.org/resource/intervention/54815", "o": "Training with the Audio-feedback device for about 30 minutes, 3 times per week for 6 weeks"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55735684"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55947317"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71654414"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71549290", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55941392", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55947280"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55779543", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55891060", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55761094"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55947318"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55835647"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55716079", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55944860", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55771791"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55736994"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55848389"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55776098"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55798391"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55909989"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55734704"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55776611"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55886302"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71627080", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55941985", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71581926", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55918549"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55835648"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55863235", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71630916"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55780379", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55909405", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55955374"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55798340"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55686872"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71654422"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55835633"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55862823", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55705261", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55723882"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55817336", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55887024"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71529087", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55705211", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71628962"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55885291"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71588931"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55919593"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55947302"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55733011"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55779916", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71563261", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55854073", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55942452", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55742527", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55891436", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71663412", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71604682", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71588407", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55718533", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55751599", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71535280", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71564554"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71583134"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55831318", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71555628", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55882435"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55761135"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55868955", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R111947877"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71543940"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55845260"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71579399"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71557627", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55947303"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55686918"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71662844", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55686938"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R103651198", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55812008"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R103642239"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71538917", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55817083", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55761134"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55723881"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55723829"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55874285", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55753339", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55686939"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55686919"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55761015"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71552457", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71570869", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55737923"}, {"p": "http://www.w3.org/2004/02/skos/core#inScheme", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55909952"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55740902"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55734902"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55686916"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55761112"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R112029099", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55742590", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71606444"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55761133"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55891125", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55928725", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55705263", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71585933"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55887573"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55705661", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R112029350", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55884409"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R112043601", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R111982002", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55909951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55761151"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55723965"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55891376", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55686917"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55742332", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55929461", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71591544", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71569022", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71647817"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55863163", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71624180", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55902670", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55810126"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71584290"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55868466", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55872612"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55817394", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55872719"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55772726"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55863205", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55779600", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R72222778", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71585302", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R103642236"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55779978", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55891059", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71627575", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55885230"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71559849"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55798376"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71553224"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55854009", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55705593", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55902549", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55923836"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55872613"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R103634425", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71641894"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71544986", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55678266", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55965805", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55698546"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55777987"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R103642235"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55941322", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55929460", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55891437", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71534753", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71526289"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55798375"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71629149"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55705264", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71654370"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R103642238"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55698861"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55772910"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71636781"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55798374"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55928727", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55825754", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71571185"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71583998"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55956120"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R111955480"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R103642237"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55871261", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55779732", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55910057"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55779733", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71577069"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71531600", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71597352", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71562121"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55779795", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71549078", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55938036", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71528889", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55761051"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55717310", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71614373"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55723899"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55717578", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55872631"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71544663"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71567871", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55714350", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71610630", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55938975", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55872701"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55848242"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55903285", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71527068"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71591898", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R103637301", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71590426", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55936582", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55791397", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71552885"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55830318", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71592177"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55830418", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55705662", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55872632"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55825142", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55761073"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71566068", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71542536"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55928971", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R103642234"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71651531", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71608012"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71660174"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55742203", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55872652"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71526147"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55779979", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71662687"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55872718"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71633956", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55742395", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55779542", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55965860", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55715287", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55835743"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55717536", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55761072"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55943023", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R103642233"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55854075", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55899479", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55705262", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55891058", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71564314", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55928726", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71562239", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71590337"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55816971", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55695034"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55761032"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55695973"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71579037", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55742204", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55854137", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55789296", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R111947590", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71647214", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R111955478"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71600669"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55923250"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55829586", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55684596", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55831619", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71539704", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55929033", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55736107"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71591239"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55891126", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55924599"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55770017"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R111955479"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55865641", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71642940", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71634480"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R103647756", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71655132"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55789870", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55774564"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55891323", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R111955476"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71539657"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71652749"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55829108", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55732723"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55779734", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55868916", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55835702"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71648263", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71560351"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71607672"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R103642240"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55770931"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55794730", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71655059", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R111955477"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55703747"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55835669"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55773924"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55723845"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55891434", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55937671", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71636768", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55792753", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55742528", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55922983"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71618117", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R111955474"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71598213"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R103650893", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55779157"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71540573"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55964815"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55793088", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55793533", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55891127", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71657886", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71618765"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55705212", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55705475", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55786947", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71565049"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55966169", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71529671"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71554762", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55909991"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71590471"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55957058"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55723867"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R111955475"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55734224"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55843881"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55910004"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71616653"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55881853"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71661434"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55909938"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55890999", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55806232"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71564978", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55864388", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71561198", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71612908", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55790557", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71653170", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55908973", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55910005"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55901009", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55891185", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55966105", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71578180"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71531420"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71610396"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71538602"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71651114", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55967368"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71580235", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55928659", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55827236", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55909990"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R111955473"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55705329", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55742589", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71562996"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55757406", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71659336", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71604117", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71538437", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55850911"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55854074", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55886993"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55947371"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55811709"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R112090460", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71571259", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55798326"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R103648067", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71646146"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55817849", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55909953"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55846057"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71536654", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55817084", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71592483"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55947372"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55854008", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55798325"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R103650478", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55713508", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55817085", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55919975"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55909954"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R72224447"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55721069", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R103653001", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71657521", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71619212"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71604600", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55928785", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71552509", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71578365"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55854372", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55686915"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R72220518", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55966049", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55928588", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55954717"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55686841"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55770314"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55817203", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55909973"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71663937"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55891061", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71527480", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55909955"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55722237", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71542879"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55732503"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55817086", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55817141", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71543505", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55705594", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55965745", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55808404"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55705330", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71533136"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71579988"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71619451", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55835660"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55686842"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R112050310", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55909956"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71535424"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71641686"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71527438"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55751646", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71628284", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71635922"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55883442"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55740048"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71574683", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55899725", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55909971"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55686824"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55835671"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55686903"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55880755"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55686843"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55928658", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55798281"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55779977", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55939798", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55807159"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55854834", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55798300"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55888808"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55965927", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55798339"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55686823"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55909972"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71617909", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55854005", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55928786", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71637459", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55900192", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55910073"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55684787", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71570675", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55798328"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55718297", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71639794", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55937116", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55846730"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55890998", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71609445", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71609027"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55752303", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55941383", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55686826"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71555193", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55910072"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55844814"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55862284", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55918307"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71581828"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55854136", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55966106", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55798327"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55705592", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R72219935"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55947370"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55798312"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71625333", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55696052"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55891375", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55928787", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55723831"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55835670"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R111960481", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55958436"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55909970"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R71623441"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "http://linkedlifedata.com/resource/umls/relation/R55686825"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R112090206", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R55854007", "o": "http://linkedlifedata.com/resource/umls/id/C0178951"}, {"p": "http://www.w3.org/2004/02/skos/core#definition", "s": "http://linkedlifedata.com/resource/umls/id/C0178951", "o": "UMD: Devices designed to measure the rate of change of an object's velocity. These devices typically consist of a sensor and transducer, an amplifier, and extension cables for connection to an electronic measuring unit. They work on the principle of seismic mass: this mass is restrained by a spring, and when the transducer case is accelerated, the mass moves relative to the case and exerts a force on the spring. The acceleration is calculated by measuring mass displacement or the mass' force on the spring, converted to an electrical signal. Acceleration transducers are available using strain gauges (e.g., metallic foil, piezoresistive), capacitive elements, and piezoelectric elements. Clinical accelerometers are intended for several purposes, including measuring the acceleration of body parts to assess a patient's mobility and/or activity (alone or as a component of activity monitors and gait analyzers respectively); assess tremor (e.g., in patients with Parkinson's disease); and activate pacemakers according"}], "ideal_answer": ["Accelerometer assessment measuring overall physical activity (PAL), constant strain postures (CSP), standing time (ST) and lying time (LT)...\nThe following parameters of physical activity were recorded: time upright (standing or walking), time standing, time walking, and step count."], "exact_answer": [["Physical activity", "PA", "PAL"], ["Constant Strain Postures", "CSP", "constant postures"], ["Standing time", "ST"], ["Lying time", "LT"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013001", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059787", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001416", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010146", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059352", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019567", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059350", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017116", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018710"], "type": "list", "id": "533f9df0c45e133714000016", "snippets": [{"offsetInBeginSection": 373, "offsetInEndSection": 511, "text": "accelerometer assessment measuring overall physical activity (PAL), constant strain postures (CSP), standing time (ST) and lying time (LT)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23865908", "endSection": "abstract"}, {"offsetInBeginSection": 690, "offsetInEndSection": 790, "text": "Physical activity was measured for 7 days at both baseline and at 3 months with an RT3 accelerometer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560880", "endSection": "abstract"}, {"offsetInBeginSection": 534, "offsetInEndSection": 600, "text": "wearing an accelerometer to assess physical activity in daily life", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21872993", "endSection": "abstract"}, {"offsetInBeginSection": 590, "offsetInEndSection": 659, "text": "An accelerometer was used to objectively assess their activity level ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21195646", "endSection": "abstract"}, {"offsetInBeginSection": 68, "offsetInEndSection": 581, "text": "objective activity data to determine whether patients with chronic lower back pain report their activity levels as accurately as controls do. DESIGN: A cross-sectional study was performed in patients and controls. SETTING: The study was carried out in the daily environment of the subjects. SUBJECTS: Thirty-two chronic lower back pain patients with symptoms more than three months and 20 healthy controls from the Netherlands, aged 18-65 years. MAIN MEASURES: A tri-axial accelerometer was worn for five weekdays", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20921030", "endSection": "abstract"}, {"offsetInBeginSection": 556, "offsetInEndSection": 666, "text": "During 14days physical activity in daily life was measured, with both an electronic diary and an accelerometer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20457489", "endSection": "abstract"}, {"offsetInBeginSection": 854, "offsetInEndSection": 920, "text": "physical activity in daily life was measured with an accelerometer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19945891", "endSection": "abstract"}, {"offsetInBeginSection": 127, "offsetInEndSection": 539, "text": "physical activity (PA) in individuals with chronic low back pain (CLBP). Thirty-eight participants with non-specific CLBP (29=distressed; 9=non-distressed) were recruited. PA levels were measured using an accelerometer (activPAL activity monitor) over a one week period. The following parameters of physical activity were recorded: time upright (standing or walking), time standing, time walking, and step count.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19945334", "endSection": "abstract"}, {"offsetInBeginSection": 781, "offsetInEndSection": 866, "text": "Physical activity levels will be measured by self report, RT3 triaxial accelerometer,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19895697", "endSection": "abstract"}, {"offsetInBeginSection": 322, "offsetInEndSection": 452, "text": "to study the time spent in different static trunk postures which was recorded by a biaxial accelerometer attached to the T12 level", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19402888", "endSection": "abstract"}, {"offsetInBeginSection": 450, "offsetInEndSection": 538, "text": "Daily activities were assessed by measuring body movement with a tri-axial accelerometer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18752975", "endSection": "abstract"}, {"offsetInBeginSection": 118, "offsetInEndSection": 556, "text": "nighttime activity data from 18 patients diagnosed with chronic back pain. The patients were followed for 6 days and 5 nights. Pain levels were collected every 90 min between 0800 hours and 2,200 hours using a computerized electronic diary. Activity levels were collected using a wrist accelerometer (Actiwatch AW-64). The Actiwatch sampled activity counts every 1 min. Patients were asked to wear the Actiwatch on their non-dominant arm.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16437292", "endSection": "abstract"}, {"offsetInBeginSection": 770, "offsetInEndSection": 884, "text": " 8-h accelerometer assessment in their daily life (physical activity level (PAL), number of constant postures (CP)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426878", "endSection": "abstract"}, {"offsetInBeginSection": 214, "offsetInEndSection": 321, "text": "The activity levels were collected automatically using a wrist accelerometer and were sampled every minute.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15271728", "endSection": "abstract"}, {"offsetInBeginSection": 572, "offsetInEndSection": 691, "text": "Physical activity in daily life, expressed as whole-body acceleration measured with a triaxial accelerometer (Tracmor),", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11387574", "endSection": "abstract"}]}, {"body": "Which dediodinases are present in kidney?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15072569", "http://www.ncbi.nlm.nih.gov/pubmed/9794474", "http://www.ncbi.nlm.nih.gov/pubmed/3595535", "http://www.ncbi.nlm.nih.gov/pubmed/7768329", "http://www.ncbi.nlm.nih.gov/pubmed/3197644"], "ideal_answer": ["Type 1 and  Type 3 deiodinases are both present in liver"], "exact_answer": [["Type 1 deiodinase"], ["Tipe 3 deiodinase"]], "type": "list", "id": "517a8c238ed59a060a000042", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Iodothyronine deiodinase in vitro activity studies in the chicken showed the presence of type I and type III iodothyronine deiodinase activity in both liver and kidney.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15072569", "endSection": "sections.0"}, {"offsetInBeginSection": 977, "offsetInEndSection": 1039, "text": "Co-expression of the deiodinases was also found in the kidney.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15072569", "endSection": "sections.0"}, {"offsetInBeginSection": 437, "offsetInEndSection": 485, "text": "high ID-I activities were found in liver, kidney", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7768329", "endSection": "sections.0"}, {"offsetInBeginSection": 1347, "offsetInEndSection": 1392, "text": "the kidney microsome 5'-deiodinase is type I.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3595535", "endSection": "sections.0"}]}, {"body": "Which are the lipid lowering drugs administered in patients with Coronary Artery Disease (CAD)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23074505", "http://www.ncbi.nlm.nih.gov/pubmed/23409830", "http://www.ncbi.nlm.nih.gov/pubmed/15174957", "http://www.ncbi.nlm.nih.gov/pubmed/19801853", "http://www.ncbi.nlm.nih.gov/pubmed/19090788", "http://www.ncbi.nlm.nih.gov/pubmed/23538020", "http://www.ncbi.nlm.nih.gov/pubmed/20574136", "http://www.ncbi.nlm.nih.gov/pubmed/10987597", "http://www.ncbi.nlm.nih.gov/pubmed/10637948", "http://www.ncbi.nlm.nih.gov/pubmed/19563393", "http://www.ncbi.nlm.nih.gov/pubmed/25934512", "http://www.ncbi.nlm.nih.gov/pubmed/15809368", "http://www.ncbi.nlm.nih.gov/pubmed/18674471", "http://www.ncbi.nlm.nih.gov/pubmed/11113401", "http://www.ncbi.nlm.nih.gov/pubmed/11597936", "http://www.ncbi.nlm.nih.gov/pubmed/24527682", "http://www.ncbi.nlm.nih.gov/pubmed/27923158", "http://www.ncbi.nlm.nih.gov/pubmed/18973424", "http://www.ncbi.nlm.nih.gov/pubmed/20671371", "http://www.ncbi.nlm.nih.gov/pubmed/16098846", "http://www.ncbi.nlm.nih.gov/pubmed/25999102", "http://www.ncbi.nlm.nih.gov/pubmed/20124992"], "ideal_answer": ["The lipid lowering drugs administered in patients with Coronary Artery Disease (CAD) are:\n1) Statins\n2) Fibrates\n3) Resins\n4) Niacin\n5) Cholesterol absorption-inhibiting drugs."], "exact_answer": [["Statins"], ["Fibrates"], ["Resins"], ["Niacin"], ["Cholesterol absorption-inhibiting drugs"]], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:3393", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003324", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003327"], "type": "list", "id": "589c42b178275d0c4a00003f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23538020", "endSection": "title"}, {"offsetInBeginSection": 544, "offsetInEndSection": 658, "text": "After maximizing statin dose, ezetimibe was added to reach the LDL cholesterol goal in 34% of patients (n\u00a0= 734). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23538020", "endSection": "abstract"}, {"offsetInBeginSection": 1212, "offsetInEndSection": 1607, "text": "Using Cox regression analysis, the most significant factors associated with achieving LDL cholesterol goals were lower baseline LDL cholesterol, average statin dose, and ezetimibe use. In conclusion, after maximizing statin dose, the addition of ezetimibe results in a substantial increase in the percentage of patients who reach LDL cholesterol goal, a key component of optimal medical therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23538020", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20574136", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 297, "text": "Remnant lipoproteinemia is a strong risk factor for cardiovascular (CV) diseases. This study examined which of 2 common lipid-lowering drugs (fibrates and statins) is more effective in patients with remnant lipoproteinemia and if lowering remnant lipoprotein levels can reduce CV risk.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20574136", "endSection": "abstract"}, {"offsetInBeginSection": 767, "offsetInEndSection": 896, "text": "RLP-C levels at 1 year of treatment were reduced more by bezafibrate than pravastatin (37% and 25% from baseline, respectively). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20574136", "endSection": "abstract"}, {"offsetInBeginSection": 1245, "offsetInEndSection": 1438, "text": "Bezafibrate therapy decreased RLP-C levels to a greater extent than pravastatin and a decrease in RLP-C level may be associated with a reduction in CV events in patients with high RLP-C levels.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20574136", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Statins are powerful lipid-lowering drugs, widely used in patients with hyperlipidemia and coronary artery disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18973424", "endSection": "abstract"}, {"offsetInBeginSection": 3479, "offsetInEndSection": 3636, "text": "Patients are frequently treated with lipid-lowering drugs such as resins, fibrates, niacin, statins and cholesterol absorption-inhibiting drugs (ezetimibe). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074505", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 590, "text": "This study sought to investigate the effect of daily glucose fluctuation on coronary plaque properties in patients with coronary artery disease (CAD) pre-treated with lipid-lowering therapy.There is growing evidence that glucose fluctuation, as a residual risk apart from dyslipidemia, is an important factor contributing to the development of CAD.This prospective study enrolled 70 consecutive CAD patients who were referred for percutaneous coronary intervention and whose low-density lipoprotein cholesterol level was &lt;120 mg/dl under statin treatment or &lt;100 mg/dl without statins", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25999102", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 319, "text": "To investigate the impact of lipid lowering therapy by different means on skin microvascular function in patients with dysglycaemia and coronary artery disease (CAD).Thirty-six patients were randomized to simvastatin 80 mg daily (S80, n = 19) or ezetimibe 10 mg and simvastatin 10 mg daily (E10/S10, n = 17) for 6 weeks", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19563393", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Large clinical trials have elucidated that lipid-lowering therapy using statins reduces cardiovascular events in patients with coronary artery disease (CAD)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20671371", "endSection": "abstract"}, {"offsetInBeginSection": 161, "offsetInEndSection": 342, "text": "The aim of the present study was to investigate whether LLT (lipid-lowering therapy) with statins could attenuate EPC telomere erosion in patients with CAD (coronary artery disease)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19090788", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11113401", "endSection": "title"}]}, {"body": "Which are the different isoforms of the mammalian Notch receptor?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23028706", "http://www.ncbi.nlm.nih.gov/pubmed/21639801", "http://www.ncbi.nlm.nih.gov/pubmed/21356309", "http://www.ncbi.nlm.nih.gov/pubmed/22842086", "http://www.ncbi.nlm.nih.gov/pubmed/11532344", "http://www.ncbi.nlm.nih.gov/pubmed/11732008", "http://www.ncbi.nlm.nih.gov/pubmed/16307184"], "ideal_answer": ["Notch signaling is an evolutionarily conserved mechanism, used to regulate cell fate decisions. Four Notch receptors have been identified in man: Notch-1, Notch-2, Notch-3 and Notch-4."], "exact_answer": [["Notch-1"], ["Notch-2"], ["Notch-3"], ["Notch-4"]], "type": "list", "id": "55072c803b8a5dc045000001", "snippets": [{"offsetInBeginSection": 346, "offsetInEndSection": 597, "text": "Here, we investigate protein interactions between NOTCH3 and other vascular Notch isoforms and characterize the effects of elevated NOTCH3 on smooth muscle gene regulation. We demonstrate that NOTCH3 forms heterodimers with NOTCH1, NOTCH3, and NOTCH4.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23028706", "endSection": "abstract"}, {"offsetInBeginSection": 1165, "offsetInEndSection": 1388, "text": "We conclude that CADASIL mutants of NOTCH3 complex with NOTCH1, 3, and 4, slow NOTCH3 clearance, and that overexpressed wild type and mutant NOTCH3 protein interfere with key NOTCH-mediated functions in smooth muscle cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23028706", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 245, "text": "In the vertebrate embryo, skeletal muscle is derived from the myotome of the somites. Notch1-3 demonstrate overlapping and distinct expression patterns in mouse somites. Notch1 and Notch2 have been shown to be inhibitors of skeletal myogenesis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21356309", "endSection": "abstract"}, {"offsetInBeginSection": 489, "offsetInEndSection": 684, "text": "In this study, we analyzed the immunohistochemical staining pattern of four Notch receptors (Notch1-4) and their ligands (Delta1 and Jagged1) in 14 synovial tissues obtained from 14 RA patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16307184", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Notch signaling is an evolutionarily conserved mechanism, used to regulate cell fate decisions. Four Notch receptors have been identified in man (Notch-1 to -4).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11732008", "endSection": "abstract"}, {"offsetInBeginSection": 409, "offsetInEndSection": 658, "text": "All 4 receptors were expressed in the adult liver, with no significant differences in the levels of Notch-1, -2, and -4 messenger RNA (mRNA) between normal and diseased liver. However, Notch-3 expression appeared to be increased in diseased tissue. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11732008", "endSection": "abstract"}, {"offsetInBeginSection": 985, "offsetInEndSection": 1142, "text": "We studied the immunohistochemical expression of NOTCH2 and its isoforms NOTCH1, NOTCH3, and NOTCH4 and the NOTCH2 primary ligand JAGGED1 in hepatoblastomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21639801", "endSection": "abstract"}, {"offsetInBeginSection": 130, "offsetInEndSection": 231, "text": "There are four different mammalian Notch receptors that can be activated by five cell surface ligands", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22842086", "endSection": "abstract"}, {"offsetInBeginSection": 169, "offsetInEndSection": 304, "text": "There are four mammalian Notch receptors that have only partially overlapping functions despite sharing similar structures and ligands.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11532344", "endSection": "abstract"}]}, {"body": "Which conditions are manifested by TRIM8 mutations?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32531461"], "ideal_answer": ["TRIM8 mutations are associated with epilepsy, epileptic encephalopathy, developmental delay and intellectual disability.", "Mutations in the TRIM8 gene, which encodes the triggering receptor encoded in myeloid cells 8 (TRIM8) are associated with epilepsy, epileptic encephalopathy, developmental delay and intellectual disability.", "Focal segmental glomerulosclerosis, severe developmental delay, intellectual disability and epilepsy.", "Mutations in TRIM8 gene have been described in patients with severe developmental delay, epileptic encephalopathy, developmental delay and intellectual disability."], "exact_answer": [["Focal segmental glomerulosclerosis"], ["Severe developmental delay"], ["Intellectual disability"], ["Epilepsy"]], "type": "list", "id": "601d6ec61cb411341a000032", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Focal segmental glomerulosclerosis and mild intellectual disability in a patient with a novel de novo truncating TRIM8 mutation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32531461", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1434, "text": "Mutations in the TRIM8 gene have been described in patients with severe developmental delay, intellectual disability and epilepsy. Only six patients have been described to date. All the previous mutations were truncating variants clustered in the C-terminus of the protein. A previous patient with TRIM8-related epileptic encephalopathy was reported to have nephrotic syndrome. Here we describe the clinical, radiological and histological features of an 8-year-old male patient with a TRIM8 mutation who, in contrast to previous patients, had only mild intellectual disability and well-controlled epilepsy. The patient was found to have proteinuria at 2 years of age. Renal biopsy findings were suggestive of focal segmental glomerulosclerosis. His kidney function declined and peritoneal dialysis was started at 5 years of age. He underwent renal transplant at 7 years of age. Trio-based whole genome sequencing identified a novel de novo heterozygous frameshift mutation in TRIM8 (NM_030912.2) c.1198_1220del, p.(Tyr400ArgfsTer2). This patient is further evidence that TRIM8 mutations cause a syndrome with both neurological and renal features. Our findings suggest the spectrum of TRIM8-related disease may be wider than previously thought with the possibility of milder neurodevelopmental problems and/or a more severe, progressive renal phenotype. We highlight the need for proteinuria screening in patients with TRIM8 mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32531461", "endSection": "abstract"}]}, {"body": "List major risk factors for Alzheimer's disease. ", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28884281", "http://www.ncbi.nlm.nih.gov/pubmed/28396259", "http://www.ncbi.nlm.nih.gov/pubmed/28435465", "http://www.ncbi.nlm.nih.gov/pubmed/28272510", "http://www.ncbi.nlm.nih.gov/pubmed/27300264"], "ideal_answer": ["Apolipoprotein E4\ntype 2 diabetes\nClusterin\nHypertension\nadvancing age\nobesity"], "exact_answer": [["Apolipoprotein E4"], ["type 2 diabetes"], ["Clusterin"], ["Hypertension"], ["advancing age"], ["obesity"]], "type": "list", "id": "5a9d96564e03427e73000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Apolipoprotein E4 (E4) and type 2 diabetes are major risk factors for cognitive decline and late onset Alzheimer's disease (AD)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28272510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Cardiovascular risk factors, especially hypertension, are also major risk factors for Alzheimer's disease (AD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28435465", "endSection": "abstract"}, {"offsetInBeginSection": 296, "offsetInEndSection": 372, "text": "Clusterin (Apo J) is one of the major risk factors for sporadic form of AD. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28396259", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Hypertension is one of the major risk factors for central nervous system (CNS) disorders like stroke and Alzheimer's disease (AD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884281", "endSection": "abstract"}, {"offsetInBeginSection": 57, "offsetInEndSection": 186, "text": "Major risk factors for AD are advancing age and diabetes. Lately, obesity has been associated with an increased risk of dementia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27300264", "endSection": "abstract"}]}, {"body": "Name scRNA-seq workflows which harness graph attention networks", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34512734", "http://www.ncbi.nlm.nih.gov/pubmed/34864884"], "ideal_answer": ["SCDRHA and CellVGAE"], "exact_answer": [["CellVGAE"], ["SCDRHA"]], "type": "list", "id": "621e5cf53a8413c65300004e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "SCDRHA: A scRNA-Seq Data Dimensionality Reduction Algorithm Based on Hierarchical Autoencoder.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34512734", "endSection": "title"}, {"offsetInBeginSection": 244, "offsetInEndSection": 922, "text": "To address this issue, in this paper, we propose a scRNA-seq data dimensionality reduction algorithm based on a hierarchical autoencoder, termed SCDRHA. The proposed SCDRHA consists of two core modules, where the first module is a deep count autoencoder (DCA) that is used to denoise data, and the second module is a graph autoencoder that projects the data into a low-dimensional space. Experimental results demonstrate that SCDRHA has better performance than existing state-of-the-art algorithms on dimension reduction and noise reduction in five real scRNA-seq datasets. Besides, SCDRHA can also dramatically improve the performance of data visualization and cell clustering.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34512734", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "CellVGAE: an unsupervised scRNA-seq analysis workflow with graph attention networks.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864884", "endSection": "title"}, {"offsetInBeginSection": 497, "offsetInEndSection": 934, "text": "With the help of several case studies, we show that our model, named CellVGAE, can be effectively used for exploratory analysis even on challenging datasets, by extracting meaningful features from the data and providing the means to visualise and interpret different aspects of the model.RESULTS: We show that CellVGAE is more interpretable than existing scRNA-seq variational architectures by analysing the graph attention coefficients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864884", "endSection": "abstract"}]}, {"body": "Which oncogenes are able to induce cellular senescence?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23216904", "http://www.ncbi.nlm.nih.gov/pubmed/19053174", "http://www.ncbi.nlm.nih.gov/pubmed/20010815", "http://www.ncbi.nlm.nih.gov/pubmed/17409421", "http://www.ncbi.nlm.nih.gov/pubmed/17634581", "http://www.ncbi.nlm.nih.gov/pubmed/11971980", "http://www.ncbi.nlm.nih.gov/pubmed/22791394", "http://www.ncbi.nlm.nih.gov/pubmed/22019769", "http://www.ncbi.nlm.nih.gov/pubmed/17664422", "http://www.ncbi.nlm.nih.gov/pubmed/20227040", "http://www.ncbi.nlm.nih.gov/pubmed/16818632", "http://www.ncbi.nlm.nih.gov/pubmed/20237562", "http://www.ncbi.nlm.nih.gov/pubmed/12581156", "http://www.ncbi.nlm.nih.gov/pubmed/21969595", "http://www.ncbi.nlm.nih.gov/pubmed/12134086", "http://www.ncbi.nlm.nih.gov/pubmed/19150958"], "ideal_answer": ["Cellular senescence can be induced through activation or inactivation of a number of oncogenes, such as Ras, c-Abl, Raf, Myc, Skp2, BRAF, AKT, HDAC2, p38 MAPK, Caveolin-1 and Mek1."], "exact_answer": [["Ras"], ["c-Abl"], ["Raf"], ["Myc"], ["Skp2"], ["BRAF"], ["AKT"], ["HDAC2"], ["p38 MAPK"], ["Caveolin-1"], ["Mek1"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016922", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:2000773", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:2000772", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:2000774", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016283", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0090398", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011905", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018631", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016315", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016313", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016374", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0090402"], "type": "list", "id": "5309f8f5970c65fa6b000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "ROS-generating oxidases Nox1 and Nox4 contribute to oncogenic Ras-induced premature senescence", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23216904", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 271, "text": "Activated oncogenes induce premature cellular senescence, a permanent state of proliferative arrest in primary rodent and human fibroblasts. Recent studies suggest that generation of reactive oxygen species (ROS) is involved in oncogenic Ras-induced premature senescence.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23216904", "endSection": "abstract"}, {"offsetInBeginSection": 1282, "offsetInEndSection": 1397, "text": "these findings suggest that Nox1- and Nox4-generated ROS play an important role in Ras-induced premature senescence", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23216904", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "A role for c-Abl in cell senescence and spontaneous immortalization", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22791394", "endSection": "title"}, {"offsetInBeginSection": 301, "offsetInEndSection": 497, "text": "Here, we report an important role for c-Abl in replicative senescence and immortalization by regulating the expression of two tumor suppressors that induce cellular senescence, p53 and p16(INK4a).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22791394", "endSection": "abstract"}, {"offsetInBeginSection": 1249, "offsetInEndSection": 1419, "text": "The role for c-Abl in regulating cell senescence and immortalization might explain some of the developmental defects in c-Abl (-/-) mice and how BCR-ABL transforms cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22791394", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Ras/Raf-prototypic oncogenes induce cellular senescence, a terminal cell-cycle arrest, as a default cellular safeguard program", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22019769", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 64, "text": "oncogene-induced senescence, Myc style", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22019769", "endSection": "title"}, {"offsetInBeginSection": 218, "offsetInEndSection": 666, "text": "We review and discuss here evidence for Myc-induced senescence - which is detectable to a limited degree as a cell-autonomous, direct response to Myc action, but occurs predominantly in a non-cell-autonomous fashion via crosstalk of the oncogene-driven cell population with non-neoplastic bystanders, namely cells of the host immune system, prompting them to release pro-senescent cytokines that strike back onto adjacent proliferating tumor cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22019769", "endSection": "abstract"}, {"offsetInBeginSection": 865, "offsetInEndSection": 1137, "text": "genetic Skp2 inactivation evokes cellular senescence even in oncogenic conditions in which the p19(Arf)-p53 response is impaired, whereas a Skp2-SCF complex inhibitor can trigger cellular senescence in p53/Pten-deficient cells and tumour regression in preclinical studies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20237562", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Activated RAS/BRAF oncogenes induce cellular senescence as a tumor-suppressive barrier in early cancer development, at least in part, via an oncogene-evoked DNA damage response (DDR).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20227040", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Cdk2 suppresses cellular senescence induced by the c-myc oncogene", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20010815", "endSection": "title"}, {"offsetInBeginSection": 528, "offsetInEndSection": 644, "text": "Loss of Cdk2 also caused sensitization to Myc-induced senescence in pancreatic beta-cells or splenic B-cells in vivo", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20010815", "endSection": "abstract"}, {"offsetInBeginSection": 816, "offsetInEndSection": 887, "text": "Myc also causes senescence in cells lacking the DNA repair protein Wrn.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20010815", "endSection": "abstract"}, {"offsetInBeginSection": 1053, "offsetInEndSection": 1225, "text": "In MEFs, Myc-induced senescence was genetically dependent on the ARF-p53-p21Cip1 and p16INK4a-pRb pathways, p21Cip1 and p16INK4a being selectively induced in Cdk2-/- cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20010815", "endSection": "abstract"}, {"offsetInBeginSection": 249, "offsetInEndSection": 362, "text": "We have found that expression of such an oncogene, Akt, causes senescence in primary mouse hepatoblasts in vitro.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19150958", "endSection": "abstract"}, {"offsetInBeginSection": 533, "offsetInEndSection": 653, "text": "hyperproliferative signaling through AKT might be a driving force of the senescence in activated hepatic stellate cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19150958", "endSection": "abstract"}, {"offsetInBeginSection": 1151, "offsetInEndSection": 1238, "text": "oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19053174", "endSection": "abstract"}, {"offsetInBeginSection": 122, "offsetInEndSection": 300, "text": "Here we report that the suppression of the c-Myc (MYC) oncogene induces cellular senescence in diverse tumor types including lymphoma, osteosarcoma, and hepatocellular carcinoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17664422", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17664422", "endSection": "title"}, {"offsetInBeginSection": 301, "offsetInEndSection": 372, "text": "MYC inactivation was associated with prototypical markers of senescence", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17664422", "endSection": "abstract"}, {"offsetInBeginSection": 807, "offsetInEndSection": 938, "text": "only after lymphomas were repaired for p53 expression did MYC inactivation induce robust senescence and sustained tumor regression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17664422", "endSection": "abstract"}, {"offsetInBeginSection": 1116, "offsetInEndSection": 1309, "text": "Replicative senescence due to telomere shortening can, for example, be induced by a dominant negative version of telomerase, premature senescence by the overexpression of oncogenic ras, or p16.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17634581", "endSection": "abstract"}, {"offsetInBeginSection": 861, "offsetInEndSection": 908, "text": "knockdown of HDAC2 induced cellular senescence.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17409421", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 219, "text": "MYC overexpression is thought to initiate tumorigenesis by inducing cellular proliferation and growth and to be restrained from causing tumorigenesis by inducing cell cycle arrest, cellular senescence, and/or apoptosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16818632", "endSection": "abstract"}, {"offsetInBeginSection": 191, "offsetInEndSection": 340, "text": "Several conditions, including oncogenic Ras over-expression and inappropriate culture conditions, also induce senescence without telomere shortening.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12581156", "endSection": "abstract"}, {"offsetInBeginSection": 481, "offsetInEndSection": 700, "text": "We demonstrate that p38 mitogen-activated protein kinase (MAPK) plays important causative roles in senescent cells following telomere shortening, Ras-Raf activation, oxidative stress or inappropriate culture conditions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12581156", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Mitogen-activated protein kinase p38 defines the common senescence-signalling pathway", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12581156", "endSection": "title"}, {"offsetInBeginSection": 1359, "offsetInEndSection": 1465, "text": "These results indicate that p38 comprises the senescence-executing pathway in response to diverse stimuli.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12581156", "endSection": "abstract"}, {"offsetInBeginSection": 907, "offsetInEndSection": 1346, "text": "this p38-activating condition appears to be defined quantitatively as a sum of continuous and low-level stresses, and remains even after the initial stimuli are withdrawn, which may explain the well-known irreversible nature of cellular senescence. We also show that papilloma virus E7 abolishes the p38-induced growth arrest but not other senescence-associated phenotypes, indicating the differential role of pRb in the downstream of p38.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12581156", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Expression of caveolin-1 induces premature cellular senescence in primary cultures of murine fibroblasts", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12134086", "endSection": "title"}, {"offsetInBeginSection": 832, "offsetInEndSection": 1224, "text": "Here, we demonstrate that mouse embryonic fibroblasts transgenically overexpressing caveolin-1 show: 1) a reduced proliferative lifespan; 2) senescence-like cell morphology; and 3) a senescence-associated increase in beta-galactosidase activity. These results indicate for the first time that the expression of caveolin-1 in vivo is sufficient to promote and maintain the senescent phenotype.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12134086", "endSection": "abstract"}, {"offsetInBeginSection": 1799, "offsetInEndSection": 2028, "text": "Interestingly, premature senescence induced by hydrogen peroxide is greatly reduced in NIH 3T3 cells harboring antisense caveolin-1. Importantly, induction of premature senescence is recovered when caveolin-1 levels are restored.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12134086", "endSection": "abstract"}, {"offsetInBeginSection": 2045, "offsetInEndSection": 2138, "text": "these results clearly indicate a central role for caveolin-1 in promoting cellular senescence", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12134086", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 196, "text": "Oncogenic activation of the mitogen-activated protein (MAP) kinase cascade in murine fibroblasts initiates a senescence-like cell cycle arrest that depends on the ARF/p53 tumor suppressor pathway.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11971980", "endSection": "abstract"}, {"offsetInBeginSection": 599, "offsetInEndSection": 841, "text": "In contrast, coexpression of oncogenic ras or activated mek1 with p53 enhanced both p53 levels and activity relative to that observed for p53 alone and produced an irreversible cell cycle arrest that displayed features of cellular senescence.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11971980", "endSection": "abstract"}, {"offsetInBeginSection": 1398, "offsetInEndSection": 1585, "text": "our results indicate that oncogenic activation of the MAP kinase pathway in murine fibroblasts converts p53 into a senescence inducer through both quantitative and qualitative mechanisms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11971980", "endSection": "abstract"}, {"offsetInBeginSection": 697, "offsetInEndSection": 1077, "text": "Myc-evoked apoptosis serves as a signal for macrophage attraction and activation, followed by the secretion of TGF-\u03b2 as a cytokine that is capable of terminally arresting Myc-driven lymphoma cells without causing further DNA damage and without launching a senescence-associated, pro-inflammatory, and, therefore, potentially detrimental cytokine response in the target population.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22019769", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "The suppression of oncogenic levels of MYC is sufficient to induce sustained tumor regression associated with proliferative arrest, differentiation, cellular senescence, and/or apoptosis, a phenomenon known as oncogene addiction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21969595", "endSection": "abstract"}]}, {"body": "Which endothelial cell migration pathways were modulated at the gene expression level by rHDL-apoE3?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34875308"], "ideal_answer": ["The most pronounced effect was observed for EC migration, with 42/198 genes being involved in the following EC migration-related pathways: 1) MEK/ERK, 2) PI3K/AKT/eNOS-MMP2/9, 3) RHO-GTPases, and 4) integrin."], "exact_answer": [["MEK/ERK"], ["PI3K/AKT/eNOS-MMP2/9"], ["RHO-GTPases"], ["integrin"]], "type": "list", "id": "6206b8c2c9dfcb9c0900003c", "snippets": [{"offsetInBeginSection": 2037, "offsetInEndSection": 2241, "text": " The most pronounced effect was observed for EC migration, with 42/198 genes being involved in the following EC migration-related pathways: 1) MEK/ERK, 2) PI3K/AKT/eNOS-MMP2/9, 3) RHO-GTPases, 4) integrin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34875308", "endSection": "abstract"}]}, {"body": "Which receptor(s) recognize lysosomal hydrolases in trans-Golgi network (TGN)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18088323", "http://www.ncbi.nlm.nih.gov/pubmed/15078903", "http://www.ncbi.nlm.nih.gov/pubmed/9668075", "http://www.ncbi.nlm.nih.gov/pubmed/17596511", "http://www.ncbi.nlm.nih.gov/pubmed/22264539", "http://www.ncbi.nlm.nih.gov/pubmed/16787435", "http://www.ncbi.nlm.nih.gov/pubmed/11408573", "http://www.ncbi.nlm.nih.gov/pubmed/19224451", "http://www.ncbi.nlm.nih.gov/pubmed/23322049", "http://www.ncbi.nlm.nih.gov/pubmed/22266136", "http://www.ncbi.nlm.nih.gov/pubmed/8577031", "http://www.ncbi.nlm.nih.gov/pubmed/17606993", "http://www.ncbi.nlm.nih.gov/pubmed/8603911", "http://www.ncbi.nlm.nih.gov/pubmed/22884962", "http://www.ncbi.nlm.nih.gov/pubmed/11387475", "http://www.ncbi.nlm.nih.gov/pubmed/18195106", "http://www.ncbi.nlm.nih.gov/pubmed/9247639", "http://www.ncbi.nlm.nih.gov/pubmed/11470415", "http://www.ncbi.nlm.nih.gov/pubmed/22907655", "http://www.ncbi.nlm.nih.gov/pubmed/3000696", "http://www.ncbi.nlm.nih.gov/pubmed/18431031", "http://www.ncbi.nlm.nih.gov/pubmed/7642698", "http://www.ncbi.nlm.nih.gov/pubmed/15976452", "http://www.ncbi.nlm.nih.gov/pubmed/7642697", "http://www.ncbi.nlm.nih.gov/pubmed/18992238", "http://www.ncbi.nlm.nih.gov/pubmed/8718666"], "ideal_answer": ["The majority of lysosomal hydrolases in trans-Golgi network (TGN) are specifically recognized by mannose 6-phosphate (M6P) receptors (MPRs), which ensure their transport to the endosomal/lysosomal system. Other receptors can also carry lysosomal hydrolases from the trans-Golgi network (TGN) to the endosomal system. These M6P alternative receptors are the lysosomal integral membrane protein (LIMP-2) and the multi-ligand receptor sortilin. These reseptors enable a mannose-6-phosphate-independent pathway from TGN to lysosomes."], "exact_answer": [["mannose 6-phosphate receptors (MPRs)"], ["sortilin"], ["lysosomal integral membrane protein (LIMP-2)"], ["cation-independent mannose 6-phosphate receptor (CI-MPR)"]], "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005802", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0090160"], "type": "list", "id": "554101d0234c5a7c75000002", "snippets": [{"offsetInBeginSection": 435, "offsetInEndSection": 655, "text": "The majority of the enzymes leave the TGN after modification with mannose-6-phosphate (M6P) residues, which are specifically recognized by M6P receptors (MPRs), ensuring their transport to the endosomal/lysosomal system.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22884962", "endSection": "abstract"}, {"offsetInBeginSection": 665, "offsetInEndSection": 785, "text": "M6P receptors play a major role in the intracellular transport of newly synthesized lysosomal enzymes in mammalian cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22884962", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "Mannose 6-phosphate receptors (MPRs) are known to be shuttled between the trans-Golgi network (TGN) and endosomes, thereby several lysosomal hydrolases are delivered through the endocytic pathway into lysosomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22264539", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Most soluble lysosomal hydrolases are sorted in the trans-Golgi network (TGN) and delivered to the lysosomes by the mannose 6-phosphate receptor (M6PR).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18992238", "endSection": "abstract"}, {"offsetInBeginSection": 239, "offsetInEndSection": 331, "text": "certain soluble lysosomal hydrolases, is sorted and trafficked to the lysosomes by sortilin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18992238", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Mannose-6-phosphate receptors (MPRs) transport lysosomal hydrolases from the trans Golgi network (TGN) to endosomes. Recently, the multi-ligand receptor sortilin has also been implicated in this transport", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18088323", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "A shortcut to the lysosome: the mannose-6-phosphate-independent pathway", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22884962", "endSection": "title"}, {"offsetInBeginSection": 787, "offsetInEndSection": 1047, "text": "several lines of evidence suggest the existence of alternative processes of lysosomal targeting. Among them, the two that are mediated by the M6P alternative receptors, lysosomal integral membrane protein (LIMP-2) and sortilin, have gained unequivocal support.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22884962", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 134, "text": "delivery of mannose 6-phosphate receptors carrying lysosomal hydrolases from the trans-Golgi network (TGN) to the endosomal system", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16787435", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "The cation-independent mannose 6-phosphate receptor (CI-MPR) mediates sorting of lysosomal hydrolase precursors from the TGN to endosomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15078903", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 209, "text": "mannose 6-phosphate (Man-6-P) recognition marker on lysosomal hydrolases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11408573", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 319, "text": "The delivery of mannose 6-phosphate receptors carrying lysosomal hydrolases from the trans-Golgi network (TGN) to the endosomal system is mediated by selective incorporation of the receptor-hydrolase complexes into vesicular transport carriers (TCs) that are coated with clathrin and the adaptor proteins, GGA and AP-1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16787435", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Mannose-6-phosphate receptors (MPRs) transport lysosomal hydrolases from the trans Golgi network (TGN) to endosomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18088323", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "Mannose 6-phosphate receptors carry newly synthesized lysosomal hydrolases from the trans-Golgi network to endosomes, then return to the trans-Golgi network for another round of enzyme delivery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9247639", "endSection": "abstract"}, {"offsetInBeginSection": 1152, "offsetInEndSection": 1434, "text": "In this way, the M6P receptors help package the hydrolases into vesicles that bud from the trans-Golgi network to deliver their contents to endosomes that ultimately will develop into mature lysosomes, where recently-delivered hydrolases may start digesting the endocyted material.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22266136", "endSection": "abstract"}, {"offsetInBeginSection": 561, "offsetInEndSection": 932, "text": "However, LS fibroblasts displayed reduced mannose 6-phosphate receptor (MPR)-mediated re-uptake of the lysosomal enzyme arylsulfatase B. In addition, endosome-to-trans Golgi network (TGN) transport of MPRs was decreased significantly, leading to higher levels of cell surface MPRs and their enrichment in enlarged, retromer-positive endosomes in OCRL-depleted HeLa cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22907655", "endSection": "abstract"}, {"offsetInBeginSection": 813, "offsetInEndSection": 1009, "text": "The M6P groups are then recognized by two independent transmembrane M6P receptors, present in the trans-Golgi network: the cation-independent M6P receptor and/or the cation-dependent M6P receptor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22266136", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 303, "text": "Two related mannose 6-phosphate receptors (MPRs) recognize this feature in the trans Golgi network (TGN) and deliver the hydrolases to the late endosome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11470415", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "The cation-independent mannose 6-phosphate receptor (CIMPR) cycles between the trans-Golgi network (TGN) and endosomes to mediate sorting of lysosomal hydrolases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17606993", "endSection": "abstract"}, {"offsetInBeginSection": 813, "offsetInEndSection": 1008, "text": "The M6P groups are then recognized by two independent transmembrane M6P receptors, present in the trans-Golgi network: the cation-independent M6P receptor and/or the cation-dependent M6P receptor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22266136", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Mannose-6-phosphate receptors (MPRs) transport lysosomal hydrolases from the trans Golgi network (TGN) to endosomes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18088323", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 318, "text": "The delivery of mannose 6-phosphate receptors carrying lysosomal hydrolases from the trans-Golgi network (TGN) to the endosomal system is mediated by selective incorporation of the receptor-hydrolase complexes into vesicular transport carriers (TCs) that are coated with clathrin and the adaptor proteins, GGA and AP-1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16787435", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "Mannose 6-phosphate receptors (MPRs) are known to be shuttled between the trans-Golgi network (TGN) and endosomes, thereby several lysosomal hydrolases are delivered through the endocytic pathway into lysosomes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22264539", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "The cation-independent mannose 6-phosphate receptor (CIMPR) cycles between the trans-Golgi network (TGN) and endosomes to mediate sorting of lysosomal hydrolases", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17606993", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 302, "text": "Two related mannose 6-phosphate receptors (MPRs) recognize this feature in the trans Golgi network (TGN) and deliver the hydrolases to the late endosome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11470415", "endSection": "abstract"}]}, {"body": "What eye disease(s) are associated with ocular toxoplasmosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31429610", "http://www.ncbi.nlm.nih.gov/pubmed/17596951", "http://www.ncbi.nlm.nih.gov/pubmed/30332547", "http://www.ncbi.nlm.nih.gov/pubmed/31589483", "http://www.ncbi.nlm.nih.gov/pubmed/15906073", "http://www.ncbi.nlm.nih.gov/pubmed/25127047", "http://www.ncbi.nlm.nih.gov/pubmed/33060522", "http://www.ncbi.nlm.nih.gov/pubmed/32068467"], "ideal_answer": ["Retinochoroiditis is the most frequent manifestation of congenital toxoplasmosis Infectious uveitis accounted for 37% of posterior uveitis cases of which toxoplasmosis was the most common cause. Toxoplasmosis was the most common cause of posterior uveitis (60%)", "A large percentage of posterior and infectious uveitis is associate with toxoplasmosis. Retinochoroiditis is associated with congenital toxoplasmosis.", "the most frequent manifestation of congenital toxoplasmosis is retinochoroiditis.", "Retinochoroiditis is the most frequent manifestation of congenital toxoplasmosis", "yes, ocular toxoplasmosis is associated with retinochoroiditis.", "Toxoplasmosis was the most common cause of posterior uveitis (60%) Retinochoroiditis is the most frequent manifestation of congenital toxoplasmosis Infectious uveitis accounted for 37% of posterior uveitis cases of which toxoplasmosis was the most common cause.", "The eye disease(s) associated with ocular toxoplasmosis are:1) ocular syphthalmia, 2) retinochoroiditis, 3) juvenile idiopathic arthritis and4) chorioretinitis.", "Toxoplasmosis was the most common cause of posterior uveitis (60%) for infectious uveritis, herpetic iridocyclitis, ocular toxoplasmosa, and bacterial endophthalmitis increased in patients with congenital tasma.", "Diseases associated with ocular toxoplasmosis are ocular syphilis, retinochoroiditis, juvenile idiopathic arthritis and chorioretinitis.", "Diseases associated with ocular toxoplasmosis are:1) ocular syphilis, 2) retinochoroiditis, 3) juvenile idiopathic arthritis and4) chorioretinitis.", "Ocular toxoplasmosis (OTS) is a rare but life threatening complication of ocular syphilis, which is followed by retinochoroiditis, juvenile idiopathic arthritis and chorioretinitis."], "exact_answer": [["retinochoroiditis"], ["posterior uveitis"], ["infectious uveitis"]], "type": "list", "id": "601d72181cb411341a000034", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 92, "text": "Retinochoroiditis is the most frequent manifestation of congenital toxoplasmosis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33060522", "endSection": "abstract"}, {"offsetInBeginSection": 479, "offsetInEndSection": 593, "text": "Infectious uveitis accounted for 37% of posterior uveitis cases of which toxoplasmosis was the most common cause. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30332547", "endSection": "abstract"}, {"offsetInBeginSection": 815, "offsetInEndSection": 881, "text": "Toxoplasmosis was the most common cause of posterior uveitis (60%)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31429610", "endSection": "abstract"}, {"offsetInBeginSection": 577, "offsetInEndSection": 703, "text": "For infectious uveitis, herpetic iridocyclitis, ocular toxoplasmosis, ocular syphilis, and bacterial endophthalmitis increased", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32068467", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 168, "text": "To evaluate quality of life in patients with uveitis-related to toxoplasmosis and its correlation with demographic, ocular involvement and psychosocial aspects", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31589483", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "Retinal detachment associated with ocular toxoplasmosis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25127047", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "PURPOSE: To assess the frequency of retinal detachment (RD) and associated clinical features in ocular toxoplasmosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25127047", "endSection": "abstract"}, {"offsetInBeginSection": 80, "offsetInEndSection": 274, "text": "Toxoplasmosis is the most common cause of posterior uveitis in immunocompetent subjects and congenital toxoplasmosis transmission was the first parasite to be linked to human lesions in the eye.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17596951", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 164, "text": "Retinochoroiditis is the most common ocular manifestation of congenital toxoplasmosis, but other associated ophthalmological pathologies can also occur.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15906073", "endSection": "abstract"}]}, {"body": "The protein neprilysin  has an positive effect on Alzheimer disease, how can it be delivered to the brain?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23378928", "http://www.ncbi.nlm.nih.gov/pubmed/22751177", "http://www.ncbi.nlm.nih.gov/pubmed/20817034", "http://www.ncbi.nlm.nih.gov/pubmed/17760499", "http://www.ncbi.nlm.nih.gov/pubmed/22114052", "http://www.ncbi.nlm.nih.gov/pubmed/21304989", "http://www.ncbi.nlm.nih.gov/pubmed/23503602", "http://www.ncbi.nlm.nih.gov/pubmed/19469700"], "ideal_answer": ["The protein neprilysin can be deliverered to the brain (crossing the blood brain barrier) through: gene tranfer, transgenesis, gene induction, ex-vivo gene therapy, intracardiac (peripheral) administration of viral neprilysin construct, syringe-focused ultrasound device, convection-enhanced delivery and the use of human adipose tissue-derived mesenchymal stem cells that secrete functional neprilysin-bound exosomes"], "exact_answer": [["Gene transfer with viral vectors"], ["Gene transfer with non-viral vectors"], ["Transgenesis"], ["Gene Induction"], ["Fusion of the Apolipoprotein B (ApoB) low-density lipoprotein (LDL) receptor-binding domain to a targeted protein"], ["ex vivo gene therapy"], ["Intracardiac (peripheral) administration of viral neprilysin construct"], ["Syringe-focused ultrasound device"], ["Convection-enhanced delivery"], ["Use of human adipose tissue-derived mesenchymal stem cells that secrete functional neprilysin-bound exosomes"]], "concepts": ["http://www.uniprot.org/uniprot/NEP_HUMAN", "http://www.disease-ontology.org/api/metadata/DOID:10652", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016503", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018014", "http://www.uniprot.org/uniprot/NEP_RABIT", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015260", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D023582", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000544"], "type": "list", "id": "5162e44f298dcd4e5100004a", "snippets": [{"offsetInBeginSection": 641, "offsetInEndSection": 816, "text": "he novel, syringe-focused US device was used to introduce purified plasmid DNA encoding human neprilysin (hNEP) into mouse hindlimb skeletal muscle concurrent with US protocol", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22114052", "endSection": "sections.0"}, {"offsetInBeginSection": 1494, "offsetInEndSection": 1673, "text": "This technique provides a safe and efficient non-viral method for in vivo gene delivery with potential applications in both basic research and in gene therapy of neuronal disease.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20817034", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "A novel system for in vivo neprilysin gene delivery using a syringe electrode.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20817034", "endSection": "title"}, {"offsetInBeginSection": 97, "offsetInEndSection": 257, "text": "Previous studies have demonstrated the therapeutic potential of viral vector-mediated neprilysin (NEP) gene therapy in mouse models of Alzheimer's disease (AD).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22751177", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Convection-enhanced delivery of neprilysin: a novel amyloid-\u03b2-degrading therapeutic strategy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22751177", "endSection": "title"}]}, {"body": "List 3 conventional synthetic DMARDs.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29231235", "http://www.ncbi.nlm.nih.gov/pubmed/24072562", "http://www.ncbi.nlm.nih.gov/pubmed/31969328"], "ideal_answer": ["Three conventional synthetic (cs) DMARDs include methotrexate (MTX), leflunomide, and sulfasalazine."], "exact_answer": [["methotrexate"], ["leflunomide"], ["sulfasalazine"]], "type": "list", "id": "6025a1e91cb411341a0000b4", "snippets": [{"offsetInBeginSection": 730, "offsetInEndSection": 1251, "text": "The task force agreed on 5 overarching principles and 12 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GCs); biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, sarilumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31969328", "endSection": "abstract"}, {"offsetInBeginSection": 721, "offsetInEndSection": 1250, "text": "RESULTS: The task force agreed on 5 overarching principles and 12 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GCs); biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, sarilumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31969328", "endSection": "abstract"}, {"offsetInBeginSection": 613, "offsetInEndSection": 762, "text": "Conventional synthetic DMARDs such as methotrexate, sulfasalazine, leflunomide, hydroxychloroquine appear to be safe during the perioperative period.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29231235", "endSection": "abstract"}, {"offsetInBeginSection": 764, "offsetInEndSection": 1178, "text": "tsDMARDs would then constitute only those that were specifically developed to target a particular molecular structure (such as tofacitinib, fostamatinib, baricitinib or apremilast, or agents not focused primarily on rheumatic diseases, such as imatinib or ibrutinib), while csDMARDs would comprise the traditional drugs (such as methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, gold salts and others).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24072562", "endSection": "abstract"}]}, {"body": "Synostosis of which cranial structures are characteristic to the Mercedes Benz syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20048621", "http://www.ncbi.nlm.nih.gov/pubmed/19396832", "http://www.ncbi.nlm.nih.gov/pubmed/9780908"], "ideal_answer": ["Synostosis of sagittal and lambdoid structures are characteristic to the Mercedes Benz syndrome."], "exact_answer": [["sagittal"], ["lambdoid"]], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:11971", "http://www.disease-ontology.org/api/metadata/DOID:2340", "http://www.disease-ontology.org/api/metadata/DOID:225"], "type": "list", "id": "54cf43abf693c3b16b000008", "snippets": [{"offsetInBeginSection": 172, "offsetInEndSection": 295, "text": "Among these are a trisutural fusion, dubbed the \"Mercedes Benz pattern,\" involving the sagittal and both lambdoid sutures. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20048621", "endSection": "abstract"}, {"offsetInBeginSection": 1449, "offsetInEndSection": 1615, "text": "CONCLUSIONS: Despite fusion of the sagittal suture, the surgical treatment for Mercedes Benz pattern craniosynostosis should include skull lengthening, not reduction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20048621", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 414, "text": "Multisutural craniosynostosis that includes bilateral lambdoid and sagittal synostosis (BLSS) results in a very characteristic head shape with frontal bossing, turribrachycephaly, biparietal narrowing, occipital concavity, and inferior displacement of the ears. This entity has been reported both in the genetics literature as craniofacial dyssynostosis and in the surgical literature as \"Mercedes Benz\" syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19396832", "endSection": "abstract"}, {"offsetInBeginSection": -1, "offsetInEndSection": 72, "text": "Bilambdoid and posterior sagittal synostosis: the Mercedes Benz syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9780908", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 281, "text": "A consistent pattern of craniosynostosis in the sagittal and bilateral lambdoid sutures is described in three patients. The external cranial ridging associated with fusion of these sutures produces a characteristic triradiate, or \"Mercedes Benz,\" appearance to the posterior skull.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9780908", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Bilambdoid and posterior sagittal synostosis: the Mercedes Benz syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9780908", "endSection": "title"}]}, {"body": "In which types of DNA repair is the UvrAB complex involved?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10913608", "http://www.ncbi.nlm.nih.gov/pubmed/8702928", "http://www.ncbi.nlm.nih.gov/pubmed/9049316", "http://www.ncbi.nlm.nih.gov/pubmed/17630776", "http://www.ncbi.nlm.nih.gov/pubmed/2665605", "http://www.ncbi.nlm.nih.gov/pubmed/12145219", "http://www.ncbi.nlm.nih.gov/pubmed/10811888", "http://www.ncbi.nlm.nih.gov/pubmed/8969181", "http://www.ncbi.nlm.nih.gov/pubmed/11101153", "http://www.ncbi.nlm.nih.gov/pubmed/22749141", "http://www.ncbi.nlm.nih.gov/pubmed/11551204", "http://www.ncbi.nlm.nih.gov/pubmed/9049317", "http://www.ncbi.nlm.nih.gov/pubmed/20227373"], "ideal_answer": ["UvrB and the lesion-recognition factor UvrA form the UvrAB complex, which plays a key role in bacterial nucleotide excision repair (NER). In transcription-coupled repair (TCR), the transcription repair coupling factor Mfd recruits uvrA, and the assembled UvrAB complex initiates repair. UvrAB complex also suppresses illegitimate recombination."], "exact_answer": [["nucleotide excision repair (NER)"], ["transcription-coupled repair (TCR)"], ["suppression of illegitimate recombination"]], "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0006281", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004260"], "type": "list", "id": "553f7a71ab98a37113000009", "snippets": [{"offsetInBeginSection": 763, "offsetInEndSection": 828, "text": "illegitimate recombination is mostly suppressed by UvrA and UvrB.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10811888", "endSection": "abstract"}, {"offsetInBeginSection": 1140, "offsetInEndSection": 1191, "text": "UvrAB complex suppresses illegitimate recombination", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10811888", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Transcription-coupled repair (TCR) is a subpathway of nucleotide excision repair (NER) that acts specifically on lesions in the transcribed strand of expressed genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22749141", "endSection": "abstract"}, {"offsetInBeginSection": 320, "offsetInEndSection": 531, "text": "the transcription repair coupling factor, Mfd. This protein recruits the NER lesion-recognition factor UvrA, and then dissociates from the DNA. UvrA binds UvrB, and the assembled UvrAB* complex initiates repair.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22749141", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "UvrB plays a key role in bacterial nucleotide excision repair. It is the ultimate damage-binding protein that interacts with both UvrA and UvrC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17630776", "endSection": "abstract"}, {"offsetInBeginSection": 410, "offsetInEndSection": 478, "text": "UvrB subunits bind to UvrA, most likely as part of a UvrA2B2 complex", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17630776", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Escherichia coli nucleotide excision repair (NER) is responsible for removing bulky DNA adducts by dual incisions of the UvrABC endonuclease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10913608", "endSection": "abstract"}, {"offsetInBeginSection": 151, "offsetInEndSection": 246, "text": "the activity of the UvrAB complex which can induce DNA conformational change is employed in NER", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10913608", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 450, "text": "The recognition by Escherichia coli Uvr nucleotide excision repair proteins of a variety of lesions with diverse chemical structures and the presence of helicase activity in the UvrAB complex which can displace short oligonucleotides annealed to single-stranded DNA led to a model in which this activity moves UvrAB along undamaged DNA to damaged sites where the lesion blocks further translocation and the protein-DNA pre-incision complex is formed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9049317", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Transcription when coupled to nucleotide excision repair specifies the location in active genes where preferential DNA repair is to take place.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8702928", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Transcription when coupled to nucleotide excision repair specifies the location in active genes where preferential DNA repair is to take place", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8702928", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 449, "text": "The recognition by Escherichia coli Uvr nucleotide excision repair proteins of a variety of lesions with diverse chemical structures and the presence of helicase activity in the UvrAB complex which can displace short oligonucleotides annealed to single-stranded DNA led to a model in which this activity moves UvrAB along undamaged DNA to damaged sites where the lesion blocks further translocation and the protein-DNA pre-incision complex is formed", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9049317", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 48, "text": "Transcription-coupled DNA repair in prokaryotes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22749141", "endSection": "title"}]}, {"body": "Intetumumab has been tested in clinical trials for treatment of which cancers?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21750555", "http://www.ncbi.nlm.nih.gov/pubmed/23104724", "http://www.ncbi.nlm.nih.gov/pubmed/22027908", "http://www.ncbi.nlm.nih.gov/pubmed/20145975", "http://www.ncbi.nlm.nih.gov/pubmed/21331745"], "ideal_answer": ["Intetumumab has been tested in clinical trials for treatment of prostate cancer, melanoma and angiosarcoma."], "exact_answer": [["prostate cancer"], ["melanoma"], ["angiosarcoma"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016430"], "type": "list", "id": "550e866271445a662f000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 261, "text": "A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human \u03b1\u03bd integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23104724", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 476, "text": "BACKGROUND: Intetumumab is a fully human mAb with antiangiogenic, antitumor properties which has shown potential therapeutic effect in castration-resistant prostate cancer (CRPC) patients. PATIENTS AND METHODS: In a phase 2, randomized, double-blind, multicenter study, men with metastatic CRPC without prior systemic nonhormonal therapy were randomly assigned to 75-mg/m(2) docetaxel (Taxotere) and 5-mg prednisone plus placebo (N = 65) or 10-mg/kg intetumumab (N = 66) q3w. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23104724", "endSection": "abstract"}, {"offsetInBeginSection": 1605, "offsetInEndSection": 1730, "text": "CONCLUSION: The addition of intetumumab to docetaxel resulted in shorter PFS without additional toxicity among CRPC patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23104724", "endSection": "abstract"}, {"offsetInBeginSection": 220, "offsetInEndSection": 491, "text": "Data from the Melanoma Subscale (MS) of the Functional Assessment of Cancer Therapy-Melanoma and the worst pain question from the Brief Pain Inventory (BPI) were taken from a clinical trial evaluating intetumumab alone or with dacarbazine in Stage IV metastatic melanoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22027908", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "A randomised, phase II study of intetumumab, an anti-\u03b1v-integrin mAb, alone and with dacarbazine in stage IV melanoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21750555", "endSection": "title"}, {"offsetInBeginSection": 1523, "offsetInEndSection": 1680, "text": "CONCLUSION: With its favourable safety profile and a nonsignificant trend towards improved OS, intetumumab merits further investigation in advanced melanoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21750555", "endSection": "abstract"}, {"offsetInBeginSection": 164, "offsetInEndSection": 446, "text": "METHODS: In a multicentre, randomised, phase II study, stage IV melanoma patients were randomised 1:1:1:1 to 1000 mg m(-2) dacarbazine+placebo (n=32), 1000 mg m(-2) dacarbazine+10 mg kg(-1) intetumumab (n=32), 10 mg kg(-1) intetumumab (n=33), or 5 mg kg(-1) intetumumab (n=32) q3w. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21750555", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331745", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 559, "text": "PURPOSE: In this Phase 1, multicenter, open-label study, intetumumab (CNTO 95), a fully human anti-\u03b1v integrin monoclonal antibody was evaluated for safety, pharmacokinetics, and pharmacodynamic activity in patients with melanoma or angiosarcoma. PATIENTS AND METHODS: Patients with histologically-confirmed inoperable melanoma or angiosarcoma refractory to standard treatment were allocated to treatment with 10 mg/kg or 20 mg/kg intetumumab, administered once every 3 weeks for up to four cycles unless unacceptable toxicity or disease progression occurred.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331745", "endSection": "abstract"}, {"offsetInBeginSection": 1546, "offsetInEndSection": 1803, "text": "CONCLUSIONS: In patients with metastatic malignant melanoma and angiosarcoma in this study, intetumumab demonstrated manageable toxicity, was well tolerated, and presented approximately dose-proportional pharmacokinetics for the 10 mg/kg and 20 mg/kg doses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331745", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 251, "text": "A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human \u03b1(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20145975", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 449, "text": "PURPOSE: We evaluated the safety and efficacy of intetumumab in combination with docetaxel in patients with castrate-resistant metastatic prostate cancer. Patients and methods In this phase 1, open-label, multicenter, nonrandomized study, 75 mg/m\u00b2 docetaxel was administered on Day 1 of each of nine 21-day treatment cycles and intetumumab 5 or 10 mg/kg was administered on Days 1, 8, and 15 of Cycles 2 and 3 and on Day 1 of all subsequent cycles. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20145975", "endSection": "abstract"}, {"offsetInBeginSection": 149, "offsetInEndSection": 421, "text": "In a multicentre, randomised, phase II study, stage IV melanoma patients were randomised 1:1:1:1 to 1000 mg m(-2) dacarbazine+placebo (n=32), 1000 mg m(-2) dacarbazine+10 mg kg(-1) intetumumab (n=32), 10 mg kg(-1) intetumumab (n=33), or 5 mg kg(-1) intetumumab (n=32) q3w.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21750555", "endSection": "abstract"}, {"offsetInBeginSection": 236, "offsetInEndSection": 526, "text": "Patients with histologically-confirmed inoperable melanoma or angiosarcoma refractory to standard treatment were allocated to treatment with 10 mg/kg or 20 mg/kg intetumumab, administered once every 3 weeks for up to four cycles unless unacceptable toxicity or disease progression occurred.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331745", "endSection": "abstract"}, {"offsetInBeginSection": 218, "offsetInEndSection": 490, "text": "Data from the Melanoma Subscale (MS) of the Functional Assessment of Cancer Therapy-Melanoma and the worst pain question from the Brief Pain Inventory (BPI) were taken from a clinical trial evaluating intetumumab alone or with dacarbazine in Stage IV metastatic melanoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22027908", "endSection": "abstract"}, {"offsetInBeginSection": 219, "offsetInEndSection": 489, "text": "Data from the Melanoma Subscale (MS) of the Functional Assessment of Cancer Therapy-Melanoma and the worst pain question from the Brief Pain Inventory (BPI) were taken from a clinical trial evaluating intetumumab alone or with dacarbazine in Stage IV metastatic melanoma", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22027908", "endSection": "abstract"}, {"offsetInBeginSection": 220, "offsetInEndSection": 490, "text": "Data from the Melanoma Subscale (MS) of the Functional Assessment of Cancer Therapy-Melanoma and the worst pain question from the Brief Pain Inventory (BPI) were taken from a clinical trial evaluating intetumumab alone or with dacarbazine in Stage IV metastatic melanoma", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22027908", "endSection": "abstract"}]}, {"body": "Which metabolic pathways have been associated with Systemic Lupus Erythematosus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24333266", "http://www.ncbi.nlm.nih.gov/pubmed/24772967", "http://www.ncbi.nlm.nih.gov/pubmed/20477100", "http://www.ncbi.nlm.nih.gov/pubmed/8159911", "http://www.ncbi.nlm.nih.gov/pubmed/25648260", "http://www.ncbi.nlm.nih.gov/pubmed/20305046", "http://www.ncbi.nlm.nih.gov/pubmed/24494566", "http://www.ncbi.nlm.nih.gov/pubmed/24040398"], "ideal_answer": ["Genetic polymorphisms of the xenobiotic metabolic pathway involved in estrogen metabolism might contribute towards pathophysiology of systemic lupus erythematosus (SLE). According to the analysis on metabolic pathway, SLE could cause significant changes in unsaturated fatty acid and amino acid metabolism pathway. Results suggest reducing FLI1 in lupus decreases the pathogenicity of T cells by decreasing TCR-specific activation and IL-4 production in part through the modulation of glycosphingolipid metabolism"], "exact_answer": [["Estrogen metabolism"], ["Unsaturated fatty acid metabolism"], ["Amino acid metabolism"], ["Glycosphingolipid metabolism"], ["One-carbon metabolic pathway"]], "type": "list", "id": "5c34a761da8336e21a000005", "snippets": [{"offsetInBeginSection": 202, "offsetInEndSection": 348, "text": "Measurement of urine neopterin, product of a metabolic pathway controlled by interferon-gamma, has been found useful in many clinical conditions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8159911", "endSection": "abstract"}, {"offsetInBeginSection": 218, "offsetInEndSection": 459, "text": "The objective of this study was to investigate the association between genetic variations in estrogen metabolic pathway genes, including estrogen receptor alpha (ESR1), estrogen receptor beta (ESR2), and aromatase (CYP19A1), and risk of SLE.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20305046", "endSection": "abstract"}, {"offsetInBeginSection": 949, "offsetInEndSection": 1092, "text": "According to the analysis on metabolic pathway, SLE could cause significant changes in unsaturated fatty acid and amino acid metabolism pathway", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24494566", "endSection": "abstract"}, {"offsetInBeginSection": 1372, "offsetInEndSection": 1584, "text": "Together, our results suggest reducing FLI1 in lupus decreases the pathogenicity of T cells by decreasing TCR-specific activation and IL-4 production in part through the modulation of glycosphingolipid metabolism", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24040398", "endSection": "abstract"}, {"offsetInBeginSection": 124, "offsetInEndSection": 292, "text": "genetic polymorphisms of the xenobiotic metabolic pathway involved in estrogen metabolism might contribute towards pathophysiology of systemic lupus erythematosus (SLE)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24772967", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 310, "text": "The current study was conducted to elucidate the effect of genetic variations in one-carbon metabolism on the epigenetic regulation of major histocompatibility complex II transactivator (MHC2TA), reduced folate carrier 1 (RFC1/SLC19A1) and human leukocyte antigen (HLA)-DR in systemic lupus erythematosus (SLE)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24333266", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 370, "text": "Putatively functional polymorphisms of one-carbon and xenobiotic metabolic pathways influence susceptibility for wide spectrum of diseases. The current study was aimed to explore gene-gene interactions among these two metabolic pathways in four diseases i.e. breast cancer, systemic lupus erythematosus (SLE), coronary artery disease (CAD) and Parkinson's disease (PD). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648260", "endSection": "abstract"}, {"offsetInBeginSection": 628, "offsetInEndSection": 788, "text": "In this regard, inflammation is not only associated with systemic lupus patients but is also present in patients with metabolic syndrome and insulin resistance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20477100", "endSection": "abstract"}]}, {"body": "List BRAF inhibitors that have been tested in clinical trials for treatment of melanoma patients", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24456413", "http://www.ncbi.nlm.nih.gov/pubmed/21639808", "http://www.ncbi.nlm.nih.gov/pubmed/24291778", "http://www.ncbi.nlm.nih.gov/pubmed/23094782", "http://www.ncbi.nlm.nih.gov/pubmed/23621583", "http://www.ncbi.nlm.nih.gov/pubmed/22804352", "http://www.ncbi.nlm.nih.gov/pubmed/24720932", "http://www.ncbi.nlm.nih.gov/pubmed/23403819", "http://www.ncbi.nlm.nih.gov/pubmed/23788912", "http://www.ncbi.nlm.nih.gov/pubmed/23833299", "http://www.ncbi.nlm.nih.gov/pubmed/22382362", "http://www.ncbi.nlm.nih.gov/pubmed/22431777", "http://www.ncbi.nlm.nih.gov/pubmed/23020132", "http://www.ncbi.nlm.nih.gov/pubmed/25056920", "http://www.ncbi.nlm.nih.gov/pubmed/22306669", "http://www.ncbi.nlm.nih.gov/pubmed/25287827", "http://www.ncbi.nlm.nih.gov/pubmed/24295639", "http://www.ncbi.nlm.nih.gov/pubmed/23918947", "http://www.ncbi.nlm.nih.gov/pubmed/24616537", "http://www.ncbi.nlm.nih.gov/pubmed/25488880", "http://www.ncbi.nlm.nih.gov/pubmed/22594466", "http://www.ncbi.nlm.nih.gov/pubmed/25037139", "http://www.ncbi.nlm.nih.gov/pubmed/24463460", "http://www.ncbi.nlm.nih.gov/pubmed/22350184", "http://www.ncbi.nlm.nih.gov/pubmed/23569304", "http://www.ncbi.nlm.nih.gov/pubmed/22332713", "http://www.ncbi.nlm.nih.gov/pubmed/23795808", "http://www.ncbi.nlm.nih.gov/pubmed/23116250", "http://www.ncbi.nlm.nih.gov/pubmed/22253555", "http://www.ncbi.nlm.nih.gov/pubmed/25265494", "http://www.ncbi.nlm.nih.gov/pubmed/24325952", "http://www.ncbi.nlm.nih.gov/pubmed/24408395", "http://www.ncbi.nlm.nih.gov/pubmed/24333389", "http://www.ncbi.nlm.nih.gov/pubmed/24080641", "http://www.ncbi.nlm.nih.gov/pubmed/23251089", "http://www.ncbi.nlm.nih.gov/pubmed/22356324", "http://www.ncbi.nlm.nih.gov/pubmed/22194965", "http://www.ncbi.nlm.nih.gov/pubmed/24958825", "http://www.ncbi.nlm.nih.gov/pubmed/24121489", "http://www.ncbi.nlm.nih.gov/pubmed/23326492", "http://www.ncbi.nlm.nih.gov/pubmed/21505227", "http://www.ncbi.nlm.nih.gov/pubmed/22394203", "http://www.ncbi.nlm.nih.gov/pubmed/25040674", "http://www.ncbi.nlm.nih.gov/pubmed/24259661", "http://www.ncbi.nlm.nih.gov/pubmed/22651703"], "ideal_answer": ["Vemurafenib and dabrafenib are BRAF inhibitors that have been tested in clinical trials for treatment of melanoma patients."], "exact_answer": [["Vemurafenib"], ["Dabrafenib"]], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:1909"], "type": "list", "id": "54d8d60d014675820d000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25287827", "endSection": "title"}, {"offsetInBeginSection": 482, "offsetInEndSection": 732, "text": " Here, we report patients treated with combination therapy after disease progression with BRAF inhibitor treatment administered before study enrollment (part B; n = 26) or after cross-over at progression with dabrafenib monotherapy (part C; n = 45). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25287827", "endSection": "abstract"}, {"offsetInBeginSection": 210, "offsetInEndSection": 335, "text": "This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25265494", "endSection": "abstract"}, {"offsetInBeginSection": 366, "offsetInEndSection": 658, "text": "METHODS: All patients treated with the BRAF inhibitors vemurafenib or dabrafenib or combination BRAF inhibitor and mitogen-activated protein kinase kinase (MEK) inhibitor therapy at Westmead Hospital, Sydney, Australia underwent regular dermatological assessments for the duration of therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25040674", "endSection": "abstract"}, {"offsetInBeginSection": 228, "offsetInEndSection": 394, "text": "We assessed the safety and efficacy of combined BRAF inhibition with vemurafenib and MEK inhibition with cobimetinib in patients with advanced BRAF-mutated melanoma. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25037139", "endSection": "abstract"}, {"offsetInBeginSection": 488, "offsetInEndSection": 598, "text": "We included individuals who had either recently progressed on vemurafenib or never received a BRAF inhibitor. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25037139", "endSection": "abstract"}, {"offsetInBeginSection": 789, "offsetInEndSection": 1181, "text": "However, it is becoming evident that the effects of paradoxical mitogen-activated protein kinase pathway activation by BRAF inhibitors in non-BRAF-mutant cells needs to be taken into account, which may be implicated in the problems encountered in the first clinical trial testing a combination of the BRAF inhibitor vemurafenib with ipilimumab (anti-CTLA4), with significant liver toxicities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24958825", "endSection": "abstract"}, {"offsetInBeginSection": 526, "offsetInEndSection": 641, "text": "The BRAF inhibitor dabrafenib recently was approved for use in patients with BRAF V600-mutated metastatic melanoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24720932", "endSection": "abstract"}, {"offsetInBeginSection": 161, "offsetInEndSection": 575, "text": "His treatment course to date has included surgery, adjuvant radiotherapy, and interferon, metastasectomies, granulocyte-macrophage colony-stimulating factors, a clinical trial with the BRAF inhibitor vemurafenib (PLX-4032), clinical trial with combination BRAF plus MEK inhibition with vemurafenib plus GDC-0973, and combination targeted and immune therapy with vemurafenib plus the anti-CTLA4 antibody ipilimumab.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24616537", "endSection": "abstract"}, {"offsetInBeginSection": 609, "offsetInEndSection": 739, "text": "Thirty-one patients commenced dabrafenib therapy including six individuals who had progressed on a prior BRAF-inhibitor treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24463460", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24408395", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Dabrafenib is a BRAF kinase inhibitor indicated for the treatment of BRAF V600E mutation-positive melanoma. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24408395", "endSection": "abstract"}, {"offsetInBeginSection": 277, "offsetInEndSection": 475, "text": "This was a prospective study of melanoma patients harboring the BRAF V600 mutation and treated with iBRAF within a clinical trial (dabrafenib) or as part of an expanded access program (vemurafenib).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24333389", "endSection": "abstract"}, {"offsetInBeginSection": 113, "offsetInEndSection": 236, "text": "We investigated the BRAF kinase inhibitor vemurafenib in patients with advanced melanoma with symptomatic brain metastases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24295639", "endSection": "abstract"}, {"offsetInBeginSection": 803, "offsetInEndSection": 900, "text": "This discovery led to the development of BRAF kinase inhibitors like vemurafenib and dabrafenib. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259661", "endSection": "abstract"}, {"offsetInBeginSection": 1524, "offsetInEndSection": 1718, "text": "CONCLUSIONS: Dabrafenib joins vemurafenib to confirm the superior clinical outcome of the BRAF inhibitors when compared with dacarbazine in patients with BRAF(V600E)-positive advanced melanoma. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259661", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23833299", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 199, "text": "PURPOSE: Dabrafenib is a selective inhibitor of V600-mutant BRAF kinase, which recently showed improved progression-free survival (PFS) as compared with dacarbazine, in metastatic melanoma patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23833299", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918947", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "PURPOSE: Dabrafenib (GSK2118436) is a potent inhibitor of mutated BRAF kinase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918947", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 264, "text": "Cutaneous squamous cell carcinoma (cSCC) is a concerning toxicity with BRAF inhibitors in the treatment for melanoma. While the two drugs shown to improve survival, vemurafenib, and dabrafenib, have similar efficacy, the reported rates of cSCC are quite different.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23795808", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 289, "text": "PURPOSE To assess pharmacodynamic effects and intrinsic and acquired resistance mechanisms of the BRAF inhibitor vemurafenib in BRAF(V600)-mutant melanoma, leading to an understanding of the mechanism of action of vemurafenib and ultimately to optimization of metastatic melanoma therapy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23569304", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 217, "text": "BACKGROUND: The cobas 4800 BRAF V600 Mutation Test is a CE-marked and FDA-approved in vitro diagnostic assay used to select patients with metastatic melanoma for treatment with the selective BRAF inhibitor vemurafenib", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326492", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "The purpose of this study is to review the development of BRAF inhibitors, with emphasis on the trials conducted with dabrafenib (GSK2118436) and the evolving role of dabrafenib in treatment for melanoma patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23251089", "endSection": "abstract"}, {"offsetInBeginSection": 365, "offsetInEndSection": 477, "text": "Dabrafenib inhibits the mutant BRAF (BRAF(mut)) protein in melanomas with BRAF(V600E) and BRAF(V600K) genotypes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23251089", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 333, "text": "To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23020132", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22804352", "endSection": "title"}, {"offsetInBeginSection": 197, "offsetInEndSection": 392, "text": "We conducted a systematic prospective dermatological review of all patients enrolled at a single institution in the phase I/II clinical trial of the mutant BRAF inhibitor dabrafenib (GSK2118436).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22804352", "endSection": "abstract"}, {"offsetInBeginSection": 1768, "offsetInEndSection": 1959, "text": "CONCLUSIONS: Administration of the mutant BRAF inhibitor dabrafenib is associated with induction of keratinocytic proliferation, which in some cases develops features of low-grade malignancy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22804352", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22594466", "endSection": "title"}, {"offsetInBeginSection": 854, "offsetInEndSection": 992, "text": "For this reason, she was enrolled into another clinical trial with the GSK2118436 BRAF inhibitor, dabrafenib, as a second line of therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22594466", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "BACKGROUND: The development of keratoacanthomas (KAs) and well-differentiated squamous cell carcinomas (SCCs) is a known adverse effect of novel BRAF inhibitors such as vemurafenib.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22431777", "endSection": "abstract"}, {"offsetInBeginSection": 295, "offsetInEndSection": 548, "text": "OBSERVATIONS: We describe a patient with stage IV melanoma who received the BRAF inhibitor vemurafenib (recently approved by the US Food and Drug Administration) as part of a clinical trial and developed numerous diffuse, pathology-proven KAs and SCCs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22431777", "endSection": "abstract"}, {"offsetInBeginSection": 837, "offsetInEndSection": 1046, "text": "CONCLUSIONS: Given vemurafenib's recent approval by the US Food and Drug Administration, we provide a timely case report on the effective use of PDT in the treatment of BRAF inhibitor-associated KAs and SCCs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22431777", "endSection": "abstract"}, {"offsetInBeginSection": 199, "offsetInEndSection": 374, "text": "The BRAF inhibitor, vemurafenib, has shown up to 78% objective response rates in melanoma patients harboring the BRAF-V600E mutation but not in patients lacking the mutation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22382362", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 338, "text": "The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22356324", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 269, "text": "CONTEXT: A polymerase chain reaction-based companion diagnostic (cobas 4800 BRAF V600 Mutation Test) was recently approved by the US Food and Drug Administration to select patients with BRAF-mutant metastatic melanoma for treatment with the BRAF inhibitor vemurafenib. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22332713", "endSection": "abstract"}, {"offsetInBeginSection": 200, "offsetInEndSection": 397, "text": "However, in the recent clinical trial of the BRAF inhibitor, vemurafenib (PLX4032), a significant percentage of BRAF V600E mutant melanoma patients did not meet the RECIST criteria for a response. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21505227", "endSection": "abstract"}, {"offsetInBeginSection": 48, "offsetInEndSection": 280, "text": "Vemurafenib (RG7204/PLX4032), a small-molecule inhibitor of mutant BRAF, has shown striking clinical efficacy in BRAFV600 mutant melanoma, creating the need for a well-validated companion diagnostic to select patients for treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22306669", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "BACKGROUND: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21639808", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Vemurafenib is the first molecularly targeted therapy to be licensed in the US and Europe for treatment of advanced melanoma", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23116250", "endSection": "abstract"}, {"offsetInBeginSection": 1518, "offsetInEndSection": 1747, "text": "Clinical trials to test the efficacy of vemurafenib in combination with immunomodulatory agents, such as ipilimumab, and MAPK kinase (MEK) inhibitors, such as GDC-0973, in the treatment of advanced melanoma are currently underway", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23116250", "endSection": "abstract"}]}, {"body": "List common features of Shapiro syndrome", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7565067", "http://www.ncbi.nlm.nih.gov/pubmed/24339619", "http://www.ncbi.nlm.nih.gov/pubmed/23578790", "http://www.ncbi.nlm.nih.gov/pubmed/24187634", "http://www.ncbi.nlm.nih.gov/pubmed/21041995", "http://www.ncbi.nlm.nih.gov/pubmed/19027594"], "triples": [{"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A18458850", "o": "C537594"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18471145", "o": "Recurrent spontaneous hypothermia with hypoplasia of the corpus callosum"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18465004", "o": "Shapiro syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18458850", "o": "Shapiro's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2931542", "o": "http://linkedlifedata.com/resource/umls/label/A18471145"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2931542", "o": "http://linkedlifedata.com/resource/umls/label/A18465004"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2931542", "o": "http://linkedlifedata.com/resource/umls/label/A18458850"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A18465004", "o": "C537594"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A18471145", "o": "C537594"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A18458850", "o": "MeSH"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A18465004", "o": "MeSH"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A18471145", "o": "MeSH"}, {"p": "http://www.w3.org/2004/02/skos/core#broader", "s": "http://linkedlifedata.com/resource/umls/id/C2931542", "o": "http://linkedlifedata.com/resource/umls/id/C0796147"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A1702570", "o": "acrocallosal syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A1702533", "o": "acrocallosal syndrome (ACS)"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18440175", "o": "Acrocallosal Syndrome [Disease/Finding]"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11975298", "o": "ACROCALLOSAL SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A1701640", "o": "Schinzel syndrome 1"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12032571", "o": "ACLS"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17700774", "o": "Acrocallosal Syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11961004", "o": "HALLUX DUPLICATION, POSTAXIAL POLYDACTYLY, AND ABSENCE OF CORPUS CALLOSUM"}, {"p": "http://www.w3.org/2004/02/skos/core#narrower", "s": "http://linkedlifedata.com/resource/umls/id/C0796147", "o": "http://linkedlifedata.com/resource/umls/id/C2931542"}, {"p": "http://linkedlifedata.com/resource/relationontology/hasSymptom", "s": "http://linkedlifedata.com/resource/umls/id/C2931542", "o": "http://linkedlifedata.com/resource/umls/id/C0020672"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17699101", "o": "BODY TEMPERATURE, DECREASED"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0393370", "o": "BODY TEMPERATURE LOW"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A1144305", "o": "hypothermia, natural"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17992132", "o": "Hypothermia [Disease/Finding]"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0463819", "o": "TEMPERATURE BODY DECREASE"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17678862", "o": "TEMPERATURE, DECREASED BODY"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0419736", "o": "HYPOPYREXIA"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17822767", "o": "hypothermia NOS"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A10802646", "o": "Decreased Core Body Temperature"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8311249", "o": "Hypothermia"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0419764", "o": "HYPOTHERMIA"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0393367", "o": "BODY TEMPERATURE DECREASED"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0481466", "o": "hypothermia"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0071500", "o": "Hypothermias"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17699102", "o": "DECREASED BODY TEMPERATURE"}], "ideal_answer": ["Shapiro syndrome is a rare entity, comprising a triad of recurrent hypothermia, hyperhidrosis and congenital agenesis of the corpus callosum. Hypermelatoninemia has also been described in a patient with Shapiro syndrome."], "exact_answer": [["recurrent hypothermia"], ["hyperhidrosis"], ["congenital agenesis of the corpus callosum"]], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:225", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577"], "type": "list", "id": "5314c7afdae131f84700000a", "snippets": [{"offsetInBeginSection": 106, "offsetInEndSection": 266, "text": "Shapiro syndrome is defined as the constellation of periodic hypothermia and hyperhidrosis along with agenesis of the corpus callosum by Shapiro et al. in 1969.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24187634", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Shapiro syndrome is a rare entity, comprising a triad of recurrent hypothermia, hyperhidrosis and congenital agenesis of the corpus callosum. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23578790", "endSection": "abstract"}, {"offsetInBeginSection": 257, "offsetInEndSection": 600, "text": "We present a case of an 80 year old woman presenting with recurrent bouts of shivering, sweating and profound malaise, who sought medical attention because the frequency and severity of attacks worsened in her later years. MRI Brain demonstrated agenesis of the corpus callosum; a rigorous work-up excluded other causes for her symptomatology.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23578790", "endSection": "abstract"}, {"offsetInBeginSection": 1002, "offsetInEndSection": 1138, "text": "These findings imply that aberrant thermoregulation in Shapiro syndrome involves a number of structures remote from the callosal region.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23578790", "endSection": "abstract"}, {"offsetInBeginSection": 328, "offsetInEndSection": 552, "text": "A 6-year-old girl previously diagnosed with Shapiro's syndrome was admitted to our hospital on several occasions during a 1-year period with complaints of altered consciousness, syncope, hypothermia and episodes of sweating.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21041995", "endSection": "abstract"}, {"offsetInBeginSection": 1316, "offsetInEndSection": 1470, "text": "Hypermelatoninemia should be considered in patients with spontaneous periodic hypothermia and hyperhidrosis, and also in patients with Shapiro's syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21041995", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 240, "text": "We present a patient diagnosed with Shapiro syndrome without corpus callosum agenesis. A 4-year-old-girl was admitted to the hospital with complaints of sweating, cooling, and drowsiness that continued during the last week of her admission.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19027594", "endSection": "abstract"}, {"offsetInBeginSection": 1519, "offsetInEndSection": 1686, "text": "Postmortem data regarding the hypothalamic and surrounding areas from future cases of Shapiro syndrome and spontaneous periodic hypothermia would be of great interest.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7565067", "endSection": "abstract"}]}, {"body": "Tumor-treating fields are effective for treatment of which cancers?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19133110", "http://www.ncbi.nlm.nih.gov/pubmed/23899985", "http://www.ncbi.nlm.nih.gov/pubmed/23095807", "http://www.ncbi.nlm.nih.gov/pubmed/18596382", "http://www.ncbi.nlm.nih.gov/pubmed/20492723", "http://www.ncbi.nlm.nih.gov/pubmed/21548832", "http://www.ncbi.nlm.nih.gov/pubmed/24555979", "http://www.ncbi.nlm.nih.gov/pubmed/24884522", "http://www.ncbi.nlm.nih.gov/pubmed/25213867", "http://www.ncbi.nlm.nih.gov/pubmed/23659608", "http://www.ncbi.nlm.nih.gov/pubmed/23891283", "http://www.ncbi.nlm.nih.gov/pubmed/25213870", "http://www.ncbi.nlm.nih.gov/pubmed/19387848"], "ideal_answer": ["Clinical trials have shown that Tumor-treating fields are effective for treatment of non-small cell lung cancer and glioblastoma. Ongoing and future trials will evaluate TTFields in solid tumor brain metastases, and ovarian, pancreatic cancers and multidrug resistance cancer cells."], "exact_answer": [["non-small cell lung cancer"], ["glioblastoma"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009369", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812"], "type": "list", "id": "56c1f007ef6e39474100003b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25213867", "endSection": "title"}, {"offsetInBeginSection": 829, "offsetInEndSection": 1219, "text": "e evaluated the effects of combining TTFields with standard chemotherapeutic agents on several NSCLC cell lines, both in vitro and in vivo. Frequency titration curves demonstrated that the inhibitory effects of TTFields were maximal at 150 kHz for all NSCLC cell lines tested, and that the addition of TTFields to chemotherapy resulted in enhanced treatment efficacy across all cell lines. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25213867", "endSection": "abstract"}, {"offsetInBeginSection": 1647, "offsetInEndSection": 1798, "text": "Together, these findings suggest that combining TTFields therapy with chemotherapy may provide an additive efficacy benefit in the management of NSCLC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25213867", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Response patterns of recurrent glioblastomas treated with tumor-treating fields.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25213870", "endSection": "title"}, {"offsetInBeginSection": 293, "offsetInEndSection": 1152, "text": "NovoTTF Therapy is a novel and US Food and Drug Administration (FDA)-approved antimitotic treatment for recurrent GBM with potential benefits compared with other options. Recurrent GBM patients from two prior trials with demonstrated radiologic tumor response to single-agent NovoTTF Therapy were analyzed to better characterize tumor response patterns and evaluate the associations between response, compliance, and OS. In addition, a compartmental tumor growth model was developed and evaluated for its ability to predict GBM response to tumor-treating fields (TTFields). The overall response rate across both trials was 15% (4% complete responses): 14% in the phase III trial (14/120) and 20% (2/10) in a pilot study. Tumor responses to NovoTTF Therapy developed slowly (median time to response, 5.2 months) but were durable (median duration, 12.9 months).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25213870", "endSection": "abstract"}, {"offsetInBeginSection": 1645, "offsetInEndSection": 1807, "text": "NovoTTF Therapy is a novel antimitotic treatment for recurrent GBM associated with slowly developing but durable tumor responses in approximately 15% of patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25213870", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF\u2122-100A system.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24884522", "endSection": "title"}, {"offsetInBeginSection": 193, "offsetInEndSection": 334, "text": " An ongoing trial is assessing its efficacy for newly diagnosed glioblastoma multiforme (GBM) and it has been FDA-approved for recurrent GBM.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24884522", "endSection": "abstract"}, {"offsetInBeginSection": 595, "offsetInEndSection": 712, "text": "We present three patients with GBM in whom the fields were adjusted at recurrence and the effects of each adjustment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24884522", "endSection": "abstract"}, {"offsetInBeginSection": 837, "offsetInEndSection": 975, "text": "The first patient underwent subtotal resection, radiotherapy with temozolomide (TMZ), and then began NovoTTF Therapy with metronomic TMZ. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24884522", "endSection": "abstract"}, {"offsetInBeginSection": 1232, "offsetInEndSection": 1713, "text": " A second patient underwent two resections followed by radiotherapy/TMZ and NovoTTF Therapy/TMZ. Six months later, two new distal lesions were noted, and he underwent further resection with adjustment of his fields. He remained stable over the subsequent year on NovoTTF Therapy and bevacizumab. A third patient on NovoTTF Therapy/TMZ remained stable for two years but developed a small, slow growing enhancing lesion, which was resected, and his fields were adjusted accordingly. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24884522", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23891283", "endSection": "title"}, {"offsetInBeginSection": 160, "offsetInEndSection": 466, "text": "Promising preclinical data have led to a single arm phase I/II trial in NSCLC patients.METHODS: Forty-two inoperable stage IIIB (with pleural effusion) and IV NSCLC patients who had had tumor progression received pemetrexed 500 mg/m(2) iv q3w together with daily TTFields therapy until disease progression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23891283", "endSection": "abstract"}, {"offsetInBeginSection": 660, "offsetInEndSection": 770, "text": "The median time to in-field progression was 28 weeks and the median time to systemic progression was 22 weeks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23891283", "endSection": "abstract"}, {"offsetInBeginSection": 989, "offsetInEndSection": 1298, "text": "CONCLUSIONS: The combination of TTFields and pemetrexed as a second line therapy for NSCLC is safe and potentially more effective than pemetrexed alone. TTFields improved disease control within the treatment field and a phase III study is planned to further investigate its role as a novel treatment in NSCLC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23891283", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 203, "text": "Tumor treating fields (TTFields) is a noninvasive, regional antimitotic treatment modality that has been approved for the treatment of recurrent glioblastoma by the U.S. FDA and has a CE mark in Europe. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23659608", "endSection": "abstract"}, {"offsetInBeginSection": 675, "offsetInEndSection": 1227, "text": "The antimitotic effect of TTFields therapy has been demonstrated in multiple cell lines when the appropriate frequency was utilized. A phase III trial of TTFields monotherapy compared to active chemotherapy in recurrent glioblastoma patients established that TTFields therapy is associated with minimal toxicity, better quality of life, and comparable efficacy to chemotherapy. Ongoing and future trials will evaluate TTFields in newly diagnosed glioblastoma, solid tumor brain metastases, nonsmall cell lung cancer, and ovarian and pancreatic cancers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23659608", "endSection": "abstract"}, {"offsetInBeginSection": 70, "offsetInEndSection": 401, "text": "The U.S. Food and Drug Administration has approved the first device, the NovoTTF-100A\u2122, that uses this technology and is indicated for use in progressive glioblastoma multiforme after standard therapies have failed. Promising clinical trial results will likely lead to expanded uses in primary brain tumors and other cancer types. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23899985", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23095807", "endSection": "title"}, {"offsetInBeginSection": 336, "offsetInEndSection": 1080, "text": "Tumor-treating fields (TTField) therapy is a novel treatment technique that has recently received CE and FDA approval for the treatment of RGBM, and is based on the principle that low intensity, intermediate frequency electric fields (100 to 300 kHz) may induce apoptosis in specific cell types. Our center was the first to apply TTField treatment to histologically proven GBM in a small pilot study of 20 individuals in 2004 and 2005, and four of those original 20 patients are still alive today. We report two cases of GBM and two cases of RGBM treated by TTField therapy, all in good health and no longer receiving any treatment more than seven years after initiating TTField therapy, with no clinical or radiological evidence of recurrence.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23095807", "endSection": "abstract"}, {"offsetInBeginSection": 113, "offsetInEndSection": 349, "text": "Tumor treating fields (TTFields) are low intensity (1 ? 2 V/cm), intermediate frequency (100 ? 200 kHz) alternating electric fields administered using insulated electrodes placed on the skin surrounding the region of a malignant tumor. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21548832", "endSection": "abstract"}, {"offsetInBeginSection": 706, "offsetInEndSection": 1113, "text": "Furthermore, it summarizes the clinical experience with TTFields, mainly in two indications: one in recurrent glioblastoma multiforme: in a large prospective randomized Phase III trial TTFields was compared with best standard care (including chemotherapy): TTFields significantly improved median overall survival (OS) compared with standard therapy (7.8 vs 6.1 months) for the patients treated per protocol.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21548832", "endSection": "abstract"}, {"offsetInBeginSection": 1182, "offsetInEndSection": 1331, "text": "The second indication was a Phase II study in second-line non-small cell lung cancer, where TTFields was administered concomitantly with pemetrexed. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21548832", "endSection": "abstract"}, {"offsetInBeginSection": 1546, "offsetInEndSection": 1711, "text": "EXPERT OPINION: The proof of concept of TTFields has been well demonstrated in the preclinical setting, and the clinical data seem promising in various tumor types. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21548832", "endSection": "abstract"}, {"offsetInBeginSection": 1568, "offsetInEndSection": 1831, "text": "CONCLUSIONS: The results indicate that TTFields alone and in combination with paclitaxel and doxorubicin effectively reduce the viability of both wild type and MDR cell sub-lines and thus can potentially be used as an effective treatment of drug resistant tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20492723", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19387848", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 314, "text": "Tumor treating fields (TTFields) are low intensity, intermediate frequency, alternating electric fields used to treat cancerous tumors. This novel treatment modality effectively inhibits the growth of solid tumors in vivo and has shown promise in pilot clinical trials in patients with advanced stage solid tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19387848", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 244, "text": "BACKGROUND: The present study explores the efficacy and toxicity of combining a new, non-toxic, cancer treatment modality, termed Tumor Treating Fields (TTFields), with chemotherapeutic treatment in-vitro, in-vivo and in a pilot clinical trial.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19133110", "endSection": "abstract"}, {"offsetInBeginSection": 489, "offsetInEndSection": 847, "text": "In addition, we studied the effects of combining chemotherapy with TTFields in an animal tumor model and in a pilot clinical trial in recurrent and newly diagnosed GBM patients.RESULTS: The efficacy of TTFields-chemotherapy combination in-vitro was found to be additive with a tendency towards synergism for all drugs and cell lines tested (combination index", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19133110", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18596382", "endSection": "title"}, {"offsetInBeginSection": 306, "offsetInEndSection": 555, "text": "PATIENTS AND METHODS: This open, prospective pilot study was designed to evaluate the safety, tolerability, and efficacy profile of TTFields treatment in patients with locally advanced and/or metastatic solid tumors using the NovoTTF100A(TM) device.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18596382", "endSection": "abstract"}, {"offsetInBeginSection": 848, "offsetInEndSection": 1442, "text": "Outcomes showed 1 partial response of a treated skin metastasis from a primary breast cancer, 3 cases where tumor growth was arrested during treatment, and 1 case of disease progression. One mesothelioma patient experienced lesion regression near TTFields with simultaneous tumor stability or progression in distal areas.CONCLUSION: Although the number of patients in this study is small, the lack of therapy toxicity and the efficacy observed in data gathered to date indicate the potential of TTFields as a new treatment modality for solid tumors, definitely warranting further investigation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18596382", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24555979", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 279, "text": "OBJECTIVES: Tumor Treating Fields (TTFields) are a non-invasive cancer treatment modality approved for the treatment of patients with recurrent glioblastoma. The present study determined the efficacy and mechanism of action of TTFields in preclinical models of pancreatic cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24555979", "endSection": "abstract"}, {"offsetInBeginSection": 507, "offsetInEndSection": 1371, "text": "RESULTS: Application of TTFields in vitro showed a significant decrease in cell count, an increase in cell volume and reduced clonogenicity. Further analysis demonstrated significant increase in the number of abnormal mitotic figures, as well as a decrease in G2-M cell population. In hamsters with orthotopic pancreatic tumors, TTFields significantly reduced tumor volume accompanied by an increase in the frequency of abnormal mitotic events. TTFields efficacy was enhanced both in vitro and in vivo when combined with chemotherapy.CONCLUSIONS: These results provide the first evidence that TTFields serve as an effective antimitotic treatment in preclinical pancreatic cancer models and have a long term negative effect on cancer cell survival. These results make TTFields an attractive candidate for testing in the treatment of patients with pancreatic cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24555979", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Tumor Treating Fields (TTFields) are a non-invasive cancer treatment modality approved for the treatment of patients with recurrent glioblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24555979", "endSection": "abstract"}, {"offsetInBeginSection": 861, "offsetInEndSection": 1013, "text": "In addition, a compartmental tumor growth model was developed and evaluated for its ability to predict GBM response to tumor-treating fields (TTFields).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25213870", "endSection": "abstract"}, {"offsetInBeginSection": 629, "offsetInEndSection": 924, "text": "Tumor-treating fields (TTField) therapy is a novel treatment technique that has recently received CE and FDA approval for the treatment of RGBM, and is based on the principle that low intensity, intermediate frequency electric fields (100 to 300 kHz) may induce apoptosis in specific cell types.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23095807", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "Tumor treating fields (TTFields) is a noninvasive, regional antimitotic treatment modality that has been approved for the treatment of recurrent glioblastoma by the U.S. FDA and has a CE mark in Europe.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23659608", "endSection": "abstract"}, {"offsetInBeginSection": 336, "offsetInEndSection": 632, "text": "Tumor-treating fields (TTField) therapy is a novel treatment technique that has recently received CE and FDA approval for the treatment of RGBM, and is based on the principle that low intensity, intermediate frequency electric fields (100 to 300 kHz) may induce apoptosis in specific cell types. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23095807", "endSection": "abstract"}, {"offsetInBeginSection": 714, "offsetInEndSection": 867, "text": "In addition, a compartmental tumor growth model was developed and evaluated for its ability to predict GBM response to tumor-treating fields (TTFields). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25213870", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "OBJECTIVES: Tumor Treating Fields (TTFields) are a non-invasive cancer treatment modality approved for the treatment of patients with recurrent glioblastoma. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24555979", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Tumor Treating Fields (TTFields) are a non-invasive cancer treatment modality approved for the treatment of patients with recurrent glioblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24555979", "endSection": "abstract"}]}, {"body": "What are the key characteristics of the syndrome caused by ANKRD17 loss-of-function variants?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33909992"], "ideal_answer": ["Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphia.", "Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphism.", "Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphism, as well as growth failure, feeding difficulties, non-specific MRI abnormalities, epilepsy, and/or abnormal EEG, and predisposition to recurrent infections."], "exact_answer": [["Intellectual disability"], ["Speech delay"], ["Dysmorphism"]], "type": "list", "id": "61f81a2d882a024a10000042", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33909992", "endSection": "title"}, {"offsetInBeginSection": 576, "offsetInEndSection": 1658, "text": "Consequently, our data indicate that loss of ANKRD17 is likely the main cause of phenotypes previously associated with large multi-gene chromosomal aberrations of the 4q13.3 region. Protein modeling suggests that most of the missense variants disrupt the stability of the ankyrin repeats through alteration of core structural residues. The major phenotypic characteristic of our cohort is a variable degree of developmental delay/intellectual disability, particularly affecting speech, while additional features include growth failure, feeding difficulties, non-specific MRI abnormalities, epilepsy and/or abnormal EEG, predisposition to recurrent infections (mostly bacterial), ophthalmological abnormalities, gait/balance disturbance, and joint hypermobility. Moreover, many individuals shared similar dysmorphic facial features. Analysis of single-cell RNA-seq data from the developing human telencephalon indicated ANKRD17 expression at multiple stages of neurogenesis, adding further evidence to the assertion that damaging ANKRD17 variants cause a neurodevelopmental disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33909992", "endSection": "abstract"}]}, {"body": "What is caused by biallelic variants in SPATA5L1?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34626583"], "ideal_answer": ["Biallelic variants in SPATA5L1 lead to intellectual disability, spastic-dystonic cerebral palsy, epilepsy, and hearing loss.", "Bi-allelic variants in SPATA5L1 lead to microcephaly, intellectual disability, spastic-dystonic cerebral palsy, epilepsy, and hearing loss."], "exact_answer": [["intellectual disability"], ["microcephaly"], ["spastic-dystonic cerebral palsy"], ["epilepsy"], ["hearing loss"]], "type": "list", "id": "620997e9c9dfcb9c09000042", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Bi-allelic variants in SPATA5L1 lead to intellectual disability, spastic-dystonic cerebral palsy, epilepsy, and hearing loss.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34626583", "endSection": "title"}, {"offsetInBeginSection": 113, "offsetInEndSection": 404, "text": "We report 28 bi-allelic variants in SPATA5L1 associated with sensorineural hearing loss in 47 individuals from 28 (26 unrelated) families. In addition, 25/47 affected individuals (53%) presented with microcephaly, developmental delay/intellectual disability, cerebral palsy, and/or epilepsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34626583", "endSection": "abstract"}]}, {"body": "Proteomic analyses have revealed proteins associated with the triple-negative breast cancers. List some proposed proteins.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19416831", "http://www.ncbi.nlm.nih.gov/pubmed/23172894", "http://www.ncbi.nlm.nih.gov/pubmed/22414580", "http://www.ncbi.nlm.nih.gov/pubmed/20068102", "http://www.ncbi.nlm.nih.gov/pubmed/21630460", "http://www.ncbi.nlm.nih.gov/pubmed/19485423", "http://www.ncbi.nlm.nih.gov/pubmed/23436753", "http://www.ncbi.nlm.nih.gov/pubmed/22178447", "http://www.ncbi.nlm.nih.gov/pubmed/22934887", "http://www.ncbi.nlm.nih.gov/pubmed/22692575", "http://www.ncbi.nlm.nih.gov/pubmed/20005186"], "ideal_answer": ["Selected proteins of interest proposed from triple-negative cancer proteomic studies are CD44, PARP1, Mage-A4, LSR, RAB25, S100A14, MUC1, Hsp90, Actin, 14-3-3, vimentin, HSP70, CK18, moesin, IDH2, CRABP2, SEC14L2, beta-catenin, MUC18, Stat1 and CD74."], "exact_answer": [["CD44"], ["PARP1"], ["Mage-A4"], ["LSR"], ["RAB25"], ["S100A14"], ["MUC1"], ["Hsp90"], ["Actin"], ["14-3-3"], ["vimentin"], ["HSP70"], ["CK18"], ["moesin"], ["IDH2"], ["CRABP2"], ["SEC14L2"], ["beta-catenin"], ["MUC18"], ["Stat1"], ["CD74"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020543", "http://www.disease-ontology.org/api/metadata/DOID:0060081", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040901"], "type": "list", "id": "51595fb0d24251bc0500009c", "snippets": [{"offsetInBeginSection": 839, "offsetInEndSection": 969, "text": "Some of these proteins are of outstanding interest in the biology and clinical management of this disease, such as CD44 and PARP1.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23436753", "endSection": "sections.0"}, {"offsetInBeginSection": 1254, "offsetInEndSection": 1532, "text": "We present here our results, including a large cumulative database of proteins based on the analysis of 78 TNBCs, and the identification and validation of one specific protein, Mage-A4, which was expressed in a significant fraction of TNBC and Her2-positive/ER negative lesions.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23172894", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 216, "text": "Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23172894", "endSection": "title"}, {"offsetInBeginSection": 912, "offsetInEndSection": 1334, "text": "Further, we performed comparative quantitative proteomic and gene array analyses of these cells and identified potential novel markers of breast cancer cells with tumor-initiating features, such as lipolysis-stimulated lipoprotein receptor (LSR), RAB25, S100A14 and mucin 1 (MUC1), as well as a novel 31-gene signature capable of predicting distant metastasis in cohorts of estrogen receptor-negative human breast cancers.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22692575", "endSection": "sections.0"}, {"offsetInBeginSection": 1503, "offsetInEndSection": 1718, "text": "he results identify Hsp90 as a critical and multimodal target in this most difficult to treat breast cancer subtype and support the use of the Hsp90 inhibitor PU-H71 for clinical trials involving patients with TNBC.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19416831", "endSection": "sections.0"}, {"offsetInBeginSection": 227, "offsetInEndSection": 511, "text": "We obtained differential expression patterns for several glycolytic enzymes (as for example MDH2, PGK1, TKT, Aldolase1), cytokeratins (CK7, 8, 9, 14, 17, 19), further structure proteins (vimentin, fibronectin, L-plastin), for NME1-NME2, lactoferrin, and members of the Annexin family.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19485423", "endSection": "sections.0"}, {"offsetInBeginSection": 1689, "offsetInEndSection": 2085, "text": "he expression of calreticulin, cellular retinoic acid-binding protein II, chloride intracellular channel protein 1, EF-1-beta, galectin 1, peroxiredoxin-2, platelet-derived endothelial cell growth factor, protein disulfide isomerase and ubiquitin carboxyl-terminal hydrolase 5 were further validated using a tissue microarray containing 70 malignant breast carcinomas of various grades of atypia.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20005186", "endSection": "sections.0"}, {"offsetInBeginSection": 484, "offsetInEndSection": 554, "text": "The first is characterized by high expression of Stat1, Mx1, and CD74.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22178447", "endSection": "sections.0"}, {"offsetInBeginSection": 915, "offsetInEndSection": 1330, "text": "This effect was accompanied with a marked increase in the membrane expression of beta-catenin, MUC18, plexins, integrins, and other proteins involved in cell adhesion and cancer metastasis. Taken together, our results show that Stat1/CD74 positive triple-negative tumors are more aggressive and suggest an approach for development of better diagnostics and more targeted therapies for triple negative breast cancer.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22178447", "endSection": "sections.0"}, {"offsetInBeginSection": 1033, "offsetInEndSection": 1185, "text": "Proteomic analysis also identified high levels of IDH2 and CRABP2 and low levels of SEC14L2 to be prognostic markers for overall breast cancer survival.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22414580", "endSection": "sections.0"}, {"offsetInBeginSection": 651, "offsetInEndSection": 796, "text": "Proteomic and validation immunohistochemical analyses revealed that alpha-defensins (DEFA) were overexpressed in tumors from patients with a pCR.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20068102", "endSection": "sections.0"}, {"offsetInBeginSection": 583, "offsetInEndSection": 913, "text": "The expression of a selected group of high abundance and/or breast cancer-specific potential biomarkers including thromobospondin 1, galectin-3 binding protein, cathepsin D, vimentin, zinc-\u03b12-glycoprotein, CD44, and EGFR from the breast cancer cell lines and in their culture media were further validated by Western blot analysis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22934887", "endSection": "sections.0"}, {"offsetInBeginSection": 1179, "offsetInEndSection": 1354, "text": "his provided novel evidence for PMA regulation of the enzymes glyceraldehyde-3-phosphate dehydrogenase, nucleolar RNA helicase 2 and Heterogeneous nuclear ribonucleoprotein M.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21630460", "endSection": "sections.0"}, {"offsetInBeginSection": 1196, "offsetInEndSection": 1501, "text": "Among them, we identify downregulation of components of the Ras/Raf/MAPK pathway and G(2)-M phase to contribute to its anti-proliferative effect, degradation of activated Akt and Bcl-xL to induce apoptosis, and inhibition of activated NF-kappaB, Akt, ERK2, Tyk2, and PKC to reduce TNBC invasive potential.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19416831", "endSection": "sections.0"}]}, {"body": "List chromosomes that have been linked to Arnold Chiari syndrome in the literature.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15742475", "http://www.ncbi.nlm.nih.gov/pubmed/2798270", "http://www.ncbi.nlm.nih.gov/pubmed/24359474", "http://www.ncbi.nlm.nih.gov/pubmed/324229", "http://www.ncbi.nlm.nih.gov/pubmed/17103432", "http://www.ncbi.nlm.nih.gov/pubmed/23620759", "http://www.ncbi.nlm.nih.gov/pubmed/20101707", "http://www.ncbi.nlm.nih.gov/pubmed/6548367", "http://www.ncbi.nlm.nih.gov/pubmed/2130777", "http://www.ncbi.nlm.nih.gov/pubmed/20571508", "http://www.ncbi.nlm.nih.gov/pubmed/11754060", "http://www.ncbi.nlm.nih.gov/pubmed/23476832", "http://www.ncbi.nlm.nih.gov/pubmed/23942271", "http://www.ncbi.nlm.nih.gov/pubmed/17190989"], "ideal_answer": ["Chromosomes 1, 3, 5, 6, 8, 9, 12, 13, 15, 16, 18, 22, X and Y have been reported in association with Arnold Chiari syndrome in genetic linkage studies and individual case reports."], "exact_answer": [["1"], ["3"], ["5"], ["6"], ["8"], ["9"], ["12"], ["13"], ["15"], ["16"], ["18"], ["22"], ["X"], ["Y"]], "type": "list", "id": "54d77bdf3706e89528000019", "snippets": [{"offsetInBeginSection": 920, "offsetInEndSection": 1247, "text": "Consistent with a genetic hypothesis for CMI, much of the PF morphology was found to be heritable and multiple genomic regions were strongly implicated from OSA, including regions on Chromosomes 1 (LOD = 3.07, p = 3 \u00d7 10(-3) ) and 22 (LOD = 3.45, p = 6 \u00d7 10(-5) ) containing several candidates warranting further investigation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24359474", "endSection": "abstract"}, {"offsetInBeginSection": 2057, "offsetInEndSection": 2206, "text": "Furthermore, we report the first case of documented Arnold-Chiari malformation type I and increased factor XIII activity associated with 6p trisomy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23942271", "endSection": "abstract"}, {"offsetInBeginSection": 1237, "offsetInEndSection": 1506, "text": "Of particular interest were two regions (Chr8, Max LOD\u200a=\u200a3.04; Chr12, Max LOD\u200a=\u200a2.09) identified within the subset of \"CTD-negative\" families, both of which harbor growth differentiation factors (GDF6, GDF3) implicated in the development of Klippel-Feil syndrome (KFS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23620759", "endSection": "abstract"}, {"offsetInBeginSection": 671, "offsetInEndSection": 766, "text": "Moreover, the performed DNA analysis showed interstitial duplication in chromosome 5 (5q35.1). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23476832", "endSection": "abstract"}, {"offsetInBeginSection": 662, "offsetInEndSection": 774, "text": "CGH microarray showed a approximately 520.7 kb microdeletion on 16p13.3 involving CREBBP, ADCY9, and SRL genes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20101707", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Pentasomy 49,XXXXY associated with a Chiari type 1 malformation and cervical syrinx.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17190989", "endSection": "title"}, {"offsetInBeginSection": 312, "offsetInEndSection": 431, "text": "A 13-year-old with pentasomy 49,XXXXY and a Chiari type 1 malformation with an associated cervical syrinx is presented.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17190989", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Phenotypic definition of Chiari type I malformation coupled with high-density SNP genome screen shows significant evidence for linkage to regions on chromosomes 9 and 15.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17103432", "endSection": "title"}, {"offsetInBeginSection": 949, "offsetInEndSection": 1101, "text": "Two-point LOD scores on chromosome 15 reached 3.3 and multipoint scores in this region identified a 13 cM region with LOD scores over 1 (15q21.1-22.3). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17103432", "endSection": "abstract"}, {"offsetInBeginSection": 1317, "offsetInEndSection": 1516, "text": "Multipoint LOD scores on chromosome 9 maximized at 3.05, identifying a 40 cM region with LOD scores over 1 (9q21.33-33.1) and a tighter region with multipoint LOD scores over 2 that was only 8.5 cM. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17103432", "endSection": "abstract"}, {"offsetInBeginSection": 809, "offsetInEndSection": 1032, "text": "In addition, this child had an Arnold-Chiari type I malformation that required surgical decompression. FISH studies using BAC clones spanning the 5q15 to 5q22 region revealed that these were all present in both homologues. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15742475", "endSection": "abstract"}, {"offsetInBeginSection": 401, "offsetInEndSection": 448, "text": "The karyotype showed 46, XY, del(1)(q23q31.2). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11754060", "endSection": "abstract"}, {"offsetInBeginSection": 1038, "offsetInEndSection": 1091, "text": "Karyotype analysis showed inversion of Y chromosome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2130777", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 557, "text": "The clinical features and morphological findings in 31 Japanese infants with trisomy 18 are presented. The majority were small-for-date infants. There was no sex predominance in our series, as opposed to male:female ratios of 1:3 reported in the literature. The average age at death was greater in females than in males. Cardiovascular anomalies were consistently present; ventricular septar defect and patent ductus arteriosus being the most common malformations. Various other internal malformations including the Arnold-Chiari malformation were observed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2798270", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "An unusual heterotopia of striated skeletal muscle and glial tissue occurred in the pontine meninges of a stillborn male showing feature of trisomy 13 and an Arnold-Chiari malformation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6548367", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Type II Arnold-Chiari malformation with normal spine in trisomy 18.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/324229", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 315, "text": "A variety of anomalies of the central nervous system are observed in trisomy 18. The present case describes an infant having a type II Arnold-Chiari malformation without spina bifida. One previous case of an Arnold-Chiari malformation was reported in trisomy 18 but that infant also had a lumbar meningomyelocoele. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/324229", "endSection": "abstract"}, {"offsetInBeginSection": 443, "offsetInEndSection": 806, "text": "Recently, a child was reported who presented with a 3p13-14.1 deletion of four genes, including FOXP1, and a constellation of deficits that included speech delay. In this study, we report the case of a patient with a single deletion of FOXP1. This patient presented with speech and motor developmental delays, a Chiari I malformation, and epileptiform discharges.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20571508", "endSection": "abstract"}]}, {"body": "List main clinical features of the POEMS syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10378364", "http://www.ncbi.nlm.nih.gov/pubmed/29157614", "http://www.ncbi.nlm.nih.gov/pubmed/29157615", "http://www.ncbi.nlm.nih.gov/pubmed/29157616", "http://www.ncbi.nlm.nih.gov/pubmed/28856089", "http://www.ncbi.nlm.nih.gov/pubmed/21035860", "http://www.ncbi.nlm.nih.gov/pubmed/2029023", "http://www.ncbi.nlm.nih.gov/pubmed/25984208", "http://www.ncbi.nlm.nih.gov/pubmed/22724593", "http://www.ncbi.nlm.nih.gov/pubmed/10978936", "http://www.ncbi.nlm.nih.gov/pubmed/17895817", "http://www.ncbi.nlm.nih.gov/pubmed/26130736", "http://www.ncbi.nlm.nih.gov/pubmed/7699917", "http://www.ncbi.nlm.nih.gov/pubmed/19863172", "http://www.ncbi.nlm.nih.gov/pubmed/27338259", "http://www.ncbi.nlm.nih.gov/pubmed/24268501", "http://www.ncbi.nlm.nih.gov/pubmed/21221584", "http://www.ncbi.nlm.nih.gov/pubmed/17940990", "http://www.ncbi.nlm.nih.gov/pubmed/25341835", "http://www.ncbi.nlm.nih.gov/pubmed/27208909", "http://www.ncbi.nlm.nih.gov/pubmed/2227242", "http://www.ncbi.nlm.nih.gov/pubmed/8699962", "http://www.ncbi.nlm.nih.gov/pubmed/19546057"], "ideal_answer": ["POEMS is an acronym for the main clinical features of the syndrome, namely, Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin abnormalities. Other features include papilledema, extravascular volume overload, sclerotic bone lesions, thrombocytosis, and Castleman disease. It is a multisystemc disorder with a good long-term prognosis."], "exact_answer": [["Polyneuropathy"], ["Organomegaly"], ["Endocrinopathy"], ["M protein"], ["Skin abnormalities"]], "concepts": ["https://meshb.nlm.nih.gov/record/ui?ui=D016878", "http://www.disease-ontology.org/api/metadata/DOID:14039"], "type": "list", "id": "5a67afb7b750ff445500000d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 375, "text": "POEMS syndrome is a rare paraneoplastic syndrome secondary to a plasma cell dyscrasia. Recognition of a combination of peripheral neuropathy, organomegaly, endocrinopathy, monoclonal plasmaproliferative disorder, skin changes, papilledema, extravascular volume overload, sclerotic bone lesions, thrombocytosis, and Castleman disease is the first step in managing the disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29157614", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 245, "text": "Treatment of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome should be directed at the underlying plasma cell clone with risk-adapted therapy based on the extent of the plasma cell disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29157615", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, skin changes (POEMS) syndrome is a rare paraneoplastic disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29157616", "endSection": "abstract"}, {"offsetInBeginSection": 137, "offsetInEndSection": 293, "text": "POEMS is an acronym for the main clinical features of the syndrome, namely, Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin abnormalities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27208909", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) is a multisystem disorder with a good long-term prognosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27338259", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "The association of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes forms a characteristic multisystem syndrome, Crow-Fukase syndrome, or acronym POEMS syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7699917", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes (POEMS) syndrome is a multisystem disorder arising from underlying plasma cell dyscrasia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26130736", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome is an uncommon condition related to a paraneoplastic syndrome secondary to an underlying plasma cell disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25341835", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 241, "text": "Pulmonary hypertension is one of the well-known clinical manifestations of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, occurring in approximately 25-30% of the affected individuals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28856089", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome is a rare disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21035860", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 245, "text": "Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes (POEMS) syndrome, a plasma cell dyscrasia associated with pulmonary hypertension, has been treated in the past with anticytokine strategies with a poor outcome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10978936", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 274, "text": "A 48-year-old man with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome had bilateral optic disc edema (ODE), bilateral cystoid macular edema (CME), anasarca, and elevated serum vascular endothelial growth factor (VEGF).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17895817", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "A 39-year-old woman presented with polyneuropathy, hepatomegaly, splenomegaly, endocrinopathy, monoclonal protein and skin changes, several of the many clinical features of the recently described POEMS syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2227242", "endSection": "abstract"}, {"offsetInBeginSection": 92, "offsetInEndSection": 250, "text": "The acronym POEMS is derived from main features of the syndrome namely 'polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin lesions'.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25984208", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "POEMS syndrome, also known as Crow-Fukase syndrome, represents a rare multisystem syndrome characterized by polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19863172", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 257, "text": "Polyneuropathy is often an initial manifestation of polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes (POEMS) syndrome and therefore this disorder is frequently misdiagnosed as chronic inflammatory demyelinating polyneuropathy (CIDP).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24268501", "endSection": "title"}, {"offsetInBeginSection": 871, "offsetInEndSection": 1192, "text": "POEMS syndrome is a rare paraneoplastic condition, commonly associated with Castleman disease, that manifests with progressive distal polyneuropathy and a monoclonal plasma cell disorder, often accompanied by endocrinopathy, organomegaly, skin changes, sclerotic bone lesions, ascites, erythrocytosis, and thrombocytosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19546057", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "POEMS syndrome, a rare multisystem disease, is a variant of osteosclerotic myeloma and is characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal proteins, and skin changes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2029023", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "We report a case of a 64-year-old man with POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) syndrome that had been previously misdiagnosed as systemic sclerosis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22724593", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "POEMS syndrome is a rare plasma cell dyscrasia characterized by polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21221584", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "The POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammapathy, and skin changes) syndrome is a rare variant of plasma cell dyscrasia with multisystemic manifestations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8699962", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 478, "text": "a 39 year old woman presented with polyneuropathy hepatomegaly splenomegaly endocrinopathy monoclonal protein and skin changes several of the many clinical features of the recently described poems syndrome in addition she had a castleman s disease angiofollicular lymph node hyperplasia in this case ascites was a main presenting feature thus the poems syndrome must be added to the list of rare causes of ascites electron microscopy of the liver showed perisinusoidal fibrosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2227242", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 825, "text": "the poems syndrome is a rare multisystemic disorder with polyneuropathy organomegaly endocrinopathy of various forms production of monoclonal m component and skin changes we describe a 46 year old man who developed ascites one year after the onset of peripheral neuropathy with accompanying muscle atrophies and increasing weakness extensive evaluation revealed that the patient had no underlying liver disease malignancy infection or cardiac or renal disease the ascites initially responded to high dose corticosteroid therapy the patient had many clinical features of the described poems syndrome including sclerotic bone lesions a persistent lambda paraprotein and refractory ascites in this case ascites was a main presenting feature thus the poems syndrome must be added to the list of rare causes of refractory ascites.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10378364", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 861, "text": "poems syndrome is a paraneoplastic manifestation associated with hematopoietic disorders such as multiple myeloma and castleman disease poems is an acronym for the main clinical features of the syndrome namely polyneuropathy organomegaly endocrinopathy m protein and skin abnormalities glomeruloid hemangiomas are considered to be a specific clinical marker of poems syndrome however while they are not pathognomonic their presence should raise suspicion of this syndrome or alert clinicians to its possible future development as these lesions can appear years before the onset of the syndrome we report the cases of 2 women with plasma cell dyscrasias and sudden onset of lesions with a vascular appearance and histologic findings consistent with glomeruloid hemangioma recognition of this vascular tumor is important for the early diagnosis of poems syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27208909", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1162, "text": "poems syndrome is a rare conglomeration of disorders associated with plasma cell dyscrasia the acronym poems is derived from main features of the syndrome namely polyneuropathy organomegaly endocrinopathy monoclonal gammopathy and skin lesions other clinical features include presence of sclerotic bone lesions castleman s disease papilledema pleural effusion edema ascites erythrocytosis and thrombocytosis myeloma is the most common plasma cell dyscrasia associated with poems syndrome renal involvement is rare and renal biopsy is characterized by glomerular involvement with membranoproliferative glomerulonephritis and endothelial injury we report a case of a 67 year old male who presented with clinical features satisfying the diagnostic criteria of poems syndrome and had rapidly progressive renal failure renal biopsy showed extensive interstitial infiltration by plasma cells and concomitant presence of classic polyarteritis nodosa although association with small vessel vasculitis has been reported in patients with poems syndrome to the best of our knowledge this is the first report of poems syndrome associated with medium sized vessel vasculitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25984208", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1074, "text": "poems syndrome also known as crow fukase syndrome represents a rare multisystem syndrome characterized by polyneuropathy organomegaly endocrinopathy m protein and skin changes hypothyroidism is one of the common endocrine abnormalities which are central features of poems syndrome the clinical data associated with the measurement of thyroid function and its clinical significance in poems syndrome is still rare herein we report 24 cases with poems syndrome which were studied thyroid function and clinical manifestations and performed an associated analysis between hypothyroidism and edema effusions of the 24 patients with poems syndrome 17 70 8 had a recognized hypothyroidism including 11 clinical hypothyroidism and 6 subclinical hypothyroidism fourteen patients 58 3 had some form of extravascular volume overload in 14 patients with edema effusions 12 were diagnosed as having hypothyroidism hypothyroidism may be one of causes of edema effusions after thyroid hormone treatment and chemotherapy symptoms of hypothyroidism and edema effusions were improved greatly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19863172", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1692, "text": "we present a case of a woman with unique multisystem disorder poems syndrome and endocrine abnormalities coexisting with it the poems acronym comprises the dominant features polyneuropathy organomegaly endocrinopathy monoclonal protein m protein skin changes association between plasma cell dyscrasia and polyneuropathy was described in 1956 year by crow the main features were coined in the acronym poems by bardwick in 1980 year the polysymptomatic clinical picture progressive course and no concurrent manifestations of main features impede the diagnosis in this case the first symptoms were the sensomotor polyneuropathy peripheral oedema osteosclerotic bone lesions skin changes organomegaly they preceded diagnosis by 3 years the first endocrinopathy was hypothyroidism definite diagnosis was delayed because we couldn t detect the presence of m protein immunoelectrophoresis didn t detect it but analysis by immunofixation detected m protein in serum and urine within 3 years of the first symptoms she developed hypogonadism hypergonadotropic at first the monotherapy with corticosteroids was used then melfalan with prednisone due to the progression of the disease a thalidomide was used in therapy it is anti vegf agent one of the side effects of the treatment of thalidomide is the progression of polyneuropathy which was observed in this patient after finishing this therapy she received chemotherapy this case report imposes the necessity of constants observation of patients with poems syndrome because there is a possibility of their developing other disorders in the event of coexistence polyneuropathy and plasma cell dyscrasia this disease should be taken into consideration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17940990", "endSection": "abstract"}]}, {"body": "Which are the common symptoms of Cushing's syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24062268", "http://www.ncbi.nlm.nih.gov/pubmed/17322955"], "ideal_answer": ["Cushing syndrome is the constellation of signs and symptoms caused by protracted exposure to glucocorticoids. Presenting features commonly include weight gain, growth retardation, hirsutism, obesity, striae, acne and hypertension."], "exact_answer": [["weight gain"], ["growth retardation"], ["hirsutism"], ["obesity"], ["striae"], ["acne"], ["hypertension"]], "type": "list", "id": "571f3b320fd6f91b68000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 347, "text": "Cushing syndrome is the constellation of signs and symptoms caused by protracted exposure to glucocorticoids. The most common cause of Cushing syndrome in children and adolescents is exogenous administration of glucocorticoids. Presenting features commonly include weight gain, growth retardation, hirsutism, obesity, striae, acne and hypertension", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24062268", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 332, "text": "This is a rare syndrome and its main endocrine manifestation, primary pigmented nodular adrenal disease (PPNAD), is an uncommon cause of adrenocorticotropic hormone-independent Cushing's syndrome.We report the case of a 20-year-old patient with a history of weight gain, hirsutism, acne, secondary amenorrhea and facial lentiginosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17322955", "endSection": "abstract"}]}, {"body": "List Kartagener Syndrome Triad.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25207108", "http://www.ncbi.nlm.nih.gov/pubmed/19529061", "http://www.ncbi.nlm.nih.gov/pubmed/6984375", "http://www.ncbi.nlm.nih.gov/pubmed/17725169", "http://www.ncbi.nlm.nih.gov/pubmed/16940490", "http://www.ncbi.nlm.nih.gov/pubmed/24019633", "http://www.ncbi.nlm.nih.gov/pubmed/24730627", "http://www.ncbi.nlm.nih.gov/pubmed/20550487", "http://www.ncbi.nlm.nih.gov/pubmed/15025618", "http://www.ncbi.nlm.nih.gov/pubmed/22966723", "http://www.ncbi.nlm.nih.gov/pubmed/17408950", "http://www.ncbi.nlm.nih.gov/pubmed/8290523", "http://www.ncbi.nlm.nih.gov/pubmed/313731", "http://www.ncbi.nlm.nih.gov/pubmed/8080604", "http://www.ncbi.nlm.nih.gov/pubmed/14551758", "http://www.ncbi.nlm.nih.gov/pubmed/9927835", "http://www.ncbi.nlm.nih.gov/pubmed/9018261"], "ideal_answer": ["The triad of situs inversus, bronchiectasis and sinusitis is known as Kartagener syndrome."], "exact_answer": [["situs inversus"], ["bronchiectasis"], ["sinusitis"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007619"], "type": "list", "id": "56be0e4aef6e394741000008", "snippets": [{"offsetInBeginSection": 414, "offsetInEndSection": 505, "text": "The triad of situs inversus, bronchiectasis and sinusitis is known as Kartagener syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24730627", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "BACKGROUND: KARTAGENER SYNDROME (KS) IS A RARE CONGENITAL DISEASE CHARACTERISED BY A CLINICAL TRIAD OF SYMPTOMS: situs inversus, chronic rhinosinusitis, and bronchiectasis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25207108", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Kartagener's syndrome is a very rare congenital malformation comprising of a classic triad of sinusitis, situs inversus and bronchiectasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24019633", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "We present a case of a patient with clinically definite ALS, who had earlier suffered from Kartagener syndrome, which is characterized by the triad comprising chronic sinusitis, bronchiectasis, and situs inversus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20550487", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Kartagener syndrome (KS), an autosomal recessively inherited disease, is characterized by the triad of situs inversus, bronchiectasis and sinusitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16940490", "endSection": "abstract"}, {"offsetInBeginSection": 315, "offsetInEndSection": 459, "text": "In 1933, Manes Kartagener, a Zurich pulmonary physician, reported four patients with the triad of sinusitis, bronchiectasis, and situs inversus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14551758", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "A case of a nine year and eight months old child with Kartagener's syndrome (triad) is described: chronic maxillary sinusitis, bronchiectasis and \"situs inversus totalis\".", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/313731", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "Kartagener's syndrome is an inherited disease characterized by a triad of symptoms--bronchiectasis, situs inversus and sinusitis--and is classified as an immotile cilia syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9927835", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Kartagener's syndrome is characterized by the clinical triad of bronchitis, sinusitis, and situs inversus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9018261", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Kartagener's syndrome is a well known classical triad of presentations consisting of bronchiectasis, sinusitis and situs inversus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8080604", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Kartagener's syndrome is a rare disorder characterized by the triad of situs inversus, including dextrocardia, bronchiectasis and paranasal sinusitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15025618", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Kartagener's syndrome is an inherited disease characterized by a triad of symptoms: bronchiectasis, situs inversus and sinusitis resulting from defective cilial motility.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17408950", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "Ear, nose and throat symptoms and signs were studied in 15 patients with Kartagener's syndrome: a triad consisting of chronic rhinosinusitis, chronic bronchitis with bronchiectasis, and situs inversus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6984375", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Kartagener syndrome (a clinical variant of primary ciliary dyskinesia) is a recessive autossomical disease characterized by the triad of chronic sinusitis, bronchiectasis and situs inversus with dextrocardia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17725169", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Kartagener Syndrome is a rare autosomal recessive disorder consisting of triad of sinusitis, bronchiectasis and situs inversus with dextrocardia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19529061", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Kartagener syndrome (KS), an autosomal recessively inherited disease, is characterized by the triad of situs inversus, bronchiectasis and sinusitis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16940490", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "Kartagener&apos;s syndrome is an inherited disease characterized by a triad of symptoms--bronchiectasis, situs inversus and sinusitis--and is classified as an immotile cilia syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9927835", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Kartagener&apos;s syndrome is a very rare congenital malformation comprising of a classic triad of sinusitis, situs inversus and bronchiectasis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24019633", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 222, "text": "A comprehensive clinicomorphological examination of 24 children with Zivert-Kartagener syndrome ascertained the complete triad (bronchiectasis, maldevelopment of the sinuses and transposition of the viscera) in all of them", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8290523", "endSection": "abstract"}, {"offsetInBeginSection": 363, "offsetInEndSection": 458, "text": "The triad situs viscerum inversus, bronchiectasis and sinusitis is known as Kartagener syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22966723", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 324, "text": "We present a case of a patient with clinically definite ALS, who had earlier suffered from Kartagener syndrome, which is characterized by the triad comprising chronic sinusitis, bronchiectasis, and situs inversus. Recent linkage and mutational analyses identified several genes that are responsible for Kartagener syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20550487", "endSection": "abstract"}]}, {"body": "Which drugs are included in the Qtern pill?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29176433", "http://www.ncbi.nlm.nih.gov/pubmed/32454718", "http://www.ncbi.nlm.nih.gov/pubmed/28884600", "http://www.ncbi.nlm.nih.gov/pubmed/28176222"], "ideal_answer": ["Qtern pill includes saxagliptin and dapagliflozin. It is indicated in the EU for the improvement of glycaemic control in adults with type 2 diabetes mellitus."], "exact_answer": [["saxagliptin"], ["dapagliflozin"]], "type": "list", "id": "61fbc3d5c9dfcb9c0900000e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Objectives: The fixed dose combination of saxagliptin and dapagliflozin is a recently approved antidiabetic medication. It is marketed under the brand name Qtern. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32454718", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of the fixed-dose combination (FDC) product, QTERN (dapagliflozin/saxagliptin) tablets.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884600", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 429, "text": "Saxagliptin/dapagliflozin fixed-dose combination tablets (Qtern\u00ae) are indicated in the EU for the improvement of glycaemic control in adults with type 2 diabetes mellitus (T2DM), either when treatment with metformin and/or a sulfonylurea plus a monocomponent of saxagliptin/dapagliflozin provides inadequate glycaemic control, or when the patient is already being treated with the free combination of saxagliptin\u00a0+\u00a0dapagliflozin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28176222", "endSection": "abstract"}, {"offsetInBeginSection": 69, "offsetInEndSection": 269, "text": "This article highlights the following new drugs: brodalumab (Siliq), dapagliflozin and saxagliptin (Qtern), dupilumab (Dupixent), oxymetazoline (Rhofade), safinamide (Xadago), and sarilumab (Kevzara).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29176433", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of the fixed-dose combination (FDC) product, QTERN (dapagliflozin/saxagliptin) table", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884600", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of the fixed-dose combination (FDC) product, QTERN (dapagliflozin/saxagliptin) tablet", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884600", "endSection": "abstract"}, {"offsetInBeginSection": 1356, "offsetInEndSection": 1686, "text": "CONCLUSION: QTERN (dapagliflozin/saxagliptin) tablets are a reasonable option for patients with T2DM not controlled on metformin, but cost, insurance coverage, and a lackluster reduction in A1C will likely limit its use until more data regarding its effects on complications of diabetes and cardiovascular outcomes become availabl", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884600", "endSection": "abstract"}, {"offsetInBeginSection": 69, "offsetInEndSection": 268, "text": "This article highlights the following new drugs: brodalumab (Siliq), dapagliflozin and saxagliptin (Qtern), dupilumab (Dupixent), oxymetazoline (Rhofade), safinamide (Xadago), and sarilumab (Kevzara)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29176433", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 287, "text": "OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of the fixed-dose combination (FDC) product, QTERN (dapagliflozin/saxagliptin) tablets.DATA SOURCES: Searches of MEDLINE (1946 to July 1, 2017) were conducted using the keywords QTERN, saxagl", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884600", "endSection": "abstract"}, {"offsetInBeginSection": 1219, "offsetInEndSection": 1598, "text": "nd dapagliflozin + metformin was -0.27 (95% CI = -0.48 to -0.05, P = 0.0166). The combination was well tolerated when added to metformin.CONCLUSION: QTERN (dapagliflozin/saxagliptin) tablets are a reasonable option for patients with T2DM not controlled on metformin, but cost, insurance coverage, and a lackluster reduction in A1C will likely limit its use until more data regard", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884600", "endSection": "abstract"}]}, {"body": "Please list 7 classes of drugs that interact with Warfarin.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24038065", "http://www.ncbi.nlm.nih.gov/pubmed/17698824", "http://www.ncbi.nlm.nih.gov/pubmed/15911722", "http://www.ncbi.nlm.nih.gov/pubmed/18315779", "http://www.ncbi.nlm.nih.gov/pubmed/20095918", "http://www.ncbi.nlm.nih.gov/pubmed/17119104", "http://www.ncbi.nlm.nih.gov/pubmed/19934391", "http://www.ncbi.nlm.nih.gov/pubmed/23033232", "http://www.ncbi.nlm.nih.gov/pubmed/22198820", "http://www.ncbi.nlm.nih.gov/pubmed/23089199", "http://www.ncbi.nlm.nih.gov/pubmed/6347619", "http://www.ncbi.nlm.nih.gov/pubmed/8792056", "http://www.ncbi.nlm.nih.gov/pubmed/27416928", "http://www.ncbi.nlm.nih.gov/pubmed/8672833", "http://www.ncbi.nlm.nih.gov/pubmed/15585436", "http://www.ncbi.nlm.nih.gov/pubmed/21332566", "http://www.ncbi.nlm.nih.gov/pubmed/27365092", "http://www.ncbi.nlm.nih.gov/pubmed/23045839"], "ideal_answer": ["The number of drugs reported to interact with warfarin continues to expand. There are reports of interactions with azole antibiotics, macrolides, quinolones, nonsteroidal anti-inflammatory drugs, including selective cyclooxygenase-2 inhibitors, selective serotonin reuptake inhibitors, omeprazole, lipid-lowering agents, protease inhibitors, amiodarone, fluorouracil, psychotropics, and oral corticosteroids.", "Seven drugs/drug classes (ibuprofen, morphine, warfarin, bupropion, paroxetine, rosiglitazone, ACE inhibitors) with known ADEs were selected to evaluate the system. This study was aimed to determine the prevalence of drug-related problems (DRPs), identify the most common drugs, and drug classes involved in DRPs as well as associated factors with the occurrence of DRPs.A prospective cross-sectional study was conducted on 225 patients admitted to medical wards of Tikur Anbessa Specialized Hospital, Addis Ababa from March to June 2014. Analysis of the data showed that albumin possesses a single strong binding site for warfarin with an association constant of 154,000 at 3 degrees C and secondary classes of several sites with a much lower affinity. Four medications or medication classes were implicated alone or in combination in 67.0% (95% CI, 60.0 to 74.1) of hospitalizations: warfarin (33.3%), insulins (13.9%), oral antiplatelet agents (13.3%), and oral hypoglycemic agents (10.7%). Drugs such as gentamycin, warfarin, nifedipine, and cimetidine have the highest probability of causing DRP. Drugs with the highest drug risk ratio were gentamycin, warfarin, nifedipine, and cimetidine. The drugs most frequently causing a DRP were angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, diuretics, warfarin, spironolactone, and \u03b2-blockers."], "exact_answer": [["SSRI"], ["antibiotics"], ["NSAIDS"], ["antimetabolites"], ["oral corticosteroids"], ["protease inhibitors"], ["psychotropics"], ["statins/lipid lowering drugs"], ["omeprazole"], ["amiodarone"], ["carbamazapine"], ["narcotics/opiods"], ["cardiovascular drugs"], ["trazodone"], ["antifungals"], ["antivirals"]], "concepts": ["https://meshb.nlm.nih.gov/record/ui?ui=D018565", "http://www.biosemantics.org/jochem#4250139", "https://meshb.nlm.nih.gov/record/ui?ui=D014859"], "type": "list", "id": "5abce6acfcf4565872000022", "snippets": [{"offsetInBeginSection": 1429, "offsetInEndSection": 1609, "text": "The combined use of warfarin and NSAIDs is generally discouraged because of the increased risk of bleeding in these patients. In patients receiving warfarin who also require NSAIDs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8672833", "endSection": "abstract"}, {"offsetInBeginSection": 1535, "offsetInEndSection": 1982, "text": "The number of drugs reported to interact with warfarin continues to expand. While most reports are of poor quality and present potentially misleading conclusions, the consistency of reports of interactions with azole antibiotics, macrolides, quinolones, nonsteroidal anti-inflammatory drugs, including selective cyclooxygenase-2 inhibitors, selective serotonin reuptake inhibitors, omeprazole, lipid-lowering agents, amiodarone, and fluorouracil, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15911722", "endSection": "abstract"}, {"offsetInBeginSection": 13, "offsetInEndSection": 126, "text": " potential drug interaction exists between oral corticosteroids and warfarin, but there is limited documentation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17119104", "endSection": "abstract"}, {"offsetInBeginSection": 1928, "offsetInEndSection": 2123, "text": "Use of oral corticosteroids in patients on long-term warfarin therapy may result in a clinically significant interaction, which requires close INR monitoring and possible warfarin dose reduction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17119104", "endSection": "abstract"}, {"offsetInBeginSection": 492, "offsetInEndSection": 623, "text": "We review the possible mechanisms of this interaction and the reported interactions between warfarin and other protease inhibitors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17698824", "endSection": "abstract"}, {"offsetInBeginSection": 1859, "offsetInEndSection": 1965, "text": "It is necessary to intensify warfarin monitoring upon initiation or alteration of hormonal contraceptives.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19934391", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 204, "text": "To report a single patient case that presented with a probable drug interaction between warfarin and 3 methods of hormonal contraceptives, as assessed by the Horn Interaction Probability Scale.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19934391", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Warfarin-antibiotic interactions in older adults of an outpatient anticoagulation clinic", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23089199", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 235, "text": "Several classes of drugs, such as antibiotics, may interact with warfarin to cause an increase in warfarins anticoagulant activity and the clinical relevance of warfarin-antibiotic interactions in older adults is not clear.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23089199", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "As the number of psychotropics on the market expands, the likelihood increases that a patient requiring anticoagulation with warfarin will receive concurrent treatment with a psychotropic drug.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23033232", "endSection": "abstract"}, {"offsetInBeginSection": 1419, "offsetInEndSection": 1659, "text": "The most commonly identified potentially interacting medication pairs were warfarin and non-steroidal anti-inflammatory drugs (6824 cases), theophylline/aminophylline and ciprofloxacin/fluvoxamine (930), and warfarin and barbiturates (567).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18315779", "endSection": "abstract"}, {"offsetInBeginSection": 702, "offsetInEndSection": 927, "text": "Among 36 drugs that may interact with warfarin, fluconazole, amiodarone, and omeprazole were associated with the requirement for 45.8, 16.7, and 16.7% lower median warfarin dose (all P<0.05 with a false discovery rate <0.05).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22198820", "endSection": "abstract"}, {"offsetInBeginSection": 1189, "offsetInEndSection": 1387, "text": "The results demonstrate a high prevalence of concomitant drug prescriptions with the potential for clinically relevant DDIs with warfarin, the most frequent being acetylsalicylic acid and amiodarone", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27365092", "endSection": "abstract"}, {"offsetInBeginSection": 969, "offsetInEndSection": 1105, "text": "We provide new support for the previous scarce evidence of interactions between warfarin and carbamazepine, bezafibrate, and lactulose. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24038065", "endSection": "abstract"}, {"offsetInBeginSection": 372, "offsetInEndSection": 733, "text": " Noteworthy are the interactions with cardiovascular or antilipidaemic drugs which are often coadministered with coumarins: amiodarone, propafenone and fibrates. Cardiovascular drugs which are obviously devoid or proven to be devoid of an interaction are angiotensin converting enzyme (ACE) inhibitors, calcium antagonists, beta-blockers and cardiac glycosides.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8792056", "endSection": "abstract"}, {"offsetInBeginSection": 646, "offsetInEndSection": 826, "text": "Of the antidepressants analyzed, those that showed relevant effects on the interaction with warfarin were, in decreasing order: paroxetine, venlafaxine, fluoxetine, and duloxetine.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23045839", "endSection": "abstract"}, {"offsetInBeginSection": 818, "offsetInEndSection": 1024, "text": "Isomeric differences in metabolism form an important basis for stereoselective metabolic interactions, especially inhibition; this has been demonstrated with phenylbutazone, metronidazole and co-trimoxazole", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6347619", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Miconazole and nystatin used as topical antifungal drugs interact equally strongly with warfarin.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21332566", "endSection": "title"}, {"offsetInBeginSection": 11, "offsetInEndSection": 179, "text": "A retrospective case series published in 2012 concluded that miconazole and nystatin used as topical antifungal drugs appear to interact equally strongly with warfarin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27416928", "endSection": "abstract"}, {"offsetInBeginSection": 1397, "offsetInEndSection": 1564, "text": " trazodone (2.2%) and carbamazepine (1.1%). The most commonly prescribed agents independently associated with increased bleeding risk were cyclooxygenase-2 inhibitors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15585436", "endSection": "abstract"}, {"offsetInBeginSection": 1228, "offsetInEndSection": 1371, "text": "Metabolic interaction between warfarin and antiretrovirals is likely, particularly if NNRTIs or PIs are included in the antiretroviral regimen.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20095918", "endSection": "abstract"}]}, {"body": "Which R/bioconductor have been developed for copy number analysis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24597965", "http://www.ncbi.nlm.nih.gov/pubmed/28088185", "http://www.ncbi.nlm.nih.gov/pubmed/22523482", "http://www.ncbi.nlm.nih.gov/pubmed/23442169", "http://www.ncbi.nlm.nih.gov/pubmed/24265680", "http://www.ncbi.nlm.nih.gov/pubmed/23419375", "http://www.ncbi.nlm.nih.gov/pubmed/31392308", "http://www.ncbi.nlm.nih.gov/pubmed/21070656"], "ideal_answer": ["CNVRanger, seqCNA, iGC, PLRS, SomatiCA, Copynumber, crlmm, KC-SMARTR are all R/bioconductor packages for copy number analysis"], "exact_answer": [["CNVRanger"], ["seqCNA"], ["iGC"], ["PLRS"], ["SomatiCA"], ["Copynumber"], ["crlmm"], ["KC-SMARTR"]], "type": "list", "id": "601ec0c91cb411341a00005f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "CNVRanger: association analysis of CNVs with gene expression and quantitative phenotypes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31392308", "endSection": "title"}, {"offsetInBeginSection": 9, "offsetInEndSection": 699, "text": "Copy number variation (CNV) is a major type of structural genomic variation that is increasingly studied across different species for association with diseases and production traits. Established protocols for experimental detection and computational inference of CNVs from SNP array and next-generation sequencing data are available. We present the CNVRanger R/Bioconductor package which implements a comprehensive toolbox for structured downstream analysis of CNVs. This includes functionality for summarizing individual CNV calls across a population, assessing overlap with functional genomic regions, and genome-wide association analysis with gene expression and quantitative phenotypes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31392308", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "seqCNA: an R package for DNA copy number analysis in cancer using high-throughput sequencing.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24597965", "endSection": "title"}, {"offsetInBeginSection": 517, "offsetInEndSection": 1264, "text": "We introduce seqCNA, a parallelized R package for an integral copy number analysis of high-throughput sequencing cancer data. The package includes novel methodology on (i) filtering, reducing false positives, and (ii) GC content correction, improving copy number profile quality, especially under great read coverage and high correlation between GC content and copy number. Adequate analysis steps are automatically chosen based on availability of paired-end mapping, matched normal samples and genome annotation.CONCLUSIONS: seqCNA, available through Bioconductor, provides accurate copy number predictions in tumoural data, thanks to the extensive filtering and better GC bias correction, while providing an integrated and parallelized workflow.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24597965", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "iGC-an integrated analysis package of gene expression and copy number alteration.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088185", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 1510, "text": "With the advancement in high-throughput technologies, researchers can simultaneously investigate gene expression and copy number alteration (CNA) data from individual patients at a lower cost. Traditional analysis methods analyze each type of data individually and integrate their results using Venn diagrams. Challenges arise, however, when the results are irreproducible and inconsistent across multiple platforms. To address these issues, one possible approach is to concurrently analyze both gene expression profiling and CNAs in the same individual.RESULTS: We have developed an open-source R/Bioconductor package (iGC). Multiple input formats are supported and users can define their own criteria for identifying differentially expressed genes driven by CNAs. The analysis of two real microarray datasets demonstrated that the CNA-driven genes identified by the iGC package showed significantly higher Pearson correlation coefficients with their gene expression levels and copy numbers than those genes located in a genomic region with CNA. Compared with the Venn diagram approach, the iGC package showed better performance.CONCLUSION: The iGC package is effective and useful for identifying CNA-driven genes. By simultaneously considering both comparative genomic and transcriptomic data, it can provide better understanding of biological and medical questions. The iGC package's source code and manual are freely available at https://www.bioconductor.org/packages/release/bioc/html/iGC.html", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088185", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "PLRS: a flexible tool for the joint analysis of DNA copy number and mRNA expression data.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23419375", "endSection": "title"}, {"offsetInBeginSection": 8, "offsetInEndSection": 877, "text": " DNA copy number and mRNA expression are commonly used data types in cancer studies. Available software for integrative analysis arbitrarily fixes the parametric form of the association between the two molecular levels and hence offers no opportunities for modelling it. We present a new tool for flexible modelling of this association. PLRS uses a wide class of interpretable models including popular ones and incorporates prior biological knowledge. It is capable to identify the gene-specific type of relationship between gene copy number and mRNA expression. Moreover, it tests the strength of the association and provides confidence intervals. We illustrate PLRS using glioblastoma data from The Cancer Genome Atlas.AVAILABILITY AND IMPLEMENTATION: PLRS is implemented as an R package and available from Bioconductor (as of version 2.12; http://bioconductor.org). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23419375", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "SomatiCA: identifying, characterizing and quantifying somatic copy number aberrations from cancer genome sequencing data.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265680", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 952, "text": "Whole genome sequencing of matched tumor-normal sample pairs is becoming routine in cancer research. However, analysis of somatic copy-number changes from sequencing data is still challenging because of insufficient sequencing coverage, unknown tumor sample purity and subclonal heterogeneity. Here we describe a computational framework, named SomatiCA, which explicitly accounts for tumor purity and subclonality in the analysis of somatic copy-number profiles. Taking read depths (RD) and lesser allele frequencies (LAF) as input, SomatiCA will output 1) admixture rate for each tumor sample, 2) somatic allelic copy-number for each genomic segment, 3) fraction of tumor cells with subclonal change in each somatic copy number aberration (SCNA), and 4) a list of substantial genomic aberration events including gain, loss and LOH. SomatiCA is available as a Bioconductor R package at http://www.bioconductor.org/packages/2.13/bioc/html/SomatiCA.html.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265680", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Copynumber: Efficient algorithms for single- and multi-track copy number segmentation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23442169", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 1218, "text": "Cancer progression is associated with genomic instability and an accumulation of gains and losses of DNA. The growing variety of tools for measuring genomic copy numbers, including various types of array-CGH, SNP arrays and high-throughput sequencing, calls for a coherent framework offering unified and consistent handling of single- and multi-track segmentation problems. In addition, there is a demand for highly computationally efficient segmentation algorithms, due to the emergence of very high density scans of copy number.RESULTS: A comprehensive Bioconductor package for copy number analysis is presented. The package offers a unified framework for single sample, multi-sample and multi-track segmentation and is based on statistically sound penalized least squares principles. Conditional on the number of breakpoints, the estimates are optimal in the least squares sense. A novel and computationally highly efficient algorithm is proposed that utilizes vector-based operations in R. Three case studies are presented.CONCLUSIONS: The R package copynumber is a software suite for segmentation of single- and multi-track copy number data using algorithms based on coherent least squares principles.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23442169", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Using the R Package crlmm for Genotyping and Copy Number Estimation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22523482", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1028, "text": "Genotyping platforms such as Affymetrix can be used to assess genotype-phenotype as well as copy number-phenotype associations at millions of markers. While genotyping algorithms are largely concordant when assessed on HapMap samples, tools to assess copy number changes are more variable and often discordant. One explanation for the discordance is that copy number estimates are susceptible to systematic differences between groups of samples that were processed at different times or by different labs. Analysis algorithms that do not adjust for batch effects are prone to spurious measures of association. The R package crlmm implements a multilevel model that adjusts for batch effects and provides allele-specific estimates of copy number. This paper illustrates a workflow for the estimation of allele-specific copy number and integration of the marker-level estimates with complimentary Bioconductor software for inferring regions of copy number gain or loss. All analyses are performed in the statistical environment R.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22523482", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "KC-SMARTR: An R package for detection of statistically significant aberrations in multi-experiment aCGH data.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21070656", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 1877, "text": "Most approaches used to find recurrent or differential DNA Copy Number Alterations (CNA) in array Comparative Genomic Hybridization (aCGH) data from groups of tumour samples depend on the discretization of the aCGH data to gain, loss or no-change states. This causes loss of valuable biological information in tumour samples, which are frequently heterogeneous. We have previously developed an algorithm, KC-SMART, that bases its estimate of the magnitude of the CNA at a given genomic location on kernel convolution (Klijn et al., 2008). This accounts for the intensity of the probe signal, its local genomic environment and the signal distribution across multiple samples.RESULTS: Here we extend the approach to allow comparative analyses of two groups of samples and introduce the R implementation of these two approaches. The comparative module allows for a supervised analysis to be performed, to enable the identification of regions that are differentially aberrated between two user-defined classes.We analyzed data from a series of B- and T-cell lymphomas and were able to retrieve all positive control regions (VDJ regions) in addition to a number of new regions. A t-test employing segmented data, that we implemented, was also able to locate all the positive control regions and a number of new regions but these regions were highly fragmented.CONCLUSIONS: KC-SMARTR offers recurrent CNA and class specific CNA detection, at different genomic scales, in a single package without the need for additional segmentation. It is memory efficient and runs on a wide range of machines. Most importantly, it does not rely on data discretization and therefore maximally exploits the biological information in the aCGH data.The program is freely available from the Bioconductor website http://www.bioconductor.org/ under the terms of the GNU General Public License.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21070656", "endSection": "abstract"}]}, {"body": "List angiocrine factors", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21148069", "http://www.ncbi.nlm.nih.gov/pubmed/24018375", "http://www.ncbi.nlm.nih.gov/pubmed/24257808", "http://www.ncbi.nlm.nih.gov/pubmed/20094048", "http://www.ncbi.nlm.nih.gov/pubmed/21068842", "http://www.ncbi.nlm.nih.gov/pubmed/24257019"], "ideal_answer": ["Angiocrine factors are: Ccl4, neurotensin, vascular endothelial growth factor, metalloproteinases-1, thrombospondin 3, Slit2, hepatocyte growth factor, Wnt2. "], "exact_answer": [["Ccl4"], ["neurotensin"], ["vascular endothelial growth factor"], ["metalloproteinases-1"], ["thrombospondin 3"], ["Slit2"], ["hepatocyte growth factor"], ["Wnt2"]], "type": "list", "id": "56e46ad951531f7e3300001a", "snippets": [{"offsetInBeginSection": 697, "offsetInEndSection": 744, "text": "Ccl4 and neurotensin (Nts) (angiocrine factors)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24257808", "endSection": "abstract"}, {"offsetInBeginSection": 738, "offsetInEndSection": 838, "text": "vascular endothelial growth factor (VEGF)-A was identified as the most abundantly expressed factor, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24018375", "endSection": "abstract"}, {"offsetInBeginSection": 1628, "offsetInEndSection": 1726, "text": "angiocrine factors tissue inhibitor of metalloproteinases-1 (Timp-1) and thrombospondin 3 (THBS3) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24257019", "endSection": "abstract"}, {"offsetInBeginSection": 444, "offsetInEndSection": 575, "text": "We found that Slit2, which is negatively regulated by endothelial EphA2 receptor, is one such tumor suppressive angiocrine factor. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21148069", "endSection": "abstract"}, {"offsetInBeginSection": 1631, "offsetInEndSection": 1701, "text": "angiocrine factors, including hepatocyte growth factor (HGF) and Wnt2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21068842", "endSection": "abstract"}]}, {"body": "What symptoms are included in the narcolepsy pentad?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32941089", "http://www.ncbi.nlm.nih.gov/pubmed/30595352", "http://www.ncbi.nlm.nih.gov/pubmed/28726523", "http://www.ncbi.nlm.nih.gov/pubmed/28162143", "http://www.ncbi.nlm.nih.gov/pubmed/31931470"], "ideal_answer": ["Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed nocturnal sleep."], "exact_answer": [["excessive daytime sleepiness"], ["cataplexy"], ["sleep paralysis"], ["hypnagogic/hypnopompic hallucinations"], ["disturbed nocturnal sleep"]], "type": "list", "id": "60274a2a1cb411341a0000e2", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Disrupted nighttime sleep is one of the pentad of symptoms defining Narcolepsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31931470", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 216, "text": "INTRODUCTION: Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed nocturnal sleep. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32941089", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "BACKGROUND: Narcolepsy is a disabling sleep-wake disorder characterized by the pentad symptoms of excessive daytime sleepiness, sleep paralysis, sleep fragmentation, sleep-related hallucinations, and cataplexy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30595352", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 216, "text": "INTRODUCTION: Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed nocturnal sleep. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28726523", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 269, "text": "STUDY OBJECTIVES: Narcolepsy, a chronic disorder of the central nervous system, is clinically characterized by a symptom pentad that includes excessive daytime sleepiness, cataplexy, sleep paralysis, hypnopompic/hypnagogic hallucinations, and disrupted nighttime sleep.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28162143", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "BACKGROUND: Narcolepsy is a disabling sleep-wake disorder characterized by the pentad symptoms of excessive daytime sleepiness, sleep paralysis, sleep fragmentation, sleep-related hallucinations, and cataplexy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30595352", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "INTRODUCTION: Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed nocturnal sleep.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28726523", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "INTRODUCTION: Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed nocturnal sleep.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32941089", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 256, "text": "STUDY OBJECTIVES: Narcolepsy, a chronic disorder of the central nervous system, is clinically characterized by a symptom pentad that includes excessive daytime sleepiness, cataplexy, sleep paralysis, hypnopompic/hypnagogic hallucinations, and disrupted nig", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28162143", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "INTRODUCTION: Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed noctur", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28726523", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "BACKGROUND: Narcolepsy is a disabling sleep-wake disorder characterized by the pentad symptoms of excessive daytime sleepiness, sleep paralysis, sleep fragmentation, sleep-related hallucinations, an", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30595352", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "INTRODUCTION: Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed no", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32941089", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "INTRODUCTION: Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed no", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28726523", "endSection": "abstract"}]}, {"body": "In which isochores are Alu elements enriched?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8828040", "http://www.ncbi.nlm.nih.gov/pubmed/19543403", "http://www.ncbi.nlm.nih.gov/pubmed/9931467", "http://www.ncbi.nlm.nih.gov/pubmed/15871047", "http://www.ncbi.nlm.nih.gov/pubmed/22057813", "http://www.ncbi.nlm.nih.gov/pubmed/11591470", "http://www.ncbi.nlm.nih.gov/pubmed/6572942", "http://www.ncbi.nlm.nih.gov/pubmed/7723057"], "ideal_answer": ["Alu elements are enriched in high GC% isochores due to reduced Alu loss by recombination in these regions. The frequency of Alu sequences increases with increasing GC, but attains a maximum in H2 isochores."], "exact_answer": [["H2"], ["H3"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D032085", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020087"], "type": "list", "id": "515bd543298dcd4e51000001", "snippets": [{"offsetInBeginSection": 146, "offsetInEndSection": 241, "text": " the vast majority of Alu sequences were shown to have the highest density in GC-rich isochores", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22057813", "endSection": "sections.0"}, {"offsetInBeginSection": 988, "offsetInEndSection": 1103, "text": "Alu sequences being unstable in the GC-poor isochores but stable in the compositionally matching GC-rich isochores,", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22057813", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Alu retrotransposons do not show a homogeneous distribution over the human genome but have a higher density in GC-rich (H) than in AT-rich (L) isochores", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15871047", "endSection": "sections.0"}, {"offsetInBeginSection": 1230, "offsetInEndSection": 1463, "text": "This result, together with the known higher selective disadvantage of recombination products in H isochores, points to Alu-Alu recombination as the main agent provoking the density shift of Alus toward the GC-rich parts of the genome", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15871047", "endSection": "sections.0"}, {"offsetInBeginSection": 175, "offsetInEndSection": 235, "text": "whereas GC-rich Alus are mostly present in GC-rich isochores", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11591470", "endSection": "sections.0"}, {"offsetInBeginSection": 1221, "offsetInEndSection": 1469, "text": "the present results on Alu and LINE stability/exclusion predict significant losses of Alu DNA from the GC-poor isochores during evolution, a phenomenon apparently due to negative selection against sequences that differ from the isochore composition", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11591470", "endSection": "sections.0"}, {"offsetInBeginSection": 780, "offsetInEndSection": 929, "text": "The frequency of Alu sequences also increases with increasing GC, but attains a maximum in H2 isochores, in agreement with previous experimental data", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9931467", "endSection": "sections.0"}, {"offsetInBeginSection": 1570, "offsetInEndSection": 1643, "text": "The CpG levels of both Alus and CpG islands increase with their GC levels", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9931467", "endSection": "sections.0"}, {"offsetInBeginSection": 327, "offsetInEndSection": 416, "text": "characterized as a GC-rich isochore enriched for CpG islands, genes, and Alu-like repeats", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8828040", "endSection": "sections.0"}, {"offsetInBeginSection": 1299, "offsetInEndSection": 1414, "text": "Microsatellites and SINES (Alu, B1, B2) are found at roughly equal frequencies in introns from all isochore classes", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7723057", "endSection": "sections.0"}, {"offsetInBeginSection": 500, "offsetInEndSection": 776, "text": "The results indicate that the short repeats of the B1 family of mouse and of the Alu I family of man are most frequent in the heavy components, whereas the long repeats of the BamHI family of mouse and of the Kpn I family of man are mainly present in the two light components.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6572942", "endSection": "sections.0"}]}, {"body": "With which personality traits has the human monoamine oxidase A (MAOA) gene been associated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17347351", "http://www.ncbi.nlm.nih.gov/pubmed/10943908", "http://www.ncbi.nlm.nih.gov/pubmed/16436187", "http://www.ncbi.nlm.nih.gov/pubmed/25497297", "http://www.ncbi.nlm.nih.gov/pubmed/15652876", "http://www.ncbi.nlm.nih.gov/pubmed/29073746", "http://www.ncbi.nlm.nih.gov/pubmed/28851912", "http://www.ncbi.nlm.nih.gov/pubmed/15870836", "http://www.ncbi.nlm.nih.gov/pubmed/26494873", "http://www.ncbi.nlm.nih.gov/pubmed/20810002", "http://www.ncbi.nlm.nih.gov/pubmed/25698585", "http://www.ncbi.nlm.nih.gov/pubmed/14697883", "http://www.ncbi.nlm.nih.gov/pubmed/12554604", "http://www.ncbi.nlm.nih.gov/pubmed/26851573", "http://www.ncbi.nlm.nih.gov/pubmed/19194374", "http://www.ncbi.nlm.nih.gov/pubmed/21554924", "http://www.ncbi.nlm.nih.gov/pubmed/17417058", "http://www.ncbi.nlm.nih.gov/pubmed/25794322"], "ideal_answer": ["Association studies suggest that the low activity variant of the monoamine oxidase A (MAOA)-uVNTR polymorphism confers risk for emotional disturbances associated with antisocial traits, particularly in males. These include antisocial and borderline personality disorders and antisocial aggression.", "Association of monoamine oxidase-A genetic variants and amygdala morphology in violent offenders with antisocial personality disorder and high psychopathic traits. The interaction of the low activity variant of the monoamine oxidase-A (MAOA-L) gene and early childhood adversity has been shown to predict aggression in clinical and non-clinical populations Monoamine Oxidase-A Genetic Variants and Childhood Abuse Predict Impulsiveness in Borderline Personality Disorder.", "Association of monoamine oxidase-A genetic variants and amygdala morphology in violent offenders with antisocial personality disorder and high psychopathic traits. ", "Association of monoamine oxidase-A genetic variants and amygdala morphology in violent offenders with antisocial personality disorder and high psychopathic traits. Monoamine oxidase a gene is associated with borderline personality disorder. Gene environment interactions with a novel variable Monoamine Oxidase A transcriptional enhancer are associated with antisocial personality disorder.", "Monoamine oxidase A (MAOA) gene has an important role in the regulation of neurotransmitter levels and a large number of human behaviors. For example, it has been shown that childhood maltreatment interacts with a monoamine oxidase A (MAOA) gene variant to predict antisocial behavior that is often associated with alcoholism, and an interaction between early life stress and a serotonin transporter promoter variant predicts alcohol abuse in nonhuman primates and depression in humans. The purpose of the present study was to examine whether a cumulative genetic score (CGS) containing the monoamine oxidase A (MAOA) and the human serotonin transporter gene linked polymorphism (5-HTTLPR) was associated with IPV perpetration after accounting for the effects of alcohol problems, drug problems, age, and length of relationship. One approach to this question is examining allelic variation in the X-linked monoamine oxidase A (MAOA) gene, previously associated with impulsive aggression in animals and humans. Allelic variation of the monoamine oxidase A (MAOA) gene has been implicated in conduct disorder and antisocial, aggressive behavior in humans when associated with early adverse experiences.", "Association of monoamine oxidase-A genetic variants and amygdala morphology in violent offenders with antisocial personality disorder and high psychopathic traits."], "exact_answer": [["antisocial personality disorder"], ["borderline personality disorder"], ["antisocial aggression"]], "type": "list", "id": "5a99566e1d1251d03b00000f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Association of monoamine oxidase-A genetic variants and amygdala morphology in violent offenders with antisocial personality disorder and high psychopathic traits.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28851912", "endSection": "title"}, {"offsetInBeginSection": 196, "offsetInEndSection": 388, "text": "The interaction of the low activity variant of the monoamine oxidase-A (MAOA-L) gene and early childhood adversity has been shown to predict aggression in clinical and non-clinical populations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29073746", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Monoamine Oxidase-A Genetic Variants and Childhood Abuse Predict Impulsiveness in Borderline Personality Disorder.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29073746", "endSection": "title"}, {"offsetInBeginSection": 1253, "offsetInEndSection": 1460, "text": " These preliminary results suggest that MAOA-L may modulate the impact of childhood abuse on impulsivity in BPD. Results additionally indicate that impulsiveness may be expressed differently in BPD and ASPD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29073746", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Elevated Monoamine Oxidase-A Distribution Volume in Borderline Personality Disorder Is Associated With Severity Across Mood Symptoms, Suicidality, and Cognition.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25698585", "endSection": "title"}, {"offsetInBeginSection": 1457, "offsetInEndSection": 1646, "text": "These results suggest that elevated MAO-A VT is associated with multiple indicators of BPD severity, including BPD symptomatology, mood symptoms, suicidality, and neurocognitive impairment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25698585", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "No association between a polymorphism in the promoter region of the MAOA gene with antisocial personality traits in alcoholics.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12554604", "endSection": "title"}, {"offsetInBeginSection": 1142, "offsetInEndSection": 1313, "text": "Taken together, these findings suggest that the three-repeat allele of the MAOAuVNTR 30-bp polymorphism is not associated with impulsive and aggressive personality traits.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12554604", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Different allele distribution of a regulatory MAOA gene promoter polymorphism in antisocial and anxious-depressive alcoholics", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10943908", "endSection": "title"}, {"offsetInBeginSection": 109, "offsetInEndSection": 320, "text": "The present study tested whether a novel functional polymorphism in the promotor region of the X-chromosomal monoamine oxidase A gene (MAOA) was related to antisocial and anxious-depressive traits in alcoholics.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10943908", "endSection": "abstract"}, {"offsetInBeginSection": 875, "offsetInEndSection": 1074, "text": "aken together, these findings suggest that the 3-repeat allele of the MAOA polymorphism contributes modestly to the dimension of overand underreactive behaviors as possible antecedents of alcoholism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10943908", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "Association studies suggest that the low activity variant of the monoamine oxidase A (MAOA)-uVNTR polymorphism confers risk for emotional disturbances associated with antisocial traits, particularly in males. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19194374", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "A polymorphism of the MAOA gene is associated with emotional brain markers and personality traits on an antisocial index", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19194374", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 126, "text": "The monoamine oxidase A (MAOA) gene has been shown to moderate the impact of maltreatment on antisocial behaviour.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26494873", "endSection": "abstract"}, {"offsetInBeginSection": 766, "offsetInEndSection": 941, "text": "Non-linear interactions between the MAOA gene and violence were detected, suggesting that the genetic moderation may come about once a certain level of violence is experienced", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26494873", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "The history of research on the association between platelet monoamine oxidase (MAO) activity and personality traits, such as sensation seeking and impulsiveness, is reviewed. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14697883", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Monoamine oxidase a gene is associated with borderline personality disorder.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17417058", "endSection": "title"}, {"offsetInBeginSection": 151, "offsetInEndSection": 319, "text": "As for its role in aggression, impulsivity, suicide and mood liability, monoamine oxidase A can be considered a functional candidate in borderline personality disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17417058", "endSection": "abstract"}, {"offsetInBeginSection": 973, "offsetInEndSection": 1123, "text": "These results show that the monoamine oxidase A gene may play an important role in the etiological development of the borderline personality disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17417058", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Gene environment interactions with a novel variable Monoamine Oxidase A transcriptional enhancer are associated with antisocial personality disorder.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21554924", "endSection": "title"}, {"offsetInBeginSection": 318, "offsetInEndSection": 422, "text": "However, clinical associations between this VNTR genotype and behavioral states have been inconsistent. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21554924", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Monoamine oxidase A gene promoter methylation and transcriptional downregulation in an offender population with antisocial personality disorder.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25497297", "endSection": "title"}, {"offsetInBeginSection": 1164, "offsetInEndSection": 1419, "text": "hese results are consistent with prior literature suggesting MAOA and serotonergic dysregulation in antisocial populations. Our results offer the first evidence suggesting epigenetic mechanisms may contribute to MAOA dysregulation in antisocial offenders.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25497297", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 348, "text": "For example, it has been shown that childhood maltreatment interacts with a monoamine oxidase A (MAOA) gene variant to predict antisocial behavior that is often associated with alcoholism, and an interaction between early life stress and a serotonin transporter promoter variant predicts alcohol abuse in nonhuman primates and depression in humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17347351", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "Allelic variation of the monoamine oxidase A (MAOA) gene has been implicated in conduct disorder and antisocial, aggressive behavior in humans when associated with early adverse experiences.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15652876", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 377, "text": "By conferring allele-specific transcriptional activity on the monoamine oxidase A (MAOA) gene in humans, length variation of a repetitive sequence [(variable number of tandem repeat (VNTR)] in the MAOA promoter influences a constellation of personality traits related to aggressive and antisocial behavior and increases the risk of neurodevelopmental and psychiatric disorders.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16436187", "endSection": "abstract"}, {"offsetInBeginSection": 133, "offsetInEndSection": 244, "text": "Genotypes with three-repeat alleles were reported to be associated with antisocial as well as impulsive traits.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12554604", "endSection": "abstract"}, {"offsetInBeginSection": 369, "offsetInEndSection": 641, "text": "Platelet MAO-B activity has been associated with psychopathy- and aggression-related personality traits, while variants of the MAOA and MAOB genes have been associated with diverse clinical phenotypes, including aggressiveness, antisocial problems and violent delinquency.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26851573", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 208, "text": "Association studies suggest that the low activity variant of the monoamine oxidase A (MAOA)-uVNTR polymorphism confers risk for emotional disturbances associated with antisocial traits, particularly in males.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19194374", "endSection": "abstract"}, {"offsetInBeginSection": 1428, "offsetInEndSection": 1598, "text": "CONCLUSION Taken together, these findings suggest that the MAOA-L genotype is to some extent associated with impulsive and antisocial personality traits in alcoholic men.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25794322", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Relationship of monoamine oxidase A binding to adaptive and maladaptive personality traits.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20810002", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Cluster B personality disorders are associated with allelic variation of monoamine oxidase A activity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15870836", "endSection": "title"}]}, {"body": "What are the computational methods for the prediction of beta-barrel transmembrane proteins?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15647112", "http://www.ncbi.nlm.nih.gov/pubmed/16844989", "http://www.ncbi.nlm.nih.gov/pubmed/23530628", "http://www.ncbi.nlm.nih.gov/pubmed/15980447", "http://www.ncbi.nlm.nih.gov/pubmed/15162482", "http://www.ncbi.nlm.nih.gov/pubmed/19153681", "http://www.ncbi.nlm.nih.gov/pubmed/22148174", "http://www.ncbi.nlm.nih.gov/pubmed/12798041", "http://www.ncbi.nlm.nih.gov/pubmed/19429691", "http://www.ncbi.nlm.nih.gov/pubmed/21328706", "http://www.ncbi.nlm.nih.gov/pubmed/17520325", "http://www.ncbi.nlm.nih.gov/pubmed/23297037", "http://www.ncbi.nlm.nih.gov/pubmed/22540951", "http://www.ncbi.nlm.nih.gov/pubmed/18989393", "http://www.ncbi.nlm.nih.gov/pubmed/19622743", "http://www.ncbi.nlm.nih.gov/pubmed/18006547", "http://www.ncbi.nlm.nih.gov/pubmed/12192075", "http://www.ncbi.nlm.nih.gov/pubmed/21935968", "http://www.ncbi.nlm.nih.gov/pubmed/21426944", "http://www.ncbi.nlm.nih.gov/pubmed/12169530", "http://www.ncbi.nlm.nih.gov/pubmed/19470175", "http://www.ncbi.nlm.nih.gov/pubmed/12070338", "http://www.ncbi.nlm.nih.gov/pubmed/18218108", "http://www.ncbi.nlm.nih.gov/pubmed/21967762", "http://www.ncbi.nlm.nih.gov/pubmed/15141026", "http://www.ncbi.nlm.nih.gov/pubmed/18467177", "http://www.ncbi.nlm.nih.gov/pubmed/19421989", "http://www.ncbi.nlm.nih.gov/pubmed/15215418", "http://www.ncbi.nlm.nih.gov/pubmed/22987359", "http://www.ncbi.nlm.nih.gov/pubmed/15070403", "http://www.ncbi.nlm.nih.gov/pubmed/15769290", "http://www.ncbi.nlm.nih.gov/pubmed/17597890", "http://www.ncbi.nlm.nih.gov/pubmed/21064129", "http://www.ncbi.nlm.nih.gov/pubmed/17597895", "http://www.ncbi.nlm.nih.gov/pubmed/15215419", "http://www.ncbi.nlm.nih.gov/pubmed/22031179", "http://www.ncbi.nlm.nih.gov/pubmed/16858668", "http://www.ncbi.nlm.nih.gov/pubmed/21531175", "http://www.ncbi.nlm.nih.gov/pubmed/17088282", "http://www.ncbi.nlm.nih.gov/pubmed/16225682", "http://www.ncbi.nlm.nih.gov/pubmed/16674095", "http://www.ncbi.nlm.nih.gov/pubmed/18312695", "http://www.ncbi.nlm.nih.gov/pubmed/10698111", "http://www.ncbi.nlm.nih.gov/pubmed/16597327", "http://www.ncbi.nlm.nih.gov/pubmed/22247276", "http://www.ncbi.nlm.nih.gov/pubmed/20488436", "http://www.ncbi.nlm.nih.gov/pubmed/11274469", "http://www.ncbi.nlm.nih.gov/pubmed/17958348", "http://www.ncbi.nlm.nih.gov/pubmed/18355838"], "ideal_answer": ["Computational tools have been developed for beta-barrel transmembrane protein discrimination, topology prediction and prediction of their structural features.\nInitial methods developed for the prediction of the transmembrane beta strands were based on hydrophobicity analysis, using sliding windows along the sequence, in order to capture the alternating patterns of hydrophobic-hydrophilic residues of the transmembrane strands, or using generalized secondary structure prediction methods. Other approaches included the construction of special empirical rules using amino-acid propensities and prior knowledge of the structural nature of the proteins, and the development of Neural Network-based predictors to predict the location of alpha-carbon atoms with respect to the membrane. During the last few years, other more refined methods, appeared, including: Neural Networks, Hidden Markov Models, Support Vector Machines, k-Nearest Neighbors, Radial Basis Functions, Bayesian Networks, Genetic Algorithms, Mahalanobis Discriminant Functions, Cellular Automata, N-to-1 Extreme Learning Machines. Hidden Markov Model-based methods are among the most successful in topology prediction, being able to capture the unique architecture of beta-barrel transmembrane proteins. Consensus methods, as well as pipelines of several related tools (e.g. subcellular localization prediciton, alpha-helical transmembrane protein prediction, signal-peptide/lipoprotein prediction) have also used for discriminating beta-barrel transmembrane proteins. Recently, a number of methods for predicting more detailed structural features (e.g. surface accessibility, residue contacts, even detailed atomic 3D models) tailored to beta-barrel transmembrane proteins have been developed, based on knowledge-based potential functions, graph theoretic models, physical models and multi-tape S-attribute grammars. Methods/tools falling in the aforementioned classes are (listed in alphabetical order): BBF (beta-barrel finder), BETAWARE, BOCTOPUS, BOMP, BTMX (Beta barrel TransMembrane eXposure), HHomp, HMM-B2TMR, OMBBpred, PROFtmb, PRED-TMBB, TMB-Hunt, TBBPred, TMBETAPRED-RBF, TMBHMM, TransFold, TMBpro, TMBKNN, Wimley"], "exact_answer": [["BBF", "beta-barrel finder"], ["BETAWARE"], ["BOCTOPUS"], ["BOMP"], ["BTMX", "Beta barrel TransMembrane eXposure"], ["HHomp"], ["HMM-B2TMR"], ["OMBBpred"], ["PROFtmb"], ["PRED-TMBB"], ["TMB-Hunt"], ["TBBPred"], ["TMBETAPRED-RBF"], ["TMBHMM"], ["TransFold"], ["TMBpro"], ["TMBKNN"], ["Wimley"], ["TMBETA-NET"]], "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0016021", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012984"], "type": "list", "id": "5149a61ed24251bc05000044", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "BETAWARE: a machine-learning tool to detect and predict transmembrane beta-barrel proteins in prokaryotes", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23297037", "endSection": "title"}, {"offsetInBeginSection": 684, "offsetInEndSection": 1063, "text": "Recently, we developed two top-performing methods based on machine-learning approaches to tackle both the detection of TMBBs in sets of proteins and the prediction of their topology. Here, we present our BETAWARE program that includes both approaches and can run as a standalone program on a linux-based computer to easily address in-home massive protein annotation or filtering.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23297037", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 618, "text": "We introduce a graph-theoretic model for predicting the supersecondary structure of transmembrane \u03b2-barrel proteins--a particular class of proteins that performs diverse important functions but it is difficult to determine their structure with experimental methods. This ab initio model resolves the protein folding problem based on pseudo-energy minimization with the aid of a simple probabilistic filter. It also allows for determining structures whose barrel follows a given permutation on the arrangement of \u03b2-strands, and allows for rapidly discriminating the transmembrane \u03b2-barrels from other kinds of proteins.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22987359", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "BOCTOPUS: improved topology prediction of transmembrane \u03b2 barrel proteins", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22247276", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Improving the detection of transmembrane \u03b2-barrel chains with N-to-1 extreme learning machines", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21967762", "endSection": "title"}, {"offsetInBeginSection": 728, "offsetInEndSection": 833, "text": "we introduce a new machine learning approach for TMBB detection based on N-to-1 Extreme Learning Machines", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21967762", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "TMBHMM: a frequency profile based HMM for predicting the topology of transmembrane beta barrel proteins and the exposure status of transmembrane residues", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21426944", "endSection": "title"}, {"offsetInBeginSection": 332, "offsetInEndSection": 838, "text": "We present here TMBHMM, a computational method based on a hidden Markov model for predicting the structural topology of putative TMBs from sequence. In addition to predicting transmembrane strands, TMBHMM also predicts the exposure status (i.e., exposed to the membrane or hidden in the protein structure) of the residues in the transmembrane region, which is a novel feature of the TMBHMM method. Furthermore, TMBHMM can also predict the membrane residues that are not part of beta barrel forming strands.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21426944", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Prediction of the exposure status of transmembrane beta barrel residues from protein sequence", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21328706", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 244, "text": "We present BTMX (Beta barrel TransMembrane eXposure), a computational method to predict the exposure status (i.e. exposed to the bilayer or hidden in the protein structure) of transmembrane residues in transmembrane beta barrel proteins (TMBs).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21328706", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Combined prediction of transmembrane topology and signal peptide of beta-barrel proteins: using a hidden Markov model and genetic algorithms", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20488436", "endSection": "title"}, {"offsetInBeginSection": 774, "offsetInEndSection": 1043, "text": "We present here, an HMM that combine a transmembrane barrel submodel and an SP submodel for both topology and SP predictions. A new genetic algorithm (GA) is presented here to training the model, at the same time the Posterior-Viterbi algorithm is adopted for decoding.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20488436", "endSection": "sections.0"}, {"offsetInBeginSection": 168, "offsetInEndSection": 332, "text": "In this work, we propose a method based on radial basis networks for predicting the number of beta-strands in OMPs and identifying their membrane spanning segments.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19421989", "endSection": "sections.0"}, {"offsetInBeginSection": 624, "offsetInEndSection": 805, "text": "We have developed a web server, TMBETAPRED-RBF for predicting the transmembrane beta-strands from amino acid sequence and it is available at http://rbf.bioinfo.tw/~sachen/tmrbf.html", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19421989", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 607, "text": "We have developed a novel approach for dissecting transmembrane beta-barrel proteins (TMBs) in genomic sequences. The features include (i) the identification of TMBs using the preference of residue pairs in globular, transmembrane helical (TMH) and TMBs, (ii) elimination of globular/TMH proteins that show sequence identity of more than 70% for the coverage of 80% residues with known structures, (iii) elimination of globular/TMH proteins that have sequence identity of more than 60% with known sequences in SWISS-PROT, and (iv) exclusion of TMH proteins using SOSUI, a prediction system for TMH proteins.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17958348", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "TMBpro: secondary structure, beta-contact and tertiary structure prediction of transmembrane beta-barrel proteins", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18006547", "endSection": "title"}, {"offsetInBeginSection": 732, "offsetInEndSection": 934, "text": "We develop a suite (TMBpro) of specialized predictors for predicting secondary structure (TMBpro-SS), beta-contacts (TMBpro-CON) and tertiary structure (TMBpro-3D) of transmembrane beta-barrel proteins.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18006547", "endSection": "sections.0"}, {"offsetInBeginSection": 100, "offsetInEndSection": 199, "text": "This paper presents a k-nearest neighbor (K-NN) method for discriminating TMB and non-TMB proteins.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18467177", "endSection": "sections.0"}, {"offsetInBeginSection": 533, "offsetInEndSection": 1022, "text": "In this paper, based on the concept of pseudo amino acid composition (PseAA) that can incorporate sequence-order information of a protein sequence so as to remarkably enhance the power of discrete models (Chou, K. C., Proteins: Structure, Function, and Genetics, 2001, 43: 246-255), cellular automata and Lempel-Ziv complexity are introduced to predict the TM regions of integral membrane proteins including both alpha-helical and beta-barrel membrane proteins, validated by jackknife test", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17520325", "endSection": "sections.0"}, {"offsetInBeginSection": 486, "offsetInEndSection": 737, "text": "we present BOCTOPUS; an improved method for the topology prediction of TMBs by employing a combination of support vector machines (SVMs) and Hidden Markov Models (HMMs). The SVMs and HMMs account for local and global residue preferences, respectively.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22247276", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "PRED-TMBB: a web server for predicting the topology of beta-barrel outer membrane proteins", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15215419", "endSection": "title"}, {"offsetInBeginSection": 346, "offsetInEndSection": 684, "text": "We present here a web server (PRED-TMBB, http://bioinformatics.biol.uoa.gr/PRED-TMBB) which is capable of predicting the transmembrane strands and the topology of beta-barrel outer membrane proteins of Gram-negative bacteria. The method is based on a Hidden Markov Model, trained according to the Conditional Maximum Likelihood criterion.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15215419", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Prediction of transmembrane regions of beta-barrel proteins using ANN- and SVM-based methods", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15162482", "endSection": "title"}, {"offsetInBeginSection": 1, "offsetInEndSection": 325, "text": "his article describes a method developed for predicting transmembrane beta-barrel regions in membrane proteins using machine learning techniques: artificial neural network (ANN) and support vector machine (SVM). The ANN used in this study is a feed-forward neural network with a standard back-propagation training algorithm.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15162482", "endSection": "sections.0"}, {"offsetInBeginSection": 527, "offsetInEndSection": 845, "text": "We have also developed an SVM-based method using a primary sequence as input and achieved an accuracy of 77.4%. The SVM model was modified by adding 36 physicochemical parameters to the amino acid sequence information. Finally, ANN- and SVM-based methods were combined to utilize the full potential of both techniques.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15162482", "endSection": "sections.0"}, {"offsetInBeginSection": 1190, "offsetInEndSection": 1291, "text": "we have developed a Web server, TBBPred, for predicting transmembrane beta-barrel regions in proteins", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15162482", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "Predicting transmembrane beta-barrels in proteomes", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15141026", "endSection": "title"}, {"offsetInBeginSection": 241, "offsetInEndSection": 386, "text": "Here we introduced the design, statistics and results of a novel profile-based hidden Markov model for the prediction and discrimination of TMBs.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15141026", "endSection": "sections.0"}, {"offsetInBeginSection": 1381, "offsetInEndSection": 1453, "text": "All proteome predictions and the PROFtmb prediction method are available", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15141026", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "The beta-barrel finder (BBF) program, allowing identification of outer membrane beta-barrel proteins encoded within prokaryotic genomes", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12192075", "endSection": "title"}, {"offsetInBeginSection": 251, "offsetInEndSection": 795, "text": "We here report computational analyses of six outer membrane proteins of known 3D structures with respect to (1) secondary structure, (2) hydropathy, and (3) amphipathicity. Using these characteristics, as well as the presence of an N-terminal targeting sequence, a program was developed allowing prediction of integral membrane beta-barrel proteins encoded within any completely sequenced prokaryotic genome. This program, termed the beta-barrel finder (BBF) program, was used to analyze the proteins encoded within the Escherichia coli genome.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12192075", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "A sequence-profile-based HMM for predicting and discriminating beta barrel membrane proteins", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12169530", "endSection": "title"}, {"offsetInBeginSection": 1003, "offsetInEndSection": 1485, "text": "We develop a HMM model, which can predict the topology of beta barrel membrane proteins using, as input, evolutionary information. The model is cyclic with 6 types of states: two for the beta strand transmembrane core, one for the beta strand cap on either side of the membrane, one for the inner loop, one for the outer loop and one for the globular domain state in the middle of each loop. The development of a specific input for HMM based on multiple sequence alignment is novel.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12169530", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Prediction of the transmembrane regions of beta-barrel membrane proteins with a neural network-based predictor", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11274469", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 330, "text": "A method based on neural networks is trained and tested on a nonredundant set of beta-barrel membrane proteins known at atomic resolution with a jackknife procedure. The method predicts the topography of transmembrane beta strands with residue accuracy as high as 78% when evolutionary information is used as input to the network.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11274469", "endSection": "sections.0"}, {"offsetInBeginSection": 570, "offsetInEndSection": 682, "text": "A web server based on the proposed method is available at http://yanbioinformatics.cs.usu.edu:8080/TMBKNNsubmit.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18467177", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Predicting three-dimensional structures of transmembrane domains of \u03b2-barrel membrane proteins", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22148174", "endSection": "title"}, {"offsetInBeginSection": 391, "offsetInEndSection": 887, "text": "We have developed a computational method for predicting structures of the transmembrane (TM) domains of \u03b2-barrel membrane proteins. Based on physical principles, our method can predict structures of the TM domain of \u03b2-barrel membrane proteins of novel topology, including those from eukaryotic mitochondria. Our method is based on a model of physical interactions, a discrete conformational state space, an empirical potential function, as well as a model to account for interstrand loop entropy.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22148174", "endSection": "sections.0"}, {"offsetInBeginSection": 25, "offsetInEndSection": 93, "text": "exposure status classification of transmembrane beta barrel residues", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21531175", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 436, "text": "Several computational methods exist for the identification of transmembrane beta barrel proteins (TMBs) from sequence. Some of these methods also provide the transmembrane (TM) boundaries of the putative TMBs. The aim of this study is to (1) derive the propensities of the TM residues to be exposed to the lipid bilayer and (2) to predict the exposure status (i.e. exposed to the bilayer or hidden in protein structure) of TMB residues.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21531175", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "The modified Mahalanobis Discriminant for predicting outer membrane proteins by using Chou's pseudo amino acid composition.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18355838", "endSection": "title"}, {"offsetInBeginSection": 224, "offsetInEndSection": 508, "text": "In this study, a method that combines increment of diversity with modified Mahalanobis Discriminant, called IDQD, is presented to predict 208 OMPs, 206 transmembrane helical proteins (TMHPs) and 673 globular proteins (GPs) by using Chou's pseudo amino acid compositions as parameters.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18355838", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Predicting transmembrane beta-barrels and interstrand residue interactions from sequence", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16858668", "endSection": "title"}, {"offsetInBeginSection": 460, "offsetInEndSection": 928, "text": "A novel method using pairwise interstrand residue statistical potentials derived from globular (nonouter membrane) proteins is introduced to predict the supersecondary structure of transmembrane beta-barrel proteins. The algorithm transFold employs a generalized hidden Markov model (i.e., multitape S-attribute grammar) to describe potential beta-barrel supersecondary structures and then computes by dynamic programming the minimum free energy beta-barrel structure.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16858668", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Predicting the solvent accessibility of transmembrane residues from protein sequence", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16674095", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 282, "text": "In this study, we propose a novel method to predict the solvent accessible surface areas of transmembrane residues. For both transmembrane alpha-helix and beta-barrel residues, the correlation coefficients between the predicted and observed accessible surface areas are around 0.65.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16674095", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "BOMP: a program to predict integral beta-barrel outer membrane proteins encoded within genomes of Gram-negative bacteria", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15215418", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 623, "text": "This work describes the development of a program that predicts whether or not a polypeptide sequence from a Gram-negative bacterium is an integral beta-barrel outer membrane protein. The program, called the beta-barrel Outer Membrane protein Predictor (BOMP), is based on two separate components to recognize integral beta-barrel proteins. The first component is a C-terminal pattern typical of many integral beta-barrel proteins. The second component calculates an integral beta-barrel score of the sequence based on the extent to which the sequence contains stretches of amino acids typical of transmembrane beta-strands.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15215418", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "A HMM-based method to predict the transmembrane regions of beta-barrel membrane proteins", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12798041", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 218, "text": "A novel method is developed to model and predict the transmembrane regions of beta-barrel membrane proteins. It is based on a Hidden Markov model (HMM) with architecture obeying those proteins' construction principles.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12798041", "endSection": "sections.0"}, {"offsetInBeginSection": 271, "offsetInEndSection": 649, "text": "First, an algorithm that calculates the mean hydrophobicity of one side of putative beta-strands predicted the positions of 16 transmembrane segments, a structure common to known porins. Second, outer loops typical of porins were assigned using an artificial neural network trained to predict the topology of bacterial outer-membrane proteins with a predominance of beta-strands", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12070338", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Prediction of the membrane-spanning beta-strands of the major outer membrane protein of Chlamydia", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12070338", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Topology prediction of Brucella abortus Omp2b and Omp2a porins after critical assessment of transmembrane beta strands prediction by several secondary structure prediction methods", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10698111", "endSection": "title"}, {"offsetInBeginSection": 162, "offsetInEndSection": 671, "text": "Four porins of known structure were selected as test-cases and their secondary structure delineated. The specificity and sensitivity of 11 methods were separately evaluated. Our critical assessment shows that some secondary structure prediction methods (PHD, Dsc, Sopma) originally designed to predict globular protein structure are useful on porin topology prediction. The overall best prediction is obtained by combining these three \"generalist\" methods with a transmembrane beta strand prediction technique", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10698111", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "A knowledge-based potential highlights unique features of membrane \u03b1-helical and \u03b2-barrel protein insertion and folding", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22031179", "endSection": "title"}, {"offsetInBeginSection": 323, "offsetInEndSection": 796, "text": "In previous work, a depth-dependent insertion potential, E(z) , was derived for \u03b1-helical inner membrane proteins. We have generated an equivalent potential for TM \u03b2-barrel proteins. The similarities and differences between these two potentials provide insight into unique aspects of the folding and insertion of \u03b2-barrel membrane proteins. This potential can predict orientation within the membrane and identify functional residues involved in intermolecular interactions.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22031179", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Improved identification of outer membrane beta barrel proteins using primary sequence, predicted secondary structure, and evolutionary information", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21064129", "endSection": "title"}, {"offsetInBeginSection": 759, "offsetInEndSection": 1035, "text": "We present an accurate sequence-based predictor of OMBBs, called OMBBpred, which utilizes a Support Vector Machine classifier and a custom-designed set of 34 novel numerical descriptors derived from predicted secondary structures, hydrophobicity, and evolutionary information.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21064129", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Predicting weakly stable regions, oligomerization state, and protein-protein interfaces in transmembrane domains of outer membrane proteins.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19622743", "endSection": "title"}, {"offsetInBeginSection": 884, "offsetInEndSection": 1461, "text": "We have also discovered that out-clamps, in-plugs, and oligomerization are 3 general mechanisms for stabilizing weakly stable TM regions. In addition, we have found that extended and contiguous weakly stable regions often signal the existence of an oligomer and that strands located in the interfaces of protein-protein interactions are considerably less stable. Based on these observations, we can predict oligomerization states and can identify the interfaces of protein-protein interactions for beta-barrel membrane proteins by using either structure or sequence information", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19622743", "endSection": "sections.0"}, {"offsetInBeginSection": 688, "offsetInEndSection": 870, "text": "Recently, we developed two top-performing methods based on machine-learning approaches to tackle both the detection of TMBBs in sets of proteins and the prediction of their topology.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23297037", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 265, "text": "We introduce a graph-theoretic model for predicting the supersecondary structure of transmembrane \u03b2-barrel proteins--a particular class of proteins that performs diverse important functions but it is difficult to determine their structure with experimental methods.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22987359", "endSection": "sections.0"}, {"offsetInBeginSection": 508, "offsetInEndSection": 609, "text": "Several computational methods have been developed to discriminate TMBBs from other types of proteins.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21967762", "endSection": "sections.0"}, {"offsetInBeginSection": 563, "offsetInEndSection": 711, "text": "To conquer this limitation, we developed a new computational model that can be used for predicting the ASA of both TM \u03b1-helix and \u03b2-barrel residues.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21935968", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Transmembrane beta barrel (TMB) proteins are found in the outer membranes of bacteria, mitochondria and chloroplasts.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21426944", "endSection": "sections.0"}, {"offsetInBeginSection": 765, "offsetInEndSection": 899, "text": "RESULTS: We present here, an HMM that combine a transmembrane barrel submodel and an SP submodel for both topology and SP predictions.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20488436", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Prediction of membrane spanning segments in beta-barrel outer membrane proteins (OMP) and their topology is an important problem in structural and functional genomics.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19421989", "endSection": "sections.0"}, {"offsetInBeginSection": 331, "offsetInEndSection": 531, "text": "In the simplest of these, the target \"model\" is another protein sequence, while the more elaborate methods group together the entire set of t ansmembrane helical or transmembrane beta-barrel proteins.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19153681", "endSection": "sections.0"}, {"offsetInBeginSection": 1169, "offsetInEndSection": 1348, "text": "Based on this study, we have developed a Web server, TBBPred, for predicting transmembrane beta-barrel regions in proteins (available at http://www.imtech.res.in/raghava/tbbpred).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15162482", "endSection": "sections.0"}]}, {"body": "Which methods exist for efficient calculation of Elementary flux modes (EFMs) in genome-scale metabolic networks (GSMNs)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32348455", "http://www.ncbi.nlm.nih.gov/pubmed/25380956"], "ideal_answer": ["EFM-Ta is a novel algorithm that uses a linear programming-based tree search and efficiently enumerates a subset of EFMs in genome-scale metabolic networks (GSMNs). The stand-alone software TreeEFM is implemented in C++ and interacts with the open-source linear solver COIN-OR Linear program Solver (CLP).", "The efficient calculation of elementary flux modes (EFMs) in genome-scale metabolic networks (GSMNs) is still a challenge. EFM-ta and treeefm are two different algorithms that use linear programming-based tree search and efficiently enumerates a subset of EFMs in GSMNs.", "Elementary flux modes (EFMs) are a key tool for analyzing genome-scale metabolic networks, and several methods have been proposed to compute them. Among them, those based on solving linear programming (LP) problems like TreeEFM and EFM-Ta are known to be very efficient if the main interest lies in computing large enough sets of EFMs.", "The efficient calculation of elementary flux modes (EFMs) in genome-scale metabolic networks (GSMNs) is a challenge. Two methods for this task have been developed, eFM-ta and treeefm."], "exact_answer": [["TreeEFM"], ["EFM-Ta"]], "type": "list", "id": "6027fcd31cb411341a0000ef", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 1136, "text": "Elementary flux modes (EFMs) analysis constitutes a fundamental tool in systems biology. However, the efficient calculation of EFMs in genome-scale metabolic networks (GSMNs) is still a challenge. We present a novel algorithm that uses a linear programming-based tree search and efficiently enumerates a subset of EFMs in GSMNs.RESULTS: Our approach is compared with the EFMEvolver approach, demonstrating a significant improvement in computation time. We also validate the usefulness of our new approach by studying the acetate overflow metabolism in the Escherichia coli bacteria. To do so, we computed 1 million EFMs for each energetic amino acid and then analysed the relevance of each energetic amino acid based on gene/protein expression data and the obtained EFMs. We found good agreement between previous experiments and the conclusions reached using EFMs. Finally, we also analysed the performance of our approach when applied to large GSMNs.AVAILABILITY AND IMPLEMENTATION: The stand-alone software TreeEFM is implemented in C++ and interacts with the open-source linear solver COIN-OR Linear program Solver (CLP).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25380956", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 794, "text": "Elementary flux modes (EFMs) are a key tool for analyzing genome-scale metabolic networks, and several methods have been proposed to compute them. Among them, those based on solving linear programming (LP) problems are known to be very efficient if the main interest lies in computing large enough sets of EFMs.RESULTS: Here, we propose a new method called EFM-Ta that boosts the efficiency rate by analyzing the information provided by the LP solver. We base our method on a further study of the final tableau of the simplex method. By performing additional elementary steps and avoiding trivial solutions consisting of two cycles, we obtain many more EFMs for each LP problem posed, improving the efficiency rate of previously proposed methods by more than one order of magnitude.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32348455", "endSection": "abstract"}]}]}